0001628280-22-027479.txt : 20221101 0001628280-22-027479.hdr.sgml : 20221101 20221101085254 ACCESSION NUMBER: 0001628280-22-027479 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 67 CONFORMED PERIOD OF REPORT: 20220930 FILED AS OF DATE: 20221101 DATE AS OF CHANGE: 20221101 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Esperion Therapeutics, Inc. CENTRAL INDEX KEY: 0001434868 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35986 FILM NUMBER: 221348638 BUSINESS ADDRESS: STREET 1: 3891 RANCHERO DRIVE, SUITE 150 CITY: ANN ARBOR STATE: MI ZIP: 48108 BUSINESS PHONE: 734-887-3903 MAIL ADDRESS: STREET 1: 3891 RANCHERO DRIVE, SUITE 150 CITY: ANN ARBOR STATE: MI ZIP: 48108 FORMER COMPANY: FORMER CONFORMED NAME: HDL THERAPEUTICS INC DATE OF NAME CHANGE: 20080513 10-Q 1 espr-20220930.htm 10-Q espr-20220930
0001434868--12-312022Q3falsehttp://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member633.33P5D00014348682022-01-012022-09-3000014348682022-10-31xbrli:shares00014348682022-09-30iso4217:USD00014348682021-12-31iso4217:USDxbrli:shares0001434868us-gaap:ProductMember2022-07-012022-09-300001434868us-gaap:ProductMember2021-07-012021-09-300001434868us-gaap:ProductMember2022-01-012022-09-300001434868us-gaap:ProductMember2021-01-012021-09-300001434868espr:CollaborationRevenueMember2022-07-012022-09-300001434868espr:CollaborationRevenueMember2021-07-012021-09-300001434868espr:CollaborationRevenueMember2022-01-012022-09-300001434868espr:CollaborationRevenueMember2021-01-012021-09-3000014348682022-07-012022-09-3000014348682021-07-012021-09-3000014348682021-01-012021-09-300001434868us-gaap:CommonStockMember2020-12-310001434868us-gaap:AdditionalPaidInCapitalMember2020-12-310001434868us-gaap:RetainedEarningsMember2020-12-310001434868us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001434868us-gaap:TreasuryStockMember2020-12-3100014348682020-12-3100014348682020-01-012020-12-310001434868us-gaap:AdditionalPaidInCapitalMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2020-12-310001434868srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:RetainedEarningsMember2020-12-310001434868srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2020-12-310001434868srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMemberus-gaap:CommonStockMember2020-12-310001434868us-gaap:AdditionalPaidInCapitalMembersrt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember2020-12-310001434868srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMemberus-gaap:RetainedEarningsMember2020-12-310001434868us-gaap:AccumulatedOtherComprehensiveIncomeMembersrt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember2020-12-310001434868us-gaap:TreasuryStockMembersrt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember2020-12-310001434868srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember2020-12-310001434868us-gaap:CommonStockMember2021-01-012021-03-310001434868us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-3100014348682021-01-012021-03-310001434868us-gaap:RetainedEarningsMember2021-01-012021-03-310001434868us-gaap:CommonStockMember2021-03-310001434868us-gaap:AdditionalPaidInCapitalMember2021-03-310001434868us-gaap:RetainedEarningsMember2021-03-310001434868us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001434868us-gaap:TreasuryStockMember2021-03-3100014348682021-03-310001434868us-gaap:CommonStockMember2021-04-012021-06-300001434868us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-3000014348682021-04-012021-06-300001434868us-gaap:RetainedEarningsMember2021-04-012021-06-300001434868us-gaap:CommonStockMember2021-06-300001434868us-gaap:AdditionalPaidInCapitalMember2021-06-300001434868us-gaap:RetainedEarningsMember2021-06-300001434868us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300001434868us-gaap:TreasuryStockMember2021-06-3000014348682021-06-300001434868us-gaap:CommonStockMember2021-07-012021-09-300001434868us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300001434868us-gaap:RetainedEarningsMember2021-07-012021-09-300001434868us-gaap:CommonStockMember2021-09-300001434868us-gaap:AdditionalPaidInCapitalMember2021-09-300001434868us-gaap:RetainedEarningsMember2021-09-300001434868us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-300001434868us-gaap:TreasuryStockMember2021-09-3000014348682021-09-300001434868us-gaap:CommonStockMember2021-12-310001434868us-gaap:AdditionalPaidInCapitalMember2021-12-310001434868us-gaap:RetainedEarningsMember2021-12-310001434868us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001434868us-gaap:TreasuryStockMember2021-12-310001434868us-gaap:CommonStockMember2022-01-012022-03-310001434868us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-3100014348682022-01-012022-03-310001434868us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001434868us-gaap:RetainedEarningsMember2022-01-012022-03-310001434868us-gaap:CommonStockMember2022-03-310001434868us-gaap:AdditionalPaidInCapitalMember2022-03-310001434868us-gaap:RetainedEarningsMember2022-03-310001434868us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001434868us-gaap:TreasuryStockMember2022-03-3100014348682022-03-310001434868us-gaap:CommonStockMember2022-04-012022-06-300001434868us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-3000014348682022-04-012022-06-300001434868us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001434868us-gaap:RetainedEarningsMember2022-04-012022-06-300001434868us-gaap:CommonStockMember2022-06-300001434868us-gaap:AdditionalPaidInCapitalMember2022-06-300001434868us-gaap:RetainedEarningsMember2022-06-300001434868us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001434868us-gaap:TreasuryStockMember2022-06-3000014348682022-06-300001434868us-gaap:CommonStockMember2022-07-012022-09-300001434868us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001434868us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300001434868us-gaap:RetainedEarningsMember2022-07-012022-09-300001434868us-gaap:CommonStockMember2022-09-300001434868us-gaap:AdditionalPaidInCapitalMember2022-09-300001434868us-gaap:RetainedEarningsMember2022-09-300001434868us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300001434868us-gaap:TreasuryStockMember2022-09-300001434868us-gaap:CustomerConcentrationRiskMemberus-gaap:TradeAccountsReceivableMember2022-01-012022-09-30espr:customer0001434868us-gaap:CustomerConcentrationRiskMemberus-gaap:TradeAccountsReceivableMember2021-01-012021-12-31espr:revenue_source0001434868us-gaap:CollaborativeArrangementMemberespr:DaiichiSankyoEuropeGmbhMember2019-01-022019-01-020001434868us-gaap:CollaborativeArrangementMembersrt:MinimumMemberespr:DaiichiSankyoEuropeGmbhMember2019-01-022019-01-02xbrli:pure0001434868us-gaap:CollaborativeArrangementMembersrt:MaximumMemberespr:DaiichiSankyoEuropeGmbhMember2019-01-022019-01-020001434868espr:DaiichiSankyoEuropeGmbhMemberespr:RoyaltyRevenueAndProductSalesBulkTabletsMember2022-07-012022-09-300001434868espr:DaiichiSankyoEuropeGmbhMemberespr:RoyaltyRevenueAndProductSalesBulkTabletsMember2022-01-012022-09-300001434868espr:DaiichiSankyoEuropeGmbhMemberespr:RoyaltyRevenueAndProductSalesBulkTabletsMember2021-07-012021-09-300001434868espr:DaiichiSankyoEuropeGmbhMemberespr:RoyaltyRevenueAndProductSalesBulkTabletsMember2021-01-012021-09-300001434868espr:ExclusiveDevelopmentalActivitiesMemberespr:OtsukaPharmaceuticalCoLtdMember2020-04-172020-04-170001434868espr:ExclusiveDevelopmentalActivitiesMemberespr:OtsukaPharmaceuticalCoLtdMember2020-04-170001434868espr:ExclusiveDevelopmentalActivitiesMemberespr:OtsukaPharmaceuticalCoLtdMembersrt:MaximumMember2020-04-170001434868espr:ExclusiveDevelopmentalActivitiesMembersrt:MinimumMemberespr:OtsukaPharmaceuticalCoLtdMember2020-04-172020-04-170001434868espr:ExclusiveDevelopmentalActivitiesMemberespr:OtsukaPharmaceuticalCoLtdMembersrt:MaximumMember2020-04-172020-04-170001434868espr:ExclusiveDevelopmentalActivitiesMemberespr:CollaborationRevenueMemberespr:OtsukaPharmaceuticalCoLtdMember2022-01-012022-09-300001434868espr:ExclusiveDevelopmentalActivitiesMemberespr:CollaborationRevenueMemberespr:OtsukaPharmaceuticalCoLtdMember2022-07-012022-09-300001434868espr:ExclusiveDevelopmentalActivitiesMemberespr:CollaborationRevenueMemberespr:OtsukaPharmaceuticalCoLtdMember2021-01-012021-09-300001434868espr:ExclusiveDevelopmentalActivitiesMemberespr:CollaborationRevenueMemberespr:OtsukaPharmaceuticalCoLtdMember2021-07-012021-09-300001434868espr:DaiichiSankyoCoLtdMemberus-gaap:CollaborativeArrangementMember2021-04-012021-04-300001434868espr:DaiichiSankyoCoLtdMemberus-gaap:CollaborativeArrangementMembersrt:MinimumMember2021-04-012021-04-300001434868espr:DaiichiSankyoCoLtdMemberus-gaap:CollaborativeArrangementMembersrt:MaximumMember2021-04-012021-04-300001434868espr:DaiichiSankyoCoLtdMemberus-gaap:CollaborativeArrangementMember2021-04-262021-04-260001434868espr:DaiichiSankyoCoLtdMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300001434868espr:DaiichiSankyoCoLtdMemberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300001434868espr:DaiichiSankyoCoLtdMemberespr:CollaborativeArrangementLicenseToIntellectualPropertyMember2021-07-012021-09-300001434868espr:DaiichiSankyoCoLtdMemberespr:CollaborativeArrangementOngoingRegulatoryAndDevelopmentActivitiesMember2021-07-012021-09-300001434868espr:DaiichiSankyoCoLtdMemberus-gaap:CollaborativeArrangementMember2021-01-012021-12-310001434868espr:DaiichiSankyoCoLtdMember2021-01-012021-12-310001434868espr:DaiichiSankyoCoLtdMemberespr:CollaborativeArrangementLicenseToIntellectualPropertyMember2021-01-012021-12-310001434868espr:DaiichiSankyoCoLtdMemberespr:CollaborativeArrangementOngoingRegulatoryAndDevelopmentActivitiesMember2021-01-012021-12-310001434868espr:DaiichiSankyoCoLtdMemberus-gaap:CollaborativeArrangementMember2022-07-012022-09-300001434868espr:DaiichiSankyoCoLtdMemberus-gaap:CollaborativeArrangementMember2022-01-012022-09-300001434868us-gaap:PendingLitigationMember2021-08-242021-08-240001434868us-gaap:PendingLitigationMember2021-01-012021-03-310001434868us-gaap:PendingLitigationMember2021-03-310001434868us-gaap:MoneyMarketFundsMemberus-gaap:CashEquivalentsMember2022-09-300001434868us-gaap:CertificatesOfDepositMemberus-gaap:CashEquivalentsMember2022-09-300001434868us-gaap:ShortTermInvestmentsMemberus-gaap:USTreasurySecuritiesMember2022-09-300001434868us-gaap:MoneyMarketFundsMemberus-gaap:CashEquivalentsMember2021-12-310001434868us-gaap:CertificatesOfDepositMemberus-gaap:CashEquivalentsMember2021-12-310001434868us-gaap:ShortTermInvestmentsMemberus-gaap:USTreasurySecuritiesMember2021-12-310001434868us-gaap:OtherNonoperatingIncomeExpenseMember2022-07-012022-09-300001434868us-gaap:OtherNonoperatingIncomeExpenseMember2022-01-012022-09-300001434868srt:MaximumMemberus-gaap:OtherNonoperatingIncomeExpenseMember2021-07-012021-09-300001434868srt:MaximumMemberus-gaap:OtherNonoperatingIncomeExpenseMember2021-01-012021-09-300001434868us-gaap:OtherNonoperatingIncomeExpenseMember2021-07-012021-09-300001434868us-gaap:OtherNonoperatingIncomeExpenseMember2021-01-012021-09-300001434868us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300001434868us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300001434868us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-01-012022-09-300001434868us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-01-012021-09-300001434868us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001434868us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001434868us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001434868us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001434868us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001434868us-gaap:FairValueInputsLevel1Memberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001434868us-gaap:FairValueInputsLevel2Memberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001434868us-gaap:FairValueInputsLevel3Memberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001434868us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001434868us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001434868us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001434868us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001434868us-gaap:FairValueMeasurementsRecurringMember2022-09-300001434868us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001434868us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001434868us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001434868us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001434868us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001434868us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001434868us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001434868us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001434868us-gaap:FairValueInputsLevel1Memberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001434868us-gaap:FairValueInputsLevel2Memberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001434868us-gaap:FairValueInputsLevel3Memberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001434868us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001434868us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001434868us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001434868us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001434868us-gaap:FairValueMeasurementsRecurringMember2021-12-310001434868us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001434868us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001434868us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001434868espr:RevenueInterestPurchaseAgreementMemberespr:EigerIiiSaLlcMember2019-06-262019-06-260001434868espr:RevenueInterestPurchaseAgreementMemberespr:EigerIiiSaLlcMember2020-03-012020-03-310001434868espr:RevenueInterestPurchaseAgreementMemberespr:EigerIiiSaLlcMember2021-04-262021-04-260001434868espr:EigerIiiSaLlcMemberespr:RevenueInterestPurchaseAgreementAmendmentMember2021-04-262021-04-260001434868espr:RevenueInterestPurchaseAgreementAmendmentMember2021-01-012021-09-300001434868espr:EigerIiiSaLlcMemberespr:RIPAAmendmentToTheSecurityAgreementAndWaiverMember2021-05-162021-05-160001434868espr:EigerIiiSaLlcMemberespr:RIPAAmendmentToTheSecurityAgreementAndWaiverMember2021-09-300001434868espr:RevenueInterestPurchaseAgreementMember2022-09-300001434868espr:RevenueInterestPurchaseAgreementMember2022-01-012022-09-300001434868espr:RevenueInterestPurchaseAgreementMemberus-gaap:OtherNonoperatingIncomeExpenseMember2022-07-012022-09-300001434868espr:RevenueInterestPurchaseAgreementMemberus-gaap:OtherNonoperatingIncomeExpenseMember2022-01-012022-09-300001434868espr:RevenueInterestPurchaseAgreementMemberus-gaap:OtherNonoperatingIncomeExpenseMember2021-07-012021-09-300001434868espr:RevenueInterestPurchaseAgreementMemberus-gaap:OtherNonoperatingIncomeExpenseMember2021-01-012021-09-300001434868espr:EigerIiiSaLlcMemberespr:RevenueInterestPurchaseAgreementAmendmentMember2019-06-262019-06-260001434868espr:RevenueInterestPurchaseAgreementMemberespr:EigerIiiSaLlcMemberespr:NetSalesThresholdOneMember2019-06-262019-06-260001434868espr:RevenueInterestPurchaseAgreementMemberespr:EigerIiiSaLlcMemberespr:NetSalesThresholdOneMember2019-06-260001434868espr:RevenueInterestPurchaseAgreementMemberespr:EigerIiiSaLlcMemberespr:NetSalesThresholdTwoMember2019-06-262019-06-260001434868espr:RevenueInterestPurchaseAgreementMemberespr:EigerIiiSaLlcMemberespr:NetSalesThresholdTwoMember2019-06-260001434868espr:RevenueInterestPurchaseAgreementMemberespr:NetSalesThresholdThreeMemberespr:EigerIiiSaLlcMember2019-06-262019-06-260001434868espr:RevenueInterestPurchaseAgreementMemberespr:NetSalesThresholdThreeMemberespr:EigerIiiSaLlcMember2019-06-260001434868espr:RevenueInterestPurchaseAgreementMemberespr:EigerIiiSaLlcMember2022-09-300001434868espr:RevenueInterestPurchaseAgreementMemberespr:EigerIiiSaLlcMember2022-01-012022-09-300001434868espr:RevenueInterestPurchaseAgreementMember2021-12-310001434868us-gaap:ConvertibleDebtMemberespr:ConvertibleSeniorNotesDue2025Member2020-11-300001434868us-gaap:ConvertibleDebtMemberespr:ConvertibleSeniorNotesDue2025Member2020-11-012020-11-3000014348682020-11-012020-11-300001434868us-gaap:DebtInstrumentRedemptionPeriodOneMemberus-gaap:ConvertibleDebtMemberespr:ConvertibleSeniorNotesDue2025Member2020-11-300001434868us-gaap:DebtInstrumentRedemptionPeriodOneMemberus-gaap:ConvertibleDebtMemberespr:ConvertibleSeniorNotesDue2025Member2020-11-012020-11-30espr:day0001434868us-gaap:ConvertibleDebtMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMemberespr:ConvertibleSeniorNotesDue2025Member2020-11-012020-11-300001434868us-gaap:ConvertibleDebtMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMemberespr:ConvertibleSeniorNotesDue2025Member2020-11-300001434868us-gaap:ConvertibleDebtMemberus-gaap:LongTermDebtMemberespr:ConvertibleSeniorNotesDue2025Member2020-11-300001434868us-gaap:AdditionalPaidInCapitalMemberus-gaap:ConvertibleDebtMemberespr:ConvertibleSeniorNotesDue2025Member2020-11-300001434868us-gaap:ConvertibleDebtMemberespr:ConvertibleSeniorNotesDue2025Member2021-01-012021-01-010001434868srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2021-01-010001434868us-gaap:ConvertibleDebtMemberespr:ConvertibleSeniorNotesDue2025Member2021-10-222021-10-220001434868us-gaap:ConvertibleDebtMemberespr:ConvertibleSeniorNotesDue2025Member2021-10-220001434868us-gaap:ConvertibleDebtMemberespr:ConvertibleSeniorNotesDue2025Member2021-11-032021-11-030001434868us-gaap:ConvertibleDebtMemberespr:ConvertibleSeniorNotesDue2025Member2022-09-300001434868us-gaap:ConvertibleDebtMemberespr:ConvertibleSeniorNotesDue2025Member2022-07-012022-09-300001434868us-gaap:ConvertibleDebtMemberespr:ConvertibleSeniorNotesDue2025Member2022-01-012022-09-300001434868us-gaap:ConvertibleDebtMemberespr:ConvertibleSeniorNotesDue2025Member2021-07-012021-09-300001434868us-gaap:ConvertibleDebtMemberespr:ConvertibleSeniorNotesDue2025Member2021-01-012021-09-300001434868us-gaap:ConvertibleDebtMemberespr:ConvertibleSeniorNotesDue2025Member2021-12-3100014348682020-11-162020-11-160001434868us-gaap:CommonClassAMemberespr:CappedCallMember2020-11-160001434868espr:StockOptionAndIncentivePlan2022Member2022-05-310001434868us-gaap:EmployeeStockMember2020-04-012020-04-300001434868us-gaap:EmployeeStockMember2022-07-012022-09-300001434868us-gaap:EmployeeStockMember2022-01-012022-09-300001434868us-gaap:EmployeeStockMember2021-07-012021-09-300001434868us-gaap:EmployeeStockMember2021-01-012021-09-300001434868us-gaap:EmployeeStockMember2022-09-302022-09-300001434868us-gaap:EmployeeStockMember2022-09-3000014348682021-01-012021-12-310001434868us-gaap:EmployeeStockOptionMember2022-07-012022-09-300001434868us-gaap:EmployeeStockOptionMember2022-01-012022-09-300001434868us-gaap:EmployeeStockOptionMember2021-07-012021-09-300001434868us-gaap:EmployeeStockOptionMember2021-01-012021-09-300001434868us-gaap:EmployeeStockOptionMember2022-09-300001434868espr:ShareBasedPaymentArrangementOptionPerformanceBasedMember2021-12-310001434868espr:ShareBasedPaymentArrangementOptionPerformanceBasedMember2021-01-012021-12-310001434868espr:ShareBasedPaymentArrangementOptionPerformanceBasedMember2022-01-012022-09-300001434868espr:ShareBasedPaymentArrangementOptionPerformanceBasedMember2022-09-300001434868espr:ShareBasedPaymentArrangementOptionPerformanceBasedMember2022-07-012022-09-300001434868us-gaap:RestrictedStockUnitsRSUMember2021-12-310001434868us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-09-300001434868us-gaap:RestrictedStockUnitsRSUMember2022-09-300001434868us-gaap:RestrictedStockUnitsRSUMember2022-07-012022-09-300001434868us-gaap:RestrictedStockUnitsRSUMember2021-07-012021-09-300001434868us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-09-300001434868us-gaap:PerformanceSharesMember2021-12-310001434868us-gaap:PerformanceSharesMember2022-01-012022-09-300001434868us-gaap:PerformanceSharesMember2022-09-300001434868us-gaap:PerformanceSharesMember2022-07-012022-09-300001434868us-gaap:PerformanceSharesMember2021-01-012021-09-300001434868us-gaap:PerformanceSharesMember2021-07-012021-09-300001434868espr:AtTheMarketProgramMember2021-08-032021-08-030001434868espr:AtTheMarketProgramMember2021-07-012021-09-300001434868espr:AtTheMarketProgramMember2021-01-012021-09-300001434868espr:AtTheMarketProgramMember2022-04-152022-04-150001434868espr:AtTheMarketProgramMember2022-07-012022-09-300001434868espr:AtTheMarketProgramMember2022-01-012022-09-3000014348682021-12-0200014348682021-12-022021-12-020001434868us-gaap:EmployeeStockOptionMember2022-01-012022-09-300001434868us-gaap:EmployeeStockOptionMember2021-01-012021-09-300001434868espr:ShareBasedPaymentArrangementOptionPerformanceBasedMember2022-01-012022-09-300001434868espr:ShareBasedPaymentArrangementOptionPerformanceBasedMember2021-01-012021-09-300001434868espr:UnvestedRestrictedStockAndRestrictedStockUnitsMember2022-01-012022-09-300001434868espr:UnvestedRestrictedStockAndRestrictedStockUnitsMember2021-01-012021-09-300001434868us-gaap:PerformanceSharesMember2022-01-012022-09-300001434868us-gaap:PerformanceSharesMember2021-01-012021-09-300001434868us-gaap:EmployeeStockMember2022-01-012022-09-300001434868us-gaap:EmployeeStockMember2021-01-012021-09-300001434868us-gaap:ConvertibleDebtSecuritiesMember2022-01-012022-09-300001434868us-gaap:ConvertibleDebtSecuritiesMember2021-01-012021-09-300001434868us-gaap:WarrantMember2022-01-012022-09-300001434868us-gaap:WarrantMember2021-01-012021-09-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2022
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                      to       
         
Commission file number: 001-35986
Esperion Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware    26-1870780
(State or other jurisdiction of
incorporation or organization)		(I.R.S. Employer
Identification No.)
3891 Ranchero Drive, Suite 150
Ann Arbor, MI 48108
(Address of principal executive office) (Zip Code)
Registrant’s telephone number, including area code:
(734) 887-3903
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.001 per share ESPR 
NASDAQ Stock Market LLC
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes x  No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes x  No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filerx    Accelerated filero
Non-accelerated filer oSmaller reporting company o
Emerging growth company
o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ☐  No x
As of October 31, 2022, there were 73,683,572 shares of the registrant’s Common Stock, $0.001 par value per share, outstanding.

Esperion Therapeutics, Inc.
INDEX
Page

2


Esperion Therapeutics, Inc.
Condensed Balance Sheets
(in thousands, except share data)
September 30,
2022		December 31,
2021
(unaudited)
Assets
Current assets:
Cash and cash equivalents$159,399 $208,892 
Short-term investments29,942 50,441 
Accounts receivable31,489 22,934 
Prepaid clinical development costs2,199 1,138 
Inventories, net29,545 34,394 
Other prepaid and current assets9,211 11,173 
Total current assets261,785 328,972 
Restricted cash50,000 50,000 
Property and equipment, net256 664 
Right of use operating lease assets730 1,898 
Intangible assets56 56 
Total assets$312,827 $381,590 
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable$18,580 $17,559 
Accrued clinical development costs3,996 7,013 
Other accrued liabilities35,395 30,410 
Revenue interest liability19,636 11,295 
Deferred revenue from collaborations4,045 5,683 
Operating lease liabilities693 1,392 
Total current liabilities82,345 73,352 
Convertible notes, net of issuance costs259,487 258,280 
Revenue interest liability265,048 245,744 
Operating lease liabilities47 524 
Deferred revenue from collaborations— 634 
Total liabilities606,927 578,534 
Commitments and contingencies (Note 5)
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized and no shares issued or outstanding as of September 30, 2022 and December 31, 2021
— — 
Common stock, $0.001 par value; 240,000,000 shares authorized as of September 30, 2022 and 120,000,000 shares authorized as of December 31, 2021; 73,739,320 shares issued at September 30, 2022 and 62,873,694 shares issued at December 31, 2021
72 61 
Additional paid-in capital1,045,468 964,401 
Treasury stock, at cost; 1,994,198 shares at September 30, 2022 and December 31, 2021
(54,998)(54,998)
Accumulated other comprehensive loss(93)(31)
Accumulated deficit(1,284,549)(1,106,377)
Total stockholders’ deficit(294,100)(196,944)
Total liabilities and stockholders’ deficit$312,827 $381,590 
See accompanying notes to the condensed financial statements.
3
Esperion Therapeutics, Inc.
Condensed Statements of Operations and Comprehensive Loss
(in thousands, except share and per share data)
(unaudited)

Three Months Ended
September 30,		Nine Months Ended
September 30,
2022202120222021
Revenues:
Product sales, net$13,964 $10,895 40,896 $27,855 
Collaboration revenue5,016 3,514 15,761 35,191 
Total Revenues18,980 14,409 56,657 63,046 
Operating expenses:
Cost of goods sold6,506 5,558 22,807 9,142 
Research and development29,143 25,331 85,894 78,359 
Selling, general and administrative24,954 39,265 84,944 146,647 
Total operating expenses60,603 70,154 193,645 234,148 
Loss from operations(41,623)(55,745)(136,988)(171,102)
Interest expense(14,153)(13,654)(42,481)(32,923)
Other income, net659 13 1,297 36 
Net loss$(55,117)$(69,386)$(178,172)$(203,989)
Net loss per common share - basic and diluted$(0.81)$(2.62)$(2.78)$(7.78)
Weighted-average shares outstanding - basic and diluted67,806,292 26,455,209 64,021,248 26,225,730 
Other comprehensive loss:
Unrealized gain (loss) on investments$204 $— $(62)$— 
Comprehensive loss$(54,913)$(69,386)$(178,234)$(203,989)
See accompanying notes to the condensed financial statements.

4
Esperion Therapeutics, Inc.
Condensed Statements of Stockholders’ Deficit
(in thousands, except share data)
(unaudited)
Common StockAdditional Paid-In CapitalAccumulated DeficitAccumulated Other Comprehensive Income (Loss)Treasury StockTotal Stockholders' Deficit
SharesAmount
Balance at December 31, 2020
25,916,168 $26 $797,655 $(838,817)$— $(54,998)$(96,134)
Adoption of ASU 2020-06— — (93,475)1,548 — — (91,927)
Balance at January 1, 202125,916,168 26 704,180 (837,269)— (54,998)(188,061)
Exercise of stock options172,268 — 2,668 — — — 2,668 
Vesting of restricted stock units43,465 — — — — — — 
Vesting of ESPP shares50,818 — 1,183 — — — 1,183 
Stock-based compensation— — 5,751 — — — 5,751 
Net loss— — — (90,935)— — (90,935)
Balance at March 31, 202126,182,719 $26 $713,782 $(928,204)$— $(54,998)$(269,394)
Exercise of stock options10,477 — 168 — — —168 
Vesting of restricted stock units81,139 — — — — —— 
Stock-based compensation— — 8,584 — — —8,584 
Net loss— — — (43,668)— — (43,668)
Balance at June 30, 202126,274,335 $26 $722,534 $(971,872)$— $(54,998)$(304,310)
Issuance of common stock from ATM program, net of issuance costs363,061 1 4,206 — — — 4,207 
Exercise of stock options45,996 — 375 — — — 375 
Vesting of restricted stock units34,581 — — — — — — 
Vesting of ESPP Shares82,396 — 912 — — — 912 
Stock-based compensation— — 5,497 — — — 5,497 
Net loss— — — (69,386)— (69,386)
Balance at September 30, 202126,800,369 $27 $733,524 $(1,041,258)$— $(54,998)$(362,705)

5
Common StockAdditional Paid-In CapitalAccumulated DeficitAccumulated Other Comprehensive Income (Loss)Treasury StockTotal Stockholders' Deficit
SharesAmount
Balance at December 31, 202160,879,496 $61 $964,401 $(1,106,377)$(31)$(54,998)$(196,944)
Vesting of restricted stock units55,286 — — — — — — 
Vesting of ESPP Shares123,785 — 431 — — — 431 
Stock-based compensation— — 4,436 — — — 4,436 
Other comprehensive loss— — — — (232)— (232)
Net loss— — — (56,731)— — (56,731)
Balance at March 31, 202261,058,567 $61 $969,268 $(1,163,108)$(263)$(54,998)$(249,040)
Vesting of restricted stock units184,407 — — — — — — 
Stock-based compensation— — 3,527 — — — 3,527 
Issuance of common stock from ATM program, net of issuance costs3,353,000 4 20,169 — — — 20,173 
Other comprehensive loss— — — — (34)— (34)
Net loss— — — (66,324)— — (66,324)
Balance at June 30, 202264,595,974 $65 $992,964 $(1,229,432)$(297)$(54,998)$(291,698)
Vesting of restricted stock units108,200 — — — — — — 
Vesting of ESPP Shares82,423 — 301 — — — 301 
Stock-based compensation— 3,537 — — — 3,537 
Issuance of common stock from ATM program, net of issuance costs6,958,525 7 48,666 — — — 48,673 
Other comprehensive income— — — — 204 — 204 
Net loss— — — (55,117)— — (55,117)
Balance at September 30, 202271,745,122 $72 $1,045,468 $(1,284,549)$(93)$(54,998)$(294,100)
See accompanying notes to the condensed financial statements.
6
Esperion Therapeutics, Inc.
Condensed Statements of Cash Flows
(in thousands)
(unaudited)
Nine Months Ended September 30,
20222021
Operating activities
Net loss$(178,172)$(203,989)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense408 459 
Amortization of premiums and discounts on investments539 — 
Amortization of debt issuance costs1,207 1,214 
Non-cash interest expense related to the revenue interest liability33,323 23,310 
Stock-based compensation expense11,500 19,832 
Changes in assets and liabilities:
Accounts receivable(8,555)(9,322)
Prepaids and other assets901 1,096 
Deferred revenue(2,272)2,251 
Inventories4,849 (17,836)
Accounts payable1,129 (30,833)
Other accrued liabilities2,788 7,715 
Net cash used in operating activities(132,355)(206,103)
Investing activities
Purchases of investments(18,102)— 
Proceeds from sales/maturities of investments38,000 — 
Net cash provided by investing activities19,898 — 
Financing activities
Proceeds from revenue interest liability, net of issuance costs— 49,917 
Proceeds from exercise of common stock options— 3,211 
Proceeds from issuance of common stock from ATM program, net of issuance costs68,861 4,388 
Payments on revenue interest liability(5,678)(2,263)
Payment of issuance costs(219)(440)
Net cash provided by financing activities62,964 54,813 
Net decrease in cash and cash equivalents(49,493)(151,290)
Cash, cash equivalents and restricted cash at beginning of period258,892 304,962 
Cash, cash equivalents and restricted cash at end of period$209,399 $153,672 
Supplemental disclosure of cash flow information:
Common stock issuance costs not yet paid$15 $181 
Non cash right of use asset8 10 
See accompanying notes to the condensed financial statements.

7
Esperion Therapeutics, Inc.
Notes to Condensed Financial Statements
(unaudited)
1. The Company and Basis of Presentation
Esperion Therapeutics, Inc. ("the Company”) is a pharmaceutical company singularly focused on developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol ("LDL-C"). Through commercial execution and advancement of the CLEAR Outcomes trial as well as the Company's pre-clinical pipeline, the Company continues to evolve into a differentiated, global cardiometabolic biotech. The Esperion team of lipid experts are dedicated to lowering bad cholesterol through the discovery, development and commercialization of innovative medicines and their combinations with established medicines. The Company's first two products were approved by the U.S. Food and Drug Administration ("FDA"), European Medicines Agency ("EMA") and Swiss Agency for Therapeutic Products ("Swissmedic") in 2020. Bempedoic acid and the bempedoic acid / ezetimibe combination tablet are oral, once-daily, non-statin, LDL-C lowering medicines for patients with atherosclerotic cardiovascular disease ("ASCVD") or heterozygous familial hypercholesterolemia ("HeFH").
On November 1, 2022, the Company announced that it is continuing to close out its CLEAR (Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen) Outcomes study of NEXLETOL®. The Company continues to anticipate reporting top-line results from the study in January 2023.
The Company's primary activities since incorporation have been conducting research and development activities, including nonclinical, preclinical and clinical testing, performing business and financial planning, recruiting personnel, and raising capital. The Company received approval by the FDA in February 2020 to commercialize NEXLETOL (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) tablet in the U.S., and accordingly commenced principal operations on March 30, 2020 with the commercialization of NEXLETOL. The Company is subject to risks and uncertainties which include the need to successfully commercialize its products, research, develop, and clinically test therapeutic products; obtain regulatory approvals for its products; manage its management, commercial and scientific staff; and finance its operations with an ultimate goal of achieving profitable operations.
The Company has sustained annual operating losses since inception and expects such losses to continue over the foreseeable future. The Company's ability to successfully launch, commercialize and generate revenue from NEXLETOL, NEXLIZET, NILEMDO® (bempedoic acid) tablet and NUSTENDI® (bempedoic acid and ezetimibe) tablet has been and may continue to be adversely affected by the economic impact of the ongoing COVID-19 pandemic. While management believes current cash resources and future cash received from the Company's net product sales and collaboration agreements with Daiichi Sankyo Europe GmbH ("DSE"), Otsuka Pharmaceutical Co., Ltd. ("Otsuka"), and Daiichi Sankyo Co. Ltd ("DS"), entered into on January 2, 2019, April 17, 2020 and April 26, 2021, respectively, will fund operations for the foreseeable future, management may continue to fund operations and advance the development of the Company's products and product candidates through a combination of collaborations with third parties, strategic alliances, licensing arrangements, permitted debt financings, permitted royalty-based financings, and permitted private and public equity offerings or through other sources. The continuing impact of COVID-19 and the uncertainty around the global pandemic could further impact the commercialization of NEXLETOL and NEXLIZET and the Company’s research and development programs and could result in lower cash flows or higher costs that could further impact the Company’s overall operations and cash needs in the future.
If adequate funds are not available, the Company may not be able to continue the development of its current products or future product candidates, or to commercialize its current or future product candidates, if approved.
Basis of Presentation
The accompanying condensed interim financial statements are unaudited and were prepared by the Company in accordance with generally accepted accounting principles in the United States of America (“GAAP”). In the opinion of management, the Company has made all adjustments, which include only normal recurring adjustments necessary for a fair presentation of the Company’s financial position and results of operations for the interim periods presented. Certain prior year amounts have been reclassified to conform with current year presentation. Certain information and disclosures normally included in the annual financial statements prepared in accordance with GAAP, but that is not required for interim reporting purposes, have been condensed or omitted. These condensed interim financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2021, and the notes thereto, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. The results of operations for the interim periods are not necessarily indicative of the results to be expected for a full year, any other interim periods or any future year or period.
8
2. Summary of Significant Accounting Policies
Use of Estimates
The preparation of financial statements in accordance with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, net revenues, expenses and related disclosures. Actual results could differ from those estimates.
Cash and Cash Equivalents
The Company invests its excess cash in bank deposits, money market accounts, and short-term investments. The Company considers all highly liquid investments with an original maturity of 90 days or less at the time of purchase to be cash equivalents. Cash equivalents are reported at fair value.
Restricted Cash
Restricted cash consists of legally restricted amounts held by financial institutions pursuant to contractual arrangements. Pursuant to the Amendment and Waiver (as defined below), the Company deposited $50.0 million in a deposit account that is subject to a block account control agreement. Eiger III SA LLC (“Oberland”), an affiliate of Oberland Capital LLC, will have sole control over the funds deposited in the account and such funds may be withdrawn only with the consent of Oberland. Refer to Note 8 "Liability Related to the Revenue Interest Purchase Agreement" for further information on the Amendment and Waiver.
Investments
Investments are considered to be available-for-sale and are carried at fair value. Unrealized gains and losses, if any, are reported in accumulated other comprehensive income (loss). The cost of investments classified as available-for-sale are adjusted for the amortization of premiums and accretion of discounts to maturity and recorded in other income, net. Realized gains and losses, if any, are determined using the specific identification method and recorded in other income, net. Investments with original maturities beyond 90 days at the date of purchase and which mature at, or less than twelve months from, the balance sheet date are classified as current. Investments with a maturity beyond twelve months from the balance sheet date are classified as long-term.
Concentration of Risk
The Company enters into a limited number of distribution agreements with distributors and specialty pharmacies. The Company's net product sales are with these customers. As of September 30, 2022, thirteen customers accounted for all of the Company's net trade receivables and as of December 31, 2021, nine customers accounted for all the Company's net trade receivables.
Revenue Recognition
In accordance with ASC 606, Revenue from Contracts with Customers, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange for the goods or services provided. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: identify the contracts with a customer; identify the performance obligations in the contract; determine the transaction price; allocate the transaction price to the performance obligations in the contract; and recognize revenue when or as the entity satisfies a performance obligation. At contract inception the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. The Company derives revenue through two primary sources: collaboration revenue and product sales. Collaboration revenue consists of the collaboration payments to the Company for collaboration arrangements outside of the United States for the development, manufacturing and commercialization, including royalties, of the Company's product candidates by the Company's partners and product sales consists of sales of NEXLETOL and NEXLIZET.
9
a.Collaboration Revenue
The Company has entered into agreements related to its activities to develop, manufacture, and commercialize its product candidates. The Company earns collaboration revenue in connection with a collaboration agreement to develop and/or commercialize product candidates where the Company deems the collaborator to be the customer. Revenue is recognized when (or as) the Company satisfies performance obligations under the terms of a contract. Depending on the terms of the arrangement, the Company may defer the recognition of all or a portion of the consideration received as the performance obligations are satisfied.
The collaboration agreements may require the Company to deliver various rights, services, and/or goods across the entire life cycle of a product or product candidate. In an agreement involving multiple goods or services promised to be transferred to a customer, the Company must assess, at the inception of the contract, whether each promise represents a separate performance obligation (i.e., is "distinct"), or whether such promises should be combined as a single performance obligation.
The terms of the agreement typically include consideration to be provided to the Company in the form of non-refundable up-front payments, development milestones, sales milestones, and royalties on sales of products within a respective territory. The Company recognizes regulatory and approval milestones consideration when it is probable that a future reversal is unlikely to occur. For sales-based milestones and royalties based on sales of product in a territory, the Company applies the sales-based royalty exception in ASC 606-10-55-65 to all of these milestones and royalties.
At the inception of the contract, the transaction price reflects the amount of consideration the Company expects to be entitled to in exchange for transferring promised goods or services to its customer. In the arrangement where the Company satisfies performance obligation(s) during the regulatory phase over time, the Company recognizes collaboration revenue typically using an input method on the basis of regulatory costs incurred relative to the total expected cost which determines the extent of progress toward completion. The Company reviews the estimate of the transaction price and the total expected cost each period and makes revisions to such estimates as necessary. Under contracted supply agreements with collaborators, the Company, through its third party contract manufacturing partners, may manufacture and supply quantities of active pharmaceutical ingredient (“API”) or bulk tablets reasonably required by collaboration partners for the development or sale of licensed products in their respective territory. The Company recognizes revenue when the collaboration partner has obtained control of the API or bulk tablets. The Company records the costs related to the supply agreement in cost of goods sold on the condensed statements of operations and comprehensive (loss) income.
Under the Company's collaboration agreements, product sales and cost of sales may be recorded by the Company's collaborators as they are deemed to be the principal in the transaction. The Company receives royalties from the commercialization of such products, and records its share of the variable consideration, representing a percentage of net product sales, as collaboration revenue in the period in which such underlying sales occur and costs are incurred by the collaborator.
b.Product Sales, Net
On February 21, 2020, the Company announced that the FDA approved NEXLETOL as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or established ASCVD who require additional lowering of LDL-C. On February 26, 2020, the Company announced that the FDA approved NEXLIZET as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or established ASCVD who require additional lowering of LDL-C. On March 30, 2020, NEXLETOL was commercially available in the U.S. through prescription and on June 4, 2020, NEXLIZET was commercially available in the U.S. through prescription. Net product sales totaled $14.0 million and $40.9 million for the three and nine months ended September 30, 2022, respectively, and $10.9 million and $27.9 million for the three and nine months ended September 30, 2021, respectively.
The Company sells NEXLETOL and NEXLIZET to wholesalers in the U.S. and, in accordance with ASC 606, recognizes revenue at the point in time when the customer is deemed to have obtained control of the product. The customer is deemed to have obtained control of the product at the time of physical receipt of the product at the customers’ distribution facilities, or free on board (“FOB”) destination, the terms of which are designated in the contract.
Product sales are recorded at the net selling price, which includes estimates of variable consideration for which reserves are established for (a) rebates and chargebacks, (b) co-pay assistance programs, (c) distribution fees, (d) product returns, and (e) other discounts. Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as current contractual and statutory requirements, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company's best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contract. The amount of variable consideration may be constrained and is included
10
in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Given the early stage of the Company’s commercial operations it has provided constraint of its variable consideration due to its potential consumption trends. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results in the future vary from estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.
Liabilities for co-pay assistance, expected product returns, rebates, and distributor fees are classified as “Other accrued liabilities” in the condensed balance sheets. Discounts, such as prompt pay discounts, and chargebacks are recorded as a reduction to trade accounts receivable in the condensed balance sheets.
Forms of Variable Consideration
Rebates and Chargebacks: The Company estimates reductions to product sales for Public Health Service Institutions, such as Medicaid, Medicare and Veterans' Administration ("VA") programs, as well as certain other qualifying federal and state government programs, and other group purchasing organizations. The Company estimates these reductions based upon the Company's contracts with government agencies and other organizations, statutorily defined discounts and estimated payor mix. These organizations purchase directly from the Company's wholesalers at a discount and the wholesalers charge the Company back the difference between the wholesaler price and the discounted price. The Company's liability for Medicaid rebates consists of estimates for claims that a state will make for a current quarter. The Company's reserve for this discounted pricing is based on expected sales to qualified healthcare providers and the chargebacks that customers have already claimed.
Co-pay assistance: Eligible patients who have commercial insurance may receive assistance from the Company to reduce the patient's out of pocket costs. The Company will buy down the difference between the amount of the eligible patient's co-pay when the drug is purchased at the pharmacy at a determined price. Liabilities for co-pay assistance are calculated by actual program participation from third-party administrators.
Distribution Fees: The Company has written contracts with its customers that include terms for distribution fees and costs for inventory management. The Company estimates and records distribution fees due to its customers based on gross sales.
Product Returns: The Company generally offers a right of return based on the product’s expiration date and certain spoilage and damaged instances. The Company estimates the amount of product sales that may be returned and records the estimate as a reduction of product sales in the period the related product sales is recognized. The Company’s estimates for expected returns are based primarily on an ongoing analysis of sales information and visibility into the inventory remaining in the distribution channel.
Discounts: The Company provides product discounts, such as prompt pay discounts, to its customers. The Company estimates cash discounts based on terms in negotiated contracts and the Company’s expectations regarding future payment patterns.
Inventories
Inventories are stated at the lower of cost or net realizable value and recognized on a first-in, first-out ("FIFO") method. The Company uses standard cost to determine the cost basis for inventory. Inventory is capitalized based on when future economic benefit is expected to be realized. The Company began capitalizing inventory upon receiving FDA approval for NEXLETOL and NEXLIZET on February 21, 2020 and February 26, 2020, respectively. Prior to the FDA approval of NEXLETOL and NEXLIZET, expenses associated with the manufacturing of the Company's products were recorded as research and development expense.
The Company analyzes its inventory levels on a periodic basis to determine if any inventory is at risk for expiration prior to sale or has a cost basis that is greater than its estimated future net realizable value. Any adjustments are recognized through cost of goods sold in the period in which they are incurred.
Recently Implemented Accounting Pronouncements
There have been no other material changes to the significant accounting policies previously disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021.
11
3. Collaborations with Third Parties
DSE Agreement Terms
On January 2, 2019, the Company entered into a license and collaboration agreement with DSE, which was furthered amended on June 18, 2020. Pursuant to the amended agreement, the Company granted DSE exclusive commercialization rights to bempedoic acid and the bempedoic acid / ezetimibe combination tablet in the European Economic Area, Turkey, and Switzerland (“DSE Territory”). DSE will be responsible for commercialization in the DSE Territory. DSE's designated affiliate in Turkey will be solely responsible, at its sole cost and expense, for all regulatory matters relating to such products in Turkey, including obtaining regulatory approval for such products in Turkey. The Company remains responsible for clinical development, regulatory and manufacturing activities for the licensed products globally, including in the DSE Territory outside of Turkey.
Pursuant to the agreement, the Company received upfront cash of $150.0 million in 2019 and a $150.0 million cash milestone payment in 2020 following the completion of the NUSTENDI Marketing Authorisation Applications ("MAA"). The Company is responsible for supplying DSE with certain manufacturing supply of the API or bulk tablets. The Company is also eligible to receive a substantial additional regulatory milestone payment upon the grant of the marketing authorisation in the European Union for the CV risk reduction label, depending on the range of relative risk reduction in the CLEAR Outcomes study. In addition, the Company is eligible to receive additional sales milestone payments related to total net sales achievements for DSE in the DSE Territory. Finally, the Company will receive tiered fifteen percent (15%) to twenty-five percent (25%) royalties on net DSE Territory sales.
The agreement calls for both parties to participate in a Joint Collaboration Committee (the “DSE JCC”). The DSE JCC is comprised of executive management from each company and the Company will lead in all aspects related to development and DSE will lead in all aspects related to commercialization in the DSE Territory.
Collaboration Revenue
In the three and nine months ended September 30, 2022, the Company recognized collaboration revenue of approximately $4.4 million and $14.7 million, respectively, and in the three and nine months ended September 30, 2021, the Company recognized collaboration revenue of $3.3 million and $6.9 million, respectively, related to royalty revenue from DSE from the sales of NILEMDO and NUSTENDI as well as the sales of bulk tablets to DSE pursuant to the supply agreement that was executed with DSE.
All remaining future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained following the concepts of ASC 606 due to the fact that such amounts hinge on development activities, regulatory approvals and sales-based milestones. Additionally, the Company expects that any consideration related to sales-based milestones will be recognized when the subsequent sales occur.
Otsuka Agreement Terms
On April 17, 2020, the Company entered into a license and collaboration agreement (the "Otsuka Agreement") with Otsuka. Pursuant to the Otsuka Agreement, the Company granted Otsuka exclusive development and commercialization rights to NEXLETOL and NEXLIZET in Japan. Otsuka will be responsible for all development, regulatory, and commercialization activities in Japan. In addition, Otsuka will fund all clinical development costs associated with the program in Japan.
Pursuant to the agreement, the consideration consists of a $60.0 million upfront cash payment and the Company will be eligible to receive additional payments of up to $450.0 million if certain regulatory and commercial milestones are achieved by Otsuka. The potential future milestone payments include up to $20.0 million upon first JNDA submissions in the Otsuka Territory, up to $70.0 million upon the first NHI Price Listing for NEXLETOL in the Otsuka Territory, and up to $50.0 million upon the achievement of the primary major adverse cardiovascular events (“MACE”) in the CLEAR Outcomes study and the CV risk reduction rate on the U.S. label, depending on the range of relative risk reduction in the CLEAR Outcomes study. In addition, the Company is eligible to receive additional sales milestone payments up to $310.0 million related to total net sales achievements for Otsuka in Japan. Finally, the Company will receive tiered fifteen percent (15%) to thirty percent (30%) royalties on net sales in Japan.
12
Collaboration Revenue
The Company considered the guidance under ASC 606 and concluded that the agreement was in the scope of ASC 606. In the three and nine months ended September 30, 2022, the Company recognized $0.4 million of collaboration revenue related to sales of bulk tablets to Otsuka pursuant to the supply agreement that was executed with Otsuka. The Company did not have any collaboration revenue from the Otsuka Agreement during the three and nine months ended September 30, 2021.
All future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained following the concepts of ASC 606 due to the fact that such amounts hinge on development activities, regulatory approvals and sales-based milestones. Additionally, the Company expects that any consideration related to royalties and sales-based milestones will be recognized when the subsequent sales occur.
The Company has not yet recognized any revenue for milestone payments as the related regulatory and commercial milestones have not yet been achieved.
DS Agreement Terms
In April 2021, the Company entered into a license and collaboration agreement with Daiichi Sankyo Co. Ltd (the "DS Agreement"). Pursuant to the DS Agreement, the Company granted DS exclusive rights to develop and commercialize bempedoic acid and the bempedoic acid / ezetimibe combination tablet in South Korea, Taiwan, Hong Kong, Thailand, Vietnam, Brazil, Macao, Cambodia and Myanmar (collectively the "DS Territory"). The agreement allows for potential expansion across geographies including Saudi Arabia, Kuwait, Oman, UAE, Qatar, Bahrain, Yemen, Colombia and other Latin American countries. Except for certain development activities in South Korea and Taiwan, DS will be responsible for development and commercialization in these territories. In addition, DS will fund all development costs associated with the program in the DS Territory. Pursuant to the agreement, the consideration consists of a $30.0 million upfront cash payment that is non-refundable, non-reimbursable and non-creditable. The Company also will be eligible to receive additional one-time payments of up to $175.0 million if certain commercial milestones are achieved by DS. Also, the Company will receive tiered royalties of five percent (5%) to twenty percent (20%) of net sales in the DS Territory.

Collaboration Revenue
The Company considered the guidance under ASC 606 and concluded that the agreement was in the scope of ASC 606. The Company concluded that the upfront payment of $30.0 million should be included in the transaction price and related to the following performance obligations under the agreement: 1) the license to the Company’s intellectual property and 2) the obligation to provide ongoing development activities. The Company used the adjusted market assessment approach in determining the standalone selling price of the Company’s intellectual property and the expected cost plus margin approach in determining the standalone selling price of the Company’s obligation to provide ongoing development activities. Accordingly, for the three and nine months ended September 30, 2021, the Company recognized $0.2 million and $28.3 million of collaboration revenue related to the $30.0 million upfront payment, consisting of $28.0 million related to the performance obligations for the license to the Company’s intellectual property and $0.3 million related to ongoing regulatory and development activities conducted during the period ended September 30, 2021. During the year ended December 31, 2021, the Company recognized $28.5 million of collaboration revenue related to the $30.0 million upfront payment. The $28.5 million relates to the performance obligations for the license to the Company’s intellectual property and a portion of ongoing regulatory and development activities conducted during the year ended December 31, 2021, in the amounts of $28.0 million and $0.5 million, respectively. For the three and nine months ended September 30, 2022, the Company recognized $0.2 million and $0.6 million, respectively, of collaboration revenue related to the ongoing regulatory and development activities. The remaining $0.9 million of the upfront payment was deferred as of September 30, 2022 due to an on-going performance obligation related to the developmental activities in South Korea and Taiwan. This deferred revenue will be recognized ratably over the period leading up to the completion of these developmental activities.
All future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained following the concepts of ASC 606 due to the fact that such amounts hinge on development activities, regulatory approvals and sales-based milestones. Additionally, the Company expects that any consideration related to royalties and sales-based milestones will be recognized when the subsequent sales occur.
13
4. Inventories, net
Inventories, net consist of the following (in thousands):
September 30, 2022December 31, 2021
Raw materials$24,785 $31,850 
Work in process2,874 663 
Finished goods1,886 1,881 
$29,545 $34,394 
5. Commitments and Contingencies
On January 12, 2016, a purported stockholder of the Company filed a putative class action lawsuit in the United States District Court for the Eastern District of Michigan, against the Company and Tim Mayleben, captioned Kevin L. Dougherty v. Esperion Therapeutics, Inc., et al. (No. 16-cv-10089). The lawsuit alleges that the Company and Mr. Mayleben violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5 by allegedly failing to disclose in an August 17, 2015, public statement that the FDA would require a cardiovascular outcomes trial before approving the Company’s lead product candidate. The lawsuit seeks, among other things, compensatory damages in connection with an allegedly inflated stock price between August 18, 2015, and September 28, 2015, as well as attorneys’ fees and costs. On March 12, 2021, the parties agreed to a settlement in principle of the securities class action, and on April 26, 2021, the parties entered into a stipulation of settlement to resolve all legal claims, in which defendants expressly deny that they have committed any act or omission giving rise to any liability under Section 10(b) of the Securities Exchange Act of 1934. Under the terms of the stipulation of settlement, which the court approved on August 24, 2021, the Company and certain of the Company's insurance carriers caused a payment of $18.25 million to be made to the plaintiff class. As a result of this settlement agreement, the Company recorded a loss on settlement of $13.25 million during the three months ended March 31, 2021 in selling, general, and administrative expenses on the statements of operations and comprehensive loss, which represents the litigation settlement of $18.25 million offset by $5.0 million in insurance claim proceeds from our insurance carriers.

There have been no material changes to the Company’s contractual obligations and commitments and contingencies outside the ordinary course of business from those previously disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021.
6. Investments
The following table summarizes the Company’s cash equivalents, restricted cash, and short-term investments (in thousands):
September 30, 2022
Amortized
Cost		Gross Unrealized GainsGross Unrealized LossesEstimated
Fair
Value
Cash equivalents and restricted cash:
Money market funds$148,850 $— $— $148,850 
Certificates of deposit400 — — 400 
Short-term investments:
U.S. treasury notes30,035 — (93)29,942 
Total$179,285 $— $(93)$179,192 
14
December 31, 2021
Amortized
Cost		Gross Unrealized GainsGross Unrealized LossesEstimated
Fair
Value
Cash equivalents:
Money market funds$188,734 $— $— $188,734 
Certificates of deposit400 — — 400 
Short-term investments:
U.S. treasury notes50,472 — (31)50,441 
Total$239,606 $— $(31)$239,575 
During the three and nine months ended September 30, 2022, other income, net in the statements of operations includes interest income on investments of $0.8 million and $1.5 million, respectively. During the three and nine months ended September 30, 2021, other income, net in the statements of operations includes interest income on investments of less than $0.1 million and less than $0.1 million, respectively. During the three and nine months ended September 30, 2022, other income, net in the statements of operations includes amortization of premiums and discounts on investments of $0.2 million and $0.6 million, respectively. There was no amortization of premiums and discounts on investments for the three and nine months ended September 30, 2021.
There were no unrealized gains or losses on investments reclassified from accumulated other comprehensive income (loss) to other income in the statements of operations during the three and nine months ended September 30, 2022 and 2021.
In the three and nine months ended September 30, 2022 and 2021, there were no allowances for credit losses and all unrealized gains (losses) for available-for-sale securities were recognized in accumulated other comprehensive income (loss). As of September 30, 2022, the Company had $0.2 million of accrued interest receivables.
7. Fair Value Measurements
The Company follows accounting guidance that emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Fair value is defined as “the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.” Fair value measurements are defined on a three level hierarchy:
Level 1 inputs:    Quoted prices for identical assets or liabilities in active markets;
Level 2 inputs:Observable inputs other than Level 1 prices, such as quoted market prices for similar assets or liabilities or other inputs that are observable or can be corroborated by market data; and
Level 3 inputs:Unobservable inputs that are supported by little or no market activity and require the reporting entity to develop assumptions that market participants would use when pricing the asset or liability.
15
The following table presents the Company’s financial assets that have been measured at fair value on a recurring basis (in thousands):
DescriptionTotalLevel 1Level 2Level 3
September 30, 2022
Cash and cash equivalents:
Money market funds$148,850 $148,850 $— $— 
Certificates of deposit400 400 — — 
Short-term investments:
U.S. treasury notes29,942 29,942 — — 
Total assets at fair value$179,192 $179,192 $— $— 
December 31, 2021
Cash and cash equivalents:
Money market funds$188,734 $188,734 $— $— 
Certificates of deposit400 400 — — 
Short-term investments:
U.S. treasury notes50,441 50,441 — — 
Total assets at fair value$239,575 $239,575 $— $— 
There were no transfers between Levels 1, 2 or 3 during the three and nine months ended September 30, 2022 and 2021.
8. Liability Related to the Revenue Interest Purchase Agreement
On June 26, 2019, the Company entered into a Revenue Interest Purchase Agreement ("RIPA") with Oberland, as agent for purchasers party thereto (the “Purchasers”), and the Purchasers named therein, to obtain financing in respect to the commercialization and further development of bempedoic acid and the bempedoic acid / ezetimibe combination tablet and other working capital needs. Pursuant to the RIPA, the Company received $125.0 million at closing, less certain issuance costs. The Company was entitled to receive up to approximately $75.0 million in subsequent installments subject to the terms and conditions set forth in the RIPA: (i) $25.0 million upon certain regulatory approval of its product candidates and (ii) $50.0 million, at the Company’s option, upon reaching $100.0 million trailing worldwide six-month net sales any time prior to December 31, 2021 (the “Third Payment”). In March 2020, the Company received $25.0 million from Oberland upon receiving regulatory approval of NEXLETOL.
As consideration for such payments, the Purchasers will have a right to receive certain revenue interests (the “Revenue Interests”) from the Company based upon net sales of the Company’s certain products, once approved, which will be tiered payments initially ranging from 2.5% to 7.5% of the Company’s net sales in the covered territory (the “Covered Territory”); provided that (a) if annual net sales equal or exceed $350.0 million by December 31, 2021 (the “Sales Threshold”), the initially tiered revenue interest rate will be decreased to a single rate of 2.5% of the Company’s net sales in the Covered Territory, beginning on January 1, 2022, and (b) if annual net sales equal or exceed the Sales Threshold and if the Purchasers receive 100% of their invested capital by December 31, 2024, the revenue interest rate will be decreased to a single rate of 0.4% of the Company’s net sales in the Covered Territory beginning on January 1, 2025. If the Third Payment is drawn down by the Company, the applicable royalty rates will increase by one-third. The Covered Territory is the United States, but is subject to expand to include the world-wide net sales if the Company’s annual U.S. net sales are less than $350.0 million for the year ended December 31, 2021. The U.S. net sales milestone thresholds are not to be taken as financial guidance. The Purchasers’ rights to receive the Revenue Interests shall terminate on the date on which the Purchasers have received Revenue Interests payments of 195% of the then aggregate purchase price (the “Cumulative Purchaser Payments”) paid to the Company, unless the RIPA is terminated earlier.

Under the RIPA, the Company has an option (the “Call Option”) to terminate the RIPA and repurchase future Revenue Interests at any time upon advance written notice. Additionally, the Purchasers have an option (the “Put Option”) to terminate the RIPA and to require the Company to repurchase future Revenue Interests upon enumerated events such as a bankruptcy event, an uncured material breach, a material adverse effect or a change of control. If the Put Option is exercised prior to the first anniversary of the closing date by the Purchasers (except pursuant to a change of control), the required repurchase price will be 120% of the Cumulative Purchaser Payments (minus all payments Company has made to the Purchasers in connection with the Revenue Interests). In all other cases, if the Put Option or the Call Option are exercised, the required repurchase price
16
will be 175% of the Cumulative Purchaser Payments (minus all payments Company has made to the Purchasers in connection with the Revenue Interests), if such option is exercised prior to the third anniversary of the closing date, and 195% of the Cumulative Purchaser Payments (minus all payments Company has made to the Purchasers in connection with the Revenue Interests), if such option is exercised thereafter.
In addition, the RIPA contains various representations and warranties, information rights, non-financial covenants, indemnification obligations and other provisions that are customary for a transaction of this nature.

RIPA Amendments

On April 26, 2021, the Company entered into Amendment No. 2 (the “RIPA Amendment”) to the RIPA with Oberland, as agent for the purchaser parties thereto. Pursuant to the RIPA Amendment, Oberland waived the original trailing six-month world-wide net sales condition to the third installment payment under the RIPA and released the final $50 million payment payable to the Company under the terms of the RIPA. The Company and Oberland also agreed to amend additional terms of the RIPA such that the purchasers will have a right to receive certain revenue interests (the “Revenue Interests”) from the Company based on net sales of the Company’s certain products, once approved, which will be tiered payments ranging from 3.33% to 10% (the “Third Payment Applicable Percentage”) of the Company’s net sales in the covered territory (the “Covered Territory”); provided that (a) prior to December 31, 2024, with respect to each country defined in the Daiichi Territory, if the percentage of net sales that Company receives from Daiichi (the “Receivables Percentage”) is less than the Third Payment Applicable Percentage, then the Revenue Interest for such country payable to the purchasers will be equal to the Receivables Percentages, (b) if annual net sales equal or exceed $350 million and if the Purchasers receive 100% of their invested capital ("Cumulative Purchaser Payments") by December 31, 2024, the revenue interest rate will be decreased to a single rate of 3.33% of the Company’s net sales in the Covered Territory for all subsequent calendar quarters and (c) if the Purchasers receive Revenue Interest payments less than 100% of Cumulative Purchaser Payments by December 31, 2024, the Third Payment Applicable Percentage will be increased to a single rate of the Company’s net sales that would have provided 100% of Cumulative Purchaser Payments had such rate applied from the initial funding by the Purchasers. The Covered Territory was originally the United States, but has been expanded to worldwide for all calendar years beginning on or after January 1, 2022.

Under the RIPA Amendment, the Company has an option (the “Call Option”) to terminate the RIPA and repurchase future Revenue Interests at any time upon advance written notice. Additionally, the Purchasers have an option (the “Put Option”) to terminate the RIPA and to require the Company to repurchase future Revenue Interests upon enumerated events such as a bankruptcy event, an uncured material breach, a material adverse effect or a change of control. If the Put Option or the Call Option are exercised, the required repurchase price will be 200% of the Cumulative Purchaser Payments (minus all payments Company has made to the Purchasers in connection with the Revenue Interests), if such option is exercised prior to the third anniversary of the closing date, and 225% of the Cumulative Purchaser Payments (minus all payments Company has made to the Purchasers in connection with the Revenue Interests), if such option is exercised thereafter.

In accordance with the guidance in ASC 470‑50, “Debt—Modifications and Extinguishments,” the RIPA Amendment was accounted for as a debt modification. The amendment resulted in a $0.1 million loss on modification of debt, consisting of third-party fees associated with the transaction, which is included in selling, general, and administrative expenses in the statements of operations for the nine months ended September 30, 2021.

On May 16, 2021, the Company entered into an Amendment to the Security Agreement and Waiver ("Amendment and Waiver") with the same parties to the Security Agreement, by and among the Company, Eiger Partners II LP (the "Purchaser") and Eiger III SA LLC (the "Purchaser Agent"), dated as of June 26, 2019 (the "Security Agreement"). Pursuant to the Amendment and Waiver, if (i) the net revenue from sales of NEXLETOL and NEXLIZET and certain other products in the United States (as reported in the Company’s financial statements as “product sales, net” in accordance with GAAP and excluding, for the avoidance of doubt, upfront or milestone payments and other collaboration revenue) (the “Specified Net Revenue”) for the calendar quarter ended September 30, 2021 does not exceed $15.0 million, or (ii) the Specified Net Revenue for any calendar quarter ending after September 30, 2021 does not exceed $15.0 million, then the Company shall deposit $50.0 million in a deposit account that is subject to a block account control agreement in favor of the Purchase Agent, no later than the earlier of (x) the date the Specified Net Revenue for such calendar quarter has been determined and (y) 45 days after the last day of such calendar quarter. Since the Specified Net Revenue for the calendar quarter ended September 30, 2021 did not exceed $15.0 million, the Company deposited $50.0 million in a deposit account that is subject to a block account control agreement, which is classified as restricted cash on the condensed balance sheets. The Purchaser Agent shall have sole dominion and control over all funds deposited in the deposited account and such funds may be withdrawn therefrom only with the consent of the Purchaser Agent. Upon the occurrence and during the continuance of a Put Option Event, the Purchaser Agent shall have the right to apply amounts held in the deposit account in payment of certain secured obligations in the manner provided for in the Security Agreement. The Amendment and Wavier does not substitute, replace or release the Pledgors from any other obligations under the RIPA or Security Agreement.

17
In connection with the arrangement, as of September 30, 2022, the Company has recorded a liability, referred to as the “Revenue interest liability” in the condensed balance sheets, of $284.7 million, net of $0.4 million of capitalized issuance costs in connection with the RIPA, which will be amortized to interest expense over the estimated term of the RIPA. The Company imputes interest expense associated with this liability using the effective interest rate method. The effective interest rate is calculated based on the rate that would enable the debt to be repaid in full over the anticipated life of the arrangement. The interest rate on this liability may vary during the term of the agreement depending on a number of factors, including the level of forecasted net sales. The Company evaluates the interest rate quarterly based on its current net sales forecasts utilizing the prospective method.

A significant increase or decrease in net sales will materially impact the revenue interest liability, interest expense and the time period for repayment. The Company recorded approximately $11.1 million and $33.3 million in interest expense related to this arrangement for the three and nine months ended September 30, 2022, respectively, and approximately $10.4 million and $23.3 million in interest expense related to this arrangement for the three and nine months ended September 30, 2021, respectively.
The repayment of the RIPA to Oberland does not have a fixed repayment schedule, rather it will be completely repaid and extinguished when the Company has repaid 200% of the aggregate purchase price if repaid prior to the third anniversary of the closing date, and 225% of the Cumulative Purchaser Payments thereafter, unless the RIPA is terminated earlier. Since there is not a fixed repayment schedule, the Company does not project its future repayments by year. Each period, the Company estimates the future expected sales of its products in the covered territory and determines the effective annual imputed interest rate, which updates and changes the timing of the Company’s payments. Under the terms of the agreement, every $100 million of net sales generated, less than or equal to $250 million in an annual aggregate year, would result in a repayment obligation of approximately $10.0 million or 10.0% at the stated repayment rate in the first year. Annual net sales for a calendar year exceeding $250 million would result in a repayment obligation of approximately $3.3 million or 3.3% for every $100 million of sales above the threshold. If the Company would have equaled or exceeded $350 million of sales in the U.S. in 2021, then the repayment amount would have dropped to $3.3 million for every $100 million of net sales starting in 2022. As U.S. net sales were less than $350 million for the year ended December 31, 2021, the Covered Territory was expanded to include worldwide sales beginning in 2022. The Company’s repayments of the RIPA are directly tied to the growth of its net sales, and as the Company’s net sales grow, the Company expects the related repayments of the RIPA to grow as well. The Company currently expects to repay $19.6 million in the next twelve months.
The effective annual imputed interest rate is 15.8% as of September 30, 2022. The Company incurred $0.6 million of issuance costs in connection with the RIPA, which will be amortized to interest expense over the estimated term of the RIPA. Payments made to Oberland as a result of the Company’s net sales will reduce the revenue interest liability.
The following table summarizes the revenue interest liability activity during the nine months ended September 30, 2022:
(in thousands)
Total revenue interest liability at December 31, 2021$257,039 
Interest expense recognized33,323 
Revenue Interests payments(5,678)
Total revenue interest liability at September 30, 2022$284,684 

9. Convertible Notes
In November 2020, the Company issued $280.0 million aggregate principal amount of 4.0% senior subordinated convertible notes due November 2025. The net proceeds the Company received from the offering was approximately $271.1 million, after deducting the initial purchasers’ discounts and commissions and offering expenses payable by the Company (the "Convertible Notes"). The Company used approximately $46.0 million of the net proceeds from the offering of the notes to pay the cost of the Capped Call (as defined below) and $55.0 million of the net proceeds from the offering of the initial notes to finance the Prepaid Forward (as defined below). The Convertible Notes are the Company's senior unsecured obligations and mature on November 15, 2025 (the “Maturity Date”), unless earlier repurchased or converted into shares of common stock under certain circumstances described below. The Convertible Notes are convertible into shares of the Company’s common stock, can be repurchased for cash, or a combination thereof, at the Company’s election, at an initial conversion rate of 30.2151 shares of common stock per $1,000 principal amount of the Convertible Notes, which is equivalent to an initial conversion price of approximately $33.096 per share of common stock, subject to adjustment. The Company will pay interest on the Convertible Notes semi-annually in arrears on May 15 and November 15 of each year.
18
The Convertible Notes are general unsecured obligations of the Company that are subordinated in right of payment to indebtedness, obligations and other liabilities under the Company’s RIPA, the revenue interests issued pursuant to such agreement, and any refinancing of the foregoing.
Holders may convert their Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding August 15, 2025 in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ended on March 31, 2021 (and only during such calendar quarter), if the last reported sale price per share of the Company’s common stock, par value $0.001 per share (“common stock”), is greater than or equal to 130% of the conversion price for each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the five business days after any five consecutive trading day period (such five consecutive trading day period, the “measurement period”) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of the Company’s common stock and the conversion rate for the notes on each such trading day; (3) if the Company calls such notes for redemption, any such notes that have been called for redemption may be converted at any time prior to the close of business on the second scheduled trading day immediately preceding the redemption date, but only with respect to the notes called for redemption; and (4) upon the occurrence of specified corporate events, as provided in the Indenture. On or after August 15, 2025, to the close of business on the second scheduled trading day immediately before the maturity date, holders may convert all or any portion of their notes at the applicable conversion rate at any time at the option of the holder regardless of the foregoing conditions.
In addition, following certain corporate events or following issuance of a notice of redemption, the Company will, in certain circumstances, increase the conversion rate for a holder who elects to convert its notes in connection with such a corporate event or to convert its notes called (or deemed called) for redemption during the related redemption period, as the case may be.
The Convertible Notes will be redeemable, in whole or in part, at the Company’s option at any time, and from time to time, on or after November 20, 2023 and before the 41st scheduled trading day immediately before the maturity date, at a cash redemption price equal to 100% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, but only if the last reported sale price per share of the Company’s common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive), including the trading day immediately preceding the date the Company sends the related redemption notice, during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which the Company sends such redemption notice. No sinking fund is provided for the notes. If the Company redeems less than all the outstanding notes, at least $125.0 million aggregate principal amount of notes must be outstanding and not subject to redemption as of the relevant redemption notice date.
If the Company undergoes a “fundamental change” (as defined in the Indenture), holders may require the Company to repurchase their notes for cash all or any portion of their notes at a fundamental change repurchase price equal to 100% of the principal amount of the notes to be repurchased, plus accrued and unpaid interest, to, but excluding, the fundamental change repurchase date. The Indenture includes customary terms and covenants, including certain events of default.
The Company incurred approximately $8.9 million of issuance costs related to the issuance of the Convertible Notes, of which, prior to the adoption of Accounting Standards Update ("ASU") 2020-06 on January 1, 2021, $5.8 million and $3.1 million were allocated and recorded to long-term debt and additional paid-in capital, respectively. The $5.8 million of issuance costs recorded as long-term debt on the condensed balance sheet was to be amortized over the five-year contractual term of the Convertible Notes using the effective interest method.
Prior to the adoption of ASU 2020-06 on January 1, 2021, the $271.1 million of proceeds received from the issuance of the Convertible Notes were allocated between long-term debt (the “liability component”) of $177.6 million and additional paid-in capital (the “equity component”) of $93.5 million. The fair value of the liability component was measured using rates determined for similar debt instruments without a conversion feature. The carrying amount of the equity component, representing the conversion option, was determined by deducting the fair value of the liability component from the aggregate face value of the Convertible Notes and was included in additional paid-in capital in the condensed balance sheet and was not remeasured as long as it did not to meet the conditions for equity classification. The liability component was to be accreted up to the face value of the Convertible Notes of $280.0 million, which resulted in additional non-cash interest expense being recognized through the Maturity Date.
With the adoption of ASU 2020-06 as of January 1, 2021, the Company reports the convertible debt liability at the aggregate principal amount less unamortized issuance costs. This resulted in the reclassification of the $93.5 million of the Company’s convertible notes recognized at December 31, 2020 from additional paid in capital to the convertible debt liability.
19
The portion of interest expense previously recognized for the accretion of the convertible debt liability and the true-up of the amortization of the issuance costs of $1.5 million was recorded as an adjustment to accumulated deficit.
On October 22, 2021, the Company entered into a privately negotiated exchange agreement (the “Exchange Agreement”) with two co-managed holders (the “Holders”) of its Convertible Notes. Under the terms of the Exchange Agreement the Holders agreed to exchange (the “Exchange”) with the Company $15.0 million aggregate principal amount of the Convertible Notes held in the aggregate by them (and accrued interest thereon) for shares of the Company’s common stock. Pursuant to the Exchange Agreement, the number of shares of common stock to be issued by the Company to the Holders upon consummation of the Exchange was determined based upon the volume-weighted-average-price per share of common stock, subject to a floor of $5.62 per share, during the five trading-day averaging period, commencing on the trading day immediately following the date of the Exchange Agreement. The Exchange closed on November 3, 2021, with 1,094,848 shares of the Company's common stock being exchanged.
As of September 30, 2022, the principal amount of convertible notes was $265.0 million, and the unamortized debt discount and issuance costs were $5.5 million, for a net carrying amount of $259.5 million.

The Company recorded $3.1 million and $9.2 million of interest expense during the three and nine months ended September 30, 2022, respectively, and $3.2 million and $9.6 million of interest expense during the three and nine months ended September 30, 2021, respectively, relating to the cash interest on the convertible notes due semi-annually and amortization of the debt issuance costs.

As of September 30, 2022, no Convertible Notes were convertible pursuant to their terms. The estimated fair value of the Convertible Notes was $148.9 million as of September 30, 2022 and $140.3 million as of December 31, 2021. The estimated fair value of the Convertible Notes was determined through consideration of quoted market prices. As of September 30, 2022, the if-converted value of the Convertible Notes did not exceed the principal value of those notes.

Capped Call Transactions
In connection with the offering of the Convertible Notes, the Company entered into privately-negotiated capped call transactions with one of the initial purchasers of the convertible notes or its affiliate and certain other financial institutions. The Company used approximately $46.0 million of the net proceeds from the offering of the Convertible Notes to pay the cost of the capped call transactions. The capped call transactions are expected generally to reduce potential dilution to the Company’s common stock upon any conversion of the Convertible Notes and/or offset any cash payments the Company is required to make in excess of the principal amount of converted notes, as the case may be, in the event that the market value per share of the Company’s common stock, as measured under the terms of the capped call transactions at the time of exercise, is greater than the strike price of the capped call transactions (which initially corresponds to the initial conversion price of the Convertible Notes, and is subject to certain adjustments), with such reduction and/or offset subject to a cap initially equal to approximately $55.16 (which represents a premium of approximately 100% over the last reported sale price of the Company’s common stock on November 11, 2020), subject to certain adjustments. The capped call transactions are separate transactions, entered into by the Company and are not part of the terms of the Convertible Notes.
Given that the transactions meet certain accounting criteria, the convertible note capped call transactions are recorded in stockholders’ equity, and they are not accounted for as derivatives and are not remeasured each reporting period. As of September 30, 2022 and December 31, 2021, the Company had not purchased any shares under the convertible note capped call transactions.
20
Prepaid Forward
In connection with the offering of the Convertible Notes, the Company entered into a prepaid forward stock repurchase transaction (“Prepaid Forward”) with a financial institution (“Forward Counterparty”). Pursuant to the Prepaid Forward, the Company used approximately $55.0 million of the net proceeds from the offering of the Convertible Notes to fund the Prepaid Forward. The aggregate number of shares of the Company’s common stock underlying the Prepaid Forward was approximately 1,994,198. The expiration date for the Prepaid Forward is November 15, 2025, although it may be settled earlier in whole or in part. Upon settlement of the Prepaid Forward, at expiration or upon any early settlement, the Forward Counterparty will deliver to the Company the number of shares of common stock underlying the Prepaid Forward or the portion thereof being settled early. The shares purchased under the Prepaid Forward are treated as treasury stock and not outstanding for purposes of the calculation of basic and diluted earnings per share, but will remain outstanding for corporate law purposes, including for purposes of any future stockholders’ votes, until the Forward Counterparty delivers the shares underlying the Prepaid Forward to the Company. As of September 30, 2022, 71,174 shares had been delivered to the Company. The Company’s Prepaid Forward hedge transaction exposes the Company to credit risk to the extent that its counterparty may be unable to meet the terms of the transaction. The Company mitigates this risk by limiting its counterparty to a major financial institution.
10. Other Accrued Liabilities
Other accrued liabilities consist of the following (in thousands):
September 30,
2022		December 31,
2021
Accrued compensation$8,512 $8,809 
Accrued variable consideration20,525 16,192 
Accrued professional fees2,344 3,917 
Accrued interest on convertible notes3,975 1,325 
Accrued other39 167 
Total other accrued liabilities$35,395 $30,410 
11. Stock Compensation
2022 Stock Option and Incentive Plan
In May 2022, the Company's stockholders approved the 2022 Stock Option and Incentive Plan (the "2022 Plan"). The number of shares of common stock available for awards under the 2022 Plan was set to 4,400,000, with any shares underlying awards that are forfeited, canceled, held back upon exercise of an option or settlement of an award to cover the exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied without the issuance or shares, or otherwise terminated (other than by exercise) under the 2022 Plan may be added back to the shares of common stock available for issuance under the 2022 Plan. The 2022 Plan provides for the award of stock options (both incentive and non-qualified options), stock appreciation rights, restricted stock, restricted stock units, unrestricted stock, cash-based awards, and dividend equivalent rights. Following the approval of the 2022 Plan, no further awards will be issued under the Company’s 2013 Stock Option and Incentive Plan (the “2013 Plan”).

Employee Stock Purchase Plan
In April 2020, the board of directors approved the Esperion Therapeutics, Inc. 2020 Employee Stock Purchase Plan (the "ESPP") which was approved by the Company's shareholders on May 28, 2020. The ESPP allows eligible employees to authorize payroll deductions of up to 10% of their base salary or wages up to $25,000 annually to be applied toward the purchase of shares of the Company's common stock on the last trading day of the offering period. Participating employees will purchase shares of the Company's common stock at a discount of up to 15% on the lesser of the closing price of the Company's common stock on the NASDAQ Global Select Market (i) on the first trading day of the offering period or (ii) the last day of any offering period. Offering periods under the ESPP will generally be in six months increments, commencing on September 1 and March 1 of each calendar year with the administrator having the right to establish different offering periods. In the three and nine months ended September 30, 2022, the Company recognized approximately $0.1 million and $0.3 million of stock compensation expense related to the ESPP, respectively. In the three and nine months ended September 30, 2021, the Company recognized approximately $0.2 million and $0.6 million of stock compensation expense related to the ESPP, respectively. As of September 30, 2022, there have been 339,422 shares issued and 485,578 shares reserved for future issuance under the ESPP.
21
Stock Options
The following table summarizes the activity relating to the Company’s options to purchase common stock for the nine months ended September 30, 2022:
Number of OptionsWeighted-Average Exercise Price Per ShareWeighted-Average Remaining Contractual Term (Years)Aggregate Intrinsic Value
(in thousands)
Outstanding at December 31, 20213,214,537 $38.38 4.18$— 
Granted1,255,600 $4.78 
Forfeited or expired(685,182)$33.01 
Exercised— $— 
Outstanding at September 30, 20223,784,955 $28.20 5.18$2,098 
Vested and expected to vest at September 30, 20223,784,955 $28.20 5.18$2,098 
Exercisable at September 30, 20222,421,198 $38.23 2.91$163 
Stock-based compensation related to stock options was $1.4 million and $4.3 million for the three and nine months ended September 30, 2022, respectively, including $0.2 million and $0.4 million that were capitalized into inventory, and $2.8 million and $12.7 million for the three and nine months ended September 30, 2021, respectively, including $0.8 million and $1.3 million that were capitalized into inventory. As of September 30, 2022, there was $8.9 million of unrecognized stock-based compensation expense related to unvested options, which will be recognized over a weighted-average period of 2.5 years.
Performance-Based Stock Options ("PBSOs")
In 2021, the Company granted PBSOs from the 2013 Plan that vest upon various performance-based milestones as set forth in the individual grant agreements, such as achievement of predetermined clinical or regulatory outcomes. The actual number of units (if any) received under these awards will depend on continued employment and actual performance over the performance period. Each quarter, the Company updates their assessment of the probability that the performance milestone will be achieved. The Company amortizes the fair value of the PBSOs based on the expected performance period to achieve the performance milestone. The Company expects the performance criteria to be met.
In 2022, the Company granted PBSOs from the 2022 Plan that vest upon various performance-based milestones as set forth in the individual grant agreements, such as achievement of predetermined clinical or regulatory outcomes. The actual number of units (if any) received under these awards will depend on continued employment and actual performance over the performance period. Each quarter, the Company updates their assessment of the probability that the performance milestone will be achieved. The Company amortizes the fair value of the PBSOs based on the expected performance period to achieve the performance milestone. The Company expects the performance criteria to be met.

The following table summarizes the activity relating to the Company’s PBSOs for the nine months ended September 30, 2022:
Number of OptionsWeighted-Average Exercise Price Per ShareWeighted-Average Remaining Contractual Term (Years)Aggregate Intrinsic Value
(in thousands)
Outstanding at December 31, 2021122,700 $8.94 9.83$— 
Granted403,000 $6.20 
Forfeited or expired(26,500)$8.94 
Exercised— $— 
Outstanding at September 30, 2022499,200 $6.73 9.58$202 
Vested and expected to vest at September 30, 2022499,200 $6.73 9.58$202 
Exercisable at September 30, 2022— $— 0$— 
22

Stock-based compensation related to PBSOs was $0.3 million and $0.5 million for the three and nine months ended September 30, 2022, respectively. As of September 30, 2022, there was approximately $1.8 million of unrecognized stock-based compensation expense related to unvested PBSOs, which will be recognized over a weighted-average period of approximately 1.6 years.
Restricted Stock Units (or RSUs)
The following table summarizes the activity relating to the Company’s RSUs for the nine months ended September 30, 2022:
Number of
RSUs		Weighted-Average
Fair Value Per
Share
Outstanding and unvested December 31, 2021698,704 $28.09 
Granted1,644,009 $4.71 
Forfeited(340,220)$12.98 
Vested(347,893)$20.77 
Outstanding and unvested September 30, 20221,654,600 $9.51 
Stock-based compensation related to RSUs was approximately $1.5 million and $5.1 million for the three and nine months ended September 30, 2022, respectively, including $0.2 million and $0.5 million that was capitalized into inventory, and approximately $2.4 million and $6.4 million for the three and nine months ended September 30, 2021, respectively, including $0.4 million and $0.6 million that was capitalized into inventory. As of September 30, 2022, there was $14.7 million of unrecognized stock-based compensation expense related to unvested RSUs, which will be recognized over a weighted-average period of 2.8 years.
Performance-based Restricted Stock Units ("PBRSUs")
In 2021, the Company granted PBRSUs from the 2013 Plan that vest upon various performance-based milestones as set forth in the individual grant agreements, such as achievement of predetermined milestones based on the Company's U.S. net product sales or clinical or regulatory outcomes. The actual number of units (if any) received under these awards will depend on continued employment and actual performance over the performance period. Each quarter, the Company updates their assessment of the probability that the performance milestone will be achieved. The Company amortizes the fair value of the PBRSUs based on the expected performance period to achieve the performance milestone. The fair value of the PBRSUs is based on the quoted market price of the Company's common stock on the date of grant. The Company expects the performance criteria to be met.
The following table summarizes the activity relating to the Company's PBRSUs for the nine months ended September 30, 2022:
Number of
PBRSUs		Weighted-average fair value per share
Outstanding December 31, 2021639,950 $9.90 
Granted— $— 
Forfeited(178,700)$10.95 
Outstanding and unvested September 30, 2022461,250 $9.50 
Stock-based compensation related to the PBRSUs was approximately $0.2 million and $1.3 million for the three and nine months ended September 30, 2022, respectively, including less than $0.1 million and $0.1 million that was capitalized into inventory. Stock-based compensation related to PBRSUs was approximately $0.1 million for the three and nine months ended September 30, 2021. As of September 30, 2022, there was approximately $1.9 million of unrecognized stock-based compensation expense related to unvested PBRSUs, which will be recognized over a weighted-average period of approximately 1.7 years.
23
12. Income Taxes
There was no provision for income taxes for the three and nine months ended September 30, 2022 and 2021, because the Company has incurred annual operating losses since inception. At September 30, 2022, the Company continues to conclude that it is not more likely than not that the Company will realize the benefit of its deferred tax assets due to its history of losses. Accordingly, a full valuation allowance has been applied against the net deferred tax assets.
13. Stockholders' Deficit

ATM Offering

On August 3, 2021, the Company filed an automatically effective registration statement on Form S-3ASR (the “Registration Statement”) with the SEC which registered the offering, issuance and sale of an unspecified amount of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof. The Company simultaneously entered into an open market sale agreement with Jefferies LLC, as sales agent, to provide for the issuance and sale by the Company of up to $250 million of common stock from time to time in “at-the-market” offerings under the Registration Statement and related prospectus filed with the Registration Statement (the “ATM Program”). During the three and nine months ended September 30, 2021, the Company issued 363,061 shares of common stock resulting in net proceeds of approximately $4.2 million after deducting $0.5 million of underwriting discounts and commissions and other expenses, pursuant to the ATM Program.

On April 15, 2022, the Company filed a new registration statement on Form S-3 to replace its prior automatically effective registration statement on Form S-3ASR filed on August 3, 2021, which registers the offering, issuance and sale of up to $239 million of common stock from time to time in “at-the-market” offerings under the Registration Statement and related prospectus filed with the Registration Statement (the “ATM Program”). The Company may continue to use an ATM Program to address potential short-term or long-term funding requirements that may arise. Such program will continue to be subject to the volatility of the price of the Company's common stock and general market conditions. During the three and nine month periods ended September 30, 2022, the Company issued 6,958,525 and 10,311,525 shares of common stock, respectively, resulting in net proceeds of approximately $48.6 million and $68.8 million after deducting $1.6 million and $2.4 million of underwriting discounts and commissions and other expenses, respectively, pursuant to the ATM Program.

Warrants

In connection with an underwriting agreement with H.C. Wainwright & Co., LLC (the "Offering"), entered into on December 2, 2021, the Company issued warrants to purchase 36,964,286 shares of common stock at an exercise price of $9.00. The warrants will terminate on December 7, 2023. The warrants were recorded at fair value of $61.9 million to additional-paid-in-capital in accordance with ASC 815-10 based upon the allocation of the proceeds between the common shares issued with the Offering and the warrants. The Company estimated the fair value of the warrants using a Black-Scholes option-pricing model, which is based, in part, upon subjective assumptions including but not limited to stock price volatility, the expected life of the warrant, the risk-free interest rate and the fair value of the common stock underlying the warrant. The Company estimates the volatility based on its historical volatility that is in line with the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury daily rate for a maturity similar to the expected remaining life of the warrants. The expected remaining life of the warrants is assumed to be equivalent to its remaining contractual term.

As of September 30, 2022 and December 31, 2021, the Company had warrants outstanding that were exercisable for a total of 36,964,286 shares of common stock at a weighted-average exercise price of $9.00 per share.

14. Net Loss Per Common Share
Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common stock equivalents outstanding for the period, including shares that potentially could be dilutive if they were exercised or vested during the period, determined using the treasury-stock method. For purposes of this calculation, warrants for common stock, stock options, PBSOs, unvested RSUs and PBRSUs, shares issuable under the ESPP and shares issuable upon conversion of the convertible notes are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.
24
The shares outstanding at the end of the respective periods presented below were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:
September 30,
20222021
Common shares under option3,784,955 3,703,938 
Common shares under PBSOs499,200 — 
Unvested RSUs1,654,600 879,349 
Unvested PBRSUs461,250 45,300 
Shares issuable related to the ESPP9,237 9,871 
Shares issuable upon conversion of convertible notes8,007,010 8,460,237 
Warrants36,964,286 — 
Total potential dilutive shares51,380,538 13,098,695 
15. Statements of Cash Flows and Restricted Cash

The following table provides a reconciliation of cash and cash equivalents and restricted cash presented on the balance sheets to the same amounts presented on the statements of cash flows on September 30, 2022 and 2021 and December 31, 2021 and 2020 (in thousands):

September 30,
2022		September 30,
2021		December 31,
2021		December 31,
2020
Cash and cash equivalents159,399 $103,672 $208,892 $304,962 
Restricted cash50,000 50,000 50,000 — 
Total cash and cash equivalents and restricted cash shown on the condensed statements of cash flows$209,399 $153,672 $258,892 $304,962 


25
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our condensed financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and our annual report on Form 10-K for the fiscal year ended December 31, 2021 and other filings that we make with the Securities and Exchange Commission.
Forward-Looking Statements
This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). These forward-looking statements are based on our management’s belief and assumptions and on information currently available to management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events, including our clinical development and commercialization plans, or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements, including in relation to the clinical development, commercialization plans, approval of expanded indications for bempedoic acid and the bempedoic acid / ezetimibe combination tablet and expectations regarding future transactions to further improve our balance sheet to be materially different from any future results, performance or achievements, including in relation to the clinical development, commercialization plans, or approval of expanded indications for bempedoic acid and the bempedoic acid / ezetimibe combination tablet, the impact of COVID-19, our corporate workforce reduction and targeted program savings on our business, clinical activities and commercial development plans, expressed or implied by these forward-looking statements.

Forward-looking statements are often identified by the use of words such as, but not limited to, “may,” “will,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue” or the negative of these terms or other similar terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and that could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those referred to or discussed in or incorporated by reference into the section titled “Risk Factors” included in Item 1A of Part II of this Quarterly Report on Form 10-Q. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance.
The forward-looking statements in this report represent our views as of the date of this quarterly report. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.
We use the terms “we,” “us,” “our,” or the "Company” in this report to refer to Esperion Therapeutics, Inc.
Overview
Corporate Overview
We are a pharmaceutical company singularly focused on developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol, or LDL-C. Through commercial execution and advancement of our CLEAR Outcomes trial as well as our pre-clinical pipeline, we continue to evolve into a differentiated, global cardiometabolic biotech. Our team of lipid experts are dedicated to lowering bad cholesterol through the discovery, development and commercialization of innovative medicines and their combinations with established medicines. Our first two products were approved by the U.S. Food and Drug Administration, or FDA, European Medicines Agency, or EMA and Swiss Agency for Therapeutic Products, or Swissmedic, in 2020. Bempedoic acid and the bempedoic acid / ezetimibe combination tablet are oral, once-daily, non-statin, LDL-C lowering medicines for patients with atherosclerotic cardiovascular disease, or ASCVD, or heterozygous familial hypercholesterolemia, or HeFH.
We were incorporated in Delaware in January 2008 and commenced our operations in April 2008. Since our inception, we have focused substantially all of our efforts and financial resources on developing bempedoic acid and the bempedoic acid / ezetimibe combination tablet. In February 2020, the FDA approved NEXLETOL and NEXLIZET. NEXLETOL was commercially available in the U.S. on March 30, 2020 and NEXLIZET was commercially available in the U.S. on June 4, 2020. We have funded our operations to date primarily through proceeds from sales of preferred stock, convertible promissory notes
26
and warrants, public offerings of common stock, the incurrence of indebtedness, through collaborations with third parties and revenue interest purchase agreements, and we have incurred losses in each year since our inception.
We have never been profitable and our net losses were $55.1 million and $178.2 million for the three and nine months ended September 30, 2022, respectively, and $69.4 million and $204.0 million for the three and nine months ended September 30, 2021, respectively. Substantially all of our net losses resulted from costs incurred in connection with research and development programs and selling, general and administrative costs associated with our operations. We expect to incur significant expenses and operating losses for the foreseeable future in connection with our ongoing activities, including, among others:

•commercializing NEXLETOL and NEXLIZET in the U.S; and
•completing the clinical development activities for the CLEAR Outcomes CVOT.
Accordingly, we may need additional financing to support our continuing operations and further the development and commercialization of our products. We may seek to fund our operations and further development activities through collaborations with third parties, strategic alliances, licensing arrangements, permitted debt financings, permitted royalty-based financings, permitted public or private equity offerings or through other sources. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a material adverse effect on our financial condition and our ability to pursue our business strategy or continue operations. We will need to generate significant revenues to achieve profitability, and we may never do so.
Product Overview
NEXLETOL is a first-in-class ATP Citrate Lyase, or ACL, inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Completed Phase 3 studies conducted in more than 3,000 patients, with over 2,000 patients treated with NEXLETOL, demonstrated an average 18 percent placebo corrected LDL-C lowering when used in patients on moderate or high-intensity statins. NEXLETOL was approved by the FDA in February 2020 as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or established ASCVD who require additional lowering of LDL-C.
NEXLIZET contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine. Phase 3 data demonstrated NEXLIZET lowered LDL-C by a mean of 38 percent compared to placebo when added on to maximally tolerated statins. NEXLIZET was approved by the FDA in February 2020 as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or established ASCVD who require additional lowering of LDL-C.
NILEMDO is a first-in-class ACL inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. NILEMDO was approved by the EC in March 2020 for use in adults with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia, as an adjunct to diet in combination with a statin or statin with other lipid-lowering therapies in adult patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or alone or in combination with other lipid-lowering therapies as an adjunct to diet in adult patients who are statin-intolerant, or for whom a statin is contraindicated.
NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine. NUSTENDI was approved by the EC in March 2020 for use in adults with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia, as an adjunct to diet in combination with a statin in adult patients unable to reach LDL-C goals with the maximum tolerated dose of a statin in addition to ezetimibe, alone in patients who are either statin-intolerant or for whom a statin is contraindicated, and are unable to reach LDL-C goals with ezetimibe alone, or as an adjunct to diet in adult patients already being treated with the combination of bempedoic acid and ezetimibe as separate tablets with or without statin.
During the nine months ended September 30, 2022, we incurred $60.2 million in expenses related to our CLEAR Outcomes CVOT and other ongoing clinical studies.
During the nine months ended September 30, 2021, we incurred $47.1 million in expenses related to our CLEAR Outcomes CVOT and other ongoing clinical studies.
27
Ongoing Clinical Studies
Global Cardiovascular Outcomes Trial—CLEAR Outcomes
CLEAR Outcomes is a Phase 3, event driven, randomized, multicenter, double-blind, placebo-controlled clinical study designed to evaluate whether treatment of bempedoic acid reduces the risk of cardiovascular events in patients with statin intolerance who have cardiovascular disease or are at high risk for cardiovascular disease. The primary endpoint of the study is the effect of bempedoic acid on major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or coronary revascularization; also referred to as "four-component MACE"). CLEAR Outcomes is designed to provide 90 percent power to detect an approximately 15 percent relative risk reduction in the primary endpoint in the bempedoic acid treatment group as compared to the placebo group and is expected to complete with a minimum of 1,620 patients experiencing the primary endpoint.
The study over-enrolled with over 14,000 patients with hypercholesterolemia and high cardiovascular disease risk at over 1,200 sites in 32 countries. Eligible patients at high risk (LDL-C >100 mg/dL in primary prevention) for cardiovascular disease or with cardiovascular disease (LDL-C between 100 mg/dL to 190 mg/dL in secondary prevention) and who are only able to tolerate less than the lowest approved daily starting dose of a statin and considered statin adverse, were randomized to receive bempedoic acid 180 mg once-daily or placebo. The expected average baseline LDL-C level in all patients is between 135 mg/dL and 140 mg/dL.
CLEAR Outcomes will conclude once the predetermined number of MACE endpoints occur. We initiated CLEAR Outcomes in December 2016 and completed enrollment in August 2019. The expected average treatment duration will be 3.75 years with a minimum treatment duration of approximately 2.25 years. The study is intended to support our submissions for a CV risk reduction indication in the U.S., Europe and other territories.
On August 2, 2022 we announced that the CLEAR Outcomes study of NEXLETOL accumulated the targeted 1,620 primary major adverse cardiovascular events (MACE-4) (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization). On November 1, 2022, we announced that the CLEAR Outcomes study achieved Last Patient Last Visit in October and that we are continuing to close out the study. We anticipate reporting top-line results from the study in January 2023.

The COVID-19 Pandemic
The full extent to which the ongoing COVID-19 pandemic, or the future outbreak of any other highly infectious or contagious diseases, may impact our business, including our CVOT and commercialization efforts will depend on continuously changing circumstances, which are highly uncertain and cannot be predicted at this time, such as the duration of such pandemic including future waves of infection, the emergence and prevalence of more contagious variants, such as the recent "Omicron" variant and the BA.2 subvariants of the virus, or the global availability and utilization of effective vaccines, the actions taken to contain the pandemic or mitigate its impact, and the direct and indirect economic effects of the pandemic and containment measures, among others. The ongoing fluidity of this situation precludes any prediction as to the full impact of the COVID-19 pandemic but it has had a material adverse effect on our business, financial condition, and results of operations. The ongoing COVID-19 pandemic may also have the effect of heightening the risks to which we are subject, including potential impacts on the progress and time to completion of our ongoing CVOT, the reliance on third parties in our supply chain for materials and manufacturing and delivery of our drugs and drug candidates, our ability to effectively promote and market our approved products, disruptions in health regulatory agencies' operations globally, the volatility of our common stock, our ability to access capital markets, and our ability to successfully commercialize and generate revenue from our approved drugs.

We are continuing to assess the long-term impact of COVID-19 on our business operations in an effort to mitigate interruption to our commercialization of our approved drugs and other business activities and to ensure the safety and well being of our employees, as well as the physicians and patients participating in our CVOT. Because COVID-19 infections have been reported throughout the U.S. and worldwide, and as new strains continue to be identified, certain national, state, and local governmental authorities have issued orders, proclamations, and/or directives aimed at minimizing the spread of COVID-19. Although some of these restrictions were eased or lifted, in response to local surges and new waves of infection, some countries, states, and local governments have reinstituted these restrictions, and additional, more restrictive orders, proclamations, and/or directives may be issued in the future. In response to the COVID-19 pandemic, we have implemented precautionary measures to protect the health and safety of our employees, partners, and patients, including encouraging all employees to work-from-home if able to perform their duties remotely, and requiring adherence to onsite occupancy limits and appropriate safety measures designed to comply with federal, state, and local guidelines.
28
Our ability to successfully launch, commercialize, and generate revenue from NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI has been and may continue to be adversely affected by the economic impact of the ongoing COVID-19 pandemic. Physicians’ offices and other medical institutions had limited access for nonpatients, which included our sales personnel. In addition, social distancing or testing requirements and precautionary measures due to COVID-19 have impacted the ability of our sales personnel to interact in-person with customers. As a result, in many circumstances we have needed to limit our interactions with physicians and payors and adapt our launch strategies and tactics to a virtual model, including developing and deploying various technology-enabled platforms for virtual engagement such as remote detailing, digital and non-personal marketing channels, and social media. These circumstances have affected and may continue to adversely affect the ability of our sales professionals to effectively market our approved drugs to physicians and the rates of uptakes for our approved drugs, which may have a negative impact on our sales and our market penetration. In addition, patient visits with physicians have decreased as a result of COVID-19, due to travel restrictions, social distancing requirements, prioritization of healthcare resources to address the pandemic, and/or fear of exposure to the virus, which we believe has adversely affected and could continue to have an adverse impact on new patient starts and overall patient treatment volume. Market disruption and unemployment caused by the COVID-19 pandemic may lead to delays in obtaining insurance coverage and reimbursement of newly approved products.
We have had to optimize our cost structure in response to the ongoing COVID-19 pandemic and its impact on the conventional healthcare model associated with normal health management practices, such as regular physician office visits, lab tests, and prescription fills. As a result of the impact COVID-19 has had on our business and demand, in October 2021, we announced our plan to align operational and expense structure to better enable future growth for NEXLETOL and NEXLIZET and prioritize our investment in the CLEAR Outcomes trial. This included reducing operational expense across the organization through a corporate workforce reduction of approximately 40% and through targeted program savings. We will focus our commercialization efforts on an optimized blend of focused outreach including a streamlined sales force, directed to targeted cardiologists and primary care physicians, and a suite of digital initiatives designed to increase awareness and utilization of our medicines in appropriate patients. We adjusted our 2021 operating expense guidance and planned 2022 operating expense budget accordingly, including our budgeted production plans. While it is not possible at this time to estimate the entirety of the impact that the ongoing COVID-19 pandemic will have on our business or operations, the continued spread or future waves of COVID-19, measures taken by governments, actions taken to protect employees, and the broad impact of the pandemic on all business activities may materially and adversely affect our preclinical activities, clinical development progress, data and timelines, commercialization efforts including any revenue from sales, supply chain continuity, and general business operations, and our business, prospects, financial condition, and results of operations could be materially harmed as a result.
To date, we have not experienced any interruption of our supply of drug products needed to support our ongoing clinical study and product sales. However, such interruptions may occur due to supply chain issues related to COVID-19, such as the demand for vaccines and potential for manufacturing facilities and materials to be commandeered under the Defense Production Act of 1950, or equivalent foreign legislation, which may make it more difficult to obtain materials or manufacturing capacity at our third-party manufacturers to the products needed for our clinical trials and commercial product, which could lead to delays in our ongoing trial and/or issues with our commercial supply. We remain focused on maintaining a strong balance sheet, liquidity and financial flexibility and continue to monitor developments as we deal with the disruptions and uncertainties from a business and financial perspective relating to COVID-19. We will continue to work diligently with our partners and stakeholders to continue supporting patient access to our approved medicines, advancing our products under regulatory review as well as in our clinical studies to the extent safe to do so for patients, caregivers and healthcare practitioners, and ensuring the continuity of our manufacturing and supply chain. For additional information related to the potential impact of COVID-19 on our business, please read Part I-Item 1A, “Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2021.
Financial Operations Overview
Product sales, net
Product sales, net is related to our sales of NEXLETOL and NEXLIZET. NEXLETOL was commercially available in the U.S. on March 30, 2020 and NEXLIZET was commercially available in the U.S. on June 4, 2020.
Collaboration revenue
Collaboration revenue is related to our collaboration agreements with Daiichi Sankyo Europe GmbH, or DSE, Otsuka Pharmaceutical Co., Ltd., or Otsuka, and Daiichi Sankyo Co. Ltd, or DS. Collaboration revenue in the three and nine months ended September 30, 2022 was primarily related to sales of bulk tablets under supply agreements and royalty revenue received from collaboration partners. Collaboration revenue in the three and nine months ended September 30, 2021 was primarily
29
related to the initial recognition of the upfront payment from our license and collaboration agreement with DS, sales of bulk tablets under supply agreements, and royalty revenue received from collaboration partners. Under contracted supply agreements with ex-U.S. collaborators, we may manufacture and supply quantities of active pharmaceutical ingredient, or API, or bulk tablets reasonably required by ex-U.S. collaboration partners for the development or sale of licensed products in their respective territory. We recognize revenue when the collaboration partner has obtained control of the API or bulk tablets. We also receive royalties from the commercialization of such products, and record our share of the variable consideration, representing a percentage of net product sales, as collaboration revenue in the period in which such underlying sales occur and costs are incurred by the collaborators.
Cost of goods sold
Cost of goods sold is related to our net product sales of NEXLETOL and NEXLIZET and the cost of goods sold from our supply agreements with collaboration partners. Prior to the FDA approval of NEXLETOL and NEXLIZET in February 2020, expenses associated with the manufacturing of our products were recorded as research and development expense.
Research and Development Expenses
Our research and development expenses consist primarily of costs incurred in connection with the development of bempedoic acid and the bempedoic acid / ezetimibe combination tablet, which include:
•expenses incurred under agreements with consultants, contract research organizations, or CROs, and investigative sites that conduct our preclinical and clinical studies;
•the cost of acquiring, developing and manufacturing clinical study materials and commercial product manufacturing supply prior to product approval, including the procurement of ezetimibe in our continued development of our bempedoic acid / ezetimibe combination tablet;
•employee-related expenses, including salaries, benefits, stock-based compensation and travel expenses;
•allocated expenses for rent and maintenance of facilities, insurance and other supplies; and
•costs related to compliance with regulatory requirements.
We expense research and development costs as incurred. To date, substantially all of our research and development work has been related to bempedoic acid and the bempedoic acid / ezetimibe combination tablet. Costs for certain development activities, such as clinical studies, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or information provided to us by our vendors. Our direct research and development expenses consist principally of external costs, such as fees paid to investigators, consultants, central laboratories and CROs in connection with our clinical studies. We do not allocate acquiring and manufacturing clinical study materials, salaries, stock-based compensation, employee benefits or other indirect costs related to our research and development function to specific programs.
We will continue to incur research and development expenses in the foreseeable future as they relate to our ongoing CLEAR Outcomes CVOT and any other development programs or additional indications we choose to pursue. We cannot determine with certainty the duration and completion costs associated with the ongoing or future clinical studies of bempedoic acid and the bempedoic acid / ezetimibe combination tablet. The duration, costs and timing associated with the development of bempedoic acid and the bempedoic acid / ezetimibe combination tablet will depend on a variety of factors, including uncertainties associated with the results of our clinical studies and our ability to obtain regulatory approval outside the U.S. and Europe. For example, if a regulatory authority were to require us to conduct clinical studies beyond those that we currently anticipate that will be required for the completion of clinical development or post-commercialization clinical studies of bempedoic acid or the bempedoic acid / ezetimibe combination tablet, we could be required to expend significant additional financial resources and time on the completion of clinical development or post-commercialization clinical studies of bempedoic acid and the bempedoic acid / ezetimibe combination tablet.
30
Selling, General and Administrative Expenses
Selling, general and administrative expenses primarily consist of salaries and related costs for personnel, including stock-based compensation, associated with our sales, executive, accounting and finance, commercial, operational and other administrative functions. Other general and administrative expenses include selling expenses, facility-related costs, communication expenses and professional fees for legal, patent prosecution, protection and review, consulting and accounting services.
As a result of the corporate workforce reduction in October 2021 and other targeted program savings, we anticipate that our selling, general and administrative expenses will decrease in 2022 compared to 2021. We expect our selling, general and administrative expenses to increase after we report full results from the CLEAR Outcomes trial in connection with potential additional global regulatory submissions for new product indications, expanded commercialization initiatives for NEXLETOL and NEXLIZET and increases in our associated headcount.

Interest Expense
Interest expense is related to our Revenue Interest Purchase Agreement, or RIPA, with Eiger III SA LLC, or Oberland, an affiliate of Oberland Capital and our convertible notes issued in November 2020.
Other Income, Net
Other income, net, primarily relates to the sale of lease vehicles in 2022 associated with the reduction in force, interest income and the accretion or amortization of premiums and discounts earned on our cash, cash equivalents and investment securities.
Critical Accounting Policies and Significant Judgments and Estimates
Our discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States of America. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in our financial statements. We evaluate our estimates and judgments on an ongoing basis. We base our estimates on historical experience, known trends and events, contractual milestones and other various factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Our actual results may differ from these estimates under different assumptions or conditions.
There have been no other material changes to the significant accounting policies previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021.
31
Results of Operations
Comparison of the Three Months Ended September 30, 2022 and 2021
Three Months Ended September 30,
20222021Change
(unaudited, in thousands)
Revenue:
Product sales, net$13,964 $10,895 $3,069 
Collaboration revenue5,016 3,514 1,502 
Operating Expenses:
Cost of goods sold6,506 5,558 948 
Research and development29,143 25,331 3,812 
Selling, general and administrative24,954 39,265 (14,311)
Loss from operations(41,623)(55,745)14,122 
Interest expense(14,153)(13,654)(499)
Other income, net659 13 646 
Net loss$(55,117)$(69,386)$14,269 
Product sales, net
Product sales, net for the three months ended September 30, 2022 was $14.0 million compared to $10.9 million for the three months ended September 30, 2021, an increase of $3.1 million. The increase is primarily due to prescription growth of NEXLETOL and NEXLIZET during the third quarter of 2022 compared to the third quarter of 2021.
Collaboration revenue
Collaboration revenue recognized from our collaboration agreements for the three months ended September 30, 2022 was $5.0 million compared to $3.5 million for the three months ended September 30, 2021, an increase of $1.5 million. The increase is primarily due to increased sales under the supply agreements and royalty revenue.
Cost of goods sold
Cost of goods sold for the three months ended September 30, 2022 was $6.5 million compared to $5.6 million for the three months ended September 30, 2021, an increase of $0.9 million. The increase is primarily related to increased product sales to our collaboration partners from our supply agreements and increased net product sales of NEXLETOL and NEXLIZET.
Research and development expenses
Research and development expenses for the three months ended September 30, 2022, were $29.1 million, compared to $25.3 million for the three months ended September 30, 2021, an increase of $3.8 million. The increase in research and development expenses was primarily attributable to an increase in CVOT costs as we accumulated 100% MACE accumulations and continued close-out activities.
Selling, general and administrative expenses
Selling, general and administrative expenses for the three months ended September 30, 2022, were $25.0 million, compared to $39.3 million for the three months ended September 30, 2021, a decrease of $14.3 million. The decrease in selling, general and administrative expenses was primarily attributable to decreases in compensation costs related to the reduction in force in the fourth quarter of 2021.
32
Interest expense
Interest expense for the three months ended September 30, 2022, was $14.2 million, compared to $13.7 million for the three months ended September 30, 2021, an increase of $0.5 million. The increase in interest expense was primarily due to additional interest expense attributable to our RIPA with Oberland.
Other income, net
Other income, net for the three months ended September 30, 2022, was $0.7 million, compared to less than $0.1 million for the three months ended September 30, 2021, an increase of approximately $0.6 million. The increase in other income, net was primarily due to higher interest income on our investments due to higher interest rates.
Comparison of the Nine Months Ended September 30, 2022 and 2021
Nine Months Ended September 30,
20222021Change
(unaudited, in thousands)
Revenue:
Product sales, net$40,896 $27,855 $13,041 
Collaboration revenue15,761 35,191 (19,430)
Operating Expenses:
Cost of goods sold22,807 9,142 13,665 
Research and development85,894 78,359 7,535 
Selling, general and administrative84,944 146,647 (61,703)
Loss from operations(136,988)(171,102)34,114 
Interest expense(42,481)(32,923)(9,558)
Other income, net1,297 36 1,261 
Net loss$(178,172)$(203,989)$25,817 
Product sales, net
Product sales, net for the nine months ended September 30, 2022 was $40.9 million compared to $27.9 million for the nine months ended September 30, 2021, an increase of $13.0 million. The increase is primarily due to prescription growth of NEXLETOL and NEXLIZET during the first three quarters of 2022 compared to the first three quarters of 2021.
Collaboration revenue
Collaboration revenue recognized from our collaboration agreements for the nine months ended September 30, 2022 was $15.8 million compared to $35.2 million for the nine months ended September 30, 2021, a decrease of $19.4 million. The decrease is primarily due to the initial recognition of the upfront payment from our license and collaboration agreement with DS for the nine months ended September 30, 2021, partially offset by an increase in product sales to collaboration partners under our supply agreements and royalty revenue from our collaboration agreements with DSE and Otsuka for the nine months ended September 30, 2022.
Cost of goods sold
Cost of goods sold for the nine months ended September 30, 2022 was $22.8 million compared to $9.1 million for the nine months ended September 30, 2021, an increase of $13.7 million. The increase is primarily related to increased product sales to our collaboration partners from our supply agreements and increased net product sales of NEXLETOL and NEXLIZET.
Research and development expenses
Research and development expenses for the nine months ended September 30, 2022, were $85.9 million, compared to $78.4 million for the nine months ended September 30, 2021, a increase of $7.5 million. The increase in research and
33
development expenses was primarily attributable to an increase in CVOT costs as we accumulated 100% MACE accumulations and started close-out activities.
Selling, general and administrative expenses
Selling, general and administrative expenses for the nine months ended September 30, 2022, were $84.9 million, compared to $146.6 million for the nine months ended September 30, 2021, a decrease of $61.7 million. The decrease in selling, general and administrative expenses was primarily attributable to decreases in compensation costs related to the reduction in force in the fourth quarter of 2021 and a $13.3 million one-time charge associated with a legal settlement in 2021.
Interest expense
Interest expense for the nine months ended September 30, 2022, was $42.5 million, compared to $32.9 million for the nine months ended September 30, 2021, an increase of $9.6 million. The increase in interest expense was primarily due to additional interest expense attributable to the third installment payment from our RIPA with Oberland.
Other income, net
Other income, net for the nine months ended September 30, 2022, was $1.3 million, compared to less than $0.1 million for the nine months ended September 30, 2021, an increase of $1.3 million. The increase in other income, net was primarily due to a gain on sale of our lease vehicles due to the reduction in force and higher interest income on our investments due to higher interest rates.
Liquidity and Capital Resources
While we began to generate revenue from the sales of our products in 2020, we have funded our operations to date primarily through proceeds from sales of preferred stock, convertible promissory notes and warrants, public offerings of common stock and warrants, the incurrence of indebtedness, milestone payments from collaboration agreements and the revenue interest purchase agreement. Pursuant to the license and collaboration agreements with Daiichi Sankyo and Otsuka, we are eligible for substantial additional sales and regulatory milestone payments and royalties. Pursuant to the license and collaboration agreements entered into April 2021 with Daiichi Sankyo, we received an upfront cash payment of $30.0 million in May 2021 and are eligible for substantial additional sales milestone payments and royalties. Pursuant to the amended RIPA with Oberland, we received an additional $50.0 million in May 2021. The amended RIPA increases the revenue interest we will pay Oberland based on the net sales of our products as outlined in Note 8 "Liability Related to the Revenue Interest Purchase Agreement" in our condensed financial statements included in this Form 10-Q for the quarter ended September 30, 2022. In December 2021, we entered into an underwriting agreement pursuant to which we sold shares of common stock and accompanying warrants to purchase shares of our common stock and received net proceeds of $208.7 million. We anticipate that we will incur losses for the foreseeable future as we continue to incur substantial expenses related to the ongoing commercialization of NEXLETOL and NEXLIZET and study completion activities for our ongoing CLEAR Outcomes CVOT. We anticipate that our current cash, cash equivalents, investments, expected future net product sales of NEXLETOL and NEXLIZET, and expected future revenue under our collaboration agreements is sufficient to allow us to complete and report results from the CLEAR Outcomes CVOT and fund continuing operations for the foreseeable future beyond the CVOT read-out.

As of September 30, 2022, our primary sources of liquidity were our cash and cash equivalents and available-for-sale investments which totaled $239.3 million, which includes $50 million that is restricted per the amendment and waiver with Oberland. We invest our cash equivalents and investments in highly liquid, interest-bearing investment-grade securities and government securities to preserve principal.
The following table summarizes the primary sources and uses of cash for the periods presented below:
Nine Months Ended September 30,
20222021
(in thousands)
Net cash used in operating activities$(132,355)$(206,103)
Net cash provided by investing activities19,898 — 
Net cash provided by financing activities62,964 54,813 
Net decrease in cash and cash equivalents$(49,493)$(151,290)
34
Operating Activities
We have incurred and expect to continue to incur, significant costs related to the commercialization of NEXLETOL and NEXLIZET and related to ongoing research and development, regulatory and other clinical study costs associated with the development of bempedoic acid and the bempedoic acid / ezetimibe combination tablet.
Net cash used in operating activities totaled $132.4 million for the nine months ended September 30, 2022, compared to $206.1 million for the nine months ended September 30, 2021. Net cash used for the nine months ended September 30, 2022 consists primarily of net product sales of NEXLETOL and NEXLIZET fully offset by cash used to fund the commercialization activities of NEXLETOL and NEXLIZET and the research and development costs related to bempedoic acid and the bempedoic acid / ezetimibe combination tablet, adjusted for non-cash expenses such as stock-based compensation expense, interest expense related to our RIPA with Oberland, depreciation and amortization and changes in working capital. Net cash for the nine months ended September 30, 2021 consisted of net product sales of NEXLETOL and NEXLIZET and $30.0 million in upfront fees from DS fully offset by cash used to fund the commercialization activities of NEXLETOL and NEXLIZET and the research and development costs related to bempedoic acid and the bempedoic acid / ezetimibe combination tablets, adjusted for non-cash expenses such as stock-based compensation expense, interest expense related to our RIPA with Oberland, depreciation and amortization and changes in working capital.
Investing Activities
Net cash provided by investing activities of $19.9 million for the nine months ended September 30, 2022 consisted primarily of proceeds from the sales of highly liquid, interest bearing investment grade and government securities. We did not have cash provided by or used in investing activities for the nine months ended September 30, 2021.
Funds invested in available-for-sale investments at September 30, 2022 will become available for our use over the next twelve months.
Financing Activities
Net cash provided by financing activities of $63.0 million for the nine months ended September 30, 2022 related primarily to proceeds from our ATM program, partially offset by payments on our revenue interest liability. Net cash provided by financing activities of $54.8 million for the nine months ended September 30, 2021 related primarily to $50 million in cash from our RIPA with Oberland and proceeds from exercise of our common stock, offset by payments on our revenue interest liability.
On August 3, 2021, we filed an automatically effective registration statement on Form S-3ASR, or Registration Statement, with the SEC which registers the offering, issuance and sale of an unspecified amount of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof. We simultaneously entered into an open market sale agreement with Jefferies LLC, as sales agent, to provide for the issuance and sale by the Company of up to $250 million of common stock from time to time in “at-the-market” offerings under the Registration Statement and related prospectus filed with the Registration Statement, or the ATM Program. During the three and nine months period ended September 30, 2021, the Company issued 363,061 shares of common stock resulting in net proceeds of approximately $4.2 million after deducting underwriting discounts and commissions and other expenses, pursuant to the ATM Program. During the year ended December 31, 2021, we issued 897,364 shares of common stock resulting in net proceeds of approximately $9.7 million after deducting underwriting discounts and commissions and other expenses, pursuant to the ATM Program. On April 15, 2022, the Company filed a new registration statement on Form S-3, which registers the offering, issuance and sale of up to $239 million of common stock from time to time in “at-the-market” offerings under the Registration Statement and related prospectus filed with the Registration Statement (the “New ATM Program”). During the three and nine month periods ended September 30, 2022, the Company issued 6,958,525 and 10,311,525 shares of common stock, respectively, resulting in net proceeds of approximately $48.6 million and $68.8 million after deducting $1.6 million and $2.4 million of underwriting discounts and commissions and other expenses, respectively, pursuant to the New ATM Program. We may continue to use the New ATM Program to address potential short-term or long-term funding requirements that may arise. Such program will continue to be subject to the volatility of the price of our common stock and general market conditions.

In December 2021, we entered into an underwriting agreement pursuant to which we sold 32,142,858 shares of common stock and issued accompanying warrants to purchase up to an aggregate of 36,964,286 shares of our common stock. The warrants are immediately exercisable and will expire two years from the date of issuance, at an exercise price of $9.00 per share, which may provide us with additional funding, if such warrants are exercised by their holders.

In 2019, we entered into a RIPA with Oberland. Pursuant to the RIPA, Oberland paid us $125.0 million at closing, less certain issuance costs, and, subject to the terms and conditions of the RIPA, we received an additional $25.0 million upon
35
regulatory approval of NEXLETOL in 2020 and were eligible to receive an additional $50.0 million at our option upon reaching certain sales thresholds. In April 2021, we entered into Amendment No. 2 to the RIPA and Oberland waived the original trailing six-month world-wide net sales condition to the third installment payment under the RIPA and released the final $50 million payment payable to us under the terms of the RIPA. The amendment also updated the tiered payment percentage. As the quarterly net revenue from sales of NEXLETOL and NEXLIZET and certain other products in the United States did not exceed $15.0 million for the quarter ended September 30, 2021, we deposited $50.0 million in a deposit account with Oberland, which reduced our unrestricted cash. As consideration for the payments, Oberland has the right to receive certain revenue interests from us based on the net sales of certain products which will be tiered payments ranging from 3.3% to 10% of our net sales in the covered territory (as detailed in the RIPA). Esperion reacquires 100% revenue rights upon repayment completion. We recorded the proceeds from the RIPA as a liability on the balance sheets and are accounting for the RIPA under the effective-interest method over the estimated life of the RIPA. Future payments under the RIPA may range from $19.6 million in the next year to a maximum total payment of $420.8 million beyond one year. Per the terms of the agreement, every $100 million of net sales generated, less than or equal to $250 million in an annual aggregate, would result in a repayment obligation of approximately $10.0 million or 10% at the stated repayment rate in the first year. In the future, as net sales thresholds set forth in the agreement are met and the repayment percentage rate changes, the amount of the obligation and timing of payment is likely to change. As the U.S. net sales were less than $350 million for the year ended December 31, 2021, the Covered Territory was expanded to include worldwide sales beginning in 2022. A significant increase or decrease in net sales will materially impact the revenue interest liability, interest expense and the time period for repayment. Refer to Note 8 "Liability Related to the Revenue Interest Purchase Agreement" in our condensed financial statements included in this Form 10-Q for the quarter ended September 30, 2022 for further information.

On November 16, 2020, we issued $250.0 million aggregate principal amount of 4.00% convertible senior subordinated notes due 2025 to certain financial institutions as the initial purchasers of the convertible notes. An additional $30.0 million of additional convertible notes (collectively, the "Convertible Notes"), which were issued pursuant to the exercise of the initial purchasers' option to purchase such convertible notes, closed on November 18, 2020. On October 22, 2021, we entered into the Exchange Agreement with the Holders of our Convertible Notes. Under the terms of the Exchange Agreement the Holders agreed to exchange with us $15.0 million aggregate principal amount of Convertible Notes held in the aggregate by them (and accrued interest thereon) for shares of our common stock, which closed on November 3, 2021. Future payments under the convertible notes include annual interest of $10.6 million and a principal payment of $265.0 million in 2025. Refer to Note 9 "Convertible Notes" in our condensed financial statements included in this Form 10-Q for the quarter ended September 30, 2022 for further information.

Plan of Operations and Funding Requirements
We expect to continue to incur significant expenses and operating losses for the foreseeable future in connection with study completion activities for our ongoing CLEAR Outcomes CVOT and our continued commercialization activities associated with NEXLETOL and NEXLIZET in the U.S. Pursuant to the license and collaboration agreements with DSE, Otsuka, and DS, we are eligible for substantial additional sales and regulatory milestone payments and royalties. We estimate that current cash resources, proceeds to be received in the future for product sales and proceeds under the collaboration agreements with Daiichi Sankyo and Otsuka are sufficient to allow us to complete and report results from the CLEAR Outcomes CVOT and fund continuing operations for the foreseeable future beyond the CVOT read-out. We have based these estimates on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. We may need to secure additional cash resources or implement certain additional cost reduction initiatives to continue to fund the commercialization and further development of bempedoic acid and the bempedoic acid / ezetimibe combination tablet, particularly if there are delays in the completion of the CLEAR Outcomes CVOT or our net product sales do not meet our expectations. Because of the numerous risks and uncertainties associated with the development and ongoing commercialization of bempedoic acid and the bempedoic acid / ezetimibe combination tablet and the extent to which we entered and may enter into collaborations with pharmaceutical partners regarding the development and commercialization of bempedoic acid and the bempedoic acid / ezetimibe combination tablet, we are unable to estimate the amounts of increased capital outlays and operating expenses associated with completing the development and commercialization of bempedoic acid and the bempedoic acid / ezetimibe combination tablet. Our future funding requirements will depend on many factors, including, but not limited to:

•our ability to successfully develop and commercialize NEXLETOL and NEXLIZET or other product candidates;
•the costs, timing and outcomes of our CLEAR Outcomes CVOT and other ongoing clinical studies of bempedoic acid and the bempedoic acid / ezetimibe combination tablet;
•the time and cost necessary to obtain regulatory approvals for bempedoic acid and the bempedoic acid / ezetimibe combination tablet outside the U.S. and Europe;
•our ability to establish any future collaboration or commercialization arrangements on favorable terms, if at all;
36
•our ability to realize the intended benefits of our existing and future collaboration and partnerships;
•the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; and
•the implementation of operational and financial information technology.
Until such time, if ever, as we can generate U.S. substantial product revenues, we expect to finance our cash needs through a combination of collaborations with third parties, strategic alliances, licensing arrangements, permitted debt financings, permitted royalty-based financings and equity offerings or other sources. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available and permitted under the terms of our RIPA, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or licensing arrangements with pharmaceutical partners or royalty-based financing arrangements, such as the collaboration arrangement with DSE, Otsuka and DS, and the RIPA with Oberland, we may have to relinquish valuable rights to our technologies, future revenue streams or grant licenses on terms that may not be favorable to us. For instance, as part of the RIPA with Oberland, Oberland has the right to receive certain revenue interests from us based on the net sales of certain products, and we have granted Oberland a senior security interest in certain of our assets. If our cash flows and capital resources are insufficient to allow us to make required payments, we may have to reduce or delay capital expenditures, sell assets or seek additional capital. If we raise funds by selling additional equity, such sale would result in dilution to our stockholders. If we are unable to raise additional funds through equity or permitted debt financings or through collaborations, strategic alliances or licensing arrangements or permitted royalty-based financing arrangements when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market bempedoic acid and the bempedoic acid / ezetimibe combination tablet that we would otherwise prefer to develop and market ourselves.

We do not currently have, nor did we have during the periods presented, any off-balance sheet arrangements as defined by Securities and Exchange Commission rules.

Item 3. Quantitative and Qualitative Disclosures About Market Risk
There have been no material changes with respect to the information appearing in Part II, Item 7A, “Quantitative and Qualitative Disclosures About Market Risk,” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities and Exchange Act of 1934 is (1) recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and (2) accumulated and communicated to our management, including our President and Chief Executive Officer, who is our principal executive officer and currently serving as our principal financial officer, to allow timely decisions regarding required disclosure.
As of September 30, 2022, our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934). Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our principal executive officer, who is also serving as our principal financial officer, has concluded based upon the evaluation described above that, as of September 30, 2022, our disclosure controls and procedures were effective at the reasonable assurance level.
Changes in Internal Control over Financial Reporting
There were no changes to our internal control over financial reporting that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
37
PART II — OTHER INFORMATION

Item 1. Legal Proceedings
The information required with respect to this item can be found under “Commitments and Contingencies” in Note 5 to our condensed financial statements included elsewhere in this Form 10-Q and is incorporated by reference into this Item 1.
In the future, we may become party to legal matters and claims arising in the ordinary course of business, the resolution of which we do not anticipate would have a material adverse impact on our financial position, results of operations or cash flows.
Item 1A. Risk Factors
Except for the historical information contained herein or incorporated by reference, this report and the information incorporated by reference contains forward-looking statements that involve risks and uncertainties. These statements include projections about our accounting and finances, plans and objectives for the future, future operating and economic performance and other statements regarding future performance. These statements are not guarantees of future performance or events. Our actual results could differ materially from those discussed in this report. Factors that could cause or contribute to these differences include, but are not limited to, those discussed in Part I, Item 2 entitled "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere throughout this report and in any documents incorporated in this report by reference.

You should consider carefully the following risk factors, together with those set forth in Part I, Item 1A in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and in all of the other information included or incorporated in this report. The following risk factors represent new risk factors or those containing changes, including material changes, to the risk factors set forth in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2021. If any of the previously identified or following risks, either alone or taken together, or other risks not presently known to us or that we currently believe to not be significant, develop into actual events, then our business, financial condition, results of operations or prospects could be materially adversely affected. If that happens, the market price of our common stock could decline, and stockholders may lose all or part of their investment.

Impact of Uncertain Capital Markets

We have in the past relied in part on sales of our common shares through our at-the-market (ATM) offering program. Increased volatility and decreases in market prices of equity securities generally and of our common shares in particular may have an adverse impact on our willingness and/or ability to continue to sell our common shares through our ATM offering. Decreases in these sales would/could affect the cost or availability of equity capital, which could in turn have an adverse effect on our business, including current operations, future growth, revenues, net income and the market prices of our common shares.

On August 3, 2021, we commenced an at-the-market, or ATM, program to raise capital under an automatically effective registration statement on Form S-3ASR, which was replaced on April 15, 2022 with a new registration statement on Form S-3. Under our ATM program, we have entered into a sales agreement to sell common shares, up to a maximum aggregate market value of $250 million, through one or more at-the-market offerings. Given the volatility in the capital markets, we may not be willing or able to continue to raise equity capital through our ATM program. We may, therefore, need to turn to other sources of funding that may have terms that are not favorable to us, or reduce our business operations given capital constraints.

Alternative financing arrangements, if we pursue any, could involve issuances of one or more types of securities, including common stock, preferred stock, convertible debt, warrants to acquire common stock or other securities. These securities could be issued at or below the then prevailing market price for our common shares. In addition, if we issue debt securities, the holders of the debt would have a claim to our assets that would be superior to the rights of stockholders until the principal, accrued and unpaid interest and any premium or make-whole has been paid.

38
Recent volatility in capital markets and lower market prices for our securities may affect our ability to access new capital through sales of shares of our common stock or issuance of indebtedness, which may materially harm our liquidity, limit our ability to grow our business, pursue acquisitions or improve our operating infrastructure and restrict our ability to compete in our markets.

Our operations consume substantial amounts of cash, and we may increase our investment in our commercial infrastructure after we report top-line results from the CLEAR Outcomes trial. Our future capital requirements may be significantly different from our current estimates and will depend on many factors, including the need to:

•finance unanticipated working capital requirements;

•develop or enhance our technological infrastructure and our existing solutions; and

•respond to competitive pressures.

Accordingly, we may need to pursue equity or debt financings to meet our capital needs. With uncertainty in the capital markets and other factors, such financing may not be available on terms favorable to us or at all. If we raise additional funds through further issuances of equity or convertible debt securities, our existing stockholders could suffer significant dilution, and any new equity securities we issue could have rights, preferences, and privileges superior to those of holders of our common stock. Any debt financing secured by us in the future could involve additional restrictive covenants relating to our capital-raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital and to pursue business opportunities, including potential acquisitions. If we are unable to obtain adequate financing or financing on terms satisfactory to us, we could face significant limitations on our ability to invest in our operations and otherwise suffer harm to our business.




39
Item 6. Exhibits
The exhibits filed or furnished as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index, which Exhibit Index is incorporated herein by reference.
EXHIBIT INDEX
Incorporated by Reference to:
Exhibit
No.		DescriptionForm or
Schedule		Exhibit
No.		Filing
Date with
SEC		SEC File
Number
8-K3.2June 12, 2013333-188595
8-K3.1May 26, 2022001-35986
8-K3.1September 20, 2022001-35986
10-Q3.1May 4, 2021001-35986
S-14.1June 12, 2013333-188595
101.SCH*Inline XBRL Taxonomy Extension Schema Document
101.CAL*Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB*Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase Document
101.DEF*Inline XBRL Taxonomy Extension Definition Linkbase Document
104*Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101.*)

*Filed herewith.
+    The certification furnished in Exhibit 32.1 hereto is deemed to be furnished with this Quarterly Report on Form 10-Q and will not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference.
40
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ESPERION THERAPEUTICS, INC.
November 1, 2022By:/s/ Sheldon L. Koenig
Sheldon L. Koenig
President and Chief Executive Officer
(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)

41
 EX-31.1 2 espr-ex311x09302022.htm EX-31.1 Document

Exhibit 31.1
Certification
I, Sheldon L. Koenig, certify that:
1.I have reviewed this quarterly report on Form 10-Q for the period ended September 30, 2022, of Esperion Therapeutics, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:November 1, 2022/s/ Sheldon L. Koenig
Sheldon L. Koenig
President and Chief Executive Officer
(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)

 EX-31.2 3 espr-ex312x09302022.htm EX-31.2 Document

Exhibit 31.2
Certification
I, Sheldon L. Koenig, certify that:
1.I have reviewed this quarterly report on Form 10-Q for the period ended September 30, 2022, of Esperion Therapeutics, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date:November 1, 2022/s/ Sheldon L. Koenig
Sheldon L. Koenig
President and Chief Executive Officer
(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)

 EX-32.1 4 espr-ex321x09302022.htm EX-32.1 Document

Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the quarterly report on Form 10-Q of Esperion Therapeutics, Inc. (the “Company”) for the period ended September 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of Esperion Therapeutics, Inc., hereby certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that, to my knowledge as of the date hereof:
1)the Report which this statement accompanies fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date:November 1, 2022/s/ Sheldon L. Koenig
Sheldon L. Koenig
President and Chief Executive Officer
(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)

 EX-101.SCH 5 espr-20220930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Condensed Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Condensed Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Condensed Statements of Stockholders' Deficit link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Condensed Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0000007 - Disclosure - The Company and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Collaborations with Third Parties link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Inventories, net link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Liability Related to the Revenue Interest Purchase Agreement link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Convertible Notes link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Other Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Stock Compensation link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Stockholders' Deficit link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Net Loss Per Common Share link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Statements of Cash Flows and Restricted Cash link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Inventories, net (Tables) link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - Liability Related to the Revenue Interest Purchase Agreement (Tables) link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - Other Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - Stock Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - Net Loss Per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - Statements of Cash Flows and Restricted Cash (Tables) link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - Collaborations with Third Parties (Details) link:presentationLink link:calculationLink link:definitionLink 0000033 - Disclosure - Inventories, net (Details) link:presentationLink link:calculationLink link:definitionLink 0000034 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 0000035 - Disclosure - Investments - Summary of Cash Equivalents, Restricted Cash, and Short-Term Investments (Details) link:presentationLink link:calculationLink link:definitionLink 0000036 - Disclosure - Investments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000037 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 0000038 - Disclosure - Liability Related to the Revenue Interest Purchase Agreement - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000039 - Disclosure - Liability Related to the Revenue Interest Purchase Agreement - Summary of Revenue Interest Liability (Details) link:presentationLink link:calculationLink link:definitionLink 0000040 - Disclosure - Convertible Notes (Details) link:presentationLink link:calculationLink link:definitionLink 0000041 - Disclosure - Other Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000042 - Disclosure - Stock Compensation - Stock Options Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000043 - Disclosure - Stock Compensation - Schedule of Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 0000044 - Disclosure - Stock Compensation - PBSOs (Details) link:presentationLink link:calculationLink link:definitionLink 0000045 - Disclosure - Stock Compensation - RSUs (Details) link:presentationLink link:calculationLink link:definitionLink 0000046 - Disclosure - Stock Compensation - PBRSUs (Details) link:presentationLink link:calculationLink link:definitionLink 0000047 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 0000048 - Disclosure - Stockholders' Deficit (Details) link:presentationLink link:calculationLink link:definitionLink 0000049 - Disclosure - Net Loss Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 0000050 - Disclosure - Statements of Cash Flows and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 espr-20220930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 espr-20220930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 espr-20220930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Schedule of Cash and Cash Equivalents Schedule of Cash and Cash Equivalents [Table Text Block] Prepaid clinical development costs Prepaid Clinical Development Costs, Current Represents the amount of consideration paid in advance for clinical development that provides economic benefits within a future period of one year or the normal operating cycle, if longer. Principal amount of convertible notes Long-Term Debt, Gross Entity Address, Postal Zip Code Entity Address, Postal Zip Code Daiichi Sankyo Europe GmbH ("DSE") Daiichi Sankyo Europe Gmbh [Member] Member stands for the Daiichi Sankyo Europe GmbH ("DSE"). Exclusive Developmental Activities Exclusive Developmental Activities [Member] Represents information pertaining to exclusive developmental activities. Unrealized gain (loss) on investments Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Preferred stock, outstanding (in shares) Preferred Stock, Shares Outstanding Average trading-day period Debt Instrument, Convertible, Threshold Consecutive Trading Days Debt Instrument [Axis] Debt Instrument [Axis] Proceeds from revenue interest liability, net of issuance costs Proceeds from Revenue Interest Purchase Agreement, Net of Issuance Costs The cash inflow from a revenue interest purchase agreement, net of issuance costs. Number of consecutive trading days Number Of Consecutive Trading Days Number Of Consecutive Trading Days Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Debt fair value Debt Instrument, Fair Value Disclosure Milestone amount for worldwide sales to receive the third payment Milestone Amount for Worldwide Sales to Receive Third Payment Milestone amount for worldwide sales to receive the Third Payment. Additional paid-in capital Additional Paid in Capital Additional Paid in Capital Financial Instruments [Domain] Financial Instruments [Domain] Range [Domain] Statistical Measurement [Domain] Depreciation expense Depreciation Exercise of stock options (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Percentage of increase in royalty rate upon drawdown of third payment Percentage of Increase in Royalty Rate Upon Drawdown of Third Payment The percentage of increase in the Royalty Rate upon drawdown of the Third Payment. Debt instrument, stated interest rate Debt Instrument, Interest Rate, Stated Percentage Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Net loss Net loss Net Income (Loss) Attributable to Parent Net (Loss) Income Per Common Share Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Total potential dilutive shares (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Equity Component [Domain] Equity Component [Domain] Debt instrument, redemption price, percentage Debt Instrument, Redemption Price, Percentage Total assets at fair value Assets, Fair Value Disclosure Aggregate Intrinsic Value Share Based Compensation Arrangement by Share Based Payment Award Aggregate Intrinsic Value [Abstract] Plan Name [Axis] Plan Name [Axis] Collaboration revenue Collaboration Revenue [Member] Represents the information pertaining to collaboration revenue. Short-term investments: Debt Securities, Available-for-Sale Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Unrecognized stock-based compensation expense, RSUs Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Plan Name [Domain] Plan Name [Domain] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Milestone payments related to total net sales achievements Future Payment Milestone, Sales Milestones The total amount of potential future payments related to total net sales achievements for Otsuka in Japan. Entity Address, State or Province Entity Address, State or Province Level 1 Fair Value, Inputs, Level 1 [Member] ESPP Shares issuable related to the ESPP Employee Stock [Member] Other comprehensive loss: Other Comprehensive Income (Loss), Net of Tax [Abstract] Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Amount of subsequent installment, subject to regulatory approval Amount of Subsequent Installment, Subject to Regulatory Approval The amount of the subsequent installment which is subject to regulatory approval. Award Type [Axis] Award Type [Axis] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Operating lease liabilities Operating Lease, Liability, Current Consecutive number of months sales must be at or above milestone amount Consecutive Number of Months Sales Must Be At or Above Milestone Amount The consecutive number of months sales must be at or above the milestone amount. Summary of Activity Relating to the Company's RSUs Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Total amount of subsequent installment, subject to RIPA terms and conditions Amount of Subsequent Installment, Subject to Revenue Interest Purchase Agreement Terms and Conditions The total amount of the subsequent installment, subject to the terms and conditions of the Revenue Interest Purchase Agreement. Consideration cash payment Future Up-Front Payment Future Up-Front Payment Collaborative Arrangement, License To Intellectual Property Collaborative Arrangement, License To Intellectual Property [Member] Collaborative Arrangement, License To Intellectual Property Certificates of deposit Certificates of Deposit [Member] Total liabilities Liabilities Stock compensation Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Issuance of common stock from ATM program, net of issuance costs Stock Issued During Period, Value, New Issues Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Preferred stock, issued (in shares) Preferred Stock, Shares Issued Document Type Document Type Number of business days Number Of Business Days Number Of Business Days Revenue interest rate which will take effect if annual net sales equals or exceeds the sales threshold by December 31, 2021 Revenue Interest Rate, Tier Two The Revenue Interest Rate which will take effect if annual net sales equal or exceed $350.0 million by December 31, 2021. Weighted-Average Exercise Price Per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Number of RSUs Number of PBRSUs Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Debt instrument, convertible, threshold percentage of last reported sale price Debt Instrument, Convertible, Threshold Percentage Of Last Reported Sale Price Debt Instrument, Convertible, Threshold Percentage Of Last Reported Sale Price Forfeited or expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Outstanding and at the beginning of period (in dollars per share) Outstanding and unvested at the at the end of the period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Convertible Notes Debt Disclosure [Text Block] Product and Service [Domain] Product and Service [Domain] Entity Shell Company Entity Shell Company Revenue interest rate if annual net sales equal or exceed the Sales Threshold and if the Purchasers receive 100% of their invested capital by December 31, 2024 Revenue Interest Rate, Tier Three The Revenue Interest Rate which will take effect if annual net sales equals or exceeds the Sales Threshold and if the Purchasers receive 100% of their invested capital by December 31, 2024. Purchase of capped call options associated with convertible notes Payments for Derivative Instrument, Financing Activities Percentage of revenue interests payment on which agreement terminates, after the third anniversary of the closing date, if put option is exercised Percentage Of Revenue Interests Payment on Which Agreement Terminates After the Third Anniversary Of Closing Date If Put Option Is Exercised Percentage of revenue interests payment on which agreement terminates, after the third anniversary of the closing date, if put option is exercised. Milestone payment, first JNDA submissions Future Payment Milestone, First Submission of Japanese New Drug Application, Otsuka Territory The amount of a potential future payment which becomes due with the submission of a Japanese New Drug Application (JNDA). in the Otsuka Territory. Other Accrued Liabilities Other Liabilities Disclosure [Text Block] Financial Instrument [Axis] Financial Instrument [Axis] Document Period End Date Document Period End Date Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Total assets Assets Debt Disclosure [Abstract] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Antidilutive Securities [Axis] Antidilutive Securities [Axis] PBRSUs Unvested PBRSUs Performance Shares [Member] Trade Receivables Trade Accounts Receivable [Member] Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Accounting Policies [Abstract] Accounting Policies [Abstract] Debt interest expense Interest Expense, Debt Accrued compensation Employee-related Liabilities, Current Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Other prepaid and current assets Prepaid Expense and Other Assets, Current Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] Net Loss Per Common Share Earnings Per Share [Text Block] Liability from Sale of Future Revenues [Table] Liability from Sale of Future Revenues [Table] Disclosure of information about liabilities from the sale of future royalty revenues. Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Short-term Investments Short-Term Investments [Member] Equity Award [Domain] Award Type [Domain] Warrants issued for shares of common stock (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Weighted-average period over which remaining unrecognized compensation cost will be recognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Entity Registrant Name Entity Registrant Name Issuance of common stock, net of issuance costs (in shares) Stock Issued During Period, Shares, New Issues Summary of Revenue Interest Liability Activity During the Period Schedule of Revenue Interest Liability [Table Text Block] Tabular disclosure of information pertaining to the revenue interest liability. Entity Address, City or Town Entity Address, City or Town Purchase discount Employee Stock Purchase Plan, Percentage Discount on Shares The discount at which shares may be purchased under the employee stock purchase plan, calculated as a stated percentage of the lesser of the closing price of the Company's common stock on the NASDAQ Global Select Market (i) on the first trading day of the offering period or (ii) the last day of any offering period. Operating expenses: Operating Expenses [Abstract] Proceeds from debt, net of issuance costs Proceeds from Debt, Net of Issuance Costs Percentage of revenue interest payments to qualify for third payment applicable percentage Percentage Of Revenue Interest Payments Received By December 31, 2024, To Qualify For Third Payment Applicable Percentage Percentage Of Revenue Interest Payments Received By December 31, 2024, To Qualify For Third Payment Applicable Percentage Minimum Minimum [Member] Collaborative Arrangement, Ongoing Regulatory And Development Activities Collaborative Arrangement, Ongoing Regulatory And Development Activities [Member] Collaborative Arrangement, Ongoing Regulatory And Development Activities Debt instrument, convertible, conversion ratio Debt Instrument, Convertible, Conversion Ratio Percentage of revenue interests payment on which agreement terminates, prior to the third anniversary of the closing date, if put option is exercised Percentage Of Revenue Interests Payment on Which Agreement Terminates Prior to the Third Anniversary Of Closing Date If Put Option Is Exercised Percentage of revenue interests payment on which agreement terminates, prior to the third anniversary of the closing date, if put option is exercised. Duration of offering periods Employee Stock Purchase Plan, Duration of Offering Period The duration of offering periods in which employees may purchase stock, , in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Raw materials Inventory, Raw Materials, Net of Reserves Unamortized debt discount and issuance costs Debt Issuance Costs, Net Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Trading Symbol Trading Symbol Entity File Number Entity File Number Shares issuable upon conversion of convertible notes Convertible Debt Securities [Member] Weighted-Average Remaining Contractual Term (Years) Share Based Compensation Arrangement by Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract] Upfront cash payment received (paid) Up-Front Payment The amount of up-front payment received (paid) . Deferred revenue from collaborations Contract with Customer, Liability, Noncurrent Accrued interest on convertible notes Interest Payable, Current Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period RSUs Restricted Stock Units (RSUs) [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Net Sales Threshold [Axis] Net Sales Threshold [Axis] Net Sales Threshold Use of Estimates Use of Estimates, Policy [Policy Text Block] Cash and cash equivalents: Cash and Cash Equivalents, Fair Value Disclosure Revenue interest liability Revenue Interest Liability, NonCurrent Liability related to Revenue Interest Purchase Agreement ("RIPA"), classified as noncurrent. Accounts payable Increase (Decrease) in Accounts Payable Significant Accounting Policies [Table] Significant Accounting Policies [Table] Disclosure of information about significant accounting policies. Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Income Taxes Income Tax Disclosure [Text Block] Exchange Agreement, threshold trading days Debt Instrument, Exchange Agreement, Convertible, Threshold Trading Days Debt Instrument, Exchange Agreement, Convertible, Threshold Trading Days Number of revenue sources Number Of Sources Of Revenue Number Of Sources Of Revenue Finished goods Inventory, Finished Goods, Net of Reserves Exercise price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Net loss per common share - basic (in dollars per share) Earnings Per Share, Basic Daiichi Sankyo Co. Ltd Daiichi Sankyo Co. Ltd [Member] Daiichi Sankyo Co. Ltd Restrictions on Cash and Cash Equivalents Restrictions on Cash and Cash Equivalents [Table Text Block] Inventories Inventory, Policy [Policy Text Block] Cash payment to the Company upon first commercial sales in the DSE Territory Cash Payment to be Received upon First Commercial Sales The amount of cash payment to the Company upon first commercial sales in the DSE Territory. Concentration Risk Type [Domain] Concentration Risk Type [Domain] Counterparty Name [Domain] Counterparty Name [Domain] Treasury Stock Treasury Stock [Member] Total stockholders’ deficit Beginning balance Ending balance Stockholders' Equity Attributable to Parent Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Transfer of assets between levels Fair Value Measurement Asset Transfers between Levels Represents the transfer of assets between the levels of fair value hierarchy that have taken place during the period. Potential additional future payments Aggregate Amount of Potential Future Revenue, Total Development and Sales Milestones The aggregate amount of potential future revenue which may be received under the terms of the agreement conditional upon achievement of specified total development and sales milestones. Allowance for credit loss Debt Securities, Available-for-Sale, Allowance for Credit Loss Entity Interactive Data Current Entity Interactive Data Current Issued stock (in shares) Sale of Stock, Number of Shares Issued in Transaction Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Money market funds Money Market Funds [Member] Capitalized issuance costs Unamortized Transaction Costs on Revenue Interest Agreement Amount of transaction costs on revenue interest agreement. Accumulated Deficit Retained Earnings [Member] Unrecognized stock-based compensation expense, options Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Other Nonoperating Income (Expense) Other Nonoperating Income (Expense) [Member] Loss related to litigation settlement Gain (Loss) Related to Litigation Settlement Litigation Status [Domain] Litigation Status [Domain] Common Stock Common Stock [Member] Other comprehensive loss Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Prepayment of forward stock repurchase transaction Payments for Repurchase of Common Stock Class of Stock [Axis] Class of Stock [Axis] Revenue Recognition Revenue [Policy Text Block] Investments Marketable Securities, Policy [Policy Text Block] Statement [Table] Statement [Table] Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Summary of Activity Relating to the Company's PBRSU's Schedule of Nonvested Performance-Based Units Activity [Table Text Block] Document Quarterly Report Document Quarterly Report Liability Related to the Revenue Interest Purchase Agreement Liability from Sale of Future Revenues [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Current assets: Assets, Current [Abstract] Operating lease liabilities Operating Lease, Liability, Noncurrent Otsuka Pharmaceutical Co, Ltd. Otsuka Pharmaceutical Co Ltd [Member] Represents information pertaining to Otsuka Pharmaceutical Co, Ltd. Statistical Measurement [Axis] Statistical Measurement [Axis] Underlying common stock (in shares) Treasury Stock, Shares, Acquired Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Collaborations with Third Parties Collaborations with Third Parties n/a RIPA Amendment To The Security Agreement And Waiver RIPA Amendment To The Security Agreement And Waiver [Member] RIPA Amendment To The Security Agreement And Waiver Accumulated deficit Accumulated Deficit Retained Earnings (Accumulated Deficit) Convertible Senior Notes Due 2025 Convertible Senior Notes Due 2025 [Member] Convertible Senior Notes Due 2025 Maximum amount of US net sales to qualify for the Covered Territory expansion to include worldwide sales by December 31, 2021 Net Sales Threshold To Include Worldwide Sales In Covered Territory Net Sales Threshold To Include Worldwide Sales In Covered Territory Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current U.S. treasury notes US Treasury and Government [Member] Equity Components [Axis] Equity Components [Axis] Recurring fair value measurement Fair Value, Recurring [Member] Exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Revenue interest liability Revenue interest liability, beginning balance Revenue interest liability, ending balance Revenue Interest Liability Represents the current and non-current portion of the Revenue Interest Liability. Interest expense recognized Revenue Interest Liability, Increase for Interest Expense Recognized The amount of increase in the revenue interest liability attributable to interest expense recognized during the period. Document Fiscal Year Focus Document Fiscal Year Focus Operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Statement Statement [Line Items] Outstanding at the beginning of period (in shares) Outstanding and unvested at the ending of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Other accrued liabilities Total other accrued liabilities Accrued Liabilities and Employee-related Liabilities, Current Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Includes obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Selling, general and administrative Selling, General and Administrative Expense Loss Contingencies [Table] Loss Contingencies [Table] Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Product sales, net Product [Member] Right of use operating lease assets Operating Lease, Right-of-Use Asset Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Vested and expected to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Document Transition Report Document Transition Report Local Phone Number Local Phone Number Exchange Agreement, amount of principal amount converted into common stock Debt Conversion, Converted Instrument, Amount Summary of Activity Relating to the Company's Options and Performance-Based Options to Purchase Common Stock Share-Based Payment Arrangement, Option, Activity [Table Text Block] Loss from operations Operating Income (Loss) Inventories Increase (Decrease) in Inventories Recently Implemented Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Cost of goods sold Other Cost and Expense, Operating Common stock being exchanged (in shares) Debt Conversion, Converted Instrument, Shares Issued Litigation Status [Axis] Litigation Status [Axis] Prepaids and other assets Increase (Decrease) in Prepaid Expense and Other Assets Number of major customers Concentration Risk, Number of Major Customers The number of the Company's major customers. Treasury stock (in shares) Treasury Stock, Shares Revenue interest liability Revenue Interest Liability, Current Liability related to Revenue Interest Purchase Agreement ("RIPA"), classified as current. Hypothetical repayment obligation Hypothetical Repayment Obligation Based On Sales Generated Hypothetical Repayment Obligation Based On Sales Generated Provision for income taxes Income Tax Expense (Benefit) Payments on revenue interest liability Revenue Interests payments Payments From Revenue Interest Purchase Agreement The cash outflow from a revenue interest purchase agreement. Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Income Statement [Abstract] Income Statement [Abstract] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Additional Paid-In Capital Additional Paid-in Capital [Member] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Document Fiscal Period Focus Document Fiscal Period Focus Cumulative Effect, Period of Adoption, Adjusted Balance Cumulative Effect, Period of Adoption, Adjusted Balance [Member] Restricted cash Restricted Cash, Noncurrent Insurance settlement recovery Loss Contingency, Receivable Percentage of cumulative purchaser payments Percentage Of Cumulative Purchaser Payments, Guarantee Percentage Of Cumulative Purchaser Payments, Guarantee Weighted-average shares outstanding - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Schedule of Inventories Schedule of Inventory, Current [Table Text Block] Percentage of royalties to be received on the net sales Percentage of Royalties to be Received on Net Sales The percentage of royalties to be received on net sales. Loss Contingencies [Line Items] Loss Contingencies [Line Items] Arrangements and Non-arrangement Transactions [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] License and Collaboration Agreement Collaborative Arrangement [Member] Investments Debt Securities, Available-for-Sale [Line Items] Debt issuance costs Debt Issuance Costs, Gross Common stock, $0.001 par value; 240,000,000 shares authorized as of September 30, 2022 and 120,000,000 shares authorized as of December 31, 2021; 73,739,320 shares issued at September 30, 2022 and 62,873,694 shares issued at December 31, 2021 Common Stock, Value, Issued Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Exchange Agreement, weighted average price per share floor (in dollars per share) Debt Instrument, Exchange Agreement, Conversion, Weighted Average Price Per Share Floor Debt Instrument, Exchange Agreement, Conversion, Weighted Average Price Per Share Floor Vesting of restricted stock units (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Gross Debt instrument, convertible, conversion price (in dollars per share) Debt Instrument, Convertible, Conversion Price Schedule of Shares Excluded From Calculation of Diluted Net (Loss) Income Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of the Company's Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Convertible Debt Convertible Debt [Member] Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Preferred stock, authorized (in shares) Preferred Stock, Shares Authorized Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Total cash and cash equivalents and restricted cash shown on the condensed statements of cash flows Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Debt instrument, required amount outstanding Debt Instrument, Covenant, Required Amount Outstanding Debt Instrument, Covenant, Required Amount Outstanding Fair value of warrants Adjustments to Additional Paid in Capital, Warrant Issued Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Current liabilities: Liabilities, Current [Abstract] Proceeds from exercise of common stock options Proceeds from Stock Options Exercised Common stock, issued (in shares) Common Stock, Shares, Issued Vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Deferred revenue from collaborations Contract with Customer, Liability, Current Cash Equivalents and Restricted Cash Cash Equivalents [Member] Schedule of Company's Cash Equivalents, Restricted Cash, and Short-Term Investments Unrealized Gain (Loss) on Investments [Table Text Block] Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Member] Income Statement Location [Domain] Income Statement Location [Domain] Convertible notes, net of issuance costs Convertible Notes Payable, Noncurrent Fair value measurements Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Royalty revenue and product sales bulk tablets Royalty Revenue And Product Sales Bulk Tablets [Member] Royalty Revenue And Product Sales Bulk Tablets Amendment Flag Amendment Flag Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities Debt instrument, face amount Debt Instrument, Face Amount Vesting of ESPP Shares Stock Issued During Period, Value, Employee Stock Purchase Plan Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Effective annual imputed interest rate (as a percent) Revenue Interest Purchase Agreement, Effective Annual Imputed Interest Rate Represents the percentage of effective annual imputed interest rate under the revenue interest purchase agreement. Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Entity Current Reporting Status Entity Current Reporting Status Exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Revenue Interest Purchase Agreement (RIPA) Revenue Interest Purchase Agreement [Member] Represents the information pertaining to revenue interest purchase agreement ("RIPA"). Liability From Sale Of Future Revenues [Roll Forward] Liability From Sale Of Future Revenues [Roll Forward] Liability From Sale Of Future Revenues Vesting of ESPP Shares (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Counterparty Name [Axis] Counterparty Name [Axis] Outstanding at the beginning of period (in shares) Outstanding at the end of the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Intangible assets Intangible Assets, Net (Including Goodwill) Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Collaborations with Third Parties Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Property and equipment, net Property, Plant and Equipment, Net Stock options Common shares under option Share-Based Payment Arrangement, Option [Member] Treasury stock, at cost; 1,994,198 shares at September 30, 2022 and December 31, 2021 Treasury Stock, Value Long-term Debt Long-Term Debt [Member] Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Long-term debt Long-Term Debt Other income, net Other Nonoperating Income (Expense) Balance Sheet Location [Axis] Balance Sheet Location [Axis] Common stock, authorized (in shares) Common Stock, Shares Authorized Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Total operating expenses Operating Expenses Maximum Maximum [Member] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Common stock Common Class A [Member] PBSOs Common shares under PBSOs Share Based Payment Arrangement, Option, Performance Based [Member] Share Based Payment Arrangement, Option, Performance Based Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Proceeds from Revenue Interest Purchase Agreement Proceeds from Revenue Interest Purchase Agreement Proceeds from Revenue Interest Purchase Agreement Deferred revenue Increase (Decrease) in Contract with Customer, Liability Total current assets Assets, Current Entity Small Business Entity Small Business Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Fair Value, Measurement Frequency [Domain] Measurement Frequency [Domain] Stockholders' Deficit Stockholders' Equity Note Disclosure [Text Block] Shares issued (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period Accrued variable consideration Accrued Variable Consideration, Current Liabilities for co-pay assistance, expected product returns, rebates, and distributor fees Revenues: Revenues [Abstract] Specified net revenue Specified Net Revenue Threshold Triggering Deposit In Blocked Account Maximum Amount of Net Revenue To Qualify For Deposit In Blocked Account Restricted cash Restricted Cash Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Debt instrument, convertible, threshold trading days Debt Instrument, Convertible, Threshold Trading Days Class of warrant or right, premium percentage Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Premium Percentage Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Premium Percentage Minimum amount of annual net sales to qualify for reduced revenue interest rate by December 31, 2024, contingent on 100% invested capital received Minimum Amount of Annual Net Sales To Qualify for Reduced Revenue Interest Rate, Contingent Threshold Minimum Amount of Annual Net Sales To Qualify for Reduced Revenue Interest Rate, Contingent Threshold Number of Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Initial revenue interest rate Revenue Interest Rate, Initial Rate The initial revenue interest rate, as a percentage of the Company's net sales in the Covered Territory. Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Accounts receivable Increase (Decrease) in Accounts Receivable Title of 12(b) Security Title of 12(b) Security Short-term investments Short-Term Investments Payables and Accruals [Abstract] Payables and Accruals [Abstract] Debt Instrument [Line Items] Debt Instrument [Line Items] Amortization of premiums and discounts on investments Accretion (Amortization) of Discounts and Premiums, Investments Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Other accrued liabilities Increase (Decrease) in Other Accrued Liabilities Stock Option And Incentive Plan 2022 Stock Option And Incentive Plan 2022 [Member] Stock Option And Incentive Plan 2022 Accrued clinical development costs Accrued Clinical Development Costs, Current Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle, if longer). Non cash right of use asset Non Cash Right Of Use Asset Represents the difference between the lease asset and the lease liability. Liability Related to the Revenue Interest Purchase Agreement Liability Related to the Revenue Interest Purchase Agreement No definition. Liabilities and stockholders’ equity Liabilities and Equity [Abstract] U.S. treasury notes US Treasury Securities [Member] Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Forfeited or expired (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Payment to plaintiff Litigation Settlement, Amount Awarded to Other Party Proceeds from stock offering, net Sale of Stock, Consideration Received on Transaction Inventories, net Total Inventory Inventory, Net Accounts payable Accounts Payable, Current Net Sales Less Than $250 Million Net Sales Threshold One [Member] Net Sales Threshold One Vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Debt instrument, convertible, threshold percentage of stock price trigger Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger Percentage of invested capital received by December 31, 2024, to qualify for second reduced revenue interest rate Percentage of Invested Capital Received By December 31, 2024, To Qualify For Second Reduced Revenue Interest Rate Percentage of invested capital received by December 31, 2024, to qualify for second reduced revenue interest rate. Warrants Warrant [Member] Entity Filer Category Entity Filer Category Proceeds from issuance of common stock, net of issuance costs Proceeds from Issuance of Common Stock Weighted-average shares outstanding - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Deferred up-front payment Deferred Up-Front Payment Deferred Up-Front Payment Litigation settlement Loss Contingency Accrual Debt instrument, convertible, carrying amount of equity component Debt Instrument, Convertible, Carrying Amount of Equity Component Stock-based compensation expense Share-Based Payment Arrangement, Expense Commitments and contingencies (Note 5) Commitments and Contingencies Security Exchange Name Security Exchange Name Outstanding at the beginning of period (in dollars per share) Outstanding at the end of the period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Company deposit value in blocked account Blocked Account Deposit Amount If Specified Net Revenue Does Not Meet Threshold Blocked Account Deposit Amount If Specified Net Revenue Does Not Meet Threshold Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Loss on modification of debt Gains (Losses) on Restructuring of Debt Preferred stock, $0.001 par value; 5,000,000 shares authorized and no shares issued or outstanding as of September 30, 2022 and December 31, 2021 Preferred Stock, Value, Issued Gross proceeds from revenue interest liability Gross Proceeds from Revenue Interest Purchase Agreement The cash inflow from a revenue interest purchase agreement. Total Revenues Collaboration revenue Revenue from Contract with Customer, Excluding Assessed Tax Milestone payment, achievement of the primary MACE in the CLEAR Outcomes study and CV risk reduction rate on the U.S. label Future Payment Milestone, Achievement of Drug Trial Outcomes Studies The amount of potential future payment which becomes due with the achievement of the primary MACE in the CLEAR Outcomes study and the CV risk reduction rate on the U.S. label, depending on the range of relative risk reduction in the CLEAR Outcomes study. Shares reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Liability Related to the Revenue Interest Purchase Agreement Liability Related to The Revenue Interest Purchase Agreement [Text Block] The entire disclosure of liabilities related to the Revenue Interest Purchase Agreement entered into by the Company with Eiger III SA LLC ("Oberland"). Cover [Abstract] Cover [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Pending Litigation Pending Litigation [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Stock Compensation Share-Based Payment Arrangement [Text Block] Work in process Inventory, Work in Process, Net of Reserves RIPA Amendment Revenue Interest Purchase Agreement Amendment [Member] Revenue Interest Purchase Agreement Amendment Period Two Debt Instrument, Redemption, Period Two [Member] Total liabilities and stockholders’ deficit Liabilities and Equity Maximum annual contributions per employee, as a percentage of base salary Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Percent Maximum percentage of employee gross pay the employee may contribute to an employee stock purchase plan. Debt instrument, term Debt Instrument, Term Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Amortization of debt issuance costs Amortization of Debt Issuance Costs Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Shares delivered to the company (in shares) Stock Issued During Period, Shares, Treasury Stock Reissued Level 2 Fair Value, Inputs, Level 2 [Member] Period One Debt Instrument, Redemption, Period One [Member] Purchases of investments Payments to Acquire Investments Current Fiscal Year End Date Current Fiscal Year End Date Repayment amount expected to pay in next twelve months Revenue Interest, Repayment Obligation Amount Expected In Next Twelve Months Revenue Interest, Repayment Obligation Amount Expected In Next Twelve Months Net loss per common share - diluted (in dollars per share) Earnings Per Share, Diluted Sale of Stock [Domain] Sale of Stock [Domain] Payment of issuance costs Payment of issuance costs Payments of Stock Issuance Costs Amount of subsequent installment, subject to achievement of sales threshold Amount of Subsequent Installment, Subject to Achievement of Sales Threshold The amount of the subsequent installment which is subject to the achievement of the Sales Threshold as defined in the Revenue Interest Purchase Agreement. Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Concentration Risk Type [Axis] Concentration Risk Type [Axis] Total current liabilities Liabilities, Current Customer Concentration Risk Customer Concentration Risk [Member] Unvested RSUs Unvested Restricted Stock And Restricted Stock Units [Member] Represents information pertaining to unvested restricted stock and restricted stock units. Provision for income taxes Income Tax Expense (Benefit), Continuing Operations [Abstract] Hypothetical sales generated amount Hypothetical Sales Generated Amount Hypothetical Sales Generated Amount Cumulative Effect, Period of Adoption, Adjustment Cumulative Effect, Period of Adoption, Adjustment [Member] Entity Address, Address Line One Entity Address, Address Line One Stock-based compensation capitalized into inventory Share-Based Payment Arrangement, Amount Capitalized Capped Call Capped Call [Member] Capped Call Product and Service [Axis] Product and Service [Axis] Class of Stock [Domain] Class of Stock [Domain] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Subsidiary, Sale of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] Interest expense Interest expense Interest Expense Amount of maximum annual contributions per employee Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Amount Maximum amount the employee may contribute to an employee stock purchase plan. Proceeds from sales/maturities of investments Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale Cash payment to be received upon certain commercial milestones Cash Payment To Be Received Upon Certain Commercial Milestones Cash Payment To Be Received Upon Certain Commercial Milestones Schedule of Other Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract] Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] Inventories, net Inventory Disclosure [Text Block] Equity [Abstract] Percentage of revenue interests payment on which agreement terminates Percentage Of Revenue Interests Payment on Which Agreement Terminates Percentage of revenue interests payment on which agreement terminates. Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Milestone payment, first NHI Price Listing for NEXLETOL in the Otsuka Territory Future Payment Milestone, First National Health Insurance Price Listing, Otsuka Territory The amount of a potential future payment which becomes due with the first National Health Insurance price listing for NEXLETOL in the Otsuka Territory. Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Entity Tax Identification Number Entity Tax Identification Number Number of commons stock shares available for issuance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Oberland Eiger Iii Sa Llc [Member] Represents the information pertaining to revenue interest purchase agreement ("RIPA") with Oberland. Research and development Research and Development Expense (Excluding Acquired in Process Cost) Common stock issuance costs not yet paid Common Stock Issuance Costs Incurred Common Stock Issuance Costs Incurred Net decrease in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Accrued interest receivable Accrued Investment Income Receivable Summary of Significant Accounting Policies Significant Accounting Policies [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Statements of Cash Flows and Restricted Cash Cash and Cash Equivalents Disclosure [Text Block] Entity Central Index Key Entity Central Index Key Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Interest income on investments Investment Income, Interest Measurement Frequency [Axis] Measurement Frequency [Axis] Weighted-Average Fair Value Per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Collaborations with Third Parties Collaborative Arrangement Disclosure [Text Block] Concentration of Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Accrued other Other Accrued Liabilities, Current Aggregate offering price shares Sale Of Stock, Authorized Amount Sale Of Stock, Authorized Amount City Area Code City Area Code Accrued professional fees Accrued Professional Fees, Current Assets Assets [Abstract] At The Market Program At The Market Program [Member] At The Market Program Non-cash interest expense related to the revenue interest liability Non Cash Interest Expense Related to Revenue Interest Liability The amount of non-cash expense included in interest expense associated with the revenue interest liability. Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Sale of Stock [Axis] Sale of Stock [Axis] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Percentage of revenue interests payment on which agreement terminates, if prior to the anniversary of the closing date, if put option is exercised Percentage Of Revenue Interests Payment on Which Agreement Terminates If Prior to the Anniversary Of Closing Date If Put Option Is Exercised Percentage of revenue interests payment on which agreement terminates, if prior to the anniversary of the closing date, if put option is exercised. Financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Total shares of common stock from exercisable warrants outstanding Class of Warrant or Right, Outstanding Net Sales Threshold [Domain] Net Sales Threshold [Domain] Net Sales Threshold Net Sales Greater Than $250 Million But Less Than $350 Million Net Sales Threshold Two [Member] Net Sales Threshold Two Net Sales Greater Than $350 Million Net Sales Threshold Three [Member] Net Sales Threshold Three Minimum amount of annual net sales to qualify for reduced revenue interest rate by December 31, 2021 Minimum Amount of Annual Net Sales To Qualify for Reduced Revenue Interest Rate The minimum amount of annual net sales to qualify for reduced revenue interest rate by December 31, 2021. The Company and Basis of Presentation Business Description and Basis of Presentation [Text Block] Accounting Standards Update [Extensible Enumeration] Accounting Standards Update [Extensible Enumeration] Accounting Standards Update 2020-06 [Member] EX-101.PRE 9 espr-20220930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 10 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover Page - shares
 9 Months Ended
Sep. 30, 2022
Oct. 31, 2022
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2022  
Document Transition Report false  
Entity File Number 001-35986  
Entity Registrant Name Esperion Therapeutics, Inc.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 26-1870780  
Entity Address, Address Line One 3891 Ranchero Drive, Suite 150  
Entity Address, City or Town Ann Arbor  
Entity Address, State or Province MI  
Entity Address, Postal Zip Code 48108  
City Area Code 734  
Local Phone Number 887-3903  
Title of 12(b) Security Common Stock, par value $0.001 per share  
Trading Symbol ESPR  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   73,683,572
Entity Central Index Key 0001434868  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q3  
Amendment Flag false  
XML 11 R2.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 159,399 $ 208,892
Short-term investments 29,942 50,441
Accounts receivable 31,489 22,934
Prepaid clinical development costs 2,199 1,138
Inventories, net 29,545 34,394
Other prepaid and current assets 9,211 11,173
Total current assets 261,785 328,972
Restricted cash 50,000 50,000
Property and equipment, net 256 664
Right of use operating lease assets 730 1,898
Intangible assets 56 56
Total assets 312,827 381,590
Current liabilities:    
Accounts payable 18,580 17,559
Accrued clinical development costs 3,996 7,013
Other accrued liabilities 35,395 30,410
Revenue interest liability 19,636 11,295
Deferred revenue from collaborations 4,045 5,683
Operating lease liabilities 693 1,392
Total current liabilities 82,345 73,352
Convertible notes, net of issuance costs 259,487 258,280
Revenue interest liability 265,048 245,744
Operating lease liabilities 47 524
Deferred revenue from collaborations 0 634
Total liabilities 606,927 578,534
Commitments and contingencies (Note 5)
Stockholders’ equity:    
Preferred stock, $0.001 par value; 5,000,000 shares authorized and no shares issued or outstanding as of September 30, 2022 and December 31, 2021 0 0
Common stock, $0.001 par value; 240,000,000 shares authorized as of September 30, 2022 and 120,000,000 shares authorized as of December 31, 2021; 73,739,320 shares issued at September 30, 2022 and 62,873,694 shares issued at December 31, 2021 72 61
Additional paid-in capital 1,045,468 964,401
Treasury stock, at cost; 1,994,198 shares at September 30, 2022 and December 31, 2021 (54,998) (54,998)
Accumulated other comprehensive loss (93) (31)
Accumulated deficit (1,284,549) (1,106,377)
Total stockholders’ deficit (294,100) (196,944)
Total liabilities and stockholders’ deficit $ 312,827 $ 381,590
XML 12 R3.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, authorized (in shares) 5,000,000 5,000,000
Preferred stock, issued (in shares) 0 0
Preferred stock, outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, authorized (in shares) 240,000,000 120,000,000
Common stock, issued (in shares) 73,739,320 62,873,694
Treasury stock (in shares) 1,994,198 1,994,198
XML 13 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenues:        
Total Revenues $ 18,980 $ 14,409 $ 56,657 $ 63,046
Operating expenses:        
Cost of goods sold 6,506 5,558 22,807 9,142
Research and development 29,143 25,331 85,894 78,359
Selling, general and administrative 24,954 39,265 84,944 146,647
Total operating expenses 60,603 70,154 193,645 234,148
Loss from operations (41,623) (55,745) (136,988) (171,102)
Interest expense (14,153) (13,654) (42,481) (32,923)
Other income, net 659 13 1,297 36
Net loss $ (55,117) $ (69,386) $ (178,172) $ (203,989)
Net loss per common share - basic (in dollars per share) $ (0.81) $ (2.62) $ (2.78) $ (7.78)
Net loss per common share - diluted (in dollars per share) $ (0.81) $ (2.62) $ (2.78) $ (7.78)
Weighted-average shares outstanding - basic (in shares) 67,806,292 26,455,209 64,021,248 26,225,730
Weighted-average shares outstanding - diluted (in shares) 67,806,292 26,455,209 64,021,248 26,225,730
Other comprehensive loss:        
Unrealized gain (loss) on investments $ 204 $ 0 $ (62) $ 0
Comprehensive loss (54,913) (69,386) (178,234) (203,989)
Product sales, net        
Revenues:        
Total Revenues 13,964 10,895 40,896 27,855
Collaboration revenue        
Revenues:        
Total Revenues $ 5,016 $ 3,514 $ 15,761 $ 35,191
XML 14 R5.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Statements of Stockholders' Deficit - USD ($)
$ in Thousands
Total
Cumulative Effect, Period of Adoption, Adjustment
Cumulative Effect, Period of Adoption, Adjusted Balance
Common Stock
Common Stock
Cumulative Effect, Period of Adoption, Adjusted Balance
Additional Paid-In Capital
Additional Paid-In Capital
Cumulative Effect, Period of Adoption, Adjustment
Additional Paid-In Capital
Cumulative Effect, Period of Adoption, Adjusted Balance
Accumulated Deficit
Accumulated Deficit
Cumulative Effect, Period of Adoption, Adjustment
Accumulated Deficit
Cumulative Effect, Period of Adoption, Adjusted Balance
Accumulated Other Comprehensive Income (Loss)
Accumulated Other Comprehensive Income (Loss)
Cumulative Effect, Period of Adoption, Adjusted Balance
Treasury Stock
Treasury Stock
Cumulative Effect, Period of Adoption, Adjusted Balance
Beginning balance (in shares) at Dec. 31, 2020       25,916,168 25,916,168                    
Beginning balance at Dec. 31, 2020 $ (96,134) $ (91,927) $ (188,061) $ 26 $ 26 $ 797,655 $ (93,475) $ 704,180 $ (838,817) $ 1,548 $ (837,269) $ 0 $ 0 $ (54,998) $ (54,998)
Increase (Decrease) in Stockholders' Equity                              
Exercise of stock options (in shares)       172,268                      
Exercise of stock options 2,668         2,668                  
Vesting of restricted stock units (in shares)       43,465                      
Vesting of ESPP Shares (in shares)       50,818                      
Vesting of ESPP Shares 1,183         1,183                  
Stock-based compensation 5,751         5,751                  
Net loss (90,935)               (90,935)            
Ending balance (in shares) at Mar. 31, 2021       26,182,719                      
Ending balance at Mar. 31, 2021 (269,394)     $ 26   713,782     (928,204)     0   (54,998)  
Beginning balance (in shares) at Dec. 31, 2020       25,916,168 25,916,168                    
Beginning balance at Dec. 31, 2020 (96,134) $ (91,927) $ (188,061) $ 26 $ 26 797,655 $ (93,475) $ 704,180 (838,817) $ 1,548 $ (837,269) 0 $ 0 (54,998) $ (54,998)
Increase (Decrease) in Stockholders' Equity                              
Net loss (203,989)                            
Ending balance (in shares) at Sep. 30, 2021       26,800,369                      
Ending balance at Sep. 30, 2021 (362,705)     $ 27   733,524     (1,041,258)     0   (54,998)  
Beginning balance (in shares) at Mar. 31, 2021       26,182,719                      
Beginning balance at Mar. 31, 2021 (269,394)     $ 26   713,782     (928,204)     0   (54,998)  
Increase (Decrease) in Stockholders' Equity                              
Exercise of stock options (in shares)       10,477                      
Exercise of stock options 168         168                  
Vesting of restricted stock units (in shares)       81,139                      
Stock-based compensation 8,584         8,584                  
Net loss (43,668)               (43,668)            
Ending balance (in shares) at Jun. 30, 2021       26,274,335                      
Ending balance at Jun. 30, 2021 (304,310)     $ 26   722,534     (971,872)     0   (54,998)  
Increase (Decrease) in Stockholders' Equity                              
Issuance of common stock, net of issuance costs (in shares)       363,061                      
Issuance of common stock from ATM program, net of issuance costs 4,207     $ 1   4,206                  
Exercise of stock options (in shares)       45,996                      
Exercise of stock options 375         375                  
Vesting of restricted stock units (in shares)       34,581                      
Vesting of ESPP Shares (in shares)       82,396                      
Vesting of ESPP Shares 912         912                  
Stock-based compensation 5,497         5,497                  
Net loss (69,386)               (69,386)            
Ending balance (in shares) at Sep. 30, 2021       26,800,369                      
Ending balance at Sep. 30, 2021 (362,705)     $ 27   733,524     (1,041,258)     0   (54,998)  
Beginning balance (in shares) at Dec. 31, 2021       60,879,496                      
Beginning balance at Dec. 31, 2021 (196,944)     $ 61   964,401     (1,106,377)     (31)   (54,998)  
Increase (Decrease) in Stockholders' Equity                              
Vesting of restricted stock units (in shares)       55,286                      
Vesting of ESPP Shares (in shares)       123,785                      
Vesting of ESPP Shares 431         431                  
Stock-based compensation 4,436         4,436                  
Other comprehensive loss (232)                     (232)      
Net loss (56,731)               (56,731)            
Ending balance (in shares) at Mar. 31, 2022       61,058,567                      
Ending balance at Mar. 31, 2022 (249,040)     $ 61   969,268     (1,163,108)     (263)   (54,998)  
Beginning balance (in shares) at Dec. 31, 2021       60,879,496                      
Beginning balance at Dec. 31, 2021 $ (196,944)     $ 61   964,401     (1,106,377)     (31)   (54,998)  
Increase (Decrease) in Stockholders' Equity                              
Exercise of stock options (in shares) 0                            
Net loss $ (178,172)                            
Ending balance (in shares) at Sep. 30, 2022       71,745,122                      
Ending balance at Sep. 30, 2022 (294,100)     $ 72   1,045,468     (1,284,549)     (93)   (54,998)  
Beginning balance (in shares) at Mar. 31, 2022       61,058,567                      
Beginning balance at Mar. 31, 2022 (249,040)     $ 61   969,268     (1,163,108)     (263)   (54,998)  
Increase (Decrease) in Stockholders' Equity                              
Issuance of common stock, net of issuance costs (in shares)       3,353,000                      
Issuance of common stock from ATM program, net of issuance costs 20,173     $ 4   20,169                  
Vesting of restricted stock units (in shares)       184,407                      
Stock-based compensation 3,527         3,527                  
Other comprehensive loss (34)                     (34)      
Net loss (66,324)               (66,324)            
Ending balance (in shares) at Jun. 30, 2022       64,595,974                      
Ending balance at Jun. 30, 2022 (291,698)     $ 65   992,964     (1,229,432)     (297)   (54,998)  
Increase (Decrease) in Stockholders' Equity                              
Issuance of common stock, net of issuance costs (in shares)       6,958,525                      
Issuance of common stock from ATM program, net of issuance costs 48,673     $ 7   48,666                  
Vesting of restricted stock units (in shares)       108,200                      
Vesting of ESPP Shares (in shares)       82,423                      
Vesting of ESPP Shares 301         301                  
Stock-based compensation 3,537         3,537                  
Other comprehensive loss 204                     204      
Net loss (55,117)               (55,117)            
Ending balance (in shares) at Sep. 30, 2022       71,745,122                      
Ending balance at Sep. 30, 2022 $ (294,100)     $ 72   $ 1,045,468     $ (1,284,549)     $ (93)   $ (54,998)  
XML 15 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Operating activities    
Net loss $ (178,172) $ (203,989)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation expense 408 459
Amortization of premiums and discounts on investments 539 0
Amortization of debt issuance costs 1,207 1,214
Non-cash interest expense related to the revenue interest liability 33,323 23,310
Stock-based compensation expense 11,500 19,832
Changes in assets and liabilities:    
Accounts receivable (8,555) (9,322)
Prepaids and other assets 901 1,096
Deferred revenue (2,272) 2,251
Inventories 4,849 (17,836)
Accounts payable 1,129 (30,833)
Other accrued liabilities 2,788 7,715
Net cash used in operating activities (132,355) (206,103)
Investing activities    
Purchases of investments (18,102) 0
Proceeds from sales/maturities of investments 38,000 0
Net cash provided by investing activities 19,898 0
Financing activities    
Proceeds from revenue interest liability, net of issuance costs 0 49,917
Proceeds from exercise of common stock options 0 3,211
Proceeds from issuance of common stock, net of issuance costs 68,861 4,388
Payments on revenue interest liability (5,678) (2,263)
Payment of issuance costs (219) (440)
Net cash provided by financing activities 62,964 54,813
Net decrease in cash and cash equivalents (49,493) (151,290)
Cash, cash equivalents and restricted cash at beginning of period 258,892 304,962
Cash, cash equivalents and restricted cash at end of period 209,399 153,672
Supplemental disclosure of cash flow information:    
Common stock issuance costs not yet paid 15 181
Non cash right of use asset $ 8 $ 10
XML 16 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
The Company and Basis of Presentation
 9 Months Ended
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
The Company and Basis of Presentation The Company and Basis of Presentation
Esperion Therapeutics, Inc. ("the Company”) is a pharmaceutical company singularly focused on developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol ("LDL-C"). Through commercial execution and advancement of the CLEAR Outcomes trial as well as the Company's pre-clinical pipeline, the Company continues to evolve into a differentiated, global cardiometabolic biotech. The Esperion team of lipid experts are dedicated to lowering bad cholesterol through the discovery, development and commercialization of innovative medicines and their combinations with established medicines. The Company's first two products were approved by the U.S. Food and Drug Administration ("FDA"), European Medicines Agency ("EMA") and Swiss Agency for Therapeutic Products ("Swissmedic") in 2020. Bempedoic acid and the bempedoic acid / ezetimibe combination tablet are oral, once-daily, non-statin, LDL-C lowering medicines for patients with atherosclerotic cardiovascular disease ("ASCVD") or heterozygous familial hypercholesterolemia ("HeFH").
On November 1, 2022, the Company announced that it is continuing to close out its CLEAR (Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen) Outcomes study of NEXLETOL®. The Company continues to anticipate reporting top-line results from the study in January 2023.
The Company's primary activities since incorporation have been conducting research and development activities, including nonclinical, preclinical and clinical testing, performing business and financial planning, recruiting personnel, and raising capital. The Company received approval by the FDA in February 2020 to commercialize NEXLETOL (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) tablet in the U.S., and accordingly commenced principal operations on March 30, 2020 with the commercialization of NEXLETOL. The Company is subject to risks and uncertainties which include the need to successfully commercialize its products, research, develop, and clinically test therapeutic products; obtain regulatory approvals for its products; manage its management, commercial and scientific staff; and finance its operations with an ultimate goal of achieving profitable operations.
The Company has sustained annual operating losses since inception and expects such losses to continue over the foreseeable future. The Company's ability to successfully launch, commercialize and generate revenue from NEXLETOL, NEXLIZET, NILEMDO® (bempedoic acid) tablet and NUSTENDI® (bempedoic acid and ezetimibe) tablet has been and may continue to be adversely affected by the economic impact of the ongoing COVID-19 pandemic. While management believes current cash resources and future cash received from the Company's net product sales and collaboration agreements with Daiichi Sankyo Europe GmbH ("DSE"), Otsuka Pharmaceutical Co., Ltd. ("Otsuka"), and Daiichi Sankyo Co. Ltd ("DS"), entered into on January 2, 2019, April 17, 2020 and April 26, 2021, respectively, will fund operations for the foreseeable future, management may continue to fund operations and advance the development of the Company's products and product candidates through a combination of collaborations with third parties, strategic alliances, licensing arrangements, permitted debt financings, permitted royalty-based financings, and permitted private and public equity offerings or through other sources. The continuing impact of COVID-19 and the uncertainty around the global pandemic could further impact the commercialization of NEXLETOL and NEXLIZET and the Company’s research and development programs and could result in lower cash flows or higher costs that could further impact the Company’s overall operations and cash needs in the future.
If adequate funds are not available, the Company may not be able to continue the development of its current products or future product candidates, or to commercialize its current or future product candidates, if approved.
Basis of Presentation
The accompanying condensed interim financial statements are unaudited and were prepared by the Company in accordance with generally accepted accounting principles in the United States of America (“GAAP”). In the opinion of management, the Company has made all adjustments, which include only normal recurring adjustments necessary for a fair presentation of the Company’s financial position and results of operations for the interim periods presented. Certain prior year amounts have been reclassified to conform with current year presentation. Certain information and disclosures normally included in the annual financial statements prepared in accordance with GAAP, but that is not required for interim reporting purposes, have been condensed or omitted. These condensed interim financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2021, and the notes thereto, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. The results of operations for the interim periods are not necessarily indicative of the results to be expected for a full year, any other interim periods or any future year or period.
XML 17 R8.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Significant Accounting Policies
 9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Use of Estimates
The preparation of financial statements in accordance with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, net revenues, expenses and related disclosures. Actual results could differ from those estimates.
Cash and Cash Equivalents
The Company invests its excess cash in bank deposits, money market accounts, and short-term investments. The Company considers all highly liquid investments with an original maturity of 90 days or less at the time of purchase to be cash equivalents. Cash equivalents are reported at fair value.
Restricted Cash
Restricted cash consists of legally restricted amounts held by financial institutions pursuant to contractual arrangements. Pursuant to the Amendment and Waiver (as defined below), the Company deposited $50.0 million in a deposit account that is subject to a block account control agreement. Eiger III SA LLC (“Oberland”), an affiliate of Oberland Capital LLC, will have sole control over the funds deposited in the account and such funds may be withdrawn only with the consent of Oberland. Refer to Note 8 "Liability Related to the Revenue Interest Purchase Agreement" for further information on the Amendment and Waiver.
Investments
Investments are considered to be available-for-sale and are carried at fair value. Unrealized gains and losses, if any, are reported in accumulated other comprehensive income (loss). The cost of investments classified as available-for-sale are adjusted for the amortization of premiums and accretion of discounts to maturity and recorded in other income, net. Realized gains and losses, if any, are determined using the specific identification method and recorded in other income, net. Investments with original maturities beyond 90 days at the date of purchase and which mature at, or less than twelve months from, the balance sheet date are classified as current. Investments with a maturity beyond twelve months from the balance sheet date are classified as long-term.
Concentration of Risk
The Company enters into a limited number of distribution agreements with distributors and specialty pharmacies. The Company's net product sales are with these customers. As of September 30, 2022, thirteen customers accounted for all of the Company's net trade receivables and as of December 31, 2021, nine customers accounted for all the Company's net trade receivables.
Revenue Recognition
In accordance with ASC 606, Revenue from Contracts with Customers, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange for the goods or services provided. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: identify the contracts with a customer; identify the performance obligations in the contract; determine the transaction price; allocate the transaction price to the performance obligations in the contract; and recognize revenue when or as the entity satisfies a performance obligation. At contract inception the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. The Company derives revenue through two primary sources: collaboration revenue and product sales. Collaboration revenue consists of the collaboration payments to the Company for collaboration arrangements outside of the United States for the development, manufacturing and commercialization, including royalties, of the Company's product candidates by the Company's partners and product sales consists of sales of NEXLETOL and NEXLIZET.
a.Collaboration Revenue
The Company has entered into agreements related to its activities to develop, manufacture, and commercialize its product candidates. The Company earns collaboration revenue in connection with a collaboration agreement to develop and/or commercialize product candidates where the Company deems the collaborator to be the customer. Revenue is recognized when (or as) the Company satisfies performance obligations under the terms of a contract. Depending on the terms of the arrangement, the Company may defer the recognition of all or a portion of the consideration received as the performance obligations are satisfied.
The collaboration agreements may require the Company to deliver various rights, services, and/or goods across the entire life cycle of a product or product candidate. In an agreement involving multiple goods or services promised to be transferred to a customer, the Company must assess, at the inception of the contract, whether each promise represents a separate performance obligation (i.e., is "distinct"), or whether such promises should be combined as a single performance obligation.
The terms of the agreement typically include consideration to be provided to the Company in the form of non-refundable up-front payments, development milestones, sales milestones, and royalties on sales of products within a respective territory. The Company recognizes regulatory and approval milestones consideration when it is probable that a future reversal is unlikely to occur. For sales-based milestones and royalties based on sales of product in a territory, the Company applies the sales-based royalty exception in ASC 606-10-55-65 to all of these milestones and royalties.
At the inception of the contract, the transaction price reflects the amount of consideration the Company expects to be entitled to in exchange for transferring promised goods or services to its customer. In the arrangement where the Company satisfies performance obligation(s) during the regulatory phase over time, the Company recognizes collaboration revenue typically using an input method on the basis of regulatory costs incurred relative to the total expected cost which determines the extent of progress toward completion. The Company reviews the estimate of the transaction price and the total expected cost each period and makes revisions to such estimates as necessary. Under contracted supply agreements with collaborators, the Company, through its third party contract manufacturing partners, may manufacture and supply quantities of active pharmaceutical ingredient (“API”) or bulk tablets reasonably required by collaboration partners for the development or sale of licensed products in their respective territory. The Company recognizes revenue when the collaboration partner has obtained control of the API or bulk tablets. The Company records the costs related to the supply agreement in cost of goods sold on the condensed statements of operations and comprehensive (loss) income.
Under the Company's collaboration agreements, product sales and cost of sales may be recorded by the Company's collaborators as they are deemed to be the principal in the transaction. The Company receives royalties from the commercialization of such products, and records its share of the variable consideration, representing a percentage of net product sales, as collaboration revenue in the period in which such underlying sales occur and costs are incurred by the collaborator.
b.Product Sales, Net
On February 21, 2020, the Company announced that the FDA approved NEXLETOL as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or established ASCVD who require additional lowering of LDL-C. On February 26, 2020, the Company announced that the FDA approved NEXLIZET as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or established ASCVD who require additional lowering of LDL-C. On March 30, 2020, NEXLETOL was commercially available in the U.S. through prescription and on June 4, 2020, NEXLIZET was commercially available in the U.S. through prescription. Net product sales totaled $14.0 million and $40.9 million for the three and nine months ended September 30, 2022, respectively, and $10.9 million and $27.9 million for the three and nine months ended September 30, 2021, respectively.
The Company sells NEXLETOL and NEXLIZET to wholesalers in the U.S. and, in accordance with ASC 606, recognizes revenue at the point in time when the customer is deemed to have obtained control of the product. The customer is deemed to have obtained control of the product at the time of physical receipt of the product at the customers’ distribution facilities, or free on board (“FOB”) destination, the terms of which are designated in the contract.
Product sales are recorded at the net selling price, which includes estimates of variable consideration for which reserves are established for (a) rebates and chargebacks, (b) co-pay assistance programs, (c) distribution fees, (d) product returns, and (e) other discounts. Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as current contractual and statutory requirements, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company's best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contract. The amount of variable consideration may be constrained and is included
in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Given the early stage of the Company’s commercial operations it has provided constraint of its variable consideration due to its potential consumption trends. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results in the future vary from estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.
Liabilities for co-pay assistance, expected product returns, rebates, and distributor fees are classified as “Other accrued liabilities” in the condensed balance sheets. Discounts, such as prompt pay discounts, and chargebacks are recorded as a reduction to trade accounts receivable in the condensed balance sheets.
Forms of Variable Consideration
Rebates and Chargebacks: The Company estimates reductions to product sales for Public Health Service Institutions, such as Medicaid, Medicare and Veterans' Administration ("VA") programs, as well as certain other qualifying federal and state government programs, and other group purchasing organizations. The Company estimates these reductions based upon the Company's contracts with government agencies and other organizations, statutorily defined discounts and estimated payor mix. These organizations purchase directly from the Company's wholesalers at a discount and the wholesalers charge the Company back the difference between the wholesaler price and the discounted price. The Company's liability for Medicaid rebates consists of estimates for claims that a state will make for a current quarter. The Company's reserve for this discounted pricing is based on expected sales to qualified healthcare providers and the chargebacks that customers have already claimed.
Co-pay assistance: Eligible patients who have commercial insurance may receive assistance from the Company to reduce the patient's out of pocket costs. The Company will buy down the difference between the amount of the eligible patient's co-pay when the drug is purchased at the pharmacy at a determined price. Liabilities for co-pay assistance are calculated by actual program participation from third-party administrators.
Distribution Fees: The Company has written contracts with its customers that include terms for distribution fees and costs for inventory management. The Company estimates and records distribution fees due to its customers based on gross sales.
Product Returns: The Company generally offers a right of return based on the product’s expiration date and certain spoilage and damaged instances. The Company estimates the amount of product sales that may be returned and records the estimate as a reduction of product sales in the period the related product sales is recognized. The Company’s estimates for expected returns are based primarily on an ongoing analysis of sales information and visibility into the inventory remaining in the distribution channel.
Discounts: The Company provides product discounts, such as prompt pay discounts, to its customers. The Company estimates cash discounts based on terms in negotiated contracts and the Company’s expectations regarding future payment patterns.
Inventories
Inventories are stated at the lower of cost or net realizable value and recognized on a first-in, first-out ("FIFO") method. The Company uses standard cost to determine the cost basis for inventory. Inventory is capitalized based on when future economic benefit is expected to be realized. The Company began capitalizing inventory upon receiving FDA approval for NEXLETOL and NEXLIZET on February 21, 2020 and February 26, 2020, respectively. Prior to the FDA approval of NEXLETOL and NEXLIZET, expenses associated with the manufacturing of the Company's products were recorded as research and development expense.
The Company analyzes its inventory levels on a periodic basis to determine if any inventory is at risk for expiration prior to sale or has a cost basis that is greater than its estimated future net realizable value. Any adjustments are recognized through cost of goods sold in the period in which they are incurred.
Recently Implemented Accounting Pronouncements
There have been no other material changes to the significant accounting policies previously disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021.
XML 18 R9.htm IDEA: XBRL DOCUMENT v3.22.2.2
Collaborations with Third Parties
 9 Months Ended
Sep. 30, 2022
Collaborations with Third Parties  
Collaborations with Third Parties Collaborations with Third Parties
DSE Agreement Terms
On January 2, 2019, the Company entered into a license and collaboration agreement with DSE, which was furthered amended on June 18, 2020. Pursuant to the amended agreement, the Company granted DSE exclusive commercialization rights to bempedoic acid and the bempedoic acid / ezetimibe combination tablet in the European Economic Area, Turkey, and Switzerland (“DSE Territory”). DSE will be responsible for commercialization in the DSE Territory. DSE's designated affiliate in Turkey will be solely responsible, at its sole cost and expense, for all regulatory matters relating to such products in Turkey, including obtaining regulatory approval for such products in Turkey. The Company remains responsible for clinical development, regulatory and manufacturing activities for the licensed products globally, including in the DSE Territory outside of Turkey.
Pursuant to the agreement, the Company received upfront cash of $150.0 million in 2019 and a $150.0 million cash milestone payment in 2020 following the completion of the NUSTENDI Marketing Authorisation Applications ("MAA"). The Company is responsible for supplying DSE with certain manufacturing supply of the API or bulk tablets. The Company is also eligible to receive a substantial additional regulatory milestone payment upon the grant of the marketing authorisation in the European Union for the CV risk reduction label, depending on the range of relative risk reduction in the CLEAR Outcomes study. In addition, the Company is eligible to receive additional sales milestone payments related to total net sales achievements for DSE in the DSE Territory. Finally, the Company will receive tiered fifteen percent (15%) to twenty-five percent (25%) royalties on net DSE Territory sales.
The agreement calls for both parties to participate in a Joint Collaboration Committee (the “DSE JCC”). The DSE JCC is comprised of executive management from each company and the Company will lead in all aspects related to development and DSE will lead in all aspects related to commercialization in the DSE Territory.
Collaboration Revenue
In the three and nine months ended September 30, 2022, the Company recognized collaboration revenue of approximately $4.4 million and $14.7 million, respectively, and in the three and nine months ended September 30, 2021, the Company recognized collaboration revenue of $3.3 million and $6.9 million, respectively, related to royalty revenue from DSE from the sales of NILEMDO and NUSTENDI as well as the sales of bulk tablets to DSE pursuant to the supply agreement that was executed with DSE.
All remaining future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained following the concepts of ASC 606 due to the fact that such amounts hinge on development activities, regulatory approvals and sales-based milestones. Additionally, the Company expects that any consideration related to sales-based milestones will be recognized when the subsequent sales occur.
Otsuka Agreement Terms
On April 17, 2020, the Company entered into a license and collaboration agreement (the "Otsuka Agreement") with Otsuka. Pursuant to the Otsuka Agreement, the Company granted Otsuka exclusive development and commercialization rights to NEXLETOL and NEXLIZET in Japan. Otsuka will be responsible for all development, regulatory, and commercialization activities in Japan. In addition, Otsuka will fund all clinical development costs associated with the program in Japan.
Pursuant to the agreement, the consideration consists of a $60.0 million upfront cash payment and the Company will be eligible to receive additional payments of up to $450.0 million if certain regulatory and commercial milestones are achieved by Otsuka. The potential future milestone payments include up to $20.0 million upon first JNDA submissions in the Otsuka Territory, up to $70.0 million upon the first NHI Price Listing for NEXLETOL in the Otsuka Territory, and up to $50.0 million upon the achievement of the primary major adverse cardiovascular events (“MACE”) in the CLEAR Outcomes study and the CV risk reduction rate on the U.S. label, depending on the range of relative risk reduction in the CLEAR Outcomes study. In addition, the Company is eligible to receive additional sales milestone payments up to $310.0 million related to total net sales achievements for Otsuka in Japan. Finally, the Company will receive tiered fifteen percent (15%) to thirty percent (30%) royalties on net sales in Japan.
Collaboration Revenue
The Company considered the guidance under ASC 606 and concluded that the agreement was in the scope of ASC 606. In the three and nine months ended September 30, 2022, the Company recognized $0.4 million of collaboration revenue related to sales of bulk tablets to Otsuka pursuant to the supply agreement that was executed with Otsuka. The Company did not have any collaboration revenue from the Otsuka Agreement during the three and nine months ended September 30, 2021.
All future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained following the concepts of ASC 606 due to the fact that such amounts hinge on development activities, regulatory approvals and sales-based milestones. Additionally, the Company expects that any consideration related to royalties and sales-based milestones will be recognized when the subsequent sales occur.
The Company has not yet recognized any revenue for milestone payments as the related regulatory and commercial milestones have not yet been achieved.
DS Agreement Terms
In April 2021, the Company entered into a license and collaboration agreement with Daiichi Sankyo Co. Ltd (the "DS Agreement"). Pursuant to the DS Agreement, the Company granted DS exclusive rights to develop and commercialize bempedoic acid and the bempedoic acid / ezetimibe combination tablet in South Korea, Taiwan, Hong Kong, Thailand, Vietnam, Brazil, Macao, Cambodia and Myanmar (collectively the "DS Territory"). The agreement allows for potential expansion across geographies including Saudi Arabia, Kuwait, Oman, UAE, Qatar, Bahrain, Yemen, Colombia and other Latin American countries. Except for certain development activities in South Korea and Taiwan, DS will be responsible for development and commercialization in these territories. In addition, DS will fund all development costs associated with the program in the DS Territory. Pursuant to the agreement, the consideration consists of a $30.0 million upfront cash payment that is non-refundable, non-reimbursable and non-creditable. The Company also will be eligible to receive additional one-time payments of up to $175.0 million if certain commercial milestones are achieved by DS. Also, the Company will receive tiered royalties of five percent (5%) to twenty percent (20%) of net sales in the DS Territory.

Collaboration Revenue
The Company considered the guidance under ASC 606 and concluded that the agreement was in the scope of ASC 606. The Company concluded that the upfront payment of $30.0 million should be included in the transaction price and related to the following performance obligations under the agreement: 1) the license to the Company’s intellectual property and 2) the obligation to provide ongoing development activities. The Company used the adjusted market assessment approach in determining the standalone selling price of the Company’s intellectual property and the expected cost plus margin approach in determining the standalone selling price of the Company’s obligation to provide ongoing development activities. Accordingly, for the three and nine months ended September 30, 2021, the Company recognized $0.2 million and $28.3 million of collaboration revenue related to the $30.0 million upfront payment, consisting of $28.0 million related to the performance obligations for the license to the Company’s intellectual property and $0.3 million related to ongoing regulatory and development activities conducted during the period ended September 30, 2021. During the year ended December 31, 2021, the Company recognized $28.5 million of collaboration revenue related to the $30.0 million upfront payment. The $28.5 million relates to the performance obligations for the license to the Company’s intellectual property and a portion of ongoing regulatory and development activities conducted during the year ended December 31, 2021, in the amounts of $28.0 million and $0.5 million, respectively. For the three and nine months ended September 30, 2022, the Company recognized $0.2 million and $0.6 million, respectively, of collaboration revenue related to the ongoing regulatory and development activities. The remaining $0.9 million of the upfront payment was deferred as of September 30, 2022 due to an on-going performance obligation related to the developmental activities in South Korea and Taiwan. This deferred revenue will be recognized ratably over the period leading up to the completion of these developmental activities.
All future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained following the concepts of ASC 606 due to the fact that such amounts hinge on development activities, regulatory approvals and sales-based milestones. Additionally, the Company expects that any consideration related to royalties and sales-based milestones will be recognized when the subsequent sales occur.
XML 19 R10.htm IDEA: XBRL DOCUMENT v3.22.2.2
Inventories, net
 9 Months Ended
Sep. 30, 2022
Inventory Disclosure [Abstract]  
Inventories, net Inventories, net
Inventories, net consist of the following (in thousands):
September 30, 2022December 31, 2021
Raw materials$24,785 $31,850 
Work in process2,874 663 
Finished goods1,886 1,881 
$29,545 $34,394 
XML 20 R11.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
On January 12, 2016, a purported stockholder of the Company filed a putative class action lawsuit in the United States District Court for the Eastern District of Michigan, against the Company and Tim Mayleben, captioned Kevin L. Dougherty v. Esperion Therapeutics, Inc., et al. (No. 16-cv-10089). The lawsuit alleges that the Company and Mr. Mayleben violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5 by allegedly failing to disclose in an August 17, 2015, public statement that the FDA would require a cardiovascular outcomes trial before approving the Company’s lead product candidate. The lawsuit seeks, among other things, compensatory damages in connection with an allegedly inflated stock price between August 18, 2015, and September 28, 2015, as well as attorneys’ fees and costs. On March 12, 2021, the parties agreed to a settlement in principle of the securities class action, and on April 26, 2021, the parties entered into a stipulation of settlement to resolve all legal claims, in which defendants expressly deny that they have committed any act or omission giving rise to any liability under Section 10(b) of the Securities Exchange Act of 1934. Under the terms of the stipulation of settlement, which the court approved on August 24, 2021, the Company and certain of the Company's insurance carriers caused a payment of $18.25 million to be made to the plaintiff class. As a result of this settlement agreement, the Company recorded a loss on settlement of $13.25 million during the three months ended March 31, 2021 in selling, general, and administrative expenses on the statements of operations and comprehensive loss, which represents the litigation settlement of $18.25 million offset by $5.0 million in insurance claim proceeds from our insurance carriers.

There have been no material changes to the Company’s contractual obligations and commitments and contingencies outside the ordinary course of business from those previously disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021.
XML 21 R12.htm IDEA: XBRL DOCUMENT v3.22.2.2
Investments
 9 Months Ended
Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]  
Investments Investments
The following table summarizes the Company’s cash equivalents, restricted cash, and short-term investments (in thousands):
September 30, 2022
Amortized
Cost		Gross Unrealized GainsGross Unrealized LossesEstimated
Fair
Value
Cash equivalents and restricted cash:
Money market funds$148,850 $— $— $148,850 
Certificates of deposit400 — — 400 
Short-term investments:
U.S. treasury notes30,035 — (93)29,942 
Total$179,285 $— $(93)$179,192 
December 31, 2021
Amortized
Cost		Gross Unrealized GainsGross Unrealized LossesEstimated
Fair
Value
Cash equivalents:
Money market funds$188,734 $— $— $188,734 
Certificates of deposit400 — — 400 
Short-term investments:
U.S. treasury notes50,472 — (31)50,441 
Total$239,606 $— $(31)$239,575 
During the three and nine months ended September 30, 2022, other income, net in the statements of operations includes interest income on investments of $0.8 million and $1.5 million, respectively. During the three and nine months ended September 30, 2021, other income, net in the statements of operations includes interest income on investments of less than $0.1 million and less than $0.1 million, respectively. During the three and nine months ended September 30, 2022, other income, net in the statements of operations includes amortization of premiums and discounts on investments of $0.2 million and $0.6 million, respectively. There was no amortization of premiums and discounts on investments for the three and nine months ended September 30, 2021.
There were no unrealized gains or losses on investments reclassified from accumulated other comprehensive income (loss) to other income in the statements of operations during the three and nine months ended September 30, 2022 and 2021.
In the three and nine months ended September 30, 2022 and 2021, there were no allowances for credit losses and all unrealized gains (losses) for available-for-sale securities were recognized in accumulated other comprehensive income (loss). As of September 30, 2022, the Company had $0.2 million of accrued interest receivables.
XML 22 R13.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value Measurements
 9 Months Ended
Sep. 30, 2022
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
The Company follows accounting guidance that emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Fair value is defined as “the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.” Fair value measurements are defined on a three level hierarchy:
Level 1 inputs:    Quoted prices for identical assets or liabilities in active markets;
Level 2 inputs:Observable inputs other than Level 1 prices, such as quoted market prices for similar assets or liabilities or other inputs that are observable or can be corroborated by market data; and
Level 3 inputs:Unobservable inputs that are supported by little or no market activity and require the reporting entity to develop assumptions that market participants would use when pricing the asset or liability.
The following table presents the Company’s financial assets that have been measured at fair value on a recurring basis (in thousands):
DescriptionTotalLevel 1Level 2Level 3
September 30, 2022
Cash and cash equivalents:
Money market funds$148,850 $148,850 $— $— 
Certificates of deposit400 400 — — 
Short-term investments:
U.S. treasury notes29,942 29,942 — — 
Total assets at fair value$179,192 $179,192 $— $— 
December 31, 2021
Cash and cash equivalents:
Money market funds$188,734 $188,734 $— $— 
Certificates of deposit400 400 — — 
Short-term investments:
U.S. treasury notes50,441 50,441 — — 
Total assets at fair value$239,575 $239,575 $— $— 
There were no transfers between Levels 1, 2 or 3 during the three and nine months ended September 30, 2022 and 2021.
XML 23 R14.htm IDEA: XBRL DOCUMENT v3.22.2.2
Liability Related to the Revenue Interest Purchase Agreement
 9 Months Ended
Sep. 30, 2022
Liability Related to the Revenue Interest Purchase Agreement  
Liability Related to the Revenue Interest Purchase Agreement Liability Related to the Revenue Interest Purchase Agreement
On June 26, 2019, the Company entered into a Revenue Interest Purchase Agreement ("RIPA") with Oberland, as agent for purchasers party thereto (the “Purchasers”), and the Purchasers named therein, to obtain financing in respect to the commercialization and further development of bempedoic acid and the bempedoic acid / ezetimibe combination tablet and other working capital needs. Pursuant to the RIPA, the Company received $125.0 million at closing, less certain issuance costs. The Company was entitled to receive up to approximately $75.0 million in subsequent installments subject to the terms and conditions set forth in the RIPA: (i) $25.0 million upon certain regulatory approval of its product candidates and (ii) $50.0 million, at the Company’s option, upon reaching $100.0 million trailing worldwide six-month net sales any time prior to December 31, 2021 (the “Third Payment”). In March 2020, the Company received $25.0 million from Oberland upon receiving regulatory approval of NEXLETOL.
As consideration for such payments, the Purchasers will have a right to receive certain revenue interests (the “Revenue Interests”) from the Company based upon net sales of the Company’s certain products, once approved, which will be tiered payments initially ranging from 2.5% to 7.5% of the Company’s net sales in the covered territory (the “Covered Territory”); provided that (a) if annual net sales equal or exceed $350.0 million by December 31, 2021 (the “Sales Threshold”), the initially tiered revenue interest rate will be decreased to a single rate of 2.5% of the Company’s net sales in the Covered Territory, beginning on January 1, 2022, and (b) if annual net sales equal or exceed the Sales Threshold and if the Purchasers receive 100% of their invested capital by December 31, 2024, the revenue interest rate will be decreased to a single rate of 0.4% of the Company’s net sales in the Covered Territory beginning on January 1, 2025. If the Third Payment is drawn down by the Company, the applicable royalty rates will increase by one-third. The Covered Territory is the United States, but is subject to expand to include the world-wide net sales if the Company’s annual U.S. net sales are less than $350.0 million for the year ended December 31, 2021. The U.S. net sales milestone thresholds are not to be taken as financial guidance. The Purchasers’ rights to receive the Revenue Interests shall terminate on the date on which the Purchasers have received Revenue Interests payments of 195% of the then aggregate purchase price (the “Cumulative Purchaser Payments”) paid to the Company, unless the RIPA is terminated earlier.

Under the RIPA, the Company has an option (the “Call Option”) to terminate the RIPA and repurchase future Revenue Interests at any time upon advance written notice. Additionally, the Purchasers have an option (the “Put Option”) to terminate the RIPA and to require the Company to repurchase future Revenue Interests upon enumerated events such as a bankruptcy event, an uncured material breach, a material adverse effect or a change of control. If the Put Option is exercised prior to the first anniversary of the closing date by the Purchasers (except pursuant to a change of control), the required repurchase price will be 120% of the Cumulative Purchaser Payments (minus all payments Company has made to the Purchasers in connection with the Revenue Interests). In all other cases, if the Put Option or the Call Option are exercised, the required repurchase price
will be 175% of the Cumulative Purchaser Payments (minus all payments Company has made to the Purchasers in connection with the Revenue Interests), if such option is exercised prior to the third anniversary of the closing date, and 195% of the Cumulative Purchaser Payments (minus all payments Company has made to the Purchasers in connection with the Revenue Interests), if such option is exercised thereafter.
In addition, the RIPA contains various representations and warranties, information rights, non-financial covenants, indemnification obligations and other provisions that are customary for a transaction of this nature.

RIPA Amendments

On April 26, 2021, the Company entered into Amendment No. 2 (the “RIPA Amendment”) to the RIPA with Oberland, as agent for the purchaser parties thereto. Pursuant to the RIPA Amendment, Oberland waived the original trailing six-month world-wide net sales condition to the third installment payment under the RIPA and released the final $50 million payment payable to the Company under the terms of the RIPA. The Company and Oberland also agreed to amend additional terms of the RIPA such that the purchasers will have a right to receive certain revenue interests (the “Revenue Interests”) from the Company based on net sales of the Company’s certain products, once approved, which will be tiered payments ranging from 3.33% to 10% (the “Third Payment Applicable Percentage”) of the Company’s net sales in the covered territory (the “Covered Territory”); provided that (a) prior to December 31, 2024, with respect to each country defined in the Daiichi Territory, if the percentage of net sales that Company receives from Daiichi (the “Receivables Percentage”) is less than the Third Payment Applicable Percentage, then the Revenue Interest for such country payable to the purchasers will be equal to the Receivables Percentages, (b) if annual net sales equal or exceed $350 million and if the Purchasers receive 100% of their invested capital ("Cumulative Purchaser Payments") by December 31, 2024, the revenue interest rate will be decreased to a single rate of 3.33% of the Company’s net sales in the Covered Territory for all subsequent calendar quarters and (c) if the Purchasers receive Revenue Interest payments less than 100% of Cumulative Purchaser Payments by December 31, 2024, the Third Payment Applicable Percentage will be increased to a single rate of the Company’s net sales that would have provided 100% of Cumulative Purchaser Payments had such rate applied from the initial funding by the Purchasers. The Covered Territory was originally the United States, but has been expanded to worldwide for all calendar years beginning on or after January 1, 2022.

Under the RIPA Amendment, the Company has an option (the “Call Option”) to terminate the RIPA and repurchase future Revenue Interests at any time upon advance written notice. Additionally, the Purchasers have an option (the “Put Option”) to terminate the RIPA and to require the Company to repurchase future Revenue Interests upon enumerated events such as a bankruptcy event, an uncured material breach, a material adverse effect or a change of control. If the Put Option or the Call Option are exercised, the required repurchase price will be 200% of the Cumulative Purchaser Payments (minus all payments Company has made to the Purchasers in connection with the Revenue Interests), if such option is exercised prior to the third anniversary of the closing date, and 225% of the Cumulative Purchaser Payments (minus all payments Company has made to the Purchasers in connection with the Revenue Interests), if such option is exercised thereafter.

In accordance with the guidance in ASC 470‑50, “Debt—Modifications and Extinguishments,” the RIPA Amendment was accounted for as a debt modification. The amendment resulted in a $0.1 million loss on modification of debt, consisting of third-party fees associated with the transaction, which is included in selling, general, and administrative expenses in the statements of operations for the nine months ended September 30, 2021.

On May 16, 2021, the Company entered into an Amendment to the Security Agreement and Waiver ("Amendment and Waiver") with the same parties to the Security Agreement, by and among the Company, Eiger Partners II LP (the "Purchaser") and Eiger III SA LLC (the "Purchaser Agent"), dated as of June 26, 2019 (the "Security Agreement"). Pursuant to the Amendment and Waiver, if (i) the net revenue from sales of NEXLETOL and NEXLIZET and certain other products in the United States (as reported in the Company’s financial statements as “product sales, net” in accordance with GAAP and excluding, for the avoidance of doubt, upfront or milestone payments and other collaboration revenue) (the “Specified Net Revenue”) for the calendar quarter ended September 30, 2021 does not exceed $15.0 million, or (ii) the Specified Net Revenue for any calendar quarter ending after September 30, 2021 does not exceed $15.0 million, then the Company shall deposit $50.0 million in a deposit account that is subject to a block account control agreement in favor of the Purchase Agent, no later than the earlier of (x) the date the Specified Net Revenue for such calendar quarter has been determined and (y) 45 days after the last day of such calendar quarter. Since the Specified Net Revenue for the calendar quarter ended September 30, 2021 did not exceed $15.0 million, the Company deposited $50.0 million in a deposit account that is subject to a block account control agreement, which is classified as restricted cash on the condensed balance sheets. The Purchaser Agent shall have sole dominion and control over all funds deposited in the deposited account and such funds may be withdrawn therefrom only with the consent of the Purchaser Agent. Upon the occurrence and during the continuance of a Put Option Event, the Purchaser Agent shall have the right to apply amounts held in the deposit account in payment of certain secured obligations in the manner provided for in the Security Agreement. The Amendment and Wavier does not substitute, replace or release the Pledgors from any other obligations under the RIPA or Security Agreement.
In connection with the arrangement, as of September 30, 2022, the Company has recorded a liability, referred to as the “Revenue interest liability” in the condensed balance sheets, of $284.7 million, net of $0.4 million of capitalized issuance costs in connection with the RIPA, which will be amortized to interest expense over the estimated term of the RIPA. The Company imputes interest expense associated with this liability using the effective interest rate method. The effective interest rate is calculated based on the rate that would enable the debt to be repaid in full over the anticipated life of the arrangement. The interest rate on this liability may vary during the term of the agreement depending on a number of factors, including the level of forecasted net sales. The Company evaluates the interest rate quarterly based on its current net sales forecasts utilizing the prospective method.

A significant increase or decrease in net sales will materially impact the revenue interest liability, interest expense and the time period for repayment. The Company recorded approximately $11.1 million and $33.3 million in interest expense related to this arrangement for the three and nine months ended September 30, 2022, respectively, and approximately $10.4 million and $23.3 million in interest expense related to this arrangement for the three and nine months ended September 30, 2021, respectively.
The repayment of the RIPA to Oberland does not have a fixed repayment schedule, rather it will be completely repaid and extinguished when the Company has repaid 200% of the aggregate purchase price if repaid prior to the third anniversary of the closing date, and 225% of the Cumulative Purchaser Payments thereafter, unless the RIPA is terminated earlier. Since there is not a fixed repayment schedule, the Company does not project its future repayments by year. Each period, the Company estimates the future expected sales of its products in the covered territory and determines the effective annual imputed interest rate, which updates and changes the timing of the Company’s payments. Under the terms of the agreement, every $100 million of net sales generated, less than or equal to $250 million in an annual aggregate year, would result in a repayment obligation of approximately $10.0 million or 10.0% at the stated repayment rate in the first year. Annual net sales for a calendar year exceeding $250 million would result in a repayment obligation of approximately $3.3 million or 3.3% for every $100 million of sales above the threshold. If the Company would have equaled or exceeded $350 million of sales in the U.S. in 2021, then the repayment amount would have dropped to $3.3 million for every $100 million of net sales starting in 2022. As U.S. net sales were less than $350 million for the year ended December 31, 2021, the Covered Territory was expanded to include worldwide sales beginning in 2022. The Company’s repayments of the RIPA are directly tied to the growth of its net sales, and as the Company’s net sales grow, the Company expects the related repayments of the RIPA to grow as well. The Company currently expects to repay $19.6 million in the next twelve months.
The effective annual imputed interest rate is 15.8% as of September 30, 2022. The Company incurred $0.6 million of issuance costs in connection with the RIPA, which will be amortized to interest expense over the estimated term of the RIPA. Payments made to Oberland as a result of the Company’s net sales will reduce the revenue interest liability.
The following table summarizes the revenue interest liability activity during the nine months ended September 30, 2022:
(in thousands)
Total revenue interest liability at December 31, 2021$257,039 
Interest expense recognized33,323 
Revenue Interests payments(5,678)
Total revenue interest liability at September 30, 2022$284,684 
XML 24 R15.htm IDEA: XBRL DOCUMENT v3.22.2.2
Convertible Notes
 9 Months Ended
Sep. 30, 2022
Debt Disclosure [Abstract]  
Convertible Notes Convertible NotesIn November 2020, the Company issued $280.0 million aggregate principal amount of 4.0% senior subordinated convertible notes due November 2025. The net proceeds the Company received from the offering was approximately $271.1 million, after deducting the initial purchasers’ discounts and commissions and offering expenses payable by the Company (the "Convertible Notes"). The Company used approximately $46.0 million of the net proceeds from the offering of the notes to pay the cost of the Capped Call (as defined below) and $55.0 million of the net proceeds from the offering of the initial notes to finance the Prepaid Forward (as defined below). The Convertible Notes are the Company's senior unsecured obligations and mature on November 15, 2025 (the “Maturity Date”), unless earlier repurchased or converted into shares of common stock under certain circumstances described below. The Convertible Notes are convertible into shares of the Company’s common stock, can be repurchased for cash, or a combination thereof, at the Company’s election, at an initial conversion rate of 30.2151 shares of common stock per $1,000 principal amount of the Convertible Notes, which is equivalent to an initial conversion price of approximately $33.096 per share of common stock, subject to adjustment. The Company will pay interest on the Convertible Notes semi-annually in arrears on May 15 and November 15 of each year.
The Convertible Notes are general unsecured obligations of the Company that are subordinated in right of payment to indebtedness, obligations and other liabilities under the Company’s RIPA, the revenue interests issued pursuant to such agreement, and any refinancing of the foregoing.
Holders may convert their Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding August 15, 2025 in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ended on March 31, 2021 (and only during such calendar quarter), if the last reported sale price per share of the Company’s common stock, par value $0.001 per share (“common stock”), is greater than or equal to 130% of the conversion price for each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the five business days after any five consecutive trading day period (such five consecutive trading day period, the “measurement period”) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of the Company’s common stock and the conversion rate for the notes on each such trading day; (3) if the Company calls such notes for redemption, any such notes that have been called for redemption may be converted at any time prior to the close of business on the second scheduled trading day immediately preceding the redemption date, but only with respect to the notes called for redemption; and (4) upon the occurrence of specified corporate events, as provided in the Indenture. On or after August 15, 2025, to the close of business on the second scheduled trading day immediately before the maturity date, holders may convert all or any portion of their notes at the applicable conversion rate at any time at the option of the holder regardless of the foregoing conditions.
In addition, following certain corporate events or following issuance of a notice of redemption, the Company will, in certain circumstances, increase the conversion rate for a holder who elects to convert its notes in connection with such a corporate event or to convert its notes called (or deemed called) for redemption during the related redemption period, as the case may be.
The Convertible Notes will be redeemable, in whole or in part, at the Company’s option at any time, and from time to time, on or after November 20, 2023 and before the 41st scheduled trading day immediately before the maturity date, at a cash redemption price equal to 100% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, but only if the last reported sale price per share of the Company’s common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive), including the trading day immediately preceding the date the Company sends the related redemption notice, during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which the Company sends such redemption notice. No sinking fund is provided for the notes. If the Company redeems less than all the outstanding notes, at least $125.0 million aggregate principal amount of notes must be outstanding and not subject to redemption as of the relevant redemption notice date.
If the Company undergoes a “fundamental change” (as defined in the Indenture), holders may require the Company to repurchase their notes for cash all or any portion of their notes at a fundamental change repurchase price equal to 100% of the principal amount of the notes to be repurchased, plus accrued and unpaid interest, to, but excluding, the fundamental change repurchase date. The Indenture includes customary terms and covenants, including certain events of default.
The Company incurred approximately $8.9 million of issuance costs related to the issuance of the Convertible Notes, of which, prior to the adoption of Accounting Standards Update ("ASU") 2020-06 on January 1, 2021, $5.8 million and $3.1 million were allocated and recorded to long-term debt and additional paid-in capital, respectively. The $5.8 million of issuance costs recorded as long-term debt on the condensed balance sheet was to be amortized over the five-year contractual term of the Convertible Notes using the effective interest method.
Prior to the adoption of ASU 2020-06 on January 1, 2021, the $271.1 million of proceeds received from the issuance of the Convertible Notes were allocated between long-term debt (the “liability component”) of $177.6 million and additional paid-in capital (the “equity component”) of $93.5 million. The fair value of the liability component was measured using rates determined for similar debt instruments without a conversion feature. The carrying amount of the equity component, representing the conversion option, was determined by deducting the fair value of the liability component from the aggregate face value of the Convertible Notes and was included in additional paid-in capital in the condensed balance sheet and was not remeasured as long as it did not to meet the conditions for equity classification. The liability component was to be accreted up to the face value of the Convertible Notes of $280.0 million, which resulted in additional non-cash interest expense being recognized through the Maturity Date.
With the adoption of ASU 2020-06 as of January 1, 2021, the Company reports the convertible debt liability at the aggregate principal amount less unamortized issuance costs. This resulted in the reclassification of the $93.5 million of the Company’s convertible notes recognized at December 31, 2020 from additional paid in capital to the convertible debt liability.
The portion of interest expense previously recognized for the accretion of the convertible debt liability and the true-up of the amortization of the issuance costs of $1.5 million was recorded as an adjustment to accumulated deficit.
On October 22, 2021, the Company entered into a privately negotiated exchange agreement (the “Exchange Agreement”) with two co-managed holders (the “Holders”) of its Convertible Notes. Under the terms of the Exchange Agreement the Holders agreed to exchange (the “Exchange”) with the Company $15.0 million aggregate principal amount of the Convertible Notes held in the aggregate by them (and accrued interest thereon) for shares of the Company’s common stock. Pursuant to the Exchange Agreement, the number of shares of common stock to be issued by the Company to the Holders upon consummation of the Exchange was determined based upon the volume-weighted-average-price per share of common stock, subject to a floor of $5.62 per share, during the five trading-day averaging period, commencing on the trading day immediately following the date of the Exchange Agreement. The Exchange closed on November 3, 2021, with 1,094,848 shares of the Company's common stock being exchanged.
As of September 30, 2022, the principal amount of convertible notes was $265.0 million, and the unamortized debt discount and issuance costs were $5.5 million, for a net carrying amount of $259.5 million.

The Company recorded $3.1 million and $9.2 million of interest expense during the three and nine months ended September 30, 2022, respectively, and $3.2 million and $9.6 million of interest expense during the three and nine months ended September 30, 2021, respectively, relating to the cash interest on the convertible notes due semi-annually and amortization of the debt issuance costs.

As of September 30, 2022, no Convertible Notes were convertible pursuant to their terms. The estimated fair value of the Convertible Notes was $148.9 million as of September 30, 2022 and $140.3 million as of December 31, 2021. The estimated fair value of the Convertible Notes was determined through consideration of quoted market prices. As of September 30, 2022, the if-converted value of the Convertible Notes did not exceed the principal value of those notes.

Capped Call Transactions
In connection with the offering of the Convertible Notes, the Company entered into privately-negotiated capped call transactions with one of the initial purchasers of the convertible notes or its affiliate and certain other financial institutions. The Company used approximately $46.0 million of the net proceeds from the offering of the Convertible Notes to pay the cost of the capped call transactions. The capped call transactions are expected generally to reduce potential dilution to the Company’s common stock upon any conversion of the Convertible Notes and/or offset any cash payments the Company is required to make in excess of the principal amount of converted notes, as the case may be, in the event that the market value per share of the Company’s common stock, as measured under the terms of the capped call transactions at the time of exercise, is greater than the strike price of the capped call transactions (which initially corresponds to the initial conversion price of the Convertible Notes, and is subject to certain adjustments), with such reduction and/or offset subject to a cap initially equal to approximately $55.16 (which represents a premium of approximately 100% over the last reported sale price of the Company’s common stock on November 11, 2020), subject to certain adjustments. The capped call transactions are separate transactions, entered into by the Company and are not part of the terms of the Convertible Notes.
Given that the transactions meet certain accounting criteria, the convertible note capped call transactions are recorded in stockholders’ equity, and they are not accounted for as derivatives and are not remeasured each reporting period. As of September 30, 2022 and December 31, 2021, the Company had not purchased any shares under the convertible note capped call transactions.
Prepaid Forward
In connection with the offering of the Convertible Notes, the Company entered into a prepaid forward stock repurchase transaction (“Prepaid Forward”) with a financial institution (“Forward Counterparty”). Pursuant to the Prepaid Forward, the Company used approximately $55.0 million of the net proceeds from the offering of the Convertible Notes to fund the Prepaid Forward. The aggregate number of shares of the Company’s common stock underlying the Prepaid Forward was approximately 1,994,198. The expiration date for the Prepaid Forward is November 15, 2025, although it may be settled earlier in whole or in part. Upon settlement of the Prepaid Forward, at expiration or upon any early settlement, the Forward Counterparty will deliver to the Company the number of shares of common stock underlying the Prepaid Forward or the portion thereof being settled early. The shares purchased under the Prepaid Forward are treated as treasury stock and not outstanding for purposes of the calculation of basic and diluted earnings per share, but will remain outstanding for corporate law purposes, including for purposes of any future stockholders’ votes, until the Forward Counterparty delivers the shares underlying the Prepaid Forward to the Company. As of September 30, 2022, 71,174 shares had been delivered to the Company. The Company’s Prepaid Forward hedge transaction exposes the Company to credit risk to the extent that its counterparty may be unable to meet the terms of the transaction. The Company mitigates this risk by limiting its counterparty to a major financial institution.
XML 25 R16.htm IDEA: XBRL DOCUMENT v3.22.2.2
Other Accrued Liabilities
 9 Months Ended
Sep. 30, 2022
Payables and Accruals [Abstract]  
Other Accrued Liabilities Other Accrued Liabilities
Other accrued liabilities consist of the following (in thousands):
September 30,
2022		December 31,
2021
Accrued compensation$8,512 $8,809 
Accrued variable consideration20,525 16,192 
Accrued professional fees2,344 3,917 
Accrued interest on convertible notes3,975 1,325 
Accrued other39 167 
Total other accrued liabilities$35,395 $30,410 
XML 26 R17.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock Compensation
 9 Months Ended
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Stock Compensation Stock Compensation
2022 Stock Option and Incentive Plan
In May 2022, the Company's stockholders approved the 2022 Stock Option and Incentive Plan (the "2022 Plan"). The number of shares of common stock available for awards under the 2022 Plan was set to 4,400,000, with any shares underlying awards that are forfeited, canceled, held back upon exercise of an option or settlement of an award to cover the exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied without the issuance or shares, or otherwise terminated (other than by exercise) under the 2022 Plan may be added back to the shares of common stock available for issuance under the 2022 Plan. The 2022 Plan provides for the award of stock options (both incentive and non-qualified options), stock appreciation rights, restricted stock, restricted stock units, unrestricted stock, cash-based awards, and dividend equivalent rights. Following the approval of the 2022 Plan, no further awards will be issued under the Company’s 2013 Stock Option and Incentive Plan (the “2013 Plan”).

Employee Stock Purchase Plan
In April 2020, the board of directors approved the Esperion Therapeutics, Inc. 2020 Employee Stock Purchase Plan (the "ESPP") which was approved by the Company's shareholders on May 28, 2020. The ESPP allows eligible employees to authorize payroll deductions of up to 10% of their base salary or wages up to $25,000 annually to be applied toward the purchase of shares of the Company's common stock on the last trading day of the offering period. Participating employees will purchase shares of the Company's common stock at a discount of up to 15% on the lesser of the closing price of the Company's common stock on the NASDAQ Global Select Market (i) on the first trading day of the offering period or (ii) the last day of any offering period. Offering periods under the ESPP will generally be in six months increments, commencing on September 1 and March 1 of each calendar year with the administrator having the right to establish different offering periods. In the three and nine months ended September 30, 2022, the Company recognized approximately $0.1 million and $0.3 million of stock compensation expense related to the ESPP, respectively. In the three and nine months ended September 30, 2021, the Company recognized approximately $0.2 million and $0.6 million of stock compensation expense related to the ESPP, respectively. As of September 30, 2022, there have been 339,422 shares issued and 485,578 shares reserved for future issuance under the ESPP.
Stock Options
The following table summarizes the activity relating to the Company’s options to purchase common stock for the nine months ended September 30, 2022:
Number of OptionsWeighted-Average Exercise Price Per ShareWeighted-Average Remaining Contractual Term (Years)Aggregate Intrinsic Value
(in thousands)
Outstanding at December 31, 20213,214,537 $38.38 4.18$— 
Granted1,255,600 $4.78 
Forfeited or expired(685,182)$33.01 
Exercised— $— 
Outstanding at September 30, 20223,784,955 $28.20 5.18$2,098 
Vested and expected to vest at September 30, 20223,784,955 $28.20 5.18$2,098 
Exercisable at September 30, 20222,421,198 $38.23 2.91$163 
Stock-based compensation related to stock options was $1.4 million and $4.3 million for the three and nine months ended September 30, 2022, respectively, including $0.2 million and $0.4 million that were capitalized into inventory, and $2.8 million and $12.7 million for the three and nine months ended September 30, 2021, respectively, including $0.8 million and $1.3 million that were capitalized into inventory. As of September 30, 2022, there was $8.9 million of unrecognized stock-based compensation expense related to unvested options, which will be recognized over a weighted-average period of 2.5 years.
Performance-Based Stock Options ("PBSOs")
In 2021, the Company granted PBSOs from the 2013 Plan that vest upon various performance-based milestones as set forth in the individual grant agreements, such as achievement of predetermined clinical or regulatory outcomes. The actual number of units (if any) received under these awards will depend on continued employment and actual performance over the performance period. Each quarter, the Company updates their assessment of the probability that the performance milestone will be achieved. The Company amortizes the fair value of the PBSOs based on the expected performance period to achieve the performance milestone. The Company expects the performance criteria to be met.
In 2022, the Company granted PBSOs from the 2022 Plan that vest upon various performance-based milestones as set forth in the individual grant agreements, such as achievement of predetermined clinical or regulatory outcomes. The actual number of units (if any) received under these awards will depend on continued employment and actual performance over the performance period. Each quarter, the Company updates their assessment of the probability that the performance milestone will be achieved. The Company amortizes the fair value of the PBSOs based on the expected performance period to achieve the performance milestone. The Company expects the performance criteria to be met.

The following table summarizes the activity relating to the Company’s PBSOs for the nine months ended September 30, 2022:
Number of OptionsWeighted-Average Exercise Price Per ShareWeighted-Average Remaining Contractual Term (Years)Aggregate Intrinsic Value
(in thousands)
Outstanding at December 31, 2021122,700 $8.94 9.83$— 
Granted403,000 $6.20 
Forfeited or expired(26,500)$8.94 
Exercised— $— 
Outstanding at September 30, 2022499,200 $6.73 9.58$202 
Vested and expected to vest at September 30, 2022499,200 $6.73 9.58$202 
Exercisable at September 30, 2022— $— 0$— 
Stock-based compensation related to PBSOs was $0.3 million and $0.5 million for the three and nine months ended September 30, 2022, respectively. As of September 30, 2022, there was approximately $1.8 million of unrecognized stock-based compensation expense related to unvested PBSOs, which will be recognized over a weighted-average period of approximately 1.6 years.
Restricted Stock Units (or RSUs)
The following table summarizes the activity relating to the Company’s RSUs for the nine months ended September 30, 2022:
Number of
RSUs		Weighted-Average
Fair Value Per
Share
Outstanding and unvested December 31, 2021698,704 $28.09 
Granted1,644,009 $4.71 
Forfeited(340,220)$12.98 
Vested(347,893)$20.77 
Outstanding and unvested September 30, 20221,654,600 $9.51 
Stock-based compensation related to RSUs was approximately $1.5 million and $5.1 million for the three and nine months ended September 30, 2022, respectively, including $0.2 million and $0.5 million that was capitalized into inventory, and approximately $2.4 million and $6.4 million for the three and nine months ended September 30, 2021, respectively, including $0.4 million and $0.6 million that was capitalized into inventory. As of September 30, 2022, there was $14.7 million of unrecognized stock-based compensation expense related to unvested RSUs, which will be recognized over a weighted-average period of 2.8 years.
Performance-based Restricted Stock Units ("PBRSUs")
In 2021, the Company granted PBRSUs from the 2013 Plan that vest upon various performance-based milestones as set forth in the individual grant agreements, such as achievement of predetermined milestones based on the Company's U.S. net product sales or clinical or regulatory outcomes. The actual number of units (if any) received under these awards will depend on continued employment and actual performance over the performance period. Each quarter, the Company updates their assessment of the probability that the performance milestone will be achieved. The Company amortizes the fair value of the PBRSUs based on the expected performance period to achieve the performance milestone. The fair value of the PBRSUs is based on the quoted market price of the Company's common stock on the date of grant. The Company expects the performance criteria to be met.
The following table summarizes the activity relating to the Company's PBRSUs for the nine months ended September 30, 2022:
Number of
PBRSUs		Weighted-average fair value per share
Outstanding December 31, 2021639,950 $9.90 
Granted— $— 
Forfeited(178,700)$10.95 
Outstanding and unvested September 30, 2022461,250 $9.50 
Stock-based compensation related to the PBRSUs was approximately $0.2 million and $1.3 million for the three and nine months ended September 30, 2022, respectively, including less than $0.1 million and $0.1 million that was capitalized into inventory. Stock-based compensation related to PBRSUs was approximately $0.1 million for the three and nine months ended September 30, 2021. As of September 30, 2022, there was approximately $1.9 million of unrecognized stock-based compensation expense related to unvested PBRSUs, which will be recognized over a weighted-average period of approximately 1.7 years.
XML 27 R18.htm IDEA: XBRL DOCUMENT v3.22.2.2
Income Taxes
 9 Months Ended
Sep. 30, 2022
Income Tax Disclosure [Abstract]  
Income Taxes Income TaxesThere was no provision for income taxes for the three and nine months ended September 30, 2022 and 2021, because the Company has incurred annual operating losses since inception. At September 30, 2022, the Company continues to conclude that it is not more likely than not that the Company will realize the benefit of its deferred tax assets due to its history of losses. Accordingly, a full valuation allowance has been applied against the net deferred tax assets.
XML 28 R19.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stockholders' Deficit
 9 Months Ended
Sep. 30, 2022
Equity [Abstract]  
Stockholders' Deficit Stockholders' Deficit
ATM Offering

On August 3, 2021, the Company filed an automatically effective registration statement on Form S-3ASR (the “Registration Statement”) with the SEC which registered the offering, issuance and sale of an unspecified amount of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof. The Company simultaneously entered into an open market sale agreement with Jefferies LLC, as sales agent, to provide for the issuance and sale by the Company of up to $250 million of common stock from time to time in “at-the-market” offerings under the Registration Statement and related prospectus filed with the Registration Statement (the “ATM Program”). During the three and nine months ended September 30, 2021, the Company issued 363,061 shares of common stock resulting in net proceeds of approximately $4.2 million after deducting $0.5 million of underwriting discounts and commissions and other expenses, pursuant to the ATM Program.

On April 15, 2022, the Company filed a new registration statement on Form S-3 to replace its prior automatically effective registration statement on Form S-3ASR filed on August 3, 2021, which registers the offering, issuance and sale of up to $239 million of common stock from time to time in “at-the-market” offerings under the Registration Statement and related prospectus filed with the Registration Statement (the “ATM Program”). The Company may continue to use an ATM Program to address potential short-term or long-term funding requirements that may arise. Such program will continue to be subject to the volatility of the price of the Company's common stock and general market conditions. During the three and nine month periods ended September 30, 2022, the Company issued 6,958,525 and 10,311,525 shares of common stock, respectively, resulting in net proceeds of approximately $48.6 million and $68.8 million after deducting $1.6 million and $2.4 million of underwriting discounts and commissions and other expenses, respectively, pursuant to the ATM Program.

Warrants

In connection with an underwriting agreement with H.C. Wainwright & Co., LLC (the "Offering"), entered into on December 2, 2021, the Company issued warrants to purchase 36,964,286 shares of common stock at an exercise price of $9.00. The warrants will terminate on December 7, 2023. The warrants were recorded at fair value of $61.9 million to additional-paid-in-capital in accordance with ASC 815-10 based upon the allocation of the proceeds between the common shares issued with the Offering and the warrants. The Company estimated the fair value of the warrants using a Black-Scholes option-pricing model, which is based, in part, upon subjective assumptions including but not limited to stock price volatility, the expected life of the warrant, the risk-free interest rate and the fair value of the common stock underlying the warrant. The Company estimates the volatility based on its historical volatility that is in line with the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury daily rate for a maturity similar to the expected remaining life of the warrants. The expected remaining life of the warrants is assumed to be equivalent to its remaining contractual term.

As of September 30, 2022 and December 31, 2021, the Company had warrants outstanding that were exercisable for a total of 36,964,286 shares of common stock at a weighted-average exercise price of $9.00 per share.
XML 29 R20.htm IDEA: XBRL DOCUMENT v3.22.2.2
Net Loss Per Common Share
 9 Months Ended
Sep. 30, 2022
Earnings Per Share [Abstract]  
Net Loss Per Common Share Net Loss Per Common ShareBasic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common stock equivalents outstanding for the period, including shares that potentially could be dilutive if they were exercised or vested during the period, determined using the treasury-stock method. For purposes of this calculation, warrants for common stock, stock options, PBSOs, unvested RSUs and PBRSUs, shares issuable under the ESPP and shares issuable upon conversion of the convertible notes are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.
The shares outstanding at the end of the respective periods presented below were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:
September 30,
20222021
Common shares under option3,784,955 3,703,938 
Common shares under PBSOs499,200 — 
Unvested RSUs1,654,600 879,349 
Unvested PBRSUs461,250 45,300 
Shares issuable related to the ESPP9,237 9,871 
Shares issuable upon conversion of convertible notes8,007,010 8,460,237 
Warrants36,964,286 — 
Total potential dilutive shares51,380,538 13,098,695 
XML 30 R21.htm IDEA: XBRL DOCUMENT v3.22.2.2
Statements of Cash Flows and Restricted Cash
 9 Months Ended
Sep. 30, 2022
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]  
Statements of Cash Flows and Restricted Cash Statements of Cash Flows and Restricted Cash
The following table provides a reconciliation of cash and cash equivalents and restricted cash presented on the balance sheets to the same amounts presented on the statements of cash flows on September 30, 2022 and 2021 and December 31, 2021 and 2020 (in thousands):

September 30,
2022		September 30,
2021		December 31,
2021		December 31,
2020
Cash and cash equivalents159,399 $103,672 $208,892 $304,962 
Restricted cash50,000 50,000 50,000 — 
Total cash and cash equivalents and restricted cash shown on the condensed statements of cash flows$209,399 $153,672 $258,892 $304,962 
XML 31 R22.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying condensed interim financial statements are unaudited and were prepared by the Company in accordance with generally accepted accounting principles in the United States of America (“GAAP”). In the opinion of management, the Company has made all adjustments, which include only normal recurring adjustments necessary for a fair presentation of the Company’s financial position and results of operations for the interim periods presented. Certain prior year amounts have been reclassified to conform with current year presentation. Certain information and disclosures normally included in the annual financial statements prepared in accordance with GAAP, but that is not required for interim reporting purposes, have been condensed or omitted. These condensed interim financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2021, and the notes thereto, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. The results of operations for the interim periods are not necessarily indicative of the results to be expected for a full year, any other interim periods or any future year or period.
Use of Estimates
Use of Estimates
The preparation of financial statements in accordance with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, net revenues, expenses and related disclosures. Actual results could differ from those estimates.
Cash and Cash Equivalents
Cash and Cash Equivalents
The Company invests its excess cash in bank deposits, money market accounts, and short-term investments. The Company considers all highly liquid investments with an original maturity of 90 days or less at the time of purchase to be cash equivalents. Cash equivalents are reported at fair value.
Restricted Cash Restricted CashRestricted cash consists of legally restricted amounts held by financial institutions pursuant to contractual arrangements. Pursuant to the Amendment and Waiver (as defined below), the Company deposited $50.0 million in a deposit account that is subject to a block account control agreement. Eiger III SA LLC (“Oberland”), an affiliate of Oberland Capital LLC, will have sole control over the funds deposited in the account and such funds may be withdrawn only with the consent of Oberland. Refer to Note 8 "Liability Related to the Revenue Interest Purchase Agreement" for further information on the Amendment and Waiver.
Investments
Investments
Investments are considered to be available-for-sale and are carried at fair value. Unrealized gains and losses, if any, are reported in accumulated other comprehensive income (loss). The cost of investments classified as available-for-sale are adjusted for the amortization of premiums and accretion of discounts to maturity and recorded in other income, net. Realized gains and losses, if any, are determined using the specific identification method and recorded in other income, net. Investments with original maturities beyond 90 days at the date of purchase and which mature at, or less than twelve months from, the balance sheet date are classified as current. Investments with a maturity beyond twelve months from the balance sheet date are classified as long-term.
Concentration of Risk
Concentration of Risk
The Company enters into a limited number of distribution agreements with distributors and specialty pharmacies. The Company's net product sales are with these customers. As of September 30, 2022, thirteen customers accounted for all of the Company's net trade receivables and as of December 31, 2021, nine customers accounted for all the Company's net trade receivables.
Revenue Recognition
Revenue Recognition
In accordance with ASC 606, Revenue from Contracts with Customers, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange for the goods or services provided. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: identify the contracts with a customer; identify the performance obligations in the contract; determine the transaction price; allocate the transaction price to the performance obligations in the contract; and recognize revenue when or as the entity satisfies a performance obligation. At contract inception the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. The Company derives revenue through two primary sources: collaboration revenue and product sales. Collaboration revenue consists of the collaboration payments to the Company for collaboration arrangements outside of the United States for the development, manufacturing and commercialization, including royalties, of the Company's product candidates by the Company's partners and product sales consists of sales of NEXLETOL and NEXLIZET.
a.Collaboration Revenue
The Company has entered into agreements related to its activities to develop, manufacture, and commercialize its product candidates. The Company earns collaboration revenue in connection with a collaboration agreement to develop and/or commercialize product candidates where the Company deems the collaborator to be the customer. Revenue is recognized when (or as) the Company satisfies performance obligations under the terms of a contract. Depending on the terms of the arrangement, the Company may defer the recognition of all or a portion of the consideration received as the performance obligations are satisfied.
The collaboration agreements may require the Company to deliver various rights, services, and/or goods across the entire life cycle of a product or product candidate. In an agreement involving multiple goods or services promised to be transferred to a customer, the Company must assess, at the inception of the contract, whether each promise represents a separate performance obligation (i.e., is "distinct"), or whether such promises should be combined as a single performance obligation.
The terms of the agreement typically include consideration to be provided to the Company in the form of non-refundable up-front payments, development milestones, sales milestones, and royalties on sales of products within a respective territory. The Company recognizes regulatory and approval milestones consideration when it is probable that a future reversal is unlikely to occur. For sales-based milestones and royalties based on sales of product in a territory, the Company applies the sales-based royalty exception in ASC 606-10-55-65 to all of these milestones and royalties.
At the inception of the contract, the transaction price reflects the amount of consideration the Company expects to be entitled to in exchange for transferring promised goods or services to its customer. In the arrangement where the Company satisfies performance obligation(s) during the regulatory phase over time, the Company recognizes collaboration revenue typically using an input method on the basis of regulatory costs incurred relative to the total expected cost which determines the extent of progress toward completion. The Company reviews the estimate of the transaction price and the total expected cost each period and makes revisions to such estimates as necessary. Under contracted supply agreements with collaborators, the Company, through its third party contract manufacturing partners, may manufacture and supply quantities of active pharmaceutical ingredient (“API”) or bulk tablets reasonably required by collaboration partners for the development or sale of licensed products in their respective territory. The Company recognizes revenue when the collaboration partner has obtained control of the API or bulk tablets. The Company records the costs related to the supply agreement in cost of goods sold on the condensed statements of operations and comprehensive (loss) income.
Under the Company's collaboration agreements, product sales and cost of sales may be recorded by the Company's collaborators as they are deemed to be the principal in the transaction. The Company receives royalties from the commercialization of such products, and records its share of the variable consideration, representing a percentage of net product sales, as collaboration revenue in the period in which such underlying sales occur and costs are incurred by the collaborator.
b.Product Sales, Net
On February 21, 2020, the Company announced that the FDA approved NEXLETOL as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or established ASCVD who require additional lowering of LDL-C. On February 26, 2020, the Company announced that the FDA approved NEXLIZET as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or established ASCVD who require additional lowering of LDL-C. On March 30, 2020, NEXLETOL was commercially available in the U.S. through prescription and on June 4, 2020, NEXLIZET was commercially available in the U.S. through prescription. Net product sales totaled $14.0 million and $40.9 million for the three and nine months ended September 30, 2022, respectively, and $10.9 million and $27.9 million for the three and nine months ended September 30, 2021, respectively.
The Company sells NEXLETOL and NEXLIZET to wholesalers in the U.S. and, in accordance with ASC 606, recognizes revenue at the point in time when the customer is deemed to have obtained control of the product. The customer is deemed to have obtained control of the product at the time of physical receipt of the product at the customers’ distribution facilities, or free on board (“FOB”) destination, the terms of which are designated in the contract.
Product sales are recorded at the net selling price, which includes estimates of variable consideration for which reserves are established for (a) rebates and chargebacks, (b) co-pay assistance programs, (c) distribution fees, (d) product returns, and (e) other discounts. Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as current contractual and statutory requirements, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company's best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contract. The amount of variable consideration may be constrained and is included
in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Given the early stage of the Company’s commercial operations it has provided constraint of its variable consideration due to its potential consumption trends. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results in the future vary from estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.
Liabilities for co-pay assistance, expected product returns, rebates, and distributor fees are classified as “Other accrued liabilities” in the condensed balance sheets. Discounts, such as prompt pay discounts, and chargebacks are recorded as a reduction to trade accounts receivable in the condensed balance sheets.
Forms of Variable Consideration
Rebates and Chargebacks: The Company estimates reductions to product sales for Public Health Service Institutions, such as Medicaid, Medicare and Veterans' Administration ("VA") programs, as well as certain other qualifying federal and state government programs, and other group purchasing organizations. The Company estimates these reductions based upon the Company's contracts with government agencies and other organizations, statutorily defined discounts and estimated payor mix. These organizations purchase directly from the Company's wholesalers at a discount and the wholesalers charge the Company back the difference between the wholesaler price and the discounted price. The Company's liability for Medicaid rebates consists of estimates for claims that a state will make for a current quarter. The Company's reserve for this discounted pricing is based on expected sales to qualified healthcare providers and the chargebacks that customers have already claimed.
Co-pay assistance: Eligible patients who have commercial insurance may receive assistance from the Company to reduce the patient's out of pocket costs. The Company will buy down the difference between the amount of the eligible patient's co-pay when the drug is purchased at the pharmacy at a determined price. Liabilities for co-pay assistance are calculated by actual program participation from third-party administrators.
Distribution Fees: The Company has written contracts with its customers that include terms for distribution fees and costs for inventory management. The Company estimates and records distribution fees due to its customers based on gross sales.
Product Returns: The Company generally offers a right of return based on the product’s expiration date and certain spoilage and damaged instances. The Company estimates the amount of product sales that may be returned and records the estimate as a reduction of product sales in the period the related product sales is recognized. The Company’s estimates for expected returns are based primarily on an ongoing analysis of sales information and visibility into the inventory remaining in the distribution channel.
Discounts: The Company provides product discounts, such as prompt pay discounts, to its customers. The Company estimates cash discounts based on terms in negotiated contracts and the Company’s expectations regarding future payment patterns.
Inventories
Inventories
Inventories are stated at the lower of cost or net realizable value and recognized on a first-in, first-out ("FIFO") method. The Company uses standard cost to determine the cost basis for inventory. Inventory is capitalized based on when future economic benefit is expected to be realized. The Company began capitalizing inventory upon receiving FDA approval for NEXLETOL and NEXLIZET on February 21, 2020 and February 26, 2020, respectively. Prior to the FDA approval of NEXLETOL and NEXLIZET, expenses associated with the manufacturing of the Company's products were recorded as research and development expense.
The Company analyzes its inventory levels on a periodic basis to determine if any inventory is at risk for expiration prior to sale or has a cost basis that is greater than its estimated future net realizable value. Any adjustments are recognized through cost of goods sold in the period in which they are incurred.
Recently Implemented Accounting Pronouncements
Recently Implemented Accounting Pronouncements
There have been no other material changes to the significant accounting policies previously disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021.
XML 32 R23.htm IDEA: XBRL DOCUMENT v3.22.2.2
Inventories, net (Tables)
 9 Months Ended
Sep. 30, 2022
Inventory Disclosure [Abstract]  
Schedule of Inventories
Inventories, net consist of the following (in thousands):
September 30, 2022December 31, 2021
Raw materials$24,785 $31,850 
Work in process2,874 663 
Finished goods1,886 1,881 
$29,545 $34,394 
XML 33 R24.htm IDEA: XBRL DOCUMENT v3.22.2.2
Investments (Tables)
 9 Months Ended
Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]  
Schedule of Company's Cash Equivalents, Restricted Cash, and Short-Term Investments
The following table summarizes the Company’s cash equivalents, restricted cash, and short-term investments (in thousands):
September 30, 2022
Amortized
Cost		Gross Unrealized GainsGross Unrealized LossesEstimated
Fair
Value
Cash equivalents and restricted cash:
Money market funds$148,850 $— $— $148,850 
Certificates of deposit400 — — 400 
Short-term investments:
U.S. treasury notes30,035 — (93)29,942 
Total$179,285 $— $(93)$179,192 
December 31, 2021
Amortized
Cost		Gross Unrealized GainsGross Unrealized LossesEstimated
Fair
Value
Cash equivalents:
Money market funds$188,734 $— $— $188,734 
Certificates of deposit400 — — 400 
Short-term investments:
U.S. treasury notes50,472 — (31)50,441 
Total$239,606 $— $(31)$239,575 
XML 34 R25.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value Measurements (Tables)
 9 Months Ended
Sep. 30, 2022
Fair Value Disclosures [Abstract]  
Schedule of the Company's Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
The following table presents the Company’s financial assets that have been measured at fair value on a recurring basis (in thousands):
DescriptionTotalLevel 1Level 2Level 3
September 30, 2022
Cash and cash equivalents:
Money market funds$148,850 $148,850 $— $— 
Certificates of deposit400 400 — — 
Short-term investments:
U.S. treasury notes29,942 29,942 — — 
Total assets at fair value$179,192 $179,192 $— $— 
December 31, 2021
Cash and cash equivalents:
Money market funds$188,734 $188,734 $— $— 
Certificates of deposit400 400 — — 
Short-term investments:
U.S. treasury notes50,441 50,441 — — 
Total assets at fair value$239,575 $239,575 $— $— 
XML 35 R26.htm IDEA: XBRL DOCUMENT v3.22.2.2
Liability Related to the Revenue Interest Purchase Agreement (Tables)
 9 Months Ended
Sep. 30, 2022
Liability Related to the Revenue Interest Purchase Agreement  
Summary of Revenue Interest Liability Activity During the Period
The following table summarizes the revenue interest liability activity during the nine months ended September 30, 2022:
(in thousands)
Total revenue interest liability at December 31, 2021$257,039 
Interest expense recognized33,323 
Revenue Interests payments(5,678)
Total revenue interest liability at September 30, 2022$284,684 
XML 36 R27.htm IDEA: XBRL DOCUMENT v3.22.2.2
Other Accrued Liabilities (Tables)
 9 Months Ended
Sep. 30, 2022
Payables and Accruals [Abstract]  
Schedule of Other Accrued Liabilities
Other accrued liabilities consist of the following (in thousands):
September 30,
2022		December 31,
2021
Accrued compensation$8,512 $8,809 
Accrued variable consideration20,525 16,192 
Accrued professional fees2,344 3,917 
Accrued interest on convertible notes3,975 1,325 
Accrued other39 167 
Total other accrued liabilities$35,395 $30,410 
XML 37 R28.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock Compensation (Tables)
 9 Months Ended
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Summary of Activity Relating to the Company's Options and Performance-Based Options to Purchase Common Stock
The following table summarizes the activity relating to the Company’s options to purchase common stock for the nine months ended September 30, 2022:
Number of OptionsWeighted-Average Exercise Price Per ShareWeighted-Average Remaining Contractual Term (Years)Aggregate Intrinsic Value
(in thousands)
Outstanding at December 31, 20213,214,537 $38.38 4.18$— 
Granted1,255,600 $4.78 
Forfeited or expired(685,182)$33.01 
Exercised— $— 
Outstanding at September 30, 20223,784,955 $28.20 5.18$2,098 
Vested and expected to vest at September 30, 20223,784,955 $28.20 5.18$2,098 
Exercisable at September 30, 20222,421,198 $38.23 2.91$163 
The following table summarizes the activity relating to the Company’s PBSOs for the nine months ended September 30, 2022:
Number of OptionsWeighted-Average Exercise Price Per ShareWeighted-Average Remaining Contractual Term (Years)Aggregate Intrinsic Value
(in thousands)
Outstanding at December 31, 2021122,700 $8.94 9.83$— 
Granted403,000 $6.20 
Forfeited or expired(26,500)$8.94 
Exercised— $— 
Outstanding at September 30, 2022499,200 $6.73 9.58$202 
Vested and expected to vest at September 30, 2022499,200 $6.73 9.58$202 
Exercisable at September 30, 2022— $— 0$— 
Summary of Activity Relating to the Company's RSUs
The following table summarizes the activity relating to the Company’s RSUs for the nine months ended September 30, 2022:
Number of
RSUs		Weighted-Average
Fair Value Per
Share
Outstanding and unvested December 31, 2021698,704 $28.09 
Granted1,644,009 $4.71 
Forfeited(340,220)$12.98 
Vested(347,893)$20.77 
Outstanding and unvested September 30, 20221,654,600 $9.51 
Summary of Activity Relating to the Company's PBRSU's
The following table summarizes the activity relating to the Company's PBRSUs for the nine months ended September 30, 2022:
Number of
PBRSUs		Weighted-average fair value per share
Outstanding December 31, 2021639,950 $9.90 
Granted— $— 
Forfeited(178,700)$10.95 
Outstanding and unvested September 30, 2022461,250 $9.50 
XML 38 R29.htm IDEA: XBRL DOCUMENT v3.22.2.2
Net Loss Per Common Share (Tables)
 9 Months Ended
Sep. 30, 2022
Earnings Per Share [Abstract]  
Schedule of Shares Excluded From Calculation of Diluted Net (Loss) Income Per Share
The shares outstanding at the end of the respective periods presented below were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:
September 30,
20222021
Common shares under option3,784,955 3,703,938 
Common shares under PBSOs499,200 — 
Unvested RSUs1,654,600 879,349 
Unvested PBRSUs461,250 45,300 
Shares issuable related to the ESPP9,237 9,871 
Shares issuable upon conversion of convertible notes8,007,010 8,460,237 
Warrants36,964,286 — 
Total potential dilutive shares51,380,538 13,098,695 
XML 39 R30.htm IDEA: XBRL DOCUMENT v3.22.2.2
Statements of Cash Flows and Restricted Cash (Tables)
 9 Months Ended
Sep. 30, 2022
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]  
Schedule of Cash and Cash Equivalents
The following table provides a reconciliation of cash and cash equivalents and restricted cash presented on the balance sheets to the same amounts presented on the statements of cash flows on September 30, 2022 and 2021 and December 31, 2021 and 2020 (in thousands):

September 30,
2022		September 30,
2021		December 31,
2021		December 31,
2020
Cash and cash equivalents159,399 $103,672 $208,892 $304,962 
Restricted cash50,000 50,000 50,000 — 
Total cash and cash equivalents and restricted cash shown on the condensed statements of cash flows$209,399 $153,672 $258,892 $304,962 
Restrictions on Cash and Cash Equivalents
The following table provides a reconciliation of cash and cash equivalents and restricted cash presented on the balance sheets to the same amounts presented on the statements of cash flows on September 30, 2022 and 2021 and December 31, 2021 and 2020 (in thousands):

September 30,
2022		September 30,
2021		December 31,
2021		December 31,
2020
Cash and cash equivalents159,399 $103,672 $208,892 $304,962 
Restricted cash50,000 50,000 50,000 — 
Total cash and cash equivalents and restricted cash shown on the condensed statements of cash flows$209,399 $153,672 $258,892 $304,962 
XML 40 R31.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Significant Accounting Policies (Details)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2022
USD ($)
revenue_source
customer
Sep. 30, 2021
USD ($)
Dec. 31, 2021
USD ($)
customer
Dec. 31, 2020
USD ($)
Summary of Significant Accounting Policies            
Restricted cash $ 50,000 $ 50,000 $ 50,000 $ 50,000 $ 50,000 $ 0
Number of revenue sources | revenue_source     2      
Total Revenues 18,980 14,409 $ 56,657 63,046    
Product sales, net            
Summary of Significant Accounting Policies            
Total Revenues $ 13,964 $ 10,895 $ 40,896 $ 27,855    
Trade Receivables | Customer Concentration Risk            
Summary of Significant Accounting Policies            
Number of major customers | customer     13   9  
XML 41 R32.htm IDEA: XBRL DOCUMENT v3.22.2.2
Collaborations with Third Parties (Details) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Apr. 26, 2021
Apr. 17, 2020
Jan. 02, 2019
Apr. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Collaborations with Third Parties                  
Collaboration revenue         $ 18,980,000 $ 14,409,000 $ 56,657,000 $ 63,046,000  
Collaboration revenue                  
Collaborations with Third Parties                  
Collaboration revenue         5,016,000 3,514,000 15,761,000 35,191,000  
Daiichi Sankyo Europe GmbH ("DSE") | Royalty revenue and product sales bulk tablets                  
Collaborations with Third Parties                  
Collaboration revenue         4,400,000 3,300,000 14,700,000 6,900,000  
Daiichi Sankyo Europe GmbH ("DSE") | License and Collaboration Agreement                  
Collaborations with Third Parties                  
Upfront cash payment received (paid)     $ 150,000,000            
Cash payment to the Company upon first commercial sales in the DSE Territory     $ 150,000,000            
Daiichi Sankyo Europe GmbH ("DSE") | License and Collaboration Agreement | Minimum                  
Collaborations with Third Parties                  
Percentage of royalties to be received on the net sales     15.00%            
Daiichi Sankyo Europe GmbH ("DSE") | License and Collaboration Agreement | Maximum                  
Collaborations with Third Parties                  
Percentage of royalties to be received on the net sales     25.00%            
Otsuka Pharmaceutical Co, Ltd. | Exclusive Developmental Activities                  
Collaborations with Third Parties                  
Upfront cash payment received (paid)   $ 60,000,000              
Potential additional future payments   $ 450,000,000              
Otsuka Pharmaceutical Co, Ltd. | Exclusive Developmental Activities | Collaboration revenue                  
Collaborations with Third Parties                  
Collaboration revenue         400,000 0 400,000 0  
Otsuka Pharmaceutical Co, Ltd. | Exclusive Developmental Activities | Minimum                  
Collaborations with Third Parties                  
Percentage of royalties to be received on the net sales   15.00%              
Otsuka Pharmaceutical Co, Ltd. | Exclusive Developmental Activities | Maximum                  
Collaborations with Third Parties                  
Percentage of royalties to be received on the net sales   30.00%              
Milestone payment, first JNDA submissions   $ 20,000,000              
Milestone payment, first NHI Price Listing for NEXLETOL in the Otsuka Territory   70,000,000              
Milestone payment, achievement of the primary MACE in the CLEAR Outcomes study and CV risk reduction rate on the U.S. label   50,000,000              
Milestone payments related to total net sales achievements   $ 310,000,000              
Daiichi Sankyo Co. Ltd                  
Collaborations with Third Parties                  
Collaboration revenue                 $ 28,500,000
Daiichi Sankyo Co. Ltd | License and Collaboration Agreement                  
Collaborations with Third Parties                  
Collaboration revenue         $ 200,000 200,000 600,000 $ 28,300,000 28,500,000
Consideration cash payment $ 30,000,000     $ 30,000,000          
Cash payment to be received upon certain commercial milestones       $ 175,000,000          
Deferred up-front payment             $ 900,000    
Daiichi Sankyo Co. Ltd | License and Collaboration Agreement | Minimum                  
Collaborations with Third Parties                  
Percentage of royalties to be received on the net sales       5.00%          
Daiichi Sankyo Co. Ltd | License and Collaboration Agreement | Maximum                  
Collaborations with Third Parties                  
Percentage of royalties to be received on the net sales       20.00%          
Daiichi Sankyo Co. Ltd | Collaborative Arrangement, License To Intellectual Property                  
Collaborations with Third Parties                  
Collaboration revenue           28,000,000     28,000,000
Daiichi Sankyo Co. Ltd | Collaborative Arrangement, Ongoing Regulatory And Development Activities                  
Collaborations with Third Parties                  
Collaboration revenue           $ 300,000     $ 500,000
XML 42 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2
Inventories, net (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Inventory Disclosure [Abstract]    
Raw materials $ 24,785 $ 31,850
Work in process 2,874 663
Finished goods 1,886 1,881
Total Inventory $ 29,545 $ 34,394
XML 43 R34.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments and Contingencies (Details) - Pending Litigation - USD ($)
$ in Thousands
 3 Months Ended
Aug. 24, 2021
Mar. 31, 2021
Loss Contingencies [Line Items]    
Payment to plaintiff $ 18,250  
Loss related to litigation settlement   $ 13,250
Litigation settlement   18,250
Insurance settlement recovery   $ 5,000
XML 44 R35.htm IDEA: XBRL DOCUMENT v3.22.2.2
Investments - Summary of Cash Equivalents, Restricted Cash, and Short-Term Investments (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Investments    
Amortized Cost $ 179,285 $ 239,606
Gross Unrealized Gains 0 0
Gross Unrealized Losses (93) (31)
Short-term investments: 179,192 239,575
Money market funds | Cash Equivalents and Restricted Cash    
Investments    
Amortized Cost 148,850 188,734
Gross Unrealized Gains 0 0
Gross Unrealized Losses 0 0
Short-term investments: 148,850 188,734
Certificates of deposit | Cash Equivalents and Restricted Cash    
Investments    
Amortized Cost 400 400
Gross Unrealized Gains 0 0
Gross Unrealized Losses 0 0
Short-term investments: 400 400
U.S. treasury notes | Short-term Investments    
Investments    
Amortized Cost 30,035 50,472
Gross Unrealized Gains 0 0
Gross Unrealized Losses (93) (31)
Short-term investments: $ 29,942 $ 50,441
XML 45 R36.htm IDEA: XBRL DOCUMENT v3.22.2.2
Investments - Narrative (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Investments        
Other income, net $ 659,000 $ 13,000 $ 1,297,000 $ 36,000
Allowance for credit loss 0 0 0 0
Accrued interest receivable 200,000   200,000  
Amortization of premiums and discounts on investments     539,000 0
Reclassification out of Accumulated Other Comprehensive Income        
Investments        
Other income, net 0 0 0 0
Other Nonoperating Income (Expense)        
Investments        
Interest income on investments 800,000   1,500,000  
Amortization of premiums and discounts on investments $ 200,000 0 $ 600,000 0
Other Nonoperating Income (Expense) | Maximum        
Investments        
Interest income on investments   $ 100,000   $ 100,000
XML 46 R37.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value Measurements (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Fair value measurements          
Short-term investments: $ 179,192,000   $ 179,192,000   $ 239,575,000
Transfer of assets between levels 0 $ 0 0 $ 0  
Recurring fair value measurement          
Fair value measurements          
Total assets at fair value 179,192,000   179,192,000   239,575,000
Recurring fair value measurement | Money market funds          
Fair value measurements          
Cash and cash equivalents: 148,850,000   148,850,000   188,734,000
Recurring fair value measurement | Certificates of deposit          
Fair value measurements          
Cash and cash equivalents: 400,000   400,000   400,000
Recurring fair value measurement | U.S. treasury notes          
Fair value measurements          
Short-term investments: 29,942,000   29,942,000   50,441,000
Recurring fair value measurement | Level 1          
Fair value measurements          
Total assets at fair value 179,192,000   179,192,000   239,575,000
Recurring fair value measurement | Level 1 | Money market funds          
Fair value measurements          
Cash and cash equivalents: 148,850,000   148,850,000   188,734,000
Recurring fair value measurement | Level 1 | Certificates of deposit          
Fair value measurements          
Cash and cash equivalents: 400,000   400,000   400,000
Recurring fair value measurement | Level 1 | U.S. treasury notes          
Fair value measurements          
Short-term investments: 29,942,000   29,942,000   50,441,000
Recurring fair value measurement | Level 2          
Fair value measurements          
Total assets at fair value 0   0   0
Recurring fair value measurement | Level 2 | Money market funds          
Fair value measurements          
Cash and cash equivalents: 0   0   0
Recurring fair value measurement | Level 2 | Certificates of deposit          
Fair value measurements          
Cash and cash equivalents: 0   0   0
Recurring fair value measurement | Level 2 | U.S. treasury notes          
Fair value measurements          
Short-term investments: 0   0   0
Recurring fair value measurement | Level 3          
Fair value measurements          
Total assets at fair value 0   0   0
Recurring fair value measurement | Level 3 | Money market funds          
Fair value measurements          
Cash and cash equivalents: 0   0   0
Recurring fair value measurement | Level 3 | Certificates of deposit          
Fair value measurements          
Cash and cash equivalents: 0   0   0
Recurring fair value measurement | Level 3 | U.S. treasury notes          
Fair value measurements          
Short-term investments: $ 0   $ 0   $ 0
XML 47 R38.htm IDEA: XBRL DOCUMENT v3.22.2.2
Liability Related to the Revenue Interest Purchase Agreement - Narrative (Details) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
May 16, 2021
Apr. 26, 2021
Jun. 26, 2019
Mar. 31, 2020
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Dec. 31, 2020
Liability Related to the Revenue Interest Purchase Agreement                    
Restricted cash         $ 50,000,000 $ 50,000,000 $ 50,000,000 $ 50,000,000 $ 50,000,000 $ 0
Interest expense         14,153,000 13,654,000 42,481,000 32,923,000    
Revenue Interest Purchase Agreement (RIPA)                    
Liability Related to the Revenue Interest Purchase Agreement                    
Revenue interest liability         284,684,000   284,684,000   $ 257,039,000  
Capitalized issuance costs             400,000      
Revenue Interest Purchase Agreement (RIPA) | Other Nonoperating Income (Expense)                    
Liability Related to the Revenue Interest Purchase Agreement                    
Interest expense         11,100,000 10,400,000 33,300,000 23,300,000    
RIPA Amendment                    
Liability Related to the Revenue Interest Purchase Agreement                    
Loss on modification of debt               100,000    
Oberland | Revenue Interest Purchase Agreement (RIPA)                    
Liability Related to the Revenue Interest Purchase Agreement                    
Percentage of revenue interests payment on which agreement terminates, prior to the third anniversary of the closing date, if put option is exercised     175.00%              
Percentage of revenue interests payment on which agreement terminates, after the third anniversary of the closing date, if put option is exercised     195.00%              
Proceeds from Revenue Interest Purchase Agreement   $ 50,000,000   $ 25,000,000.0            
Revenue interest rate which will take effect if annual net sales equals or exceeds the sales threshold by December 31, 2021     2.50%              
Initial revenue interest rate     7.50%              
Percentage of revenue interests payment on which agreement terminates     195.00%              
Percentage of invested capital received by December 31, 2024, to qualify for second reduced revenue interest rate     100.00%              
Capitalized issuance costs     $ 600,000              
Minimum amount of annual net sales to qualify for reduced revenue interest rate by December 31, 2021     350,000,000              
Maximum amount of US net sales to qualify for the Covered Territory expansion to include worldwide sales by December 31, 2021     $ 350,000,000              
Repayment amount expected to pay in next twelve months         $ 19,600,000   $ 19,600,000      
Effective annual imputed interest rate (as a percent)             15.80%      
Consecutive number of months sales must be at or above milestone amount     6 months              
Percentage of increase in royalty rate upon drawdown of third payment     33.33%              
Gross proceeds from revenue interest liability     $ 125,000,000.0              
Total amount of subsequent installment, subject to RIPA terms and conditions     75,000,000.0              
Amount of subsequent installment, subject to regulatory approval     25,000,000.0              
Amount of subsequent installment, subject to achievement of sales threshold     50,000,000.0              
Milestone amount for worldwide sales to receive the third payment     $ 100,000,000.0              
Revenue interest rate if annual net sales equal or exceed the Sales Threshold and if the Purchasers receive 100% of their invested capital by December 31, 2024     0.40%              
Percentage of revenue interests payment on which agreement terminates, if prior to the anniversary of the closing date, if put option is exercised     120.00%              
Oberland | Revenue Interest Purchase Agreement (RIPA) | Net Sales Less Than $250 Million                    
Liability Related to the Revenue Interest Purchase Agreement                    
Initial revenue interest rate     10.00%              
Hypothetical sales generated amount     $ 100,000,000              
Minimum amount of annual net sales to qualify for reduced revenue interest rate by December 31, 2021     250,000,000              
Hypothetical repayment obligation     $ 10,000,000              
Oberland | Revenue Interest Purchase Agreement (RIPA) | Net Sales Greater Than $250 Million But Less Than $350 Million                    
Liability Related to the Revenue Interest Purchase Agreement                    
Revenue interest rate which will take effect if annual net sales equals or exceeds the sales threshold by December 31, 2021     3.30%              
Hypothetical sales generated amount     $ 100,000,000              
Minimum amount of annual net sales to qualify for reduced revenue interest rate by December 31, 2021     250,000,000              
Hypothetical repayment obligation     3,300,000              
Oberland | Revenue Interest Purchase Agreement (RIPA) | Net Sales Greater Than $350 Million                    
Liability Related to the Revenue Interest Purchase Agreement                    
Hypothetical sales generated amount     100,000,000              
Minimum amount of annual net sales to qualify for reduced revenue interest rate by December 31, 2021     350,000,000              
Hypothetical repayment obligation     $ 3,300,000              
Oberland | RIPA Amendment                    
Liability Related to the Revenue Interest Purchase Agreement                    
Percentage of revenue interests payment on which agreement terminates, prior to the third anniversary of the closing date, if put option is exercised   200.00% 200.00%              
Percentage of revenue interests payment on which agreement terminates, after the third anniversary of the closing date, if put option is exercised   225.00%                
Revenue interest rate which will take effect if annual net sales equals or exceeds the sales threshold by December 31, 2021   3.33%                
Initial revenue interest rate   10.00%                
Minimum amount of annual net sales to qualify for reduced revenue interest rate by December 31, 2024, contingent on 100% invested capital received   $ 350,000,000                
Percentage of invested capital received by December 31, 2024, to qualify for second reduced revenue interest rate   100.00%                
Percentage of revenue interest payments to qualify for third payment applicable percentage   100.00%                
Percentage of cumulative purchaser payments   100.00%                
Oberland | RIPA Amendment To The Security Agreement And Waiver                    
Liability Related to the Revenue Interest Purchase Agreement                    
Specified net revenue $ 15,000,000                  
Company deposit value in blocked account $ 50,000,000                  
Restricted cash           $ 50,000,000   $ 50,000,000    
XML 48 R39.htm IDEA: XBRL DOCUMENT v3.22.2.2
Liability Related to the Revenue Interest Purchase Agreement - Summary of Revenue Interest Liability (Details) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Liability From Sale Of Future Revenues [Roll Forward]    
Revenue Interests payments $ (5,678) $ (2,263)
Revenue Interest Purchase Agreement (RIPA)    
Liability From Sale Of Future Revenues [Roll Forward]    
Revenue interest liability, beginning balance 257,039  
Interest expense recognized 33,323  
Revenue Interests payments (5,678)  
Revenue interest liability, ending balance $ 284,684  
XML 49 R40.htm IDEA: XBRL DOCUMENT v3.22.2.2
Convertible Notes (Details)
 1 Months Ended 3 Months Ended 9 Months Ended
Nov. 03, 2021
shares
Oct. 22, 2021
USD ($)
$ / shares
Jan. 01, 2021
USD ($)
Nov. 16, 2020
USD ($)
$ / shares
shares
Nov. 30, 2020
USD ($)
day
$ / shares
Sep. 30, 2022
USD ($)
$ / shares
Sep. 30, 2021
USD ($)
Sep. 30, 2022
USD ($)
$ / shares
shares
Sep. 30, 2021
USD ($)
Dec. 31, 2021
USD ($)
$ / shares
Dec. 02, 2021
$ / shares
Debt Instrument [Line Items]                      
Purchase of capped call options associated with convertible notes       $ 46,000,000 $ 46,000,000            
Prepayment of forward stock repurchase transaction       $ 55,000,000 55,000,000            
Common stock, par value (in dollars per share) | $ / shares           $ 0.001   $ 0.001   $ 0.001  
Additional Paid in Capital           $ (1,045,468,000)   $ (1,045,468,000)   $ (964,401,000)  
Accumulated Deficit           $ 1,284,549,000   $ 1,284,549,000   $ 1,106,377,000  
Exercise price (in dollars per share) | $ / shares           $ 9.00   $ 9.00   $ 9.00 $ 9.00
Underlying common stock (in shares) | shares       1,994,198              
Shares delivered to the company (in shares) | shares               71,174      
Cumulative Effect, Period of Adoption, Adjustment                      
Debt Instrument [Line Items]                      
Additional Paid in Capital     $ 93,500,000                
Accumulated Deficit     1,500,000                
Capped Call | Common stock                      
Debt Instrument [Line Items]                      
Exercise price (in dollars per share) | $ / shares       $ 55.16              
Class of warrant or right, premium percentage       100.00%              
Convertible Senior Notes Due 2025 | Convertible Debt                      
Debt Instrument [Line Items]                      
Debt instrument, face amount         $ 280,000,000            
Debt instrument, stated interest rate         4.00%            
Proceeds from debt, net of issuance costs     $ 271,100,000   $ 271,100,000            
Debt instrument, convertible, conversion ratio         30.2151            
Debt instrument, convertible, conversion price (in dollars per share) | $ / shares         $ 33.096            
Debt instrument, redemption price, percentage         100.00%            
Debt issuance costs         $ 8,900,000            
Debt instrument, term         5 years            
Long-term debt         $ 177,600,000 $ 259,500,000   $ 259,500,000      
Debt instrument, convertible, carrying amount of equity component         $ 93,500,000            
Exchange Agreement, amount of principal amount converted into common stock   $ 15,000,000                  
Exchange Agreement, weighted average price per share floor (in dollars per share) | $ / shares   $ 5.62                  
Exchange Agreement, threshold trading days   5 days                  
Common stock being exchanged (in shares) | shares 1,094,848                    
Principal amount of convertible notes           265,000,000   265,000,000      
Unamortized debt discount and issuance costs           5,500,000   5,500,000      
Debt interest expense           3,100,000 $ 3,200,000 9,200,000 $ 9,600,000    
Debt fair value           $ 148,900,000   $ 148,900,000   $ 140,300,000  
Convertible Senior Notes Due 2025 | Convertible Debt | Period One                      
Debt Instrument [Line Items]                      
Common stock, par value (in dollars per share) | $ / shares         $ 0.001            
Debt instrument, convertible, threshold percentage of stock price trigger         130.00%            
Debt instrument, convertible, threshold trading days | day         20            
Average trading-day period | day         30            
Number of business days | day         5            
Number of consecutive trading days | day         5            
Debt instrument, convertible, threshold percentage of last reported sale price         98.00%            
Convertible Senior Notes Due 2025 | Convertible Debt | Period Two                      
Debt Instrument [Line Items]                      
Debt instrument, convertible, threshold percentage of stock price trigger         130.00%            
Debt instrument, convertible, threshold trading days | day         20            
Average trading-day period | day         30            
Debt instrument, redemption price, percentage         100.00%            
Debt instrument, required amount outstanding         $ 125,000,000            
Convertible Senior Notes Due 2025 | Convertible Debt | Long-term Debt                      
Debt Instrument [Line Items]                      
Debt issuance costs         5,800,000            
Convertible Senior Notes Due 2025 | Convertible Debt | Additional Paid-In Capital                      
Debt Instrument [Line Items]                      
Debt issuance costs         $ 3,100,000            
XML 50 R41.htm IDEA: XBRL DOCUMENT v3.22.2.2
Other Accrued Liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Payables and Accruals [Abstract]    
Accrued compensation $ 8,512 $ 8,809
Accrued variable consideration 20,525 16,192
Accrued professional fees 2,344 3,917
Accrued interest on convertible notes 3,975 1,325
Accrued other 39 167
Total other accrued liabilities $ 35,395 $ 30,410
XML 51 R42.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock Compensation - Stock Options Additional Information (Details) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Sep. 30, 2022
Apr. 30, 2020
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
May 31, 2022
Stock Option And Incentive Plan 2022              
Stock compensation              
Number of commons stock shares available for issuance (in shares)             4,400,000
ESPP              
Stock compensation              
Maximum annual contributions per employee, as a percentage of base salary   10.00%          
Amount of maximum annual contributions per employee   $ 25,000          
Purchase discount   15.00%          
Duration of offering periods   6 months          
Shares issued (in shares) 339,422            
Shares reserved for future issuance (in shares) 485,578   485,578   485,578    
Stock-based compensation expense     $ 100,000 $ 200,000 $ 300,000 $ 600,000  
Stock options              
Stock compensation              
Stock-based compensation expense     1,400,000 2,800,000 4,300,000 12,700,000  
Stock-based compensation capitalized into inventory     200,000 800,000 400,000 1,300,000  
Unrecognized stock-based compensation expense, options $ 8,900,000   8,900,000   $ 8,900,000    
Weighted-average period over which remaining unrecognized compensation cost will be recognized         2 years 6 months    
PBSOs              
Stock compensation              
Stock-based compensation expense     300,000   $ 500,000    
Unrecognized stock-based compensation expense, options 1,800,000   1,800,000   $ 1,800,000    
Weighted-average period over which remaining unrecognized compensation cost will be recognized         1 year 7 months 6 days    
RSUs              
Stock compensation              
Stock-based compensation expense     1,500,000 2,400,000 $ 5,100,000 6,400,000  
Stock-based compensation capitalized into inventory     200,000 400,000 500,000 600,000  
Unrecognized stock-based compensation expense, options 14,700,000   14,700,000   $ 14,700,000    
Weighted-average period over which remaining unrecognized compensation cost will be recognized         2 years 9 months 18 days    
PBRSUs              
Stock compensation              
Stock-based compensation expense     200,000 $ 100,000 $ 1,300,000 $ 100,000  
Stock-based compensation capitalized into inventory     100,000   $ 100,000    
Weighted-average period over which remaining unrecognized compensation cost will be recognized         1 year 8 months 12 days    
Unrecognized stock-based compensation expense, RSUs $ 1,900,000   $ 1,900,000   $ 1,900,000    
XML 52 R43.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock Compensation - Schedule of Stock Options (Details) - USD ($)
$ / shares in Units, $ in Thousands
 9 Months Ended 12 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Number of Options    
Outstanding at the beginning of period (in shares) 3,214,537  
Granted (in shares) 1,255,600  
Forfeited or expired (in shares) (685,182)  
Exercised (in shares) 0  
Outstanding at the end of the period (in shares) 3,784,955 3,214,537
Vested and expected to vest (in shares) 3,784,955  
Exercisable (in shares) 2,421,198  
Weighted-Average Exercise Price Per Share    
Outstanding at the beginning of period (in dollars per share) $ 38.38  
Granted (in dollars per share) 4.78  
Forfeited or expired (in dollars per share) 33.01  
Exercised (in dollars per share) 0  
Outstanding at the end of the period (in dollars per share) 28.20 $ 38.38
Vested and expected to vest (in dollars per share) 28.20  
Exercisable (in dollars per share) $ 38.23  
Weighted-Average Remaining Contractual Term (Years)    
Outstanding 5 years 2 months 4 days 4 years 2 months 4 days
Vested and expected to vest 5 years 2 months 4 days  
Exercisable 2 years 10 months 28 days  
Aggregate Intrinsic Value    
Outstanding $ 2,098 $ 0
Vested and expected to vest 2,098  
Exercisable $ 163  
XML 53 R44.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock Compensation - PBSOs (Details) - USD ($)
$ / shares in Units, $ in Thousands
 9 Months Ended 12 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Number of Options    
Outstanding at the beginning of period (in shares) 3,214,537  
Granted (in shares) 1,255,600  
Forfeited or expired (in shares) (685,182)  
Exercised (in shares) 0  
Outstanding at the end of the period (in shares) 3,784,955 3,214,537
Vested and expected to vest (in shares) 3,784,955  
Exercisable (in shares) 2,421,198  
Weighted-Average Exercise Price Per Share    
Outstanding at the beginning of period (in dollars per share) $ 38.38  
Granted (in dollars per share) 4.78  
Forfeited or expired (in dollars per share) 33.01  
Exercised (in dollars per share) 0  
Outstanding at the end of the period (in dollars per share) 28.20 $ 38.38
Vested and expected to vest (in dollars per share) 28.20  
Exercisable (in dollars per share) $ 38.23  
Weighted-Average Remaining Contractual Term (Years)    
Outstanding 5 years 2 months 4 days 4 years 2 months 4 days
Vested and expected to vest 5 years 2 months 4 days  
Exercisable 2 years 10 months 28 days  
Aggregate Intrinsic Value    
Outstanding $ 2,098 $ 0
Vested and expected to vest 2,098  
Exercisable $ 163  
PBSOs    
Number of Options    
Outstanding at the beginning of period (in shares) 122,700  
Granted (in shares) 403,000  
Forfeited or expired (in shares) (26,500)  
Exercised (in shares) 0  
Outstanding at the end of the period (in shares) 499,200 122,700
Vested and expected to vest (in shares) 499,200  
Exercisable (in shares) 0  
Weighted-Average Exercise Price Per Share    
Outstanding at the beginning of period (in dollars per share) $ 8.94  
Granted (in dollars per share) 6.20  
Forfeited or expired (in dollars per share) 8.94  
Exercised (in dollars per share) 0  
Outstanding at the end of the period (in dollars per share) 6.73 $ 8.94
Vested and expected to vest (in dollars per share) 6.73  
Exercisable (in dollars per share) $ 0  
Weighted-Average Remaining Contractual Term (Years)    
Outstanding 9 years 6 months 29 days 9 years 9 months 29 days
Vested and expected to vest 9 years 6 months 29 days  
Exercisable 0 years  
Aggregate Intrinsic Value    
Outstanding $ 202 $ 0
Vested and expected to vest 202  
Exercisable $ 0  
XML 54 R45.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock Compensation - RSUs (Details) - RSUs
 9 Months Ended
Sep. 30, 2022
$ / shares
shares
Number of RSUs  
Outstanding at the beginning of period (in shares) | shares 698,704
Granted (in shares) | shares 1,644,009
Forfeited (in shares) | shares (340,220)
Vested (in shares) | shares (347,893)
Outstanding and unvested at the ending of period (in shares) | shares 1,654,600
Weighted-Average Fair Value Per Share  
Outstanding and at the beginning of period (in dollars per share) | $ / shares $ 28.09
Granted (in dollars per share) | $ / shares 4.71
Forfeited (in dollars per share) | $ / shares 12.98
Vested (in dollars per share) | $ / shares 20.77
Outstanding and unvested at the at the end of the period (in dollars per share) | $ / shares $ 9.51
XML 55 R46.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock Compensation - PBRSUs (Details) - PBRSUs
 9 Months Ended
Sep. 30, 2022
$ / shares
shares
Number of PBRSUs  
Outstanding at the beginning of period (in shares) | shares 639,950
Granted (in shares) | shares 0
Forfeited (in shares) | shares (178,700)
Outstanding and unvested at the ending of period (in shares) | shares 461,250
Weighted-Average Fair Value Per Share  
Outstanding and at the beginning of period (in dollars per share) | $ / shares $ 9.90
Granted (in dollars per share) | $ / shares 0
Forfeited (in dollars per share) | $ / shares 10.95
Outstanding and unvested at the at the end of the period (in dollars per share) | $ / shares $ 9.50
XML 56 R47.htm IDEA: XBRL DOCUMENT v3.22.2.2
Income Taxes (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Provision for income taxes        
Provision for income taxes $ 0 $ 0 $ 0 $ 0
XML 57 R48.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stockholders' Deficit (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended
Apr. 15, 2022
Dec. 02, 2021
Aug. 03, 2021
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Subsidiary, Sale of Stock [Line Items]                
Payment of issuance costs           $ 219 $ 440  
Warrants issued for shares of common stock (in shares)   36,964,286            
Exercise price (in dollars per share)   $ 9.00   $ 9.00   $ 9.00   $ 9.00
Fair value of warrants   $ 61,900            
Total shares of common stock from exercisable warrants outstanding       36,964,286   36,964,286   36,964,286
At The Market Program                
Subsidiary, Sale of Stock [Line Items]                
Aggregate offering price shares $ 239,000   $ 250,000          
Issued stock (in shares)       6,958,525 363,061 10,311,525 363,061  
Proceeds from stock offering, net       $ 48,600 $ 4,200 $ 68,800 $ 4,200  
Payment of issuance costs       $ 1,600 $ 500 $ 2,400 $ 500  
XML 58 R49.htm IDEA: XBRL DOCUMENT v3.22.2.2
Net Loss Per Common Share (Details) - shares
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Net (Loss) Income Per Common Share    
Total potential dilutive shares (in shares) 51,380,538 13,098,695
Common shares under option    
Net (Loss) Income Per Common Share    
Total potential dilutive shares (in shares) 3,784,955 3,703,938
Common shares under PBSOs    
Net (Loss) Income Per Common Share    
Total potential dilutive shares (in shares) 499,200 0
Unvested RSUs    
Net (Loss) Income Per Common Share    
Total potential dilutive shares (in shares) 1,654,600 879,349
Unvested PBRSUs    
Net (Loss) Income Per Common Share    
Total potential dilutive shares (in shares) 461,250 45,300
Shares issuable related to the ESPP    
Net (Loss) Income Per Common Share    
Total potential dilutive shares (in shares) 9,237 9,871
Shares issuable upon conversion of convertible notes    
Net (Loss) Income Per Common Share    
Total potential dilutive shares (in shares) 8,007,010 8,460,237
Warrants    
Net (Loss) Income Per Common Share    
Total potential dilutive shares (in shares) 36,964,286 0
XML 59 R50.htm IDEA: XBRL DOCUMENT v3.22.2.2
Statements of Cash Flows and Restricted Cash (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Sep. 30, 2021
Dec. 31, 2020
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]        
Cash and cash equivalents $ 159,399 $ 208,892 $ 103,672 $ 304,962
Restricted cash 50,000 50,000 50,000 0
Total cash and cash equivalents and restricted cash shown on the condensed statements of cash flows $ 209,399 $ 258,892 $ 153,672 $ 304,962
XML 60 R9999.htm IDEA: XBRL DOCUMENT v3.22.2.2
Label Element Value
Accounting Standards Update [Extensible Enumeration] us-gaap_AccountingStandardsUpdateExtensibleList Accounting Standards Update 2020-06 [Member]
XML 61 espr-20220930_htm.xml IDEA: XBRL DOCUMENT 0001434868 2022-01-01 2022-09-30 0001434868 2022-10-31 0001434868 2022-09-30 0001434868 2021-12-31 0001434868 us-gaap:ProductMember 2022-07-01 2022-09-30 0001434868 us-gaap:ProductMember 2021-07-01 2021-09-30 0001434868 us-gaap:ProductMember 2022-01-01 2022-09-30 0001434868 us-gaap:ProductMember 2021-01-01 2021-09-30 0001434868 espr:CollaborationRevenueMember 2022-07-01 2022-09-30 0001434868 espr:CollaborationRevenueMember 2021-07-01 2021-09-30 0001434868 espr:CollaborationRevenueMember 2022-01-01 2022-09-30 0001434868 espr:CollaborationRevenueMember 2021-01-01 2021-09-30 0001434868 2022-07-01 2022-09-30 0001434868 2021-07-01 2021-09-30 0001434868 2021-01-01 2021-09-30 0001434868 us-gaap:CommonStockMember 2020-12-31 0001434868 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001434868 us-gaap:RetainedEarningsMember 2020-12-31 0001434868 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001434868 us-gaap:TreasuryStockMember 2020-12-31 0001434868 2020-12-31 0001434868 2020-01-01 2020-12-31 0001434868 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001434868 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2020-12-31 0001434868 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2020-12-31 0001434868 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember us-gaap:CommonStockMember 2020-12-31 0001434868 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001434868 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember us-gaap:RetainedEarningsMember 2020-12-31 0001434868 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001434868 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember us-gaap:TreasuryStockMember 2020-12-31 0001434868 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember 2020-12-31 0001434868 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001434868 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001434868 2021-01-01 2021-03-31 0001434868 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001434868 us-gaap:CommonStockMember 2021-03-31 0001434868 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001434868 us-gaap:RetainedEarningsMember 2021-03-31 0001434868 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001434868 us-gaap:TreasuryStockMember 2021-03-31 0001434868 2021-03-31 0001434868 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001434868 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001434868 2021-04-01 2021-06-30 0001434868 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001434868 us-gaap:CommonStockMember 2021-06-30 0001434868 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001434868 us-gaap:RetainedEarningsMember 2021-06-30 0001434868 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001434868 us-gaap:TreasuryStockMember 2021-06-30 0001434868 2021-06-30 0001434868 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001434868 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001434868 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001434868 us-gaap:CommonStockMember 2021-09-30 0001434868 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001434868 us-gaap:RetainedEarningsMember 2021-09-30 0001434868 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0001434868 us-gaap:TreasuryStockMember 2021-09-30 0001434868 2021-09-30 0001434868 us-gaap:CommonStockMember 2021-12-31 0001434868 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001434868 us-gaap:RetainedEarningsMember 2021-12-31 0001434868 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001434868 us-gaap:TreasuryStockMember 2021-12-31 0001434868 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001434868 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001434868 2022-01-01 2022-03-31 0001434868 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001434868 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001434868 us-gaap:CommonStockMember 2022-03-31 0001434868 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001434868 us-gaap:RetainedEarningsMember 2022-03-31 0001434868 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001434868 us-gaap:TreasuryStockMember 2022-03-31 0001434868 2022-03-31 0001434868 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001434868 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001434868 2022-04-01 2022-06-30 0001434868 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001434868 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001434868 us-gaap:CommonStockMember 2022-06-30 0001434868 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001434868 us-gaap:RetainedEarningsMember 2022-06-30 0001434868 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001434868 us-gaap:TreasuryStockMember 2022-06-30 0001434868 2022-06-30 0001434868 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001434868 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001434868 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0001434868 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001434868 us-gaap:CommonStockMember 2022-09-30 0001434868 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001434868 us-gaap:RetainedEarningsMember 2022-09-30 0001434868 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001434868 us-gaap:TreasuryStockMember 2022-09-30 0001434868 us-gaap:TradeAccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0001434868 us-gaap:TradeAccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001434868 espr:DaiichiSankyoEuropeGmbhMember us-gaap:CollaborativeArrangementMember 2019-01-02 2019-01-02 0001434868 espr:DaiichiSankyoEuropeGmbhMember srt:MinimumMember us-gaap:CollaborativeArrangementMember 2019-01-02 2019-01-02 0001434868 espr:DaiichiSankyoEuropeGmbhMember srt:MaximumMember us-gaap:CollaborativeArrangementMember 2019-01-02 2019-01-02 0001434868 espr:DaiichiSankyoEuropeGmbhMember espr:RoyaltyRevenueAndProductSalesBulkTabletsMember 2022-07-01 2022-09-30 0001434868 espr:DaiichiSankyoEuropeGmbhMember espr:RoyaltyRevenueAndProductSalesBulkTabletsMember 2022-01-01 2022-09-30 0001434868 espr:DaiichiSankyoEuropeGmbhMember espr:RoyaltyRevenueAndProductSalesBulkTabletsMember 2021-07-01 2021-09-30 0001434868 espr:DaiichiSankyoEuropeGmbhMember espr:RoyaltyRevenueAndProductSalesBulkTabletsMember 2021-01-01 2021-09-30 0001434868 espr:OtsukaPharmaceuticalCoLtdMember espr:ExclusiveDevelopmentalActivitiesMember 2020-04-17 2020-04-17 0001434868 espr:OtsukaPharmaceuticalCoLtdMember espr:ExclusiveDevelopmentalActivitiesMember 2020-04-17 0001434868 espr:OtsukaPharmaceuticalCoLtdMember srt:MaximumMember espr:ExclusiveDevelopmentalActivitiesMember 2020-04-17 0001434868 espr:OtsukaPharmaceuticalCoLtdMember srt:MinimumMember espr:ExclusiveDevelopmentalActivitiesMember 2020-04-17 2020-04-17 0001434868 espr:OtsukaPharmaceuticalCoLtdMember srt:MaximumMember espr:ExclusiveDevelopmentalActivitiesMember 2020-04-17 2020-04-17 0001434868 espr:OtsukaPharmaceuticalCoLtdMember espr:CollaborationRevenueMember espr:ExclusiveDevelopmentalActivitiesMember 2022-01-01 2022-09-30 0001434868 espr:OtsukaPharmaceuticalCoLtdMember espr:CollaborationRevenueMember espr:ExclusiveDevelopmentalActivitiesMember 2022-07-01 2022-09-30 0001434868 espr:OtsukaPharmaceuticalCoLtdMember espr:CollaborationRevenueMember espr:ExclusiveDevelopmentalActivitiesMember 2021-01-01 2021-09-30 0001434868 espr:OtsukaPharmaceuticalCoLtdMember espr:CollaborationRevenueMember espr:ExclusiveDevelopmentalActivitiesMember 2021-07-01 2021-09-30 0001434868 espr:DaiichiSankyoCoLtdMember us-gaap:CollaborativeArrangementMember 2021-04-01 2021-04-30 0001434868 espr:DaiichiSankyoCoLtdMember srt:MinimumMember us-gaap:CollaborativeArrangementMember 2021-04-01 2021-04-30 0001434868 espr:DaiichiSankyoCoLtdMember srt:MaximumMember us-gaap:CollaborativeArrangementMember 2021-04-01 2021-04-30 0001434868 espr:DaiichiSankyoCoLtdMember us-gaap:CollaborativeArrangementMember 2021-04-26 2021-04-26 0001434868 espr:DaiichiSankyoCoLtdMember us-gaap:CollaborativeArrangementMember 2021-07-01 2021-09-30 0001434868 espr:DaiichiSankyoCoLtdMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-09-30 0001434868 espr:DaiichiSankyoCoLtdMember espr:CollaborativeArrangementLicenseToIntellectualPropertyMember 2021-07-01 2021-09-30 0001434868 espr:DaiichiSankyoCoLtdMember espr:CollaborativeArrangementOngoingRegulatoryAndDevelopmentActivitiesMember 2021-07-01 2021-09-30 0001434868 espr:DaiichiSankyoCoLtdMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-12-31 0001434868 espr:DaiichiSankyoCoLtdMember 2021-01-01 2021-12-31 0001434868 espr:DaiichiSankyoCoLtdMember espr:CollaborativeArrangementLicenseToIntellectualPropertyMember 2021-01-01 2021-12-31 0001434868 espr:DaiichiSankyoCoLtdMember espr:CollaborativeArrangementOngoingRegulatoryAndDevelopmentActivitiesMember 2021-01-01 2021-12-31 0001434868 espr:DaiichiSankyoCoLtdMember us-gaap:CollaborativeArrangementMember 2022-07-01 2022-09-30 0001434868 espr:DaiichiSankyoCoLtdMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-09-30 0001434868 us-gaap:PendingLitigationMember 2021-08-24 2021-08-24 0001434868 us-gaap:PendingLitigationMember 2021-01-01 2021-03-31 0001434868 us-gaap:PendingLitigationMember 2021-03-31 0001434868 us-gaap:CashEquivalentsMember us-gaap:MoneyMarketFundsMember 2022-09-30 0001434868 us-gaap:CashEquivalentsMember us-gaap:CertificatesOfDepositMember 2022-09-30 0001434868 us-gaap:ShortTermInvestmentsMember us-gaap:USTreasurySecuritiesMember 2022-09-30 0001434868 us-gaap:CashEquivalentsMember us-gaap:MoneyMarketFundsMember 2021-12-31 0001434868 us-gaap:CashEquivalentsMember us-gaap:CertificatesOfDepositMember 2021-12-31 0001434868 us-gaap:ShortTermInvestmentsMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0001434868 us-gaap:OtherNonoperatingIncomeExpenseMember 2022-07-01 2022-09-30 0001434868 us-gaap:OtherNonoperatingIncomeExpenseMember 2022-01-01 2022-09-30 0001434868 srt:MaximumMember us-gaap:OtherNonoperatingIncomeExpenseMember 2021-07-01 2021-09-30 0001434868 srt:MaximumMember us-gaap:OtherNonoperatingIncomeExpenseMember 2021-01-01 2021-09-30 0001434868 us-gaap:OtherNonoperatingIncomeExpenseMember 2021-07-01 2021-09-30 0001434868 us-gaap:OtherNonoperatingIncomeExpenseMember 2021-01-01 2021-09-30 0001434868 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0001434868 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0001434868 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-09-30 0001434868 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-09-30 0001434868 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-09-30 0001434868 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-09-30 0001434868 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-09-30 0001434868 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-09-30 0001434868 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2022-09-30 0001434868 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2022-09-30 0001434868 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2022-09-30 0001434868 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2022-09-30 0001434868 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2022-09-30 0001434868 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2022-09-30 0001434868 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2022-09-30 0001434868 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2022-09-30 0001434868 us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001434868 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001434868 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001434868 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001434868 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-12-31 0001434868 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-12-31 0001434868 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-12-31 0001434868 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-12-31 0001434868 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2021-12-31 0001434868 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2021-12-31 0001434868 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2021-12-31 0001434868 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2021-12-31 0001434868 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2021-12-31 0001434868 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2021-12-31 0001434868 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2021-12-31 0001434868 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2021-12-31 0001434868 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001434868 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001434868 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001434868 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001434868 espr:EigerIiiSaLlcMember espr:RevenueInterestPurchaseAgreementMember 2019-06-26 2019-06-26 0001434868 espr:EigerIiiSaLlcMember espr:RevenueInterestPurchaseAgreementMember 2020-03-01 2020-03-31 0001434868 espr:EigerIiiSaLlcMember espr:RevenueInterestPurchaseAgreementMember 2021-04-26 2021-04-26 0001434868 espr:EigerIiiSaLlcMember espr:RevenueInterestPurchaseAgreementAmendmentMember 2021-04-26 2021-04-26 0001434868 espr:RevenueInterestPurchaseAgreementAmendmentMember 2021-01-01 2021-09-30 0001434868 espr:EigerIiiSaLlcMember espr:RIPAAmendmentToTheSecurityAgreementAndWaiverMember 2021-05-16 2021-05-16 0001434868 espr:EigerIiiSaLlcMember espr:RIPAAmendmentToTheSecurityAgreementAndWaiverMember 2021-09-30 0001434868 espr:RevenueInterestPurchaseAgreementMember 2022-09-30 0001434868 espr:RevenueInterestPurchaseAgreementMember 2022-01-01 2022-09-30 0001434868 us-gaap:OtherNonoperatingIncomeExpenseMember espr:RevenueInterestPurchaseAgreementMember 2022-07-01 2022-09-30 0001434868 us-gaap:OtherNonoperatingIncomeExpenseMember espr:RevenueInterestPurchaseAgreementMember 2022-01-01 2022-09-30 0001434868 us-gaap:OtherNonoperatingIncomeExpenseMember espr:RevenueInterestPurchaseAgreementMember 2021-07-01 2021-09-30 0001434868 us-gaap:OtherNonoperatingIncomeExpenseMember espr:RevenueInterestPurchaseAgreementMember 2021-01-01 2021-09-30 0001434868 espr:EigerIiiSaLlcMember espr:RevenueInterestPurchaseAgreementAmendmentMember 2019-06-26 2019-06-26 0001434868 espr:EigerIiiSaLlcMember espr:RevenueInterestPurchaseAgreementMember espr:NetSalesThresholdOneMember 2019-06-26 2019-06-26 0001434868 espr:EigerIiiSaLlcMember espr:RevenueInterestPurchaseAgreementMember espr:NetSalesThresholdOneMember 2019-06-26 0001434868 espr:EigerIiiSaLlcMember espr:RevenueInterestPurchaseAgreementMember espr:NetSalesThresholdTwoMember 2019-06-26 2019-06-26 0001434868 espr:EigerIiiSaLlcMember espr:RevenueInterestPurchaseAgreementMember espr:NetSalesThresholdTwoMember 2019-06-26 0001434868 espr:EigerIiiSaLlcMember espr:RevenueInterestPurchaseAgreementMember espr:NetSalesThresholdThreeMember 2019-06-26 2019-06-26 0001434868 espr:EigerIiiSaLlcMember espr:RevenueInterestPurchaseAgreementMember espr:NetSalesThresholdThreeMember 2019-06-26 0001434868 espr:EigerIiiSaLlcMember espr:RevenueInterestPurchaseAgreementMember 2022-09-30 0001434868 espr:EigerIiiSaLlcMember espr:RevenueInterestPurchaseAgreementMember 2022-01-01 2022-09-30 0001434868 espr:RevenueInterestPurchaseAgreementMember 2021-12-31 0001434868 espr:ConvertibleSeniorNotesDue2025Member us-gaap:ConvertibleDebtMember 2020-11-30 0001434868 espr:ConvertibleSeniorNotesDue2025Member us-gaap:ConvertibleDebtMember 2020-11-01 2020-11-30 0001434868 2020-11-01 2020-11-30 0001434868 espr:ConvertibleSeniorNotesDue2025Member us-gaap:DebtInstrumentRedemptionPeriodOneMember us-gaap:ConvertibleDebtMember 2020-11-30 0001434868 espr:ConvertibleSeniorNotesDue2025Member us-gaap:DebtInstrumentRedemptionPeriodOneMember us-gaap:ConvertibleDebtMember 2020-11-01 2020-11-30 0001434868 espr:ConvertibleSeniorNotesDue2025Member us-gaap:DebtInstrumentRedemptionPeriodTwoMember us-gaap:ConvertibleDebtMember 2020-11-01 2020-11-30 0001434868 espr:ConvertibleSeniorNotesDue2025Member us-gaap:DebtInstrumentRedemptionPeriodTwoMember us-gaap:ConvertibleDebtMember 2020-11-30 0001434868 us-gaap:LongTermDebtMember espr:ConvertibleSeniorNotesDue2025Member us-gaap:ConvertibleDebtMember 2020-11-30 0001434868 us-gaap:AdditionalPaidInCapitalMember espr:ConvertibleSeniorNotesDue2025Member us-gaap:ConvertibleDebtMember 2020-11-30 0001434868 espr:ConvertibleSeniorNotesDue2025Member us-gaap:ConvertibleDebtMember 2021-01-01 2021-01-01 0001434868 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2021-01-01 0001434868 espr:ConvertibleSeniorNotesDue2025Member us-gaap:ConvertibleDebtMember 2021-10-22 2021-10-22 0001434868 espr:ConvertibleSeniorNotesDue2025Member us-gaap:ConvertibleDebtMember 2021-10-22 0001434868 espr:ConvertibleSeniorNotesDue2025Member us-gaap:ConvertibleDebtMember 2021-11-03 2021-11-03 0001434868 espr:ConvertibleSeniorNotesDue2025Member us-gaap:ConvertibleDebtMember 2022-09-30 0001434868 espr:ConvertibleSeniorNotesDue2025Member us-gaap:ConvertibleDebtMember 2022-07-01 2022-09-30 0001434868 espr:ConvertibleSeniorNotesDue2025Member us-gaap:ConvertibleDebtMember 2022-01-01 2022-09-30 0001434868 espr:ConvertibleSeniorNotesDue2025Member us-gaap:ConvertibleDebtMember 2021-07-01 2021-09-30 0001434868 espr:ConvertibleSeniorNotesDue2025Member us-gaap:ConvertibleDebtMember 2021-01-01 2021-09-30 0001434868 espr:ConvertibleSeniorNotesDue2025Member us-gaap:ConvertibleDebtMember 2021-12-31 0001434868 2020-11-16 2020-11-16 0001434868 espr:CappedCallMember us-gaap:CommonClassAMember 2020-11-16 0001434868 espr:StockOptionAndIncentivePlan2022Member 2022-05-31 0001434868 us-gaap:EmployeeStockMember 2020-04-01 2020-04-30 0001434868 us-gaap:EmployeeStockMember 2022-07-01 2022-09-30 0001434868 us-gaap:EmployeeStockMember 2022-01-01 2022-09-30 0001434868 us-gaap:EmployeeStockMember 2021-07-01 2021-09-30 0001434868 us-gaap:EmployeeStockMember 2021-01-01 2021-09-30 0001434868 us-gaap:EmployeeStockMember 2022-09-30 2022-09-30 0001434868 us-gaap:EmployeeStockMember 2022-09-30 0001434868 2021-01-01 2021-12-31 0001434868 us-gaap:EmployeeStockOptionMember 2022-07-01 2022-09-30 0001434868 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001434868 us-gaap:EmployeeStockOptionMember 2021-07-01 2021-09-30 0001434868 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001434868 us-gaap:EmployeeStockOptionMember 2022-09-30 0001434868 espr:ShareBasedPaymentArrangementOptionPerformanceBasedMember 2021-12-31 0001434868 espr:ShareBasedPaymentArrangementOptionPerformanceBasedMember 2021-01-01 2021-12-31 0001434868 espr:ShareBasedPaymentArrangementOptionPerformanceBasedMember 2022-01-01 2022-09-30 0001434868 espr:ShareBasedPaymentArrangementOptionPerformanceBasedMember 2022-09-30 0001434868 espr:ShareBasedPaymentArrangementOptionPerformanceBasedMember 2022-07-01 2022-09-30 0001434868 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001434868 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0001434868 us-gaap:RestrictedStockUnitsRSUMember 2022-09-30 0001434868 us-gaap:RestrictedStockUnitsRSUMember 2022-07-01 2022-09-30 0001434868 us-gaap:RestrictedStockUnitsRSUMember 2021-07-01 2021-09-30 0001434868 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-09-30 0001434868 us-gaap:PerformanceSharesMember 2021-12-31 0001434868 us-gaap:PerformanceSharesMember 2022-01-01 2022-09-30 0001434868 us-gaap:PerformanceSharesMember 2022-09-30 0001434868 us-gaap:PerformanceSharesMember 2022-07-01 2022-09-30 0001434868 us-gaap:PerformanceSharesMember 2021-01-01 2021-09-30 0001434868 us-gaap:PerformanceSharesMember 2021-07-01 2021-09-30 0001434868 espr:AtTheMarketProgramMember 2021-08-03 2021-08-03 0001434868 espr:AtTheMarketProgramMember 2021-07-01 2021-09-30 0001434868 espr:AtTheMarketProgramMember 2021-01-01 2021-09-30 0001434868 espr:AtTheMarketProgramMember 2022-04-15 2022-04-15 0001434868 espr:AtTheMarketProgramMember 2022-07-01 2022-09-30 0001434868 espr:AtTheMarketProgramMember 2022-01-01 2022-09-30 0001434868 2021-12-02 0001434868 2021-12-02 2021-12-02 0001434868 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001434868 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001434868 espr:ShareBasedPaymentArrangementOptionPerformanceBasedMember 2022-01-01 2022-09-30 0001434868 espr:ShareBasedPaymentArrangementOptionPerformanceBasedMember 2021-01-01 2021-09-30 0001434868 espr:UnvestedRestrictedStockAndRestrictedStockUnitsMember 2022-01-01 2022-09-30 0001434868 espr:UnvestedRestrictedStockAndRestrictedStockUnitsMember 2021-01-01 2021-09-30 0001434868 us-gaap:PerformanceSharesMember 2022-01-01 2022-09-30 0001434868 us-gaap:PerformanceSharesMember 2021-01-01 2021-09-30 0001434868 us-gaap:EmployeeStockMember 2022-01-01 2022-09-30 0001434868 us-gaap:EmployeeStockMember 2021-01-01 2021-09-30 0001434868 us-gaap:ConvertibleDebtSecuritiesMember 2022-01-01 2022-09-30 0001434868 us-gaap:ConvertibleDebtSecuritiesMember 2021-01-01 2021-09-30 0001434868 us-gaap:WarrantMember 2022-01-01 2022-09-30 0001434868 us-gaap:WarrantMember 2021-01-01 2021-09-30 shares iso4217:USD iso4217:USD shares espr:customer espr:revenue_source pure espr:day 0001434868 --12-31 2022 Q3 false http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member P6M 0.3333 P5D 10-Q true 2022-09-30 false 001-35986 Esperion Therapeutics, Inc. DE 26-1870780 3891 Ranchero Drive, Suite 150 Ann Arbor MI 48108 734 887-3903 Common Stock, par value $0.001 per share ESPR NASDAQ Yes Yes Large Accelerated Filer false false false 73683572 159399000 208892000 29942000 50441000 31489000 22934000 2199000 1138000 29545000 34394000 9211000 11173000 261785000 328972000 50000000 50000000 256000 664000 730000 1898000 56000 56000 312827000 381590000 18580000 17559000 3996000 7013000 35395000 30410000 19636000 11295000 4045000 5683000 693000 1392000 82345000 73352000 259487000 258280000 265048000 245744000 47000 524000 0 634000 606927000 578534000 0.001 0.001 5000000 5000000 0 0 0 0 0 0 0.001 0.001 240000000 120000000 73739320 62873694 72000 61000 1045468000 964401000 1994198 1994198 54998000 54998000 -93000 -31000 -1284549000 -1106377000 -294100000 -196944000 312827000 381590000 13964000 10895000 40896000 27855000 5016000 3514000 15761000 35191000 18980000 14409000 56657000 63046000 6506000 5558000 22807000 9142000 29143000 25331000 85894000 78359000 24954000 39265000 84944000 146647000 60603000 70154000 193645000 234148000 -41623000 -55745000 -136988000 -171102000 14153000 13654000 42481000 32923000 659000 13000 1297000 36000 -55117000 -69386000 -178172000 -203989000 -0.81 -0.81 -2.62 -2.62 -2.78 -2.78 -7.78 -7.78 67806292 67806292 26455209 26455209 64021248 64021248 26225730 26225730 204000 0 -62000 0 -54913000 -69386000 -178234000 -203989000 25916168 26000 797655000 -838817000 0 -54998000 -96134000 -93475000 1548000 -91927000 25916168 26000 704180000 -837269000 0 -54998000 -188061000 172268 2668000 2668000 43465 50818 1183000 1183000 5751000 5751000 -90935000 -90935000 26182719 26000 713782000 -928204000 0 -54998000 -269394000 10477 168000 168000 81139 8584000 8584000 -43668000 -43668000 26274335 26000 722534000 -971872000 0 -54998000 -304310000 363061 1000 4206000 4207000 45996 375000 375000 34581 82396 912000 912000 5497000 5497000 -69386000 -69386000 26800369 27000 733524000 -1041258000 0 -54998000 -362705000 60879496 61000 964401000 -1106377000 -31000 -54998000 -196944000 55286 123785 431000 431000 4436000 4436000 -232000 -232000 -56731000 -56731000 61058567 61000 969268000 -1163108000 -263000 -54998000 -249040000 184407 3527000 3527000 3353000 4000 20169000 20173000 -34000 -34000 -66324000 -66324000 64595974 65000 992964000 -1229432000 -297000 -54998000 -291698000 108200 82423 301000 301000 3537000 3537000 6958525 7000 48666000 48673000 204000 204000 -55117000 -55117000 71745122 72000 1045468000 -1284549000 -93000 -54998000 -294100000 -178172000 -203989000 408000 459000 -539000 0 1207000 1214000 33323000 23310000 11500000 19832000 8555000 9322000 -901000 -1096000 -2272000 2251000 -4849000 17836000 1129000 -30833000 2788000 7715000 -132355000 -206103000 18102000 0 38000000 0 19898000 0 0 49917000 0 3211000 68861000 4388000 5678000 2263000 219000 440000 62964000 54813000 -49493000 -151290000 258892000 304962000 209399000 153672000 15000 181000 8000 10000 The Company and Basis of Presentation<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Esperion Therapeutics, Inc. ("the Company”) is a pharmaceutical company singularly focused on developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol ("LDL-C"). Through commercial execution and advancement of the CLEAR Outcomes trial as well as the Company's pre-clinical pipeline, the Company continues to evolve into a differentiated, global cardiometabolic biotech. The Esperion team of lipid experts are dedicated to lowering bad cholesterol through the discovery, development and commercialization of innovative medicines and their combinations with established medicines. The Company's first two products were approved by the U.S. Food and Drug Administration ("FDA"), European Medicines Agency ("EMA") and Swiss Agency for Therapeutic Products ("Swissmedic") in 2020. Bempedoic acid and the bempedoic acid / ezetimibe combination tablet are oral, once-daily, non-statin, LDL-C lowering medicines for patients with atherosclerotic cardiovascular disease ("ASCVD") or heterozygous familial hypercholesterolemia ("HeFH").</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2022, the Company announced that it is continuing to close out its CLEAR (Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen) Outcomes study of NEXLETOL®. The Company continues to anticipate reporting top-line results from the study in January 2023.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's primary activities since incorporation have been conducting research and development activities, including nonclinical, preclinical and clinical testing, performing business and financial planning, recruiting personnel, and raising capital. The Company received approval by the FDA in February 2020 to commercialize NEXLETOL (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) tablet in the U.S., and accordingly commenced principal operations on March 30, 2020 with the commercialization of NEXLETOL. The Company is subject to risks and uncertainties which include the need to successfully commercialize its products, research, develop, and clinically test therapeutic products; obtain regulatory approvals for its products; manage its management, commercial and scientific staff; and finance its operations with an ultimate goal of achieving profitable operations.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has sustained annual operating losses since inception and expects such losses to continue over the foreseeable future. The Company's ability to successfully launch, commercialize and generate revenue from NEXLETOL, NEXLIZET, NILEMDO® (bempedoic acid) tablet and NUSTENDI® (bempedoic acid and ezetimibe) tablet has been and may continue to be adversely affected by the economic impact of the ongoing COVID-19 pandemic. While management believes current cash resources and future cash received from the Company's net product sales and collaboration agreements with Daiichi Sankyo Europe GmbH ("DSE"), Otsuka Pharmaceutical Co., Ltd. ("Otsuka"), and Daiichi Sankyo Co. Ltd ("DS"), entered into on January 2, 2019, April 17, 2020 and April 26, 2021, respectively, will fund operations for the foreseeable future, management may continue to fund operations and advance the development of the Company's products and product candidates through a combination of collaborations with third parties, strategic alliances, licensing arrangements, permitted debt financings, permitted royalty-based financings, and permitted private and public equity offerings or through other sources. The continuing impact of COVID-19 and the uncertainty around the global pandemic could further impact the commercialization of NEXLETOL and NEXLIZET and the Company’s research and development programs and could result in lower cash flows or higher costs that could further impact the Company’s overall operations and cash needs in the future.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If adequate funds are not available, the Company may not be able to continue the development of its current products or future product candidates, or to commercialize its current or future product candidates, if approved.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed interim financial statements are unaudited and were prepared by the Company in accordance with generally accepted accounting principles in the United States of America (“GAAP”). In the opinion of management, the Company has made all adjustments, which include only normal recurring adjustments necessary for a fair presentation of the Company’s financial position and results of operations for the interim periods presented. Certain prior year amounts have been reclassified to conform with current year presentation. Certain information and disclosures normally included in the annual financial statements prepared in accordance with GAAP, but that is not required for interim reporting purposes, have been condensed or omitted. These condensed interim financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2021, and the notes thereto, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. The results of operations for the interim periods are not necessarily indicative of the results to be expected for a full year, any other interim periods or any future year or period.</span></div> <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed interim financial statements are unaudited and were prepared by the Company in accordance with generally accepted accounting principles in the United States of America (“GAAP”). In the opinion of management, the Company has made all adjustments, which include only normal recurring adjustments necessary for a fair presentation of the Company’s financial position and results of operations for the interim periods presented. Certain prior year amounts have been reclassified to conform with current year presentation. Certain information and disclosures normally included in the annual financial statements prepared in accordance with GAAP, but that is not required for interim reporting purposes, have been condensed or omitted. These condensed interim financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2021, and the notes thereto, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. The results of operations for the interim periods are not necessarily indicative of the results to be expected for a full year, any other interim periods or any future year or period.</span></div> Summary of Significant Accounting Policies<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, net revenues, expenses and related disclosures. Actual results could differ from those estimates.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests its excess cash in bank deposits, money market accounts, and short-term investments. The Company considers all highly liquid investments with an original maturity of 90 days or less at the time of purchase to be cash equivalents. Cash equivalents are reported at fair value.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Cash</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash consists of legally restricted amounts held by financial institutions pursuant to contractual arrangements. Pursuant to the Amendment and Waiver (as defined below), the Company deposited $50.0 million in a deposit account that is subject to a block account control agreement. Eiger III SA LLC (“Oberland”), an affiliate of Oberland Capital LLC, will have sole control over the funds deposited in the account and such funds may be withdrawn only with the consent of Oberland. Refer to Note 8 "Liability Related to the Revenue Interest Purchase Agreement" for further information on the Amendment and Waiver. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments are considered to be available-for-sale and are carried at fair value. Unrealized gains and losses, if any, are reported in accumulated other comprehensive income (loss). The cost of investments classified as available-for-sale are adjusted for the amortization of premiums and accretion of discounts to maturity and recorded in other income, net. Realized gains and losses, if any, are determined using the specific identification method and recorded in other income, net. Investments with original maturities beyond 90 days at the date of purchase and which mature at, or less than twelve months from, the balance sheet date are classified as current. Investments with a maturity beyond twelve months from the balance sheet date are classified as long-term.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Risk</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into a limited number of distribution agreements with distributors and specialty pharmacies. The Company's net product sales are with these customers. As of September 30, 2022, thirteen customers accounted for all of the Company's net trade receivables and as of December 31, 2021, nine customers accounted for all the Company's net trade receivables.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 606, Revenue from Contracts with Customers, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange for the goods or services provided. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: identify the contracts with a customer; identify the performance obligations in the contract; determine the transaction price; allocate the transaction price to the performance obligations in the contract; and recognize revenue when or as the entity satisfies a performance obligation. At contract inception the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. The Company derives revenue through two primary sources: collaboration revenue and product sales. Collaboration revenue consists of the collaboration payments to the Company for collaboration arrangements outside of the United States for the development, manufacturing and commercialization, including royalties, of the Company's product candidates by the Company's partners and product sales consists of sales of NEXLETOL and NEXLIZET.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Collaboration Revenue</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into agreements related to its activities to develop, manufacture, and commercialize its product candidates. The Company earns collaboration revenue in connection with a collaboration agreement to develop and/or commercialize product candidates where the Company deems the collaborator to be the customer. Revenue is recognized when (or as) the Company satisfies performance obligations under the terms of a contract. Depending on the terms of the arrangement, the Company may defer the recognition of all or a portion of the consideration received as the performance obligations are satisfied.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collaboration agreements may require the Company to deliver various rights, services, and/or goods across the entire life cycle of a product or product candidate. In an agreement involving multiple goods or services promised to be transferred to a customer, the Company must assess, at the inception of the contract, whether each promise represents a separate performance obligation (i.e., is "distinct"), or whether such promises should be combined as a single performance obligation.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the agreement typically include consideration to be provided to the Company in the form of non-refundable up-front payments, development milestones, sales milestones, and royalties on sales of products within a respective territory. The Company recognizes regulatory and approval milestones consideration when it is probable that a future reversal is unlikely to occur. For sales-based milestones and royalties based on sales of product in a territory, the Company applies the sales-based royalty exception in ASC 606-10-55-65 to all of these milestones and royalties.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the contract, the transaction price reflects the amount of consideration the Company expects to be entitled to in exchange for transferring promised goods or services to its customer. In the arrangement where the Company satisfies performance obligation(s) during the regulatory phase over time, the Company recognizes collaboration revenue typically using an input method on the basis of regulatory costs incurred relative to the total expected cost which determines the extent of progress toward completion. The Company reviews the estimate of the transaction price and the total expected cost each period and makes revisions to such estimates as necessary. Under contracted supply agreements with collaborators, the Company, through its third party contract manufacturing partners, may manufacture and supply quantities of active pharmaceutical ingredient (“API”) or bulk tablets reasonably required by collaboration partners for the development or sale of licensed products in their respective territory. The Company recognizes revenue when the collaboration partner has obtained control of the API or bulk tablets. The Company records the costs related to the supply agreement in cost of goods sold on the condensed statements of operations and comprehensive (loss) income.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company's collaboration agreements, product sales and cost of sales may be recorded by the Company's collaborators as they are deemed to be the principal in the transaction. The Company receives royalties from the commercialization of such products, and records its share of the variable consideration, representing a percentage of net product sales, as collaboration revenue in the period in which such underlying sales occur and costs are incurred by the collaborator.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.94pt">Product Sales, Net</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 21, 2020, the Company announced that the FDA approved NEXLETOL as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or established ASCVD who require additional lowering of LDL-C. On February 26, 2020, the Company announced that the FDA approved NEXLIZET as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or established ASCVD who require additional lowering of LDL-C. On March 30, 2020, NEXLETOL was commercially available in the U.S. through prescription and on June 4, 2020, NEXLIZET was commercially available in the U.S. through prescription. Net product sales totaled $14.0 million and $40.9 million for the three and nine months ended September 30, 2022, respectively, and $10.9 million and $27.9 million for the three and nine months ended September 30, 2021, respectively.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells NEXLETOL and NEXLIZET to wholesalers in the U.S. and, in accordance with ASC 606, recognizes revenue at the point in time when the customer is deemed to have obtained control of the product. The customer is deemed to have obtained control of the product at the time of physical receipt of the product at the customers’ distribution facilities, or free on board (“FOB”) destination, the terms of which are designated in the contract.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales are recorded at the net selling price, which includes estimates of variable consideration for which reserves are established for (a) rebates and chargebacks, (b) co-pay assistance programs, (c) distribution fees, (d) product returns, and (e) other discounts. Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as current contractual and statutory requirements, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company's best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contract. The amount of variable consideration may be constrained and is included </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Given the early stage of the Company’s commercial operations it has provided constraint of its variable consideration due to its potential consumption trends. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results in the future vary from estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities for co-pay assistance, expected product returns, rebates, and distributor fees are classified as “Other accrued liabilities” in the condensed balance sheets. Discounts, such as prompt pay discounts, and chargebacks are recorded as a reduction to trade accounts receivable in the condensed balance sheets.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forms of Variable Consideration</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates and Chargebacks:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company estimates reductions to product sales for Public Health Service Institutions, such as Medicaid, Medicare and Veterans' Administration ("VA") programs, as well as certain other qualifying federal and state government programs, and other group purchasing organizations. The Company estimates these reductions based upon the Company's contracts with government agencies and other organizations, statutorily defined discounts and estimated payor mix. These organizations purchase directly from the Company's wholesalers at a discount and the wholesalers charge the Company back the difference between the wholesaler price and the discounted price. The Company's liability for Medicaid rebates consists of estimates for claims that a state will make for a current quarter. The Company's reserve for this discounted pricing is based on expected sales to qualified healthcare providers and the chargebacks that customers have already claimed.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-pay assistance:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Eligible patients who have commercial insurance may receive assistance from the Company to reduce the patient's out of pocket costs. The Company will buy down the difference between the amount of the eligible patient's co-pay when the drug is purchased at the pharmacy at a determined price. Liabilities for co-pay assistance are calculated by actual program participation from third-party administrators.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distribution Fees:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has written contracts with its customers that include terms for distribution fees and costs for inventory management. The Company estimates and records distribution fees due to its customers based on gross sales.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company generally offers a right of return based on the product’s expiration date and certain spoilage and damaged instances. The Company estimates the amount of product sales that may be returned and records the estimate as a reduction of product sales in the period the related product sales is recognized. The Company’s estimates for expected returns are based primarily on an ongoing analysis of sales information and visibility into the inventory remaining in the distribution channel.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discounts:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company provides product discounts, such as prompt pay discounts, to its customers. The Company estimates cash discounts based on terms in negotiated contracts and the Company’s expectations regarding future payment patterns.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value and recognized on a first-in, first-out ("FIFO") method. The Company uses standard cost to determine the cost basis for inventory. Inventory is capitalized based on when future economic benefit is expected to be realized. The Company began capitalizing inventory upon receiving FDA approval for NEXLETOL and NEXLIZET on February 21, 2020 and February 26, 2020, respectively. Prior to the FDA approval of NEXLETOL and NEXLIZET, expenses associated with the manufacturing of the Company's products were recorded as research and development expense.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its inventory levels on a periodic basis to determine if any inventory is at risk for expiration prior to sale or has a cost basis that is greater than its estimated future net realizable value. Any adjustments are recognized through cost of goods sold in the period in which they are incurred.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Implemented Accounting Pronouncements</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no other material changes to the significant accounting policies previously disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021.</span></div> <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, net revenues, expenses and related disclosures. Actual results could differ from those estimates.</span></div> <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests its excess cash in bank deposits, money market accounts, and short-term investments. The Company considers all highly liquid investments with an original maturity of 90 days or less at the time of purchase to be cash equivalents. Cash equivalents are reported at fair value.</span></div> Restricted CashRestricted cash consists of legally restricted amounts held by financial institutions pursuant to contractual arrangements. Pursuant to the Amendment and Waiver (as defined below), the Company deposited $50.0 million in a deposit account that is subject to a block account control agreement. Eiger III SA LLC (“Oberland”), an affiliate of Oberland Capital LLC, will have sole control over the funds deposited in the account and such funds may be withdrawn only with the consent of Oberland. Refer to Note 8 "Liability Related to the Revenue Interest Purchase Agreement" for further information on the Amendment and Waiver. 50000000 <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments are considered to be available-for-sale and are carried at fair value. Unrealized gains and losses, if any, are reported in accumulated other comprehensive income (loss). The cost of investments classified as available-for-sale are adjusted for the amortization of premiums and accretion of discounts to maturity and recorded in other income, net. Realized gains and losses, if any, are determined using the specific identification method and recorded in other income, net. Investments with original maturities beyond 90 days at the date of purchase and which mature at, or less than twelve months from, the balance sheet date are classified as current. Investments with a maturity beyond twelve months from the balance sheet date are classified as long-term.</span></div> <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Risk</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into a limited number of distribution agreements with distributors and specialty pharmacies. The Company's net product sales are with these customers. As of September 30, 2022, thirteen customers accounted for all of the Company's net trade receivables and as of December 31, 2021, nine customers accounted for all the Company's net trade receivables.</span></div> 13 9 <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 606, Revenue from Contracts with Customers, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange for the goods or services provided. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: identify the contracts with a customer; identify the performance obligations in the contract; determine the transaction price; allocate the transaction price to the performance obligations in the contract; and recognize revenue when or as the entity satisfies a performance obligation. At contract inception the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. The Company derives revenue through two primary sources: collaboration revenue and product sales. Collaboration revenue consists of the collaboration payments to the Company for collaboration arrangements outside of the United States for the development, manufacturing and commercialization, including royalties, of the Company's product candidates by the Company's partners and product sales consists of sales of NEXLETOL and NEXLIZET.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Collaboration Revenue</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into agreements related to its activities to develop, manufacture, and commercialize its product candidates. The Company earns collaboration revenue in connection with a collaboration agreement to develop and/or commercialize product candidates where the Company deems the collaborator to be the customer. Revenue is recognized when (or as) the Company satisfies performance obligations under the terms of a contract. Depending on the terms of the arrangement, the Company may defer the recognition of all or a portion of the consideration received as the performance obligations are satisfied.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collaboration agreements may require the Company to deliver various rights, services, and/or goods across the entire life cycle of a product or product candidate. In an agreement involving multiple goods or services promised to be transferred to a customer, the Company must assess, at the inception of the contract, whether each promise represents a separate performance obligation (i.e., is "distinct"), or whether such promises should be combined as a single performance obligation.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the agreement typically include consideration to be provided to the Company in the form of non-refundable up-front payments, development milestones, sales milestones, and royalties on sales of products within a respective territory. The Company recognizes regulatory and approval milestones consideration when it is probable that a future reversal is unlikely to occur. For sales-based milestones and royalties based on sales of product in a territory, the Company applies the sales-based royalty exception in ASC 606-10-55-65 to all of these milestones and royalties.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the contract, the transaction price reflects the amount of consideration the Company expects to be entitled to in exchange for transferring promised goods or services to its customer. In the arrangement where the Company satisfies performance obligation(s) during the regulatory phase over time, the Company recognizes collaboration revenue typically using an input method on the basis of regulatory costs incurred relative to the total expected cost which determines the extent of progress toward completion. The Company reviews the estimate of the transaction price and the total expected cost each period and makes revisions to such estimates as necessary. Under contracted supply agreements with collaborators, the Company, through its third party contract manufacturing partners, may manufacture and supply quantities of active pharmaceutical ingredient (“API”) or bulk tablets reasonably required by collaboration partners for the development or sale of licensed products in their respective territory. The Company recognizes revenue when the collaboration partner has obtained control of the API or bulk tablets. The Company records the costs related to the supply agreement in cost of goods sold on the condensed statements of operations and comprehensive (loss) income.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company's collaboration agreements, product sales and cost of sales may be recorded by the Company's collaborators as they are deemed to be the principal in the transaction. The Company receives royalties from the commercialization of such products, and records its share of the variable consideration, representing a percentage of net product sales, as collaboration revenue in the period in which such underlying sales occur and costs are incurred by the collaborator.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.94pt">Product Sales, Net</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 21, 2020, the Company announced that the FDA approved NEXLETOL as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or established ASCVD who require additional lowering of LDL-C. On February 26, 2020, the Company announced that the FDA approved NEXLIZET as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or established ASCVD who require additional lowering of LDL-C. On March 30, 2020, NEXLETOL was commercially available in the U.S. through prescription and on June 4, 2020, NEXLIZET was commercially available in the U.S. through prescription. Net product sales totaled $14.0 million and $40.9 million for the three and nine months ended September 30, 2022, respectively, and $10.9 million and $27.9 million for the three and nine months ended September 30, 2021, respectively.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells NEXLETOL and NEXLIZET to wholesalers in the U.S. and, in accordance with ASC 606, recognizes revenue at the point in time when the customer is deemed to have obtained control of the product. The customer is deemed to have obtained control of the product at the time of physical receipt of the product at the customers’ distribution facilities, or free on board (“FOB”) destination, the terms of which are designated in the contract.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales are recorded at the net selling price, which includes estimates of variable consideration for which reserves are established for (a) rebates and chargebacks, (b) co-pay assistance programs, (c) distribution fees, (d) product returns, and (e) other discounts. Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as current contractual and statutory requirements, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company's best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contract. The amount of variable consideration may be constrained and is included </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Given the early stage of the Company’s commercial operations it has provided constraint of its variable consideration due to its potential consumption trends. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results in the future vary from estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities for co-pay assistance, expected product returns, rebates, and distributor fees are classified as “Other accrued liabilities” in the condensed balance sheets. Discounts, such as prompt pay discounts, and chargebacks are recorded as a reduction to trade accounts receivable in the condensed balance sheets.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forms of Variable Consideration</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates and Chargebacks:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company estimates reductions to product sales for Public Health Service Institutions, such as Medicaid, Medicare and Veterans' Administration ("VA") programs, as well as certain other qualifying federal and state government programs, and other group purchasing organizations. The Company estimates these reductions based upon the Company's contracts with government agencies and other organizations, statutorily defined discounts and estimated payor mix. These organizations purchase directly from the Company's wholesalers at a discount and the wholesalers charge the Company back the difference between the wholesaler price and the discounted price. The Company's liability for Medicaid rebates consists of estimates for claims that a state will make for a current quarter. The Company's reserve for this discounted pricing is based on expected sales to qualified healthcare providers and the chargebacks that customers have already claimed.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-pay assistance:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Eligible patients who have commercial insurance may receive assistance from the Company to reduce the patient's out of pocket costs. The Company will buy down the difference between the amount of the eligible patient's co-pay when the drug is purchased at the pharmacy at a determined price. Liabilities for co-pay assistance are calculated by actual program participation from third-party administrators.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distribution Fees:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has written contracts with its customers that include terms for distribution fees and costs for inventory management. The Company estimates and records distribution fees due to its customers based on gross sales.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company generally offers a right of return based on the product’s expiration date and certain spoilage and damaged instances. The Company estimates the amount of product sales that may be returned and records the estimate as a reduction of product sales in the period the related product sales is recognized. The Company’s estimates for expected returns are based primarily on an ongoing analysis of sales information and visibility into the inventory remaining in the distribution channel.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discounts:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company provides product discounts, such as prompt pay discounts, to its customers. The Company estimates cash discounts based on terms in negotiated contracts and the Company’s expectations regarding future payment patterns.</span></div> 2 14000000 40900000 10900000 27900000 <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value and recognized on a first-in, first-out ("FIFO") method. The Company uses standard cost to determine the cost basis for inventory. Inventory is capitalized based on when future economic benefit is expected to be realized. The Company began capitalizing inventory upon receiving FDA approval for NEXLETOL and NEXLIZET on February 21, 2020 and February 26, 2020, respectively. Prior to the FDA approval of NEXLETOL and NEXLIZET, expenses associated with the manufacturing of the Company's products were recorded as research and development expense.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its inventory levels on a periodic basis to determine if any inventory is at risk for expiration prior to sale or has a cost basis that is greater than its estimated future net realizable value. Any adjustments are recognized through cost of goods sold in the period in which they are incurred.</span></div> <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Implemented Accounting Pronouncements</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no other material changes to the significant accounting policies previously disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021.</span></div> Collaborations with Third Parties<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DSE Agreement Terms</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 2, 2019, the Company entered into a license and collaboration agreement with DSE, which was furthered amended on June 18, 2020. Pursuant to the amended agreement, the Company granted DSE exclusive commercialization rights to bempedoic acid and the bempedoic acid / ezetimibe combination tablet in the European Economic Area, Turkey, and Switzerland (“DSE Territory”). DSE will be responsible for commercialization in the DSE Territory. DSE's designated affiliate in Turkey will be solely responsible, at its sole cost and expense, for all regulatory matters relating to such products in Turkey, including obtaining regulatory approval for such products in Turkey. The Company remains responsible for clinical development, regulatory and manufacturing activities for the licensed products globally, including in the DSE Territory outside of Turkey.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the agreement, the Company received upfront cash of $150.0 million in 2019 and a $150.0 million cash milestone payment in 2020 following the completion of the NUSTENDI Marketing Authorisation Applications ("MAA"). The Company is responsible for supplying DSE with certain manufacturing supply of the API or bulk tablets. The Company is also eligible to receive a substantial additional regulatory milestone payment upon the grant of the marketing authorisation in the European Union for the CV risk reduction label, depending on the range of relative risk reduction in the CLEAR Outcomes study. In addition, the Company is eligible to receive additional sales milestone payments related to total net sales achievements for DSE in the DSE Territory. Finally, the Company will receive tiered fifteen percent (15%) to twenty-five percent (25%) royalties on net DSE Territory sales.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement calls for both parties to participate in a Joint Collaboration Committee (the “DSE JCC”). The DSE JCC is comprised of executive management from each company and the Company will lead in all aspects related to development and DSE will lead in all aspects related to commercialization in the DSE Territory.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenue</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the three and nine months ended September 30, 2022, the Company recognized collaboration revenue of approximately $4.4 million and $14.7 million, respectively, and in the three and nine months ended September 30, 2021, the Company recognized collaboration revenue of $3.3 million and $6.9 million, respectively, related to royalty revenue from DSE from the sales of NILEMDO and NUSTENDI as well as the sales of bulk tablets to DSE pursuant to the supply agreement that was executed with DSE. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All remaining future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained following the concepts of ASC 606 due to the fact that such amounts hinge on development activities, regulatory approvals and sales-based milestones. Additionally, the Company expects that any consideration related to sales-based milestones will be recognized when the subsequent sales occur.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Otsuka Agreement Terms</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 17, 2020, the Company entered into a license and collaboration agreement (the "Otsuka Agreement") with Otsuka. Pursuant to the Otsuka Agreement, the Company granted Otsuka exclusive development and commercialization rights to NEXLETOL and NEXLIZET in Japan. Otsuka will be responsible for all development, regulatory, and commercialization activities in Japan. In addition, Otsuka will fund all clinical development costs associated with the program in Japan.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the agreement, the consideration consists of a $60.0 million upfront cash payment and the Company will be eligible to receive additional payments of up to $450.0 million if certain regulatory and commercial milestones are achieved by Otsuka. The potential future milestone payments include up to $20.0 million upon first JNDA submissions in the Otsuka Territory, up to $70.0 million upon the first NHI Price Listing for NEXLETOL in the Otsuka Territory, and up to $50.0 million upon the achievement of the primary major adverse cardiovascular events (“MACE”) in the CLEAR Outcomes study and the CV risk reduction rate on the U.S. label, depending on the range of relative risk reduction in the CLEAR Outcomes study. In addition, the Company is eligible to receive additional sales milestone payments up to $310.0 million related to total net sales achievements for Otsuka in Japan. Finally, the Company will receive tiered fifteen percent (15%) to thirty percent (30%) royalties on net sales in Japan.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenue</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considered the guidance under ASC 606 and concluded that the agreement was in the scope of ASC 606. In the three and nine months ended September 30, 2022, the Company recognized $0.4 million of collaboration revenue related to sales of bulk tablets to Otsuka pursuant to the supply agreement that was executed with Otsuka. The Company did not have any collaboration revenue from the Otsuka Agreement during the three and nine months ended September 30, 2021.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained following the concepts of ASC 606 due to the fact that such amounts hinge on development activities, regulatory approvals and sales-based milestones. Additionally, the Company expects that any consideration related to royalties and sales-based milestones will be recognized when the subsequent sales occur.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not yet recognized any revenue for milestone payments as the related regulatory and commercial milestones have not yet been achieved.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DS Agreement Terms</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2021, the Company entered into a license and collaboration agreement with Daiichi Sankyo Co. Ltd (the "DS Agreement"). Pursuant to the DS Agreement, the Company granted DS exclusive rights to develop and commercialize bempedoic acid and the bempedoic acid / ezetimibe combination tablet in South Korea, Taiwan, Hong Kong, Thailand, Vietnam, Brazil, Macao, Cambodia and Myanmar (collectively the "DS Territory"). The agreement allows for potential expansion across geographies including Saudi Arabia, Kuwait, Oman, UAE, Qatar, Bahrain, Yemen, Colombia and other Latin American countries. Except for certain development activities in South Korea and Taiwan, DS will be responsible for development and commercialization in these territories. In addition, DS will fund all development costs associated with the program in the DS Territory. Pursuant to the agreement, the consideration consists of a $30.0 million upfront cash payment that is non-refundable, non-reimbursable and non-creditable. The Company also will be eligible to receive additional one-time payments of up to $175.0 million if certain commercial milestones are achieved by DS. Also, the Company will receive tiered royalties of five percent (5%) to twenty percent (20%) of net sales in the DS Territory.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenue</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considered the guidance under ASC 606 and concluded that the agreement was in the scope of ASC 606. The Company concluded that the upfront payment of $30.0 million should be included in the transaction price and related to the following performance obligations under the agreement: 1) the license to the Company’s intellectual property and 2) the obligation to provide ongoing development activities. The Company used the adjusted market assessment approach in determining the standalone selling price of the Company’s intellectual property and the expected cost plus margin approach in determining the standalone selling price of the Company’s obligation to provide ongoing development activities. Accordingly, for the three and nine months ended September 30, 2021, the Company recognized $0.2 million and $28.3 million of collaboration revenue related to the $30.0 million upfront payment, consisting of $28.0 million related to the performance obligations for the license to the Company’s intellectual property and $0.3 million related to ongoing regulatory and development activities conducted during the period ended September 30, 2021. During the year ended December 31, 2021, the Company recognized $28.5 million of collaboration revenue related to the $30.0 million upfront payment. The $28.5 million relates to the performance obligations for the license to the Company’s intellectual property and a portion of ongoing regulatory and development activities conducted during the year ended December 31, 2021, in the amounts of $28.0 million and $0.5 million, respectively. For the three and nine months ended September 30, 2022, the Company recognized $0.2 million and $0.6 million, respectively, of collaboration revenue related to the ongoing regulatory and development activities. The remaining $0.9 million of the upfront payment was deferred as of September 30, 2022 due to an on-going performance obligation related to the developmental activities in South Korea and Taiwan. This deferred revenue will be recognized ratably over the period leading up to the completion of these developmental activities.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained following the concepts of ASC 606 due to the fact that such amounts hinge on development activities, regulatory approvals and sales-based milestones. Additionally, the Company expects that any consideration related to royalties and sales-based milestones will be recognized when the subsequent sales occur.</span></div> 150000000 150000000 0.15 0.25 4400000 14700000 3300000 6900000 60000000 450000000 20000000 70000000 50000000 310000000 0.15 0.30 400000 400000 0 0 30000000 175000000 0.05 0.20 30000000 200000 28300000 30000000 28000000 300000 28500000 30000000 28500000 28000000 500000 200000 600000 900000 Inventories, net<div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net consist of the following (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,785 </span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,850 </span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,874 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,886 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,881 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,545 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,394 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div> <div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net consist of the following (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,785 </span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,850 </span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,874 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,886 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,881 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,545 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,394 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div> 24785000 31850000 2874000 663000 1886000 1881000 29545000 34394000 Commitments and Contingencies <div style="text-indent:18pt"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"/><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On January 12, 2016, a purported stockholder of the Company filed a putative class action lawsuit in the United States District Court for the Eastern District of Michigan, against the Company and Tim Mayleben, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Kevin L. Dougherty v. Esperion Therapeutics, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (No. 16-cv-10089). The lawsuit alleges that the Company and Mr. Mayleben violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5 by allegedly failing to disclose in an August 17, 2015, public statement that the FDA would require a cardiovascular outcomes trial before approving the Company’s lead product candidate. The lawsuit seeks, among other things, compensatory damages in connection with an allegedly inflated stock price between August 18, 2015, and September 28, 2015, as well as attorneys’ fees and costs. On March 12, 2021, the parties agreed to a settlement in principle of the securities class action, and on April 26, 2021, the parties entered into a stipulation of settlement to resolve all legal claims, in which defendants expressly deny that they have committed any act or omission giving rise to any liability under Section 10(b) of the Securities Exchange Act of 1934. Under the terms of the stipulation of settlement, which the court approved on August 24, 2021, the Company and certain of the Company's insurance carriers caused a payment of $18.25 million to be made to the plaintiff class. As a result of this settlement agreement, the Company recorded a loss on settlement of $13.25 million during the three months ended March 31, 2021 in selling, general, and administrative expenses on the statements of operations and comprehensive loss, which represents the litigation settlement of $18.25 million offset by $5.0 million in insurance claim proceeds from our insurance carriers.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to the Company’s contractual obligations and commitments and contingencies outside the ordinary course of business from those previously disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021.</span></div> 18250000 -13250000 18250000 5000000 Investments<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s cash equivalents, restricted cash, and short-term investments (in thousands):</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized <br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated <br/>Fair <br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash equivalents and restricted cash:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,850 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,850 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Short-term investments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,035 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,942 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,285 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,192 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized <br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated <br/>Fair <br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,734 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,734 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Short-term investments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,472 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,441 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,606 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,575 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2022, other income, net in the statements of operations includes interest income on investments of $0.8 million and $1.5 million, respectively. During the three and nine months ended September 30, 2021, other income, net in the statements of operations includes interest income on investments of less than $0.1 million and less than $0.1 million, respectively. During the three and nine months ended September 30, 2022, other income, net in the statements of operations includes amortization of premiums and discounts on investments of $0.2 million and $0.6 million, respectively. There was no amortization of premiums and discounts on investments for the three and nine months ended September 30, 2021.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no unrealized gains or losses on investments reclassified from accumulated other comprehensive income (loss) to other income in the statements of operations during the three and nine months ended September 30, 2022 and 2021.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the three and nine months ended September 30, 2022 and 2021, there were no allowances for credit losses and all unrealized gains (losses) for available-for-sale securities were recognized in accumulated other comprehensive income (loss). As of September 30, 2022, the Company had $0.2 million of accrued interest receivables.</span></div> <div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s cash equivalents, restricted cash, and short-term investments (in thousands):</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized <br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated <br/>Fair <br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash equivalents and restricted cash:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,850 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,850 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Short-term investments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,035 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,942 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,285 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,192 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized <br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated <br/>Fair <br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,734 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,734 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Short-term investments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,472 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,441 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,606 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,575 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 148850000 0 0 148850000 400000 0 0 400000 30035000 0 93000 29942000 179285000 0 93000 179192000 188734000 0 0 188734000 400000 0 0 400000 50472000 0 31000 50441000 239606000 0 31000 239575000 800000 1500000 100000 100000 -200000 -600000 0 0 0 0 0 0 0 0 200000 Fair Value Measurements<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows accounting guidance that emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Fair value is defined as “the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.” Fair value measurements are defined on a three level hierarchy:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:81.159%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1 inputs:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quoted prices for identical assets or liabilities in active markets;</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2 inputs:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Observable inputs other than Level 1 prices, such as quoted market prices for similar assets or liabilities or other inputs that are observable or can be corroborated by market data; and</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3 inputs:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unobservable inputs that are supported by little or no market activity and require the reporting entity to develop assumptions that market participants would use when pricing the asset or liability.</span></td></tr></table></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s financial assets that have been measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.020%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,850 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,850 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,942 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,942 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,192 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,192 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,734 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,734 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,441 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,441 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,575 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,575 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Levels 1, 2 or 3 during the three and nine months ended September 30, 2022 and 2021.</span></div> <div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s financial assets that have been measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.020%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,850 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,850 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,942 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,942 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,192 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,192 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,734 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,734 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,441 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,441 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,575 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,575 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 148850000 148850000 0 0 400000 400000 0 0 29942000 29942000 0 0 179192000 179192000 0 0 188734000 188734000 0 0 400000 400000 0 0 50441000 50441000 0 0 239575000 239575000 0 0 0 0 0 0 Liability Related to the Revenue Interest Purchase Agreement<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 26, 2019, the Company entered into a Revenue Interest Purchase Agreement ("RIPA") with Oberland, as agent for purchasers party thereto (the “Purchasers”), and the Purchasers named therein, to obtain financing in respect to the commercialization and further development of bempedoic acid and the bempedoic acid / ezetimibe combination tablet and other working capital needs. Pursuant to the RIPA, the Company received $125.0 million at closing, less certain issuance costs. The Company was entitled to receive up to approximately $75.0 million in subsequent installments subject to the terms and conditions set forth in the RIPA: (i) $25.0 million upon certain regulatory approval of its product candidates and (ii) $50.0 million, at the Company’s option, upon reaching $100.0 million trailing worldwide six-month net sales any time prior to December 31, 2021 (the “Third Payment”). In March 2020, the Company received $25.0 million from Oberland upon receiving regulatory approval of NEXLETOL.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As consideration for such payments, the Purchasers will have a right to receive certain revenue interests (the “Revenue Interests”) from the Company based upon net sales of the Company’s certain products, once approved, which will be tiered payments initially ranging from 2.5% to 7.5% of the Company’s net sales in the covered territory (the “Covered Territory”); provided that (a) if annual net sales equal or exceed $350.0 million by December 31, 2021 (the “Sales Threshold”), the initially tiered revenue interest rate will be decreased to a single rate of 2.5% of the Company’s net sales in the Covered Territory, beginning on January 1, 2022, and (b) if annual net sales equal or exceed the Sales Threshold and if the Purchasers receive 100% of their invested capital by December 31, 2024, the revenue interest rate will be decreased to a single rate of 0.4% of the Company’s net sales in the Covered Territory beginning on January 1, 2025. If the Third Payment is drawn down by the Company, the applicable royalty rates will increase by one-third. The Covered Territory is the United States, but is subject to expand to include the world-wide net sales if the Company’s annual U.S. net sales are less than $350.0 million for the year ended December 31, 2021. The U.S. net sales milestone thresholds are not to be taken as financial guidance. The Purchasers’ rights to receive the Revenue Interests shall terminate on the date on which the Purchasers have received Revenue Interests payments of 195% of the then aggregate purchase price (the “Cumulative Purchaser Payments”) paid to the Company, unless the RIPA is terminated earlier.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the RIPA, the Company has an option (the “Call Option”) to terminate the RIPA and repurchase future Revenue Interests at any time upon advance written notice. Additionally, the Purchasers have an option (the “Put Option”) to terminate the RIPA and to require the Company to repurchase future Revenue Interests upon enumerated events such as a bankruptcy event, an uncured material breach, a material adverse effect or a change of control. If the Put Option is exercised prior to the first anniversary of the closing date by the Purchasers (except pursuant to a change of control), the required repurchase price will be 120% of the Cumulative Purchaser Payments (minus all payments Company has made to the Purchasers in connection with the Revenue Interests). In all other cases, if the Put Option or the Call Option are exercised, the required repurchase price </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will be 175% of the Cumulative Purchaser Payments (minus all payments Company has made to the Purchasers in connection with the Revenue Interests), if such option is exercised prior to the third anniversary of the closing date, and 195% of the Cumulative Purchaser Payments (minus all payments Company has made to the Purchasers in connection with the Revenue Interests), if such option is exercised thereafter.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the RIPA contains various representations and warranties, information rights, non-financial covenants, indemnification obligations and other provisions that are customary for a transaction of this nature.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RIPA Amendments</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 26, 2021, the Company entered into Amendment No. 2 (the “RIPA Amendment”) to the RIPA with Oberland, as agent for the purchaser parties thereto. Pursuant to the RIPA Amendment, Oberland waived the original trailing six-month world-wide net sales condition to the third installment payment under the RIPA and released the final $50 million payment payable to the Company under the terms of the RIPA. The Company and Oberland also agreed to amend additional terms of the RIPA such that the purchasers will have a right to receive certain revenue interests (the “Revenue Interests”) from the Company based on net sales of the Company’s certain products, once approved, which will be tiered payments ranging from 3.33% to 10% (the “Third Payment Applicable Percentage”) of the Company’s net sales in the covered territory (the “Covered Territory”); provided that (a) prior to December 31, 2024, with respect to each country defined in the Daiichi Territory, if the percentage of net sales that Company receives from Daiichi (the “Receivables Percentage”) is less than the Third Payment Applicable Percentage, then the Revenue Interest for such country payable to the purchasers will be equal to the Receivables Percentages, (b) if annual net sales equal or exceed $350 million and if the Purchasers receive 100% of their invested capital ("Cumulative Purchaser Payments") by December 31, 2024, the revenue interest rate will be decreased to a single rate of 3.33% of the Company’s net sales in the Covered Territory for all subsequent calendar quarters and (c) if the Purchasers receive Revenue Interest payments less than 100% of Cumulative Purchaser Payments by December 31, 2024, the Third Payment Applicable Percentage will be increased to a single rate of the Company’s net sales that would have provided 100% of Cumulative Purchaser Payments had such rate applied from the initial funding by the Purchasers. The Covered Territory was originally the United States, but has been expanded to worldwide for all calendar years beginning on or after January 1, 2022. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the RIPA Amendment, the Company has an option (the “Call Option”) to terminate the RIPA and repurchase future Revenue Interests at any time upon advance written notice. Additionally, the Purchasers have an option (the “Put Option”) to terminate the RIPA and to require the Company to repurchase future Revenue Interests upon enumerated events such as a bankruptcy event, an uncured material breach, a material adverse effect or a change of control. If the Put Option or the Call Option are exercised, the required repurchase price will be 200% of the Cumulative Purchaser Payments (minus all payments Company has made to the Purchasers in connection with the Revenue Interests), if such option is exercised prior to the third anniversary of the closing date, and 225% of the Cumulative Purchaser Payments (minus all payments Company has made to the Purchasers in connection with the Revenue Interests), if such option is exercised thereafter. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In accordance with the guidance in ASC 470‑50, “Debt—Modifications and Extinguishments,” the RIPA Amendment was accounted for as a debt modification. The amendment resulted in a $0.1 million loss on modification of debt, consisting of third-party fees associated with the transaction, which is included in selling, general, and administrative expenses in the statements of operations for the nine months ended September 30, 2021.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 16, 2021, the Company entered into an Amendment to the Security Agreement and Waiver ("Amendment and Waiver") with the same parties to the Security Agreement, by and among the Company, Eiger Partners II LP (the "Purchaser") and Eiger III SA LLC (the "Purchaser Agent"), dated as of June 26, 2019 (the "Security Agreement"). Pursuant to the Amendment and Waiver, if (i) the net revenue from sales of NEXLETOL and NEXLIZET and certain other products in the United States (as reported in the Company’s financial statements as “product sales, net” in accordance with GAAP and excluding, for the avoidance of doubt, upfront or milestone payments and other collaboration revenue) (the “Specified Net Revenue”) for the calendar quarter ended September 30, 2021 does not exceed $15.0 million, or (ii) the Specified Net Revenue for any calendar quarter ending after September 30, 2021 does not exceed $15.0 million, then the Company shall deposit $50.0 million in a deposit account that is subject to a block account control agreement in favor of the Purchase Agent, no later than the earlier of (x) the date the Specified Net Revenue for such calendar quarter has been determined and (y) 45 days after the last day of such calendar quarter. Since the Specified Net Revenue for the calendar quarter ended September 30, 2021 did not exceed $15.0 million, the Company deposited $50.0 million in a deposit account that is subject to a block account control agreement, which is classified as restricted cash on the condensed balance sheets. The Purchaser Agent shall have sole dominion and control over all funds deposited in the deposited account and such funds may be withdrawn therefrom only with the consent of the Purchaser Agent. Upon the occurrence and during the continuance of a Put Option Event, the Purchaser Agent shall have the right to apply amounts held in the deposit account in payment of certain secured obligations in the manner provided for in the Security Agreement. The Amendment and Wavier does not substitute, replace or release the Pledgors from any other obligations under the RIPA or Security Agreement.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the arrangement, as of September 30, 2022, the Company has recorded a liability, referred to as the “Revenue interest liability” in the condensed balance sheets, of $284.7 million, net of $0.4 million of capitalized issuance costs in connection with the RIPA, which will be amortized to interest expense over the estimated term of the RIPA. The Company imputes interest expense associated with this liability using the effective interest rate method. The effective interest rate is calculated based on the rate that would enable the debt to be repaid in full over the anticipated life of the arrangement. The interest rate on this liability may vary during the term of the agreement depending on a number of factors, including the level of forecasted net sales. The Company evaluates the interest rate quarterly based on its current net sales forecasts utilizing the prospective method.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant increase or decrease in net sales will materially impact the revenue interest liability, interest expense and the time period for repayment. The Company recorded approximately $11.1 million and $33.3 million in interest expense related to this arrangement for the three and nine months ended September 30, 2022, respectively, and approximately $10.4 million and $23.3 million in interest expense related to this arrangement for the three and nine months ended September 30, 2021, respectively.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The repayment of the RIPA to Oberland does not have a fixed repayment schedule, rather it will be completely repaid and extinguished when the Company has repaid 200% of the aggregate purchase price if repaid prior to the third anniversary of the closing date, and 225% of the Cumulative Purchaser Payments thereafter, unless the RIPA is terminated earlier. Since there is not a fixed repayment schedule, the Company does not project its future repayments by year. Each period, the Company estimates the future expected sales of its products in the covered territory and determines the effective annual imputed interest rate, which updates and changes the timing of the Company’s payments. Under the terms of the agreement, every $100 million of net sales generated, less than or equal to $250 million in an annual aggregate year, would result in a repayment obligation of approximately $10.0 million or 10.0% at the stated repayment rate in the first year. Annual net sales for a calendar year exceeding $250 million would result in a repayment obligation of approximately $3.3 million or 3.3% for every $100 million of sales above the threshold. If the Company would have equaled or exceeded $350 million of sales in the U.S. in 2021, then the repayment amount would have dropped to $3.3 million for every $100 million of net sales starting in 2022. As U.S. net sales were less than $350 million for the year ended December 31, 2021, the Covered Territory was expanded to include worldwide sales beginning in 2022. The Company’s repayments of the RIPA are directly tied to the growth of its net sales, and as the Company’s net sales grow, the Company expects the related repayments of the RIPA to grow as well. The Company currently expects to repay $19.6 million in the next twelve months. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective annual imputed interest rate is 15.8% as of September 30, 2022. The Company incurred $0.6 million of issuance costs in connection with the RIPA, which will be amortized to interest expense over the estimated term of the RIPA. Payments made to Oberland as a result of the Company’s net sales will reduce the revenue interest liability.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the revenue interest liability activity during the nine months ended September 30, 2022:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue interest liability at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,039 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense recognized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,323 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue Interests payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,678)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue interest liability at September 30, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,684 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 125000000.0 75000000.0 25000000.0 50000000.0 100000000.0 25000000.0 0.025 0.075 350000000.0 0.025 1 0.004 350000000 1.95 1.20 1.75 1.95 50000000 0.0333 0.10 350000000 1 0.0333 1 1 2 2.25 100000 15000000 15000000 50000000 15000000 50000000 284700000 400000 11100000 33300000 10400000 23300000 2 2.25 100000000 250000000 10000000 0.100 250000000 3300000 0.033 100000000 350000000 3300000 100000000 350000000 19600000 0.158 600000 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the revenue interest liability activity during the nine months ended September 30, 2022:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue interest liability at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,039 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense recognized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,323 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue Interests payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,678)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue interest liability at September 30, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,684 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 257039000 33323000 5678000 284684000 Convertible NotesIn November 2020, the Company issued $280.0 million aggregate principal amount of 4.0% senior subordinated convertible notes due November 2025. The net proceeds the Company received from the offering was approximately $271.1 million, after deducting the initial purchasers’ discounts and commissions and offering expenses payable by the Company (the "Convertible Notes"). The Company used approximately $46.0 million of the net proceeds from the offering of the notes to pay the cost of the Capped Call (as defined below) and $55.0 million of the net proceeds from the offering of the initial notes to finance the Prepaid Forward (as defined below). The Convertible Notes are the Company's senior unsecured obligations and mature on November 15, 2025 (the “Maturity Date”), unless earlier repurchased or converted into shares of common stock under certain circumstances described below. The Convertible Notes are convertible into shares of the Company’s common stock, can be repurchased for cash, or a combination thereof, at the Company’s election, at an initial conversion rate of 30.2151 shares of common stock per $1,000 principal amount of the Convertible Notes, which is equivalent to an initial conversion price of approximately $33.096 per share of common stock, subject to adjustment. The Company will pay interest on the Convertible Notes semi-annually in arrears on May 15 and November 15 of each year.<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Convertible Notes are general unsecured obligations of the Company that are subordinated in right of payment to indebtedness, obligations and other liabilities under the Company’s RIPA, the revenue interests issued pursuant to such agreement, and any refinancing of the foregoing.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding August 15, 2025 in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ended on March 31, 2021 (and only during such calendar quarter), if the last reported sale price per share of the Company’s common stock, par value $0.001 per share (“common stock”), is greater than or equal to 130% of the conversion price for each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the five business days after any five consecutive trading day period (such five consecutive trading day period, the “measurement period”) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of the Company’s common stock and the conversion rate for the notes on each such trading day; (3) if the Company calls such notes for redemption, any such notes that have been called for redemption may be converted at any time prior to the close of business on the second scheduled trading day immediately preceding the redemption date, but only with respect to the notes called for redemption; and (4) upon the occurrence of specified corporate events, as provided in the Indenture. On or after August 15, 2025, to the close of business on the second scheduled trading day immediately before the maturity date, holders may convert all or any portion of their notes at the applicable conversion rate at any time at the option of the holder regardless of the foregoing conditions.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, following certain corporate events or following issuance of a notice of redemption, the Company will, in certain circumstances, increase the conversion rate for a holder who elects to convert its notes in connection with such a corporate event or to convert its notes called (or deemed called) for redemption during the related redemption period, as the case may be.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Convertible Notes will be redeemable, in whole or in part, at the Company’s option at any time, and from time to time, on or after November 20, 2023 and before the 41st scheduled trading day immediately before the maturity date, at a cash redemption price equal to 100% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, but only if the last reported sale price per share of the Company’s common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive), including the trading day immediately preceding the date the Company sends the related redemption notice, during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which the Company sends such redemption notice. No sinking fund is provided for the notes. If the Company redeems less than all the outstanding notes, at least $125.0 million aggregate principal amount of notes must be outstanding and not subject to redemption as of the relevant redemption notice date.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company undergoes a “fundamental change” (as defined in the Indenture), holders may require the Company to repurchase their notes for cash all or any portion of their notes at a fundamental change repurchase price equal to 100% of the principal amount of the notes to be repurchased, plus accrued and unpaid interest, to, but excluding, the fundamental change repurchase date. The Indenture includes customary terms and covenants, including certain events of default.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred approximately $8.9 million of issuance costs related to the issuance of the Convertible Notes, of which, prior to the adoption of Accounting Standards Update ("ASU") 2020-06 on January 1, 2021, $5.8 million and $3.1 million were allocated and recorded to long-term debt and additional paid-in capital, respectively. The $5.8 million of issuance costs recorded as long-term debt on the condensed balance sheet was to be amortized over the five-year contractual term of the Convertible Notes using the effective interest method. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the adoption of ASU 2020-06 on January 1, 2021, the $271.1 million of proceeds received from the issuance of the Convertible Notes were allocated between long-term debt (the “liability component”) of $177.6 million and additional paid-in capital (the “equity component”) of $93.5 million. The fair value of the liability component was measured using rates determined for similar debt instruments without a conversion feature. The carrying amount of the equity component, representing the conversion option, was determined by deducting the fair value of the liability component from the aggregate face value of the Convertible Notes and was included in additional paid-in capital in the condensed balance sheet and was not remeasured as long as it did not to meet the conditions for equity classification. The liability component was to be accreted up to the face value of the Convertible Notes of $280.0 million, which resulted in additional non-cash interest expense being recognized through the Maturity Date. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the adoption of ASU 2020-06 as of January 1, 2021, the Company reports the convertible debt liability at the aggregate principal amount less unamortized issuance costs. This resulted in the reclassification of the $93.5 million of the Company’s convertible notes recognized at December 31, 2020 from additional paid in capital to the convertible debt liability. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The portion of interest expense previously recognized for the accretion of the convertible debt liability and the true-up of the amortization of the issuance costs of $1.5 million was recorded as an adjustment to accumulated deficit. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 22, 2021, the Company entered into a privately negotiated exchange agreement (the “Exchange Agreement”) with two co-managed holders (the “Holders”) of its Convertible Notes. Under the terms of the Exchange Agreement the Holders agreed to exchange (the “Exchange”) with the Company $15.0 million aggregate principal amount of the Convertible Notes held in the aggregate by them (and accrued interest thereon) for shares of the Company’s common stock. Pursuant to the Exchange Agreement, the number of shares of common stock to be issued by the Company to the Holders upon consummation of the Exchange was determined based upon the volume-weighted-average-price per share of common stock, subject to a floor of $5.62 per share, during the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQzZjFkNDkxZjQxYzQ4YzZhYWY2MzkyYTUzY2U3MmI1L3NlYzo0M2YxZDQ5MWY0MWM0OGM2YWFmNjM5MmE1M2NlNzJiNV81OC9mcmFnOmNkNDM5YWVhOTFjNDQwMDBhNTBmOTI5YWUwOWUzMTJjL3RleHRyZWdpb246Y2Q0MzlhZWE5MWM0NDAwMGE1MGY5MjlhZTA5ZTMxMmNfODIwOA_4866d5e3-0d26-4ef9-b902-84c7fd40ce7b">five</span> trading-day averaging period, commencing on the trading day immediately following the date of the Exchange Agreement. The Exchange closed on November 3, 2021, with 1,094,848 shares of the Company's common stock being exchanged.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As of September 30, 2022, the principal amount of convertible notes was $265.0 million, and the unamortized debt discount and issuance costs were $5.5 million, for a net carrying amount of $259.5 million.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company recorded $3.1 million and $9.2 million of interest expense during the three and nine months ended September 30, 2022, respectively, and $3.2 million and $9.6 million of interest expense during the three and nine months ended September 30, 2021, respectively, relating to the cash interest on the convertible notes due semi-annually and amortization of the debt issuance costs. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As of September 30, 2022, no Convertible Notes were convertible pursuant to their terms. The estimated fair value of the Convertible Notes was $148.9 million as of September 30, 2022 and $140.3 million as of December 31, 2021. The estimated fair value of the Convertible Notes was determined through consideration of quoted market prices. As of September 30, 2022, the if-converted value of the Convertible Notes did not exceed the principal value of those notes.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capped Call Transactions</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the offering of the Convertible Notes, the Company entered into privately-negotiated capped call transactions with one of the initial purchasers of the convertible notes or its affiliate and certain other financial institutions. The Company used approximately $46.0 million of the net proceeds from the offering of the Convertible Notes to pay the cost of the capped call transactions. The capped call transactions are expected generally to reduce potential dilution to the Company’s common stock upon any conversion of the Convertible Notes and/or offset any cash payments the Company is required to make in excess of the principal amount of converted notes, as the case may be, in the event that the market value per share of the Company’s common stock, as measured under the terms of the capped call transactions at the time of exercise, is greater than the strike price of the capped call transactions (which initially corresponds to the initial conversion price of the Convertible Notes, and is subject to certain adjustments), with such reduction and/or offset subject to a cap initially equal to approximately $55.16 (which represents a premium of approximately 100% over the last reported sale price of the Company’s common stock on November 11, 2020), subject to certain adjustments. The capped call transactions are separate transactions, entered into by the Company and are not part of the terms of the Convertible Notes.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given that the transactions meet certain accounting criteria, the convertible note capped call transactions are recorded in stockholders’ equity, and they are not accounted for as derivatives and are not remeasured each reporting period. As of September 30, 2022 and December 31, 2021, the Company had not purchased any shares under the convertible note capped call transactions.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prepaid Forward</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the offering of the Convertible Notes, the Company entered into a prepaid forward stock repurchase transaction (“Prepaid Forward”) with a financial institution (“Forward Counterparty”). Pursuant to the Prepaid Forward, the Company used approximately $55.0 million of the net proceeds from the offering of the Convertible Notes to fund the Prepaid Forward. The aggregate number of shares of the Company’s common stock underlying the Prepaid Forward was approximately 1,994,198. The expiration date for the Prepaid Forward is November 15, 2025, although it may be settled earlier in whole or in part. Upon settlement of the Prepaid Forward, at expiration or upon any early settlement, the Forward Counterparty will deliver to the Company the number of shares of common stock underlying the Prepaid Forward or the portion thereof being settled early. The shares purchased under the Prepaid Forward are treated as treasury stock and not outstanding for purposes of the calculation of basic and diluted earnings per share, but will remain outstanding for corporate law purposes, including for purposes of any future stockholders’ votes, until the Forward Counterparty delivers the shares underlying the Prepaid Forward to the Company. As of September 30, 2022, 71,174 shares had been delivered to the Company. The Company’s Prepaid Forward hedge transaction exposes the Company to credit risk to the extent that its counterparty may be unable to meet the terms of the transaction. The Company mitigates this risk by limiting its counterparty to a major financial institution.</span></div> 280000000 0.040 271100000 46000000 55000000 30.2151 33.096 0.001 1.30 20 30 5 5 5 0.98 1 1.30 20 30 125000000 1 8900000 5800000 3100000 5800000 P5Y 271100000 177600000 93500000 280000000 -93500000 -1500000 15000000 5.62 1094848 265000000 5500000 259500000 3100000 9200000 3200000 9600000 148900000 140300000 46000000 55.16 1 55000000 1994198 71174 Other Accrued Liabilities<div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued liabilities consist of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,512 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,809 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued variable consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,525 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,192 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,344 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,917 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest on convertible notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,975 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,325 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,395 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,410 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued liabilities consist of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,512 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,809 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued variable consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,525 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,192 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,344 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,917 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest on convertible notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,975 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,325 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,395 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,410 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 8512000 8809000 20525000 16192000 2344000 3917000 3975000 1325000 39000 167000 35395000 30410000 Stock Compensation<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Stock Option and Incentive Plan</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2022, the Company's stockholders approved the 2022 Stock Option and Incentive Plan (the "2022 Plan"). The number of shares of common stock available for awards under the 2022 Plan was set to 4,400,000, with any shares underlying awards that are forfeited, canceled, held back upon exercise of an option or settlement of an award to cover the exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied without the issuance or shares, or otherwise terminated (other than by exercise) under the 2022 Plan may be added back to the shares of common stock available for issuance under the 2022 Plan. The 2022 Plan provides for the award of stock options (both incentive and non-qualified options), stock appreciation rights, restricted stock, restricted stock units, unrestricted stock, cash-based awards, and dividend equivalent rights. Following the approval of the 2022 Plan, no further awards will be issued under the Company’s 2013 Stock Option and Incentive Plan (the “2013 Plan”). </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the board of directors approved the Esperion Therapeutics, Inc. 2020 Employee Stock Purchase Plan (the "ESPP") which was approved by the Company's shareholders on May 28, 2020. The ESPP allows eligible employees to authorize payroll deductions of up to 10% of their base salary or wages up to $25,000 annually to be applied toward the purchase of shares of the Company's common stock on the last trading day of the offering period. Participating employees will purchase shares of the Company's common stock at a discount of up to 15% on the lesser of the closing price of the Company's common stock on the NASDAQ Global Select Market (i) on the first trading day of the offering period or (ii) the last day of any offering period. Offering periods under the ESPP will generally be in six months increments, commencing on September 1 and March 1 of each calendar year with the administrator having the right to establish different offering periods. In the three and nine months ended September 30, 2022, the Company recognized approximately $0.1 million and $0.3 million of stock compensation expense related to the ESPP, respectively. In the three and nine months ended September 30, 2021, the Company recognized approximately $0.2 million and $0.6 million of stock compensation expense related to the ESPP, respectively. As of September 30, 2022, there have been 339,422 shares issued and 485,578 shares reserved for future issuance under the ESPP.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity relating to the Company’s options to purchase common stock for the nine months ended September 30, 2022:</span></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,214,537 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.18</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,255,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(685,182)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.01 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,784,955 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.18</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,098 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,784,955 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,098 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,421,198 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.91</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation related to stock options was $1.4 million and $4.3 million for the three and nine months ended September 30, 2022, respectively, including $0.2 million and $0.4 million that were capitalized into inventory, and $2.8 million and $12.7 million for the three and nine months ended September 30, 2021, respectively, including $0.8 million and $1.3 million that were capitalized into inventory. As of September 30, 2022, there was $8.9 million of unrecognized stock-based compensation expense related to unvested options, which will be recognized over a weighted-average period of 2.5 years. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance-Based Stock Options ("PBSOs")</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, the Company granted PBSOs from the 2013 Plan that vest upon various performance-based milestones as set forth in the individual grant agreements, such as achievement of predetermined clinical or regulatory outcomes. The actual number of units (if any) received under these awards will depend on continued employment and actual performance over the performance period. Each quarter, the Company updates their assessment of the probability that the performance milestone will be achieved. The Company amortizes the fair value of the PBSOs based on the expected performance period to achieve the performance milestone. The Company expects the performance criteria to be met. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, the Company granted PBSOs from the 2022 Plan that vest upon various performance-based milestones as set forth in the individual grant agreements, such as achievement of predetermined clinical or regulatory outcomes. The actual number of units (if any) received under these awards will depend on continued employment and actual performance over the performance period. Each quarter, the Company updates their assessment of the probability that the performance milestone will be achieved. The Company amortizes the fair value of the PBSOs based on the expected performance period to achieve the performance milestone. The Company expects the performance criteria to be met. </span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity relating to the Company’s PBSOs for the nine months ended September 30, 2022:</span></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.94 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.83</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.94 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499,200 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.73 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.58</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499,200 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.58</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation related to PBSOs was $0.3 million and $0.5 million for the three and nine months ended September 30, 2022, respectively. As of September 30, 2022, there was approximately $1.8 million of unrecognized stock-based compensation expense related to unvested PBSOs, which will be recognized over a weighted-average period of approximately 1.6 years.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units (or RSUs)</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity relating to the Company’s RSUs for the nine months ended September 30, 2022:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.254%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.004%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of <br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Fair Value Per <br/>Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and unvested December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698,704 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.09 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,644,009 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.71 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(340,220)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.98 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(347,893)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.77 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and unvested September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,654,600 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.51 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation related to RSUs was approximately $1.5 million and $5.1 million for the three and nine months ended September 30, 2022, respectively, including $0.2 million and $0.5 million that was capitalized into inventory, and approximately $2.4 million and $6.4 million for the three and nine months ended September 30, 2021, respectively, including $0.4 million and $0.6 million that was capitalized into inventory. As of September 30, 2022, there was $14.7 million of unrecognized stock-based compensation expense related to unvested RSUs, which will be recognized over a weighted-average period of 2.8 years.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance-based Restricted Stock Units ("PBRSUs")</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, the Company granted PBRSUs from the 2013 Plan that vest upon various performance-based milestones as set forth in the individual grant agreements, such as achievement of predetermined milestones based on the Company's U.S. net product sales or clinical or regulatory outcomes. The actual number of units (if any) received under these awards will depend on continued employment and actual performance over the performance period. Each quarter, the Company updates their assessment of the probability that the performance milestone will be achieved. The Company amortizes the fair value of the PBRSUs based on the expected performance period to achieve the performance milestone. The fair value of the PBRSUs is based on the quoted market price of the Company's common stock on the date of grant. The Company expects the performance criteria to be met. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity relating to the Company's PBRSUs for the nine months ended September 30, 2022:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"/><td style="width:64.815%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.916%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of <br/>PBRSUs</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average fair value per share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639,950 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.90 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(178,700)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.95 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and unvested September 30, 2022</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461,250 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.50 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation related to the PBRSUs was approximately $0.2 million and $1.3 million for the three and nine months ended September 30, 2022, respectively, including less than $0.1 million and $0.1 million that was capitalized into inventory. Stock-based compensation related to PBRSUs was approximately $0.1 million for the three and nine months ended September 30, 2021. As of September 30, 2022, there was approximately $1.9 million of unrecognized stock-based compensation expense related to unvested PBRSUs, which will be recognized over a weighted-average period of approximately 1.7 years.</span></div> 4400000 0.10 25000 0.15 P6M 100000 300000 200000 600000 339422 485578 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity relating to the Company’s options to purchase common stock for the nine months ended September 30, 2022:</span></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,214,537 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.18</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,255,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(685,182)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.01 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,784,955 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.18</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,098 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,784,955 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,098 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,421,198 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.91</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity relating to the Company’s PBSOs for the nine months ended September 30, 2022:</span></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.94 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.83</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.94 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499,200 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.73 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.58</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499,200 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.58</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3214537 38.38 P4Y2M4D 0 1255600 4.78 685182 33.01 0 0 3784955 28.20 P5Y2M4D 2098000 3784955 28.20 P5Y2M4D 2098000 2421198 38.23 P2Y10M28D 163000 1400000 4300000 200000 400000 2800000 12700000 800000 1300000 8900000 P2Y6M 122700 8.94 P9Y9M29D 0 403000 6.20 26500 8.94 0 0 499200 6.73 P9Y6M29D 202000 499200 6.73 P9Y6M29D 202000 0 0 P0Y 0 300000 500000 1800000 P1Y7M6D <div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity relating to the Company’s RSUs for the nine months ended September 30, 2022:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.254%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.004%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of <br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Fair Value Per <br/>Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and unvested December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698,704 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.09 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,644,009 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.71 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(340,220)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.98 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(347,893)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.77 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and unvested September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,654,600 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.51 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 698704 28.09 1644009 4.71 340220 12.98 347893 20.77 1654600 9.51 1500000 5100000 200000 500000 2400000 6400000 400000 600000 14700000 P2Y9M18D <div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity relating to the Company's PBRSUs for the nine months ended September 30, 2022:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"/><td style="width:64.815%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.916%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of <br/>PBRSUs</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average fair value per share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639,950 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.90 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(178,700)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.95 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and unvested September 30, 2022</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461,250 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.50 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 639950 9.90 0 0 178700 10.95 461250 9.50 200000 1300000 100000 100000 100000 100000 1900000 P1Y8M12D Income TaxesThere was no provision for income taxes for the three and nine months ended September 30, 2022 and 2021, because the Company has incurred annual operating losses since inception. At September 30, 2022, the Company continues to conclude that it is not more likely than not that the Company will realize the benefit of its deferred tax assets due to its history of losses. Accordingly, a full valuation allowance has been applied against the net deferred tax assets. 0 0 0 0 Stockholders' Deficit<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ATM Offering </span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 3, 2021, the Company filed an automatically effective registration statement on Form S-3ASR (the “Registration Statement”) with the SEC which registered the offering, issuance and sale of an unspecified amount of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof. The Company simultaneously entered into an open market sale agreement with Jefferies LLC, as sales agent, to provide for the issuance and sale by the Company of up to $250 million of common stock from time to time in “at-the-market” offerings under the Registration Statement and related prospectus filed with the Registration Statement (the “ATM Program”). During the three and nine months ended September 30, 2021, the Company issued 363,061 shares of common stock resulting in net proceeds of approximately $4.2 million after deducting $0.5 million of underwriting discounts and commissions and other expenses, pursuant to the ATM Program.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 15, 2022, the Company filed a new registration statement on Form S-3 to replace its prior automatically effective registration statement on Form S-3ASR filed on August 3, 2021, which registers the offering, issuance and sale of up to $239 million of common stock from time to time in “at-the-market” offerings under the Registration Statement and related prospectus filed with the Registration Statement (the “ATM Program”). The Company may continue to use an ATM Program to address potential short-term or long-term funding requirements that may arise. Such program will continue to be subject to the volatility of the price of the Company's common stock and general market conditions. During the three and nine month periods ended September 30, 2022, the Company issued 6,958,525 and 10,311,525 shares of common stock, respectively, resulting in net proceeds of approximately $48.6 million and $68.8 million after deducting $1.6 million and $2.4 million of underwriting discounts and commissions and other expenses, respectively, pursuant to the ATM Program.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with an underwriting agreement with H.C. Wainwright &amp; Co., LLC (the "Offering"), entered into on December 2, 2021, the Company issued warrants to purchase 36,964,286 shares of common stock at an exercise price of $9.00. The warrants will terminate on December 7, 2023. The warrants were recorded at fair value of $61.9 million to additional-paid-in-capital in accordance with ASC 815-10 based upon the allocation of the proceeds between the common shares issued with the Offering and the warrants. The Company estimated the fair value of the warrants using a Black-Scholes option-pricing model, which is based, in part, upon subjective assumptions including but not limited to stock price volatility, the expected life of the warrant, the risk-free interest rate and the fair value of the common stock underlying the warrant. The Company estimates the volatility based on its historical volatility that is in line with the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury daily rate for a maturity similar to the expected remaining life of the warrants. The expected remaining life of the warrants is assumed to be equivalent to its remaining contractual term.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and December 31, 2021, the Company had warrants outstanding that were exercisable for a total of 36,964,286 shares of common stock at a weighted-average exercise price of $9.00 per share.</span></div> 250000000 363061 363061 4200000 4200000 500000 500000 239000000 6958525 10311525 48600000 68800000 1600000 2400000 36964286 9.00 61900000 36964286 36964286 9.00 9.00 Net Loss Per Common ShareBasic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common stock equivalents outstanding for the period, including shares that potentially could be dilutive if they were exercised or vested during the period, determined using the treasury-stock method. For purposes of this calculation, warrants for common stock, stock options, PBSOs, unvested RSUs and PBRSUs, shares issuable under the ESPP and shares issuable upon conversion of the convertible notes are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.<div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares outstanding at the end of the respective periods presented below were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.198%"><tr><td style="width:1.0%"/><td style="width:57.421%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.612%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.615%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares under option</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,784,955 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,703,938 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares under PBSOs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499,200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,654,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879,349 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested PBRSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable related to the ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,237 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,871 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable upon conversion of convertible notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,007,010 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,460,237 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,964,286 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total potential dilutive shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,380,538 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,098,695 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares outstanding at the end of the respective periods presented below were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.198%"><tr><td style="width:1.0%"/><td style="width:57.421%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.612%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.615%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares under option</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,784,955 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,703,938 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares under PBSOs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499,200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,654,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879,349 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested PBRSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable related to the ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,237 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,871 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable upon conversion of convertible notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,007,010 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,460,237 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,964,286 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total potential dilutive shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,380,538 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,098,695 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3784955 3703938 499200 0 1654600 879349 461250 45300 9237 9871 8007010 8460237 36964286 0 51380538 13098695 Statements of Cash Flows and Restricted Cash<div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash and cash equivalents and restricted cash presented on the balance sheets to the same amounts presented on the statements of cash flows on September 30, 2022 and 2021 and December 31, 2021 and 2020 (in thousands): </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"/><td style="width:42.258%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.487%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.487%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.487%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.492%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,399 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,672 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,892 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304,962 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and restricted cash shown on the condensed statements of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,399 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,672 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,892 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304,962 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash and cash equivalents and restricted cash presented on the balance sheets to the same amounts presented on the statements of cash flows on September 30, 2022 and 2021 and December 31, 2021 and 2020 (in thousands): </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"/><td style="width:42.258%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.487%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.487%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.487%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.492%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,399 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,672 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,892 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304,962 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and restricted cash shown on the condensed statements of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,399 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,672 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,892 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304,962 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash and cash equivalents and restricted cash presented on the balance sheets to the same amounts presented on the statements of cash flows on September 30, 2022 and 2021 and December 31, 2021 and 2020 (in thousands): </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"/><td style="width:42.258%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.487%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.487%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.487%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.492%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,399 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,672 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,892 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304,962 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and restricted cash shown on the condensed statements of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,399 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,672 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,892 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304,962 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 159399000 103672000 208892000 304962000 50000000 50000000 50000000 0 209399000 153672000 258892000 304962000 EXCEL 62 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

!T8$%1O4"HV,7&-<+C(_]#&?U F?'CG!> M+W!^[ @7]0(7QR[0[SW]S?6.7F3[E[U9Z39KR7H5LZ(RNKK,LPH/ MZ_5TO;QIF_,\S#BUOZQ8/5 MXFGQ_D7;7\9+[UV./NBO1^^U_5WH%_\JEG+QWGIQLV5Q]_C%VSZ[]\=&]__8 MZ(%^<4O$VU]=V^+A\8OW-&OA8!ORP=H;_ DA;WGW'S>C#=M'JW8"WA?+*!8? M3N16OA#YO3BY^H]_ZX][_]46 1*S2,PF,8?$7!+S2,PGL8#$0@A3 CCG]\[P< M^T+OV!?ZQ[XP./:%X?X+FU#3<7^OV7S@TA^?]_;5N_X4#\\+<'SH@ M/W (8]4CA3,R@"1FD9A-8@Z)N23FD9A/8@&)A1"F!/!\&\#S MH[9WR5/.TJ=$ML5+:W6-%XE9)&:3F'.^MP]EG@_'Y_N[92XYK'?TL#XY;'"^ M=U1ACLYZ@XO]XP]H6&6MO]BN]1?:M?XF6B9EE";_*S)L+HPW]F:2H/4P2O\6NB8.U2Q4LU'-0347U3Q4 M\U$M0+60TM2 /CO!VG_50ZIZ."J,I&:AFHUJ#JJYJ.:AFH]J :J%E*:&T6S" M:/[A.7$]T3E@I&:AFHUJ3JTI\]W]?MOIF+97]MKV^KR65PX&@[;]PY97FJVO M#-!/'5*:ND(W9_;[VO.65]6>G7$MMQ63@]L+]&P]JEFH9J.:@VHNJGFHYJ-: M@&HAI:GQ:L[;]X>ON_.&GN9'-0O5;%1S4,U%-0_5?%0+4"VD-#6,39^AKR\T M_)(5A9$MC'DV2:9)'*T[V=G4F(C;]K"A[094LU#-1C4'U5Q4\U#-[[=4-%IW M&=$^!:6I,6H:%7U]I>(?MR)/H\7$^-=1)>_#[0K].)WSA?8K4,U&-0?57%3S M4,U'M0#50DI34]@4+?JOV[3HHU4+5+-0S48U!]5<5/-0S4>U -5"2E/#V)0N M^OK6Q6>1QS)7T9VH]B?SG0Y&82RCQ_6V4.YO/LR2>&9$V\VC?,D\6<@ %V^- M99YD^5..RUF23XQHL4CN15Y$^6-%5S^(TZRHSKQ-Y$)OC61J+%=27J[W9I/" M$#_DFTF*ULN7/NH_1^>4HY6/6KMXOC/U[FRD[DK9Z)@.JKFHYJ&:CVH!JH64 MIJ:W*8_T]>T1*+W15'[U)T87K:V@FE5K:G0O]J*+-E)0S44U#]5\5 M0+:0T M]>K8IKUBZMLKG_,L%F)2&-,\F__LKJ]^C*[)JK67K]BQT''MEG'-4=NX#CJN MBVH>JOFH%J!:2&EJOCTD:6J4T7=AB.E4Q&6UI9); MLU64&@M1&D64"KFQ^EU^71ARAU7\V&2PVL)M?E;.)#G+THEQ^VA8(A;S6[EI MU%S0_%'_;CMG$&VEU%K5 ]I&J_>N9^YNW]!1'51S4U -5"2E-S MU-1<3'W-!3G$:\T;VHY!-:O67C@J0\=T4,U%-0_5?%0+4"VD-#5M3>O%U)[( MWTE;LKB7&5O?NF)]E8Z,7RR2>]&ZFQ MSOE!VR^U]GRN8]PRTV&CHSJHYJ*:AVH^J@6H%E*:&J*F_6+JVR^?DD4R7\V- M:)ZMJAW&EIF1G0V8=LMU_ 0)6I9!-:O6E)9]^YRGC0[LH)J+:AZJ^:@6H%I( M:6HBFR:,J3VY?_4I^K&3R-^^'DYC-4EYD]W+!$Z,;R+/DS++'ZO+>:+-;7[E MRY-%G*XFHKJ9;SIY2"9/LYI'1Q6MTJ":56OC8Z**]F10S44U#]5\5 M0+:0T M-:I-3\9\Z>XD3Q,M=5BKR^CBNKPF?R2C)Y/[HS3*!Y'>"V.^OIMN:\;0(@NJ M6:AFHYIC[M_0HW_1MN_LHN-Z1X_KH^,&J!92FAJ?IJABZHLJ]OIL7'6W['J? M,YDO5U5ZU%W*-U%A1,9R,PG3VKS6C],Y/6B7!-5L5'-0S44UK]9VSJ[T1^>[ M^4+;)*@64IIZE^NF33+0MTENLD4AXM4Z88O5>C]/[DUN-D+U/N!\)5-V*P-8 M5F>^H]NLVDHE\B=EMA#U5JTM]?MD80K9B@FC5HK9@,Y#\[!V7HL ZJN:CFH9J/:@&JA92F!J[IF ST M'1,WKZZ+72I-RKVY2NUM)/4#=$X66CJI->7 H[T7::,#.ZCFHIJ':CZJ!:@6 M4IJ:K6I#/;."IP="![[I!3V42GLLU+8 MAZ6P3TMA'Y?R9U10!DT%9:"OH%QWB5PN[E9IM#X1$"WEAO ^2EO#AC9*4,VJ M->7V50?"AA9+4,U%-0_5?%0+4"VD-#5L3;%DH"^6= I;%,\2N7>YJ5M.=R\8 M:,T=VD1!-6NP?P>0 Z?3T'$=5'-1S4,U']4"5 LI3UR>X M=\]:K[=OZ\+ELVM3==,D:-$$U:Q:4P[F>@?BAA9-4,U%-0_5?%0+4"VD-#5N M3=%DH"^:M%\R=_#:N.;2N'7POJY_\FU[95QU<)=L+@M_NDPU+[91E:OUO]=7 MC2?Y?H6ZK3G=&F:TBH)J5JWM7@[4&^XF&>VAH)J+:AZJ^:@6H%I(:6J2FQ[* MX%7NUU+=P.'Y+5O@.S[H/T3G\*(=ET';S5K,W>2BU154)?Y;9YLP7^11359CA:&'\S1SU#[D.G,HRM^4-;,JAF MH9J-:@ZJN:CFH9J/:@&JA92F/K"ZZ=(,-S6!U[H_X1 MT*":A6HVJCFHYJ*: MAVH^J@6H%E*:&L:F4S/4=VHZWT9"[W5.&]J5J;7GNYZ]=[N7SZ)#.JCFHIJ' M:CZJ!:@64IH:HJ8G,]3W9+S'928W8&42RR1MYGGNQ*)Z#I[I;,\HF+M]>K)?=ILG=^G$I MK7%":S&H9M5:VP9N-TUH+0;57%3S4,U'M0#50DI3T]348H;Z6LP?GZMTFZXT/J[*YS.9 _U,IOZ-=HXHVJ!!-1O5'%1S4JOFH%J!:2&EJ2IM^S5#?K_G9J5*T\()JUK#E M!B:'IDK1V@NJN:CFH9J/:@&JA92F!JJIO0SUM9>_;*H4K<"@FE5K1TV5HOT6 M5'-1S4,U']4"5 LI34GDJ.FWC/1W1?FIJ5*]V35.J&;5FG(3ST%;F-!A'51S M4G[*?1,Z0O3H?IWTSF&:+L%U6Q4QOK>R_^S K;^W7;-:*WM5Z9W.M,6 M.JR-:@ZJN:CFH9J/:@&JA92FQK1IU(SA.[[HO+18ZI(UJ#JJYJ.:A MFH]J :J%E*:&J*FZC/5W?'F%DX'#M]437DJYBUKO[ZYO_+MWO]_ZML"MNZGZ M#]$YN?NWA#EPLL]"![91S4$U%]4\5/-1+4"UD-+4_#;MF+&^';/[*,$#H3J0 MRYUH%Z)Z%),^X:WQ1+LVM:;<=W]M6YY547H+F&Z5J^ M_)]1=;JB-6-H]0;5+%2S4O-U*>)DFL@05I.F]<%>:\I:;K#2 M^@3;&_V(G1-$:C:J.:CFHIJ':CZJ!:@64IJ:H*8L,]:796ZR^3):/!H3LA7T\]#U3Z9?Z-_$YU#A=984,U!-1?5/%3S M42U M9#2E%"=-366LY=J+$69)_'F=$ Q:\N.7NBZVX=J%JK9J.:@FEMK+_\? MS$/']8\>-T#'#2EMDXO38B9$:45E='4Y%_F=N!%I6ACK[45U /7LNW+?;"IS MTW]_;9Z<[GW?Z;]W^RW?]_KO_?7W3QO^ZG(9W8E/47Z7+ HC%5,Y5._=V>C$ MR).[V?:+,EM^..F?&+=966;S]1]G(IJ(O'J!_/DTR\JG+ZH!'K+\^_KC7/T? M4$L#!!0 ( )E&857#5&Z30@, )<+ 9 >&PO=V]R:W-H965TZ&:$:E&LS&4U$H1GE M.).@BBPC\O$:F=A.G9ZS6YC3=:KM@AM-K/^4R:F=NP)#1#KJC@('$U M=:YZES<]SP+*'7]3W*J],5@I2R&^VG4&3F0X(H43,_%]D^L!0TL7RR8*G]A M6^_U'(@+I456@TT$&>75/WFHC=@#&)YV@%\#_&- _SN H 8$I= JLE+6+=$D MFDBQ!6EW&S8[*+TIT48-Y3:-"RW-4VIP.OJ+DB5E5#_"'!G1F( 6H%,TTPWR M N&>:Y2H-,P*&:?&,+A:2T2320WO8%%E'\3J.>")^NP6-:%,G1O$Y\4MG+TY MAS= .7Q*1:$(3]3$U4:,#[[?$L_-S\-['>$$36*"DB_X86+NI,A@01C"QQ7<%;J0 M3784?)D+QL!4]);(Y&N;C=4Q_?9C["UQJ7(2X]0QUX!"N4$G^OVW7NB];_/@ M1&0'CO0;1_I=[-%Q@2G(R:.MP];JJ;C"DLO>99OHW2 & MC2/#GRH,NBL,MK/H+2QQ33FG?&V^2HSP&-N^7J#X9>,#ZJZLXH7JEQ MU&@<=6ILBAX?3*MA:EYB+-:<_G=\25>*1L\4!4'@!T>".H]\I:!Q(VA\PFMG M_$Q/V[73>>(K]?2\IT^^]^HR1)[\H 9K\OT[TQ_UPU'_2&-W$"\5Z>ZU.!G* M==GY*8A%P77UC6]6F^[RJNRICM:O;==9MDY/-%7+^H%(\PHJ8+@RE-[%T&11 M5EU@-=$B+QNII="F+2N'J>F<4=H-YOE*"+V;V .:7CSZ'U!+ P04 " "9 M1F%5;)*2UC<0 $WP &0 'AL+W=OQO&W0GFGMKJKW+8 (5D9QU5I\Q^FQS79GKW8V@LB'=ML2Z !9"=3 M\^(7)&QT)'PLDN_T1<=VQ.>';#^1$(\.U\]Y\4?Y*$2E?5TML_+CV6-5K3]< M7I;S1[%*RHM\+;+Z;^[S8I54]:?%PV6Y+D2RV&ZT6EX:H]'DZ6)P_BLZA^ M7]\5]6>7K\HB78FL3/-,*\3]Q[-/^H=XLMU@>XN_I^*YW/M8:^[*ESS_H_DD M6'P\&S5[))9B7C5$4O_Q)&[%/9U9FV$/?)9EG]+7_V17N'K,:;Y\MR^W_MN;WMZ$R;;\HJ7[4; MUWNP2K/=G\G7]ANQMX&AO[&!T6Y@'&Q@FF]L8+8;F(<3C#A^F[0;34^_#5;O!U:GW8=9N,#MU@CYZ^9D"['HV=Y3;V^^MWV@WGZFV/ZR_L:\?G>,E^_.KX82 M_"U_NM!&YKEFC Q=*Q^30I0]NW6K5OXZKRXTPVB5WS_;VD]_^EG[DW;YMFBK MQ3#)ZOW29;&'<4ZX>_IDRXQZ=NSM_7-/@,W1 ;Q(OJGOM:=6/XOUJVJ<]GWT M3Q=5W\?@QW;L[?T+F?V+U(PMYC6C#_D%C$\01R^_TF])4N;,UW^1S"UMODE_ MJ;0@*ZMB4S_:5]K_Q/4-M* 2J_)_>W;TUYTV[M>:)S$?RG4R%Q_/ZF MQ-G-?_Z'/AG]N2_()&:3F$-B+HEY).:36$!B(8E%)!9#F)36\6M:QRK]YFY3 MS!_K9\%:?J_-D_5:+.H_EDLM7S=/LDLM*73?EQ/O:%'[IY/8@&)A206D5@, M85(4K=6,H=DC,9O$'.LH4I;5F[W=#:UW;^B1N^>36$!B(8E%)!9#F)2]R6OV)LKL MW>:K59[MPG:NK9-">TJ6&Z']E&;:(E\NDZ+4UJ+8/4O^6?N7^LGWK\IA0T-( M8C:).23FDIBWPZ9[J1]=C$:Z''F?'!F<-#(D1T8GC8RAD5*NIJ^YFBIS]6FQ M2)M'JF2IW27I0JOC=)NLTRI9]L5&:0V-#8G9).:0F$MBWO3H4?47?32VQI.K MH\=+GQP<#!@SX_R0\.RXDQT7OCHM5MY!RH8^ZTX;6_-ZC*&8.#2FHVJCFHYJ*:AVH^J@6H%J): MA&HQINBFH=J/JH%J!:B6H1J,:7)H>Q:+KJZ MYG+BJ0RU,CB-:)-%/RZ5Z/UA),>ZJ.:AFH]J :J%J!:A6DQI:CFHUJ :B&J1:@64YHVJ/+JZR\.4$=1#!@<:+?N@ MFM-J5WO/MBWK0I\D:&4(U6Q4_N[]I+AKJ]M+_ZP6>1I74^=XL@V!O1O+79VA[4 M=K=IGC7WY50]9FA.4A@']4"5 M1+4*UF-+D7'8-)D-9 MLSC.95EMS[ZF627J>956U)_V!A2M,J&:C6H.JKFMMG\P/+H8C0^SB5:44"U MM1#5(E2+*4W.9E=1,M05I;LBGPNQ*+7[(E]IBSJIYUHFMBN I&6Y2;)YT_(O MJ][7@-7VX'RBC27CN+%D3'6]KR6!#G9/'^RA@WU4"U M1+4(U6)*DQ/8]9$, M=1_IZ-%Q;XFKET]V:]8F59KWQA"M*J&:C6H.JKFMINM[435'%X9NZ8=!1;M* MJ!:@6HAJ$:K%E"8'M>LJ&>JNTLE!_:'SJNJ=&!QFM..$:@ZJN<;Q8C2F>3&: M30ZCC+:74"U M1#5(E2+*4V.,M3+ AU%N1 +L=J^,VZ7WO-W3JRJ_<$I M1>M,J.:@FMMJBM.T'CK01[4 U4)4BU MIC0YH%U'R5!WE'8!??\ %"TAH9J- M:@ZJN<;QNCE7L]XC5+2&A&H!JH6H%J%:3&ER&+L:DJ&N(1T]6E:B6/7&$:T; MH9J-:@ZJN>]\_RWMFZB/(GK/>Z(M)%0+4"U$M0C58DJ3KW?0M9!,=0LISK.' M7YI,;E^_[0NF&A@:3%2S4V,5%?7, MP;%#NT&HYJ":VVKOO]O<0^?ZJ!:@6HAJ$:K%E"9GM^O]F.K>C_-U_IAD#T+[ M]% (L8MO%]1UD6;S=)TL7[[6)GM70,BE90=[0XRVA,SC[HS>>ST &YWKH)J+ M:AZJ^:@6H%J(:A&JQ90FAWCOJEWJDE!?B)^WU\"L@YK4@4T>7MZQ]GHV1;M? MYGGQO6=:U#LT.-@[37J7V,7$. PU>TTO]J)>[%6]V,MZL=?U8B_LQ5[9B[VT MU[^C761V[2)3W2[J"W7U6$]ZS)>+YDI"B^9)]2+YUA]0M%[TSJY:;^V&C>Z& M@VHNJGFHYJ-:@&HAJD6H%E.:G-FNCV2J^TC[B[!H7T034-'&>''R0K]FSPI% MH]GX:GRP6/6M>F<&']2B;2-4H%E.: MG+ZN1&2J2T2_9W7JZJ3]LWY<;$Z\:(NTG&]CF&2+$\H+:GYP"-$.$:HYJ.:B MFM=J/1?H/(P@VB0Z=6R(CHU0+:8T.8!=2<@\I23T\B8R\74MLK*WK:=V!B<- MK0FAFH-J+JIYK;;_*V_VO2W&-X_;2:;1<\.@1YSUW3#L$6=]9W$C]!['E";G MH^OMF"?T=NZ3M+V8;&\RT,8.JMFHYJ":BVJ>>7QA+7W<6\CST<'!Z8-#='#4 M.WAD]@R.J<%2B,9=N6;,+_%3?ZF]Y,I?L][8J6<.C1VJV:CFH)J+:AZJ^:@6 MH%J(:A&JQ90FY[LK_HS9]7[&:*<'U6Q4CBY&H\/W=:%# M?50+4"U$M0C58DJ3(]NU?,8#EP*2:K9=-:![]V5S3F-W+G)7_JF*].%!%+T! M1@L]J&:CFH-J[OAXN2#]PCR,+]KG0;4 U4)4BU MIC0YOEV?9ZPNR9P:W_UF M3_VX6__1FU>TWX-J-JHYJ.:VFG3Z[K 8CT[T42U M1#5(E2+*4V.:U?E&;]S MJ;.V-MO&\9 M9;)LWSG6FV"T&X1J-JHYJ.:VFKS&].SJ,,3H^D&H%J!:B&H1JL64)H>XZR&- MW[F,V0]5*/[KN7?16_7,P;E%FTNHYJ":BVH>JOFH%J!:B&H1JL64)N7;ZBI2 MU@BM4%AH^PG5;%1S4,U%-0_5?%0+4"U$M0C58DJ3H]NUGZP?6?;H!\_'JFJR<&A1$M-J.:@ MFMMJRO.QZ$0?U0)4"U$M0K68TN10=ITF:V"G:>BU(-3^X(2B-294_.) M-II0S48U!]7<5I/>HVGTKA+BH8-]5 M0+42U"-5B2I-SVA6;+'6QZ3M/\W2K MU]MOK%ZOGCLXP&@!"M4<5'-1S4,U']4"5 M1+4*UF-+DC'==*6O*GNI!^U&H M9J.:@VHNJGFHYJ-:@&HAJD6H%E.:'-VN2F4AEU13*X,3B_:A4,U!-=1FIQ2D7KW>;-:&9Q8M.R$:@ZJN9/C M:[WUK@KJH6-]5 M0+42U"-5B2MN%\;)\%**RDRJYN5Z)XD'N/9_6]_9)75;[:?O@HDH4HFAO4?W^?UT_8VT^: M <]Y\$" !1" &0 'AL+W=O MDD(_ML M)I.16&O.2IA)HM9%0>7S+7"Q'3N^\_+@CJUR;1ZXR:BB*YB#?JAF$D=NJY*Q M DK%1$DD+,?.C7\]&9AX&_"#P5;MW!/C9"'$HQE\R<:.9X" 0ZJ- L7+!B; MN1%"C#^-IM-.:1)W[U_4/UGOZ&5!%4P$_\DRG8^=@4,R6-(UUW=B^QD:/Y'1 M2P57]I=LZ]@89TS72HNB2<9QP90 M79'0>T\"+P@ZTB>OIT\AQ73?IOO[Z2[Z;LT'K?G ZH4G]&;TF2XX>D4W=0TH M5^37S4)IB=_7[RZ#M6*O6]'LN6M5T13&#FXJ!7(#3O+VC1]['[OL_B>Q/?-A M:SY\33UY6?-4%-@2%#6[JLMPK1);%=,3-LD@\G'Q-KM&.H(&WK -V@/LM8"] MLP W5#*S3$B*S2,#>1*UUHMV* (O"J(#UN,H/_:'03=LU,)&9\%64BQ!F1Y' M.5D"=&Z2Z)@S[/4.,(^#PJ'?[Z:,6\KX+$I6:L O2A-LI%C5#4C-3(5+H;N) MXPZ8_F%ACX/\<*?Z>\3]EKA_%K$P?:J+K-]!=L!U'.+')PHY:+$&KV+="XWK M:Z'P)*H1^;_FV04Z.-HB810.#VO8$>7U?.^ UMUI^.:P_4;EBI6*<%ABGG?5 M1[.R/L#J@1:5/0,60N.)8F]S//-!F@!\OQ2X\LW '"OMOXCD+U!+ P04 M" "91F%50[:*_L(( #O6 &0 'AL+W=O3HS<)*<9@_](M5SEE8!25QGPX&XW["HK1W>5Z=F^67Y]FZC*.4 MSW)2K).$Y<_7/,Z>+GI6[^7$Y^AA6*B=V6=!?9$!E0E_H[X4['UFLA+N<^RK_+@0WC1&\@:\9C/2XE@XL\C MO^%Q+$FB'O\TT-XFIPS?L M*>#-!8TD;Y[%1?6;/#5E!STR7Q=EEC3!H@9)E-9_V;?F@]@*L(9[ F@30%\' MC/8$V$V ?6S L D8'ENE41,P>A5 ]V48-P'C8S-,FH#)ZP![3\"T"9A6K5LW M1]66#BO9Y7F>/9%5B0JS",Y"L6DP]I_6V1Q=XXO&117+P5 7>W#GGS^]OS?BFJ M),']>9/^IDY/]Z2WR,[S,(=?K?)-^$#W!PH\!A1;>-"IQO M=D/"'"3,1<(\),Q'P@(03-';:*.WD;''^VN=W/.<9 NIN42._$6E MP&+)1#+"'L5HS^YC3L0<@$1%L6:B1R1OHK0IH1O^KXTIN\H3"7.0,!<)\Y P M'PD+:MBH@LE5T>/E<#B0/^?]1XWRQAOEC8W*N$L#1=BW7S7"PR\^A^72^H5V*4Y8&%KE*;FZ8 ]L? M#HQ:FZWS^5+V5V%4S*7L=$HR,[I*J:&]ZK-&KZ0$S>E":1Z4YD-I 8JFZFG+ MC[:,>G+6>>TOB]XK6RQX'J4/LJ>*LK#02LN(ZRPM<^7&)*GL8JU1C:R("Z5Y M4)H/I04HFJHWVNJ-FGW>VMV0?@8/#[D9#6M[ 6S;IT/I!#\J,C+F[#KYA])< M*,V#TGPH+4#15&6U-Q"L W<0:F4UZ+"RS1;KW]B7>R_5>J+@3A'^3K[73V02UX*,UI:-L3%&NH'=QV"]*I=G3;+3C4#V^:U'2B'>!^ MANMMM;:W9?:]][;YG*VBDL71O^*-*"TS\>N1B[]ZA]N MGFJN^,9?NKMOI()@[)TS*:+\4"6CZ#+6W ];:TU.XE*TKR%,4QN>>D+:13E;E"7?L6 M*,V!TEPHS3O0D)0\[I#93F0&DNE.9!:3Z4%J!HJO!:#YL> M\11\QS6<&=E9AE!KF^Z:S+HYM O-ZC6T[:G=2#>S@V8-4#15.JVU3:UJ,:"UV7UH>F#5 T52VM,T[-SO@O6 = K78H MS8'27"C-.]"05K4.()-F&2#6 R%[UJ\&H"X[BJ;JMW79J?D1]L^W=_J^"^JK M0VD.E.9":1Z4YD-I 8JF2JWUU2GB678*==*A- =*F*O4M8&/SNM"\WH-;7PPKP_-&Z!HJF!:7]PV^^+__TK. M7*&NO0N4YD!I+I3F'6C(ESLZIR]+.6NZ=RT'K5B HJD*;MUVV_Q(^.QZWVK. M'-A9:5"''4ISH30/2O.AM !%4\6VM5TSZ<=R0P0%VN MVMZMPVX?\>SYCR_ES%DZ2P!JF]N[^Y-H__L FM5K:(?:WX=F#5 T54VMWVV; M_>Y?,,N'.NE0F@.EN5":=Z AF_LUT\TDG^Z?Y$-==!1-%7#KHMOFI],[^AI[ M5P23W2^_]AE5&PO=V]R:W-H965T'Z#S?PQPPWCKV(!(-%;%,;BUEI(N;RQ;>$M(**B MQ980JRLSQB,JU2F?VV+)@?J)413:Q'%Z=D2#V!H-D[9'/AJRE0R#&!XY$JLH MHOS]'D*VN;6PM6UX"N8+J1OLT7!)YS !^;Q\Y.K,SKWX002Q"%B,.,QNK3M\ M,R8];9#T> E@(TK'2*-,&7O5)]_\6\O1$4$(GM0NJ/I;PQC"4'M2)M:()8GT;)Y*KJX&RDZ.)9-XK&K-(S0M!D\Q>HXF:+/XJ M!,1F*.WP8ZDO"73U )(&H?BL>CU/'M#5I\_H$[*16% . @4Q>HX#*;ZH1G7\ M<\%6@L:^&-I2Q:I'M+TLKOLT+G(@K@'ZSF*Y$.AK[(-?8S\VVV-B<&"K).69 M(MM,W1.CQPDL6ZCM?$'$(:0N(+/Y WC*'"?FV!!..[]Q[<1?^X"_?U;1%+B^ M0]F]J"8ASL1)1>CM(S MHJCG[ P"#<,X@K=EP(]S]?:XKGMN%[NDPF4<^42N?L[5-W)]?0/N!>(X3'\/ MIGI[C .=B.'F&.Y'UQ3$OEY-^K#9BG+W5U3?[0RZW0IG3;_*RMM!&.0( R/" M"P@]O12$GE]*&:@3R=!:-1^+?- PA4%>,C0)FG,A'I M$(P';H7(/.2I2"7!@8V%ZU>BK,"_OEL#5TH1;9<3>N2!IWY559MHS%I(?,Z* M=BYONYD@12;(N8J:S\*08E, ZK?X>UR44"BXD"C9KE(/EKB%D9Q^RW6XYN$IY"76""WF"S?ID MM_@U1-M7*]5":![U5*I"J6"S5&E<"QL"]_;O)7%;51&3=3N\7G=I"GV"S0+E M6%EL"-%O!G$)#8,+$8/-*J9:(1NRN769)^TJFW'L4]D*=8,''RN53Z!W9O0D M':N76TX]N:(A^@D\0E?_@L*NASV3ALER<@E%1 I%1,R*J+12ZUB/6'?1NTX3 M(BA*=P_.XR.>.DT\[3(6$HD8A8=I_=8RF[U]A/D2@H@4@HB8!5%I M+==RFJU)QHF=+2AQ#Y->0@.10@,1\^[-W7S.84XEH&]J'0>Q"#ST0L-5/?=9 MMW'.Y6V7O%!)I/%.3BUK:MTKUQQG[Q6FII=37S1)(6R(6=A\=-'M:YJZ0"\A M:T@A:XA9UAQ;4+V]-.)>M0::A_@H@EW:JHZ SY,=?($\MHIENFN=M^9?">Z2 MO7&[Z)Y^8OA.N7I9$BB$F3)U6GV5:Y[NVJ\IDY)%R>$"J ]<=U#7 M9XS)[8D>(/]V,OH?4$L#!!0 ( )E&8544F,#0U@8 /0N 9 >&PO M=V]R:W-H965T1YJ_?/'^*Q?=D MR[E$SV$0)1>3K92[=[-9LMKRT$NF\8Y'ZI.'6(2>5*=B,TMV@GOK+"@,9L2R MG%GH^=%D>9Y=NQ7+\W@O S_BMP(E^S#TQ(\K'L1/%Q,\>;GPR=]L97IAMCS? M>1M^Q^67W:U09[-#EK4?\BCQXP@)_G QN<3OKNTL(+OCJ\^?DM(Q2E'NX_A[ M>O)^?3&QTA;Q@*]DFL)3_Q[Y-0^"-)-JQ[]%TLFA9AI8/G[)_D<&KV#NO81? MQ\$W?RVW%Q-W@M;\P=L'\E/\]!BKNM29HM4]D'!;!J@6A M'^7_O>>B(TH!Q#D20(H 4@^PCP30(H!FH'G+,JP;3WK+K;*E!UG? M9-&*QH_2QW@GA?K45W%R>2?CU7=T'8=J7"1>UK-OT>W5W<<$G=UPZ?E!\EI= M^7)W@\Y>O4:OT PE6T_P!/D1^A+Y,GFC+JKCS]MXGWC1.CF?2=6N-/ML5;3A M*F\#.=*&!?H01W*;H-^C-5\;XJ_A>$R !#/5(8=>(2^]H.( M18BI07#X#5^I<)R%8Z Y]/"0:):/'LGW]SZ\YP+%#^CC+GU$QC[.4S!SBO3; MX%VR\U;\8J*F>\+%(Y\L?_T%.]9O)KZ!DE5HV8&60=F7'_1+) M+4?W?.-'47I!]<&."S]>HS,UZ/*A^-K4'7D-.ZN1?I<]+BG!S*;S\]ECF11L M2T]2^T!J@Z1_"B^2O!7%;J!@8MN.9=50P&(]49P#B@.BJ._4!^ZG,+% _'GG MBW8NI\'UUG%M[)(:%UBY)]?\P#4'N7Y_YF+E)^TP\P9,_?& A7IBN <,]]0Y MQ:-U.IO2PVXSRFW.J+G+%K9=XS3<5YMY%83% 6$!(GSE23J\%$0ZOI0*4"!M0D:E,1!C!>.'6B."2?9%*X@*# M"]>W3$7Q]=O+1RZ4*D0OTPG="G^E_JI5[2[%-$+B(5>TH;)5>X+HGB!#+6KK M. @\D:27\C%@'@)Y/;<\J-TI;0P L%E]L;5PP:!2J*QP';GRA)B4P-ATWN : M0Z%@+5$PK%&.+G<=(5D3DM*IA>N48Z@3K.4)AO5)=?'KB-94*_6%$*[:ETHK M%0Q+EKD5WDKNO0!]YB)$9_]P MA6V&'4C#%'TRAB(B6A$16!&59JJ)M27:1C_2;D($A;D[P-#:^V%Z=[YNR<2Z M9*HR:HE$0.$!S5\C,YSM%.8Q!!'1@HC @J@TEXV<<#0I.+'U DKJ_FL1\E_@I]]8*]F7M0&V>H;%5RK9)(9R?'R)I'.^4U MQVJ\PACNLLR+)M'"AL#"YM1)U]0TIH:.(6N(EC4$EC5M$\II="-VZFL@7*(O M@M8R!-8RF>]L;/Q NJ.@'$/%$*UBB/OS;BX92(T4Q&-H&Z*U#8&MFV$<7=*T M<3 A\X8-"C>F)RS5HH7"8J&CJ4N;%@ZSJ-6@@:OUI='RA,*"HH^O6Z2L&+O$ ML9MH8R@0JA4([:1 .O"0UE=:N%1?E-+O0[#-,H2]6Y2H#,C%@C2?6O.^VC2L M0FBU0&&U\!,&+VW^VF-N^QA^"M6R@W;R4[HXO+3=1H&+]871>H,ZXWF[=""A M4?3$&+*%:ME"8=DRN+=;U"L[%NYTP>K/?PP90[6,H; 9<[JU6R2LF$Q.PV." MR_;%TEJ%PEKE)YW=(GN%T?3LQM H3&L4UNFGII/(6%.PU+^1X*I]J;168;!6 M&=C8+:K5ANN\_LY4W'9TLE9AM#IAL#H9QM'[.0?;;W'4]NN8 M:@&FJE)J<<1@,^9$@ZDEVTG48V@AIK40Z[1?YI@+U1)MY:!&KC'4#M-JA\&F MS4DF+AO4O!DJ6Y5<"R+6V;PQLBX,)FY=TQEN.O*Z:&L-8\,:YL0I9ANVS#3: M"9?LNQM0"Q@;%C MDZ>(AA8\N,"I +/2ON*0BTVVW3I!JW@?R7R+\>'J84OW M9;:1>:9OS_>#?_"$>B-*4, ?5*@UG:L'(?(MUOF)C'?9+N7[6,HXS ZWW%MS MD=Z@/G^(8_ERDA8X;'1?_@=02P,$% @ F49A5>U>/]5 P #0L !D M !X;"]W;W)K&ULM99?;YLP$,"_BL6FJ976 Y) MH$N0^F?=]M M:M3VV0F78!5L9INDD_;A9P,AV0*LZ;07L,^^NY_//OO&&RZ> M9 R@T'.:,#FQ8J6R<]N6BQA2(GL\ Z9'EERD1.FN6-DR$T"B0BE-;.PX0SLE ME%GAN)!-13CFN4HH@ZE ,D]3(GY<0L(W$\NUMH([NHJ5$=CA.",KF(&ZSZ9" M]^S:2D138))RA@0L)]:%>W[I>D:AF/% 82/WVL@L9<[YD^E\B2:68X@@@84R M)HC^K>$*DL18TAS?*Z-6[=,H[K>WUF^*Q>O%S(F$*YX\TDC%$\NW4 1+DB?J MCF\^0[6@@;&WX(DLOFA3S74LM,BEXFFEK E2RLH_>:X"L:?0QRT*N%+ !7?I MJ*"\)HJ$8\$W2)C9VIII%$LMM#4<96979DKH4:KU5#A3?/&$KGBJMUF2(E!G MZ&YV+]')-2A"$WE:"<:VTOZ,EKVH;%^6MG&+[0#=PE[C0X@ZR'^LY[A!V,T5MD(QD3 ;+Z=7CHU^'H%Q[Z+1Z^YNDM[^J YS2"C&F34 M"?( \AB*41/%R _ZS11^3>&__.BP".5L77)5YPC*H>,/D=^P?0-OZ+1$+:AY M@\Y$?"RN4XC.+M8@]/. ;@@5Z($D.:"ISM"9 6KB"?Y#?KK.[C9UC@KS7[(T MXDE"A#2B,L0FUKM[K?'*+0'\O8!CO]>6+>[>.^"^.&U?@U4],WB/R^N-W!8L MO,/"1Z3Q:\#P(9B+>X'?0K9[*=S.JWX_KU^#U3_$PDYO-&K!VCT1[A%O1$.B M[_+=G$73_,?SZ!VM=E!7.;GI9 M*-X2H9-)H@266E6'3-\]HJR]RH[B65'OS+G2U5/1C'6]"L),T.-+SM6V8QS4 M%7#X"U!+ P04 " "91F%5F?5Z'0T# #E"0 &0 'AL+W=O!W,#$NXY/2!)"H=.0,')3#'!56W?/45JH"ZQE[,J;2_:%7M M]1P4%U+QK%+6!!EAY1<_58G84F@'>Q2"2L$FPBT=6Z[N:M08.UL#CH-'@%/(6:GL?4> % M 7J/7"13+$!6GP8/[3HE;>NAOAI,(L(6R!L$(J!32#!6',"#1U#H+P!)T0 M5N7D%/W>F9TRE-)9USHS/;R,>NTP['I#=[D#LEM#=ALAOPC,%!Q.T7U!L0>@ M5P/T&@%TS\Z!'(/0>X%PYO<'?6\/2+\&Z1]>+I:@@BU!&JZJ=E N'5^X_@O> M3L\/]A5N4.,.&O_]#_8<@^3L8@E"G\OH&A.![C$M $UT6TP-SRZE_L)7LL!7NSK3O;[^ F>0539?V MIO&WK@/_B+9Y#51UWP1;5+[7"KM[R((-6?"F/MJTDZFV&;ZMXA7.\Y+_'86[ M=?-F(!;V?2%1S NFRDNXEM9OF(ORYMYL+Q] -UCH?ZM$%.9:U6OU=5U%^:8H M)XKG]AZ?<:5?!7:8ZG<8"+-!K\\Y5^N)<5"_[*(_4$L#!!0 ( )E&854K M;HBD8P( )\' 9 >&PO=V]R:W-H965T0T2I0MO4- ML9W[_\YW%^[B+1>/L@!0:%>53(Z\0JEZB+',"JB([/$:F'ZSY*(B2F_%"LM: M ,FMJ"IQX/L#7!'*O"2V9S.1Q'RM2LI@)I!<5Q41O\90\NW(ZWO[@WNZ*I0Y MP$E'T\C86X/O%+;R8(U,) O.'\WF M-A]YOKD0E) I0R#ZL8$)E*4!Z6O\;)A>Z]((#]=[^HV-7<>R(!(FO/Q!RF%)UJ6ZY]NOT,1S97@9+Z7]15MG&X8>RM92\:H1ZQM4E+DGV35Y.!!H M3K<@: 3!GR0C;.L=6EYXA#<3?$/MGUSW&$1=]96I?E>E'2OJ M9ID6-I0UR6#DZ1XE06S 2]Z]Z0_\+UUI?DU8^IJPZ2O!GA0D:@L2G:+_94$< M:V!99@1L$C_&F\,LOVB1OF@Q/67A@L0'':<"L;*M7J*,KYER'V-[VDZ3:]M$ MGYV/^\-)O^,\U=/'#8L_>#>Z[HA84291"4OMRN]]U U1N''@-HK7MM\MN-+= MTRX+/4%!& /]?LFYVF^,@W8F)[\!4$L#!!0 ( )E&857/R"9$604 !4E M 9 >&PO=V]R:W-H965T0 MTFN*(CG?4?;"UX0(]"W/"GX]6@NQN=(T'J])CODEW9!"7EE2EF,A3]E*XQM& M<%*)\DPS==W1$4>B'C:W#-YIK64),U)P5-:($:6UZ,;XRHRQJ6@BO@K)3M^<(S* MICQ3^E*>1,GU2"]K1#(2BQ*!Y;]7RK"3)>OS;0$=MSE)X>+RG^U7C96.> M,2=W-/N:)F)]/9J.4$*6>)N)+W07DJ9!=LF+:<:KOVA7QTYD<+SE@N:-6-8@ M3XOZ/_[6W(@#@6RH6F V G.HP&H$UE#!N!&,CP7V.P*[$=A#,SB-P!F:8=(( M)D,S3!O!=*A@U@AFE1WJYU<]?!<+O)@SND.LC):T\J!R4*66SSPM2K,_"":O MIE(G%@^"QB]KFB6$\=^02Y9IG KTT24"IQG_A'Y'3P\N^OCA$_J -,37F!&. MT@(]%:G@%[)0'C^NZ9;C(N%S3<@JE6 M;M)[=7KSG?06^DP+L>;(*Q*2*/1! MOW[6H]?DK6COA[F_'[=F+_!FPRZ185\@4S=-17WN^N4NB2^1;E9R0R%W?Y!] MNY)RZUVYUR]_()M+9.GO5MX?+E=E#WXN>_ASV:,!=]XR5/*.$:SVAV%5/.N] MZFR?>9JD\@5P@1YP1A!=HNK'@O[^4X:B2)"<_Z.HYVW-':NYYHXSFX=9_"5WXC"9)#\_T(0IHPIGDN1[N\ MZE,_RF%$?>F3RHZ]>IS6OTVM>[QMA<[<6>ZU7GY"=^U FX MD.F\'Z;S(=,%/TP70J:+^M)U/#)I/3+I]8B/4X9><;:M1H>[IKM3F:*7UUYB,5.'OO9;MD-$>D M[M_PL_RTV3L7T:W@0G[)I\5*Y>+>G.>Z&!+F0L*\Z< !@@^9-1B:-83,&@W( MVC'@K#7@K-> -P(]K@GZC-D+$>B>T17#N[ZYFUIQNB=*%_(X61,2,+K+YG: M/ON>[ (51"@-!+HN TIS06E>0^M,#$^=XT[35X69QU&!(LJ93H_#PD&P"*J= M7=^\K8 8@$L@_:RS_0*Z" )*\XS3A01#89?3*/O4+8IUB_&I60:@(J@VUE[1 M#K9(Y(2MJOTU7#[];2'J1>&VM-W#&ULM5E=C^(V%/TK5BI5,U([B1T2DBD@+>Q67:G;HJ'3 M??80 ]$F<6H;V/[[VDDFP21819B7(1_WGMQS?6(.=R9'RK[Q'2$"?,^S@D^= MG1#EL^OR]8[DF#_1DA3RSH:R' MYRK8N+QG!29649R[RO-#-<5HXLTEU;8_3LG&3U.'>B\7WA)MSNA+KBS28FW9$7$:[ED\LQM49(T M)P5/:0$8V4R=#_!Y@0*54$7\G9(C/SD&BLH;I=_4R>=DZGBJ(I*1M5 06'X< MR()DF4*2=?S3@#KM,U7BZ?$[^J\5>4GF#7.RH-G7-!&[J1,Y("$;O,_$"SW^ M1AI"58%KFO'J+SC6L8'O@/6>"YHWR;*"/"WJ3_R]:<1)@L093D!- CI/&%U( M\)L$OR):5U;1^H@%GDT8/0*FHB6:.JAZ4V5+-FFAEG$EF+R;RCPQ^T,JY7?* M.5@2!A8TSV5K5SO,"'CX2 1.,_X(?@9<7>$35\@GJCQWW:#/:W1T 3T&7V@A M=AQ\*A*2Z/FNK+0M%[V7.T=&P!4IGX#O_020A]! /8O_GPX-Y?AM]_P*SS=T M[T&U[Q%\+M8T)[TV#O6LQAP-8ZKW]IF7>$VFCGPQ.6$'XLQ^_ &&WB]#A"V! M:?1'+?V1"7WV%Q4X R45I!"I/$K2;*_>RD8OX"$MFL/'H3[4X$$%KK:;PRR M?N0%?C1Q#Z<<^X'0]^(HC(,V4*L_:.L/C/4W"]54NY<:98"6:GL9*M>(=>VR M60+3:(NF24PC77ASV$,?_:=;*%IK-%'5MT!Z4V MH+9:8 E-;T%GBJ#1=-RL5;__=1\&H[ OUGY@-([]47Q!L9VM@69?TRIV.;^H M62/"U0MF"4WGV]D@&-Q#LU8-D2TTO06=)8)&RW&S9L/^_AI"%/0D.Q 7^-ZE M/;:S--#L:59UE2GG>_R6$?D#.\-*P(("L2/@TVJY'"S;B'KU$EI"TWO0&2,8 MW4/%5CV2+32]!9U+@D87=PD-GAG$MX7\IE M6U.Y%;-J9D0WS9E(U>U"DASF\$X)WT#2R:JALH>DMZ P5 M,KJ56S7=H&LFP?/&'CS?FH<"I>DXU;_.H/-#R.R'OF+&<"&&U6IU&&0+32?: M^28TNH=:K5HI6VAZ"SHKAG)>GPA:5L/G-RH$S:O#'<$)82I WM]0V:KF1#V@_?_%[#]02P,$% @ MF49A5=#2ID;> @ 1@D !D !X;"]W;W)K&UL MK59=3]LP%/TK5H8F)G7DNU"61H*F:'N8A"AL#],>W.2FL4CB8+LM^_>SG1!2 M:JH^T(?6CL\YOO>>6SO1EK)'7@ (]%R5-9]:A1#-I6WSM( *\S/:0"U7,,"9)E6E[3G.V*XPJ:TXTL]N61S1M2A)#;<,\7558?;O&DJZG5JN M]?+@CJP*H1[8<=3@%2Q /#2W3,[L7B4C%=2 WX1V/+! M&*E,EI0^JLF/;&HY*B H(15* 0JD3P1+P06('T7'-$$/,?S#/3987H"J:2[FNX:Z,GQNYOH\^-W=W;IMC2B=\/KW?"TGO^.GJKR MJ*WU_&E--KA4SHS>&C$RNC-@H#]72[DH_X5_38ZT003F(-3)=,D;G,+4DDMM2:/]4.V M6PG$"[JMD;P;10$HI74F+UNYQG<.8(W,U0%LJEQH: !#GQA@H:%/]F%N:.B3 M?9BQ3^S!':3>,'YBMB(U1R7DDNB'A7S1 :8 M&ULG51=3]LP%/TK5M[!:4H90FDDZ(J8 M!%)%!7M :'*2F\3"'YE]LW3_?K:3AFYJ>=A+[&O?<\X]]G727IMWVP @V4FA M[#)J$-MK2FW1@&3V7+>@W$ZEC63H0E-3VQI@90!)09,XOJ22<15E:5C;F"S5 M'0JN8&.([:1DYO+S0\(+A]X>S(EWDFO][H-OY3**?4$@H$#/P-SP"U8@A"=R9?P< M.:-)T@,/YWOVN^#=>L$/NG^'D8_"\]7:&'#E_1# M[F(>D:*SJ.4(=A5(KH:1[<9S. !<7)T )",@^1>P. &8CX!Y,#I4%FQ]9
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end XML 63 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 64 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 65 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 277 299 1 false 63 0 false 7 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.esperion.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Statement - Condensed Balance Sheets Sheet http://www.esperion.com/role/CondensedBalanceSheets Condensed Balance Sheets Statements 2 false false R3.htm 0000003 - Statement - Condensed Balance Sheets (Parenthetical) Sheet http://www.esperion.com/role/CondensedBalanceSheetsParenthetical Condensed Balance Sheets (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - Condensed Statements of Operations and Comprehensive Loss Sheet http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss Condensed Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 0000005 - Statement - Condensed Statements of Stockholders' Deficit Sheet http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit Condensed Statements of Stockholders' Deficit Statements 5 false false R6.htm 0000006 - Statement - Condensed Statements of Cash Flows Sheet http://www.esperion.com/role/CondensedStatementsofCashFlows Condensed Statements of Cash Flows Statements 6 false false R7.htm 0000007 - Disclosure - The Company and Basis of Presentation Sheet http://www.esperion.com/role/TheCompanyandBasisofPresentation The Company and Basis of Presentation Notes 7 false false R8.htm 0000008 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.esperion.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 0000009 - Disclosure - Collaborations with Third Parties Sheet http://www.esperion.com/role/CollaborationswithThirdParties Collaborations with Third Parties Notes 9 false false R10.htm 0000010 - Disclosure - Inventories, net Sheet http://www.esperion.com/role/Inventoriesnet Inventories, net Notes 10 false false R11.htm 0000011 - Disclosure - Commitments and Contingencies Sheet http://www.esperion.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 11 false false R12.htm 0000012 - Disclosure - Investments Sheet http://www.esperion.com/role/Investments Investments Notes 12 false false R13.htm 0000013 - Disclosure - Fair Value Measurements Sheet http://www.esperion.com/role/FairValueMeasurements Fair Value Measurements Notes 13 false false R14.htm 0000014 - Disclosure - Liability Related to the Revenue Interest Purchase Agreement Sheet http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreement Liability Related to the Revenue Interest Purchase Agreement Notes 14 false false R15.htm 0000015 - Disclosure - Convertible Notes Notes http://www.esperion.com/role/ConvertibleNotes Convertible Notes Notes 15 false false R16.htm 0000016 - Disclosure - Other Accrued Liabilities Sheet http://www.esperion.com/role/OtherAccruedLiabilities Other Accrued Liabilities Notes 16 false false R17.htm 0000017 - Disclosure - Stock Compensation Sheet http://www.esperion.com/role/StockCompensation Stock Compensation Notes 17 false false R18.htm 0000018 - Disclosure - Income Taxes Sheet http://www.esperion.com/role/IncomeTaxes Income Taxes Notes 18 false false R19.htm 0000019 - Disclosure - Stockholders' Deficit Sheet http://www.esperion.com/role/StockholdersDeficit Stockholders' Deficit Notes 19 false false R20.htm 0000020 - Disclosure - Net Loss Per Common Share Sheet http://www.esperion.com/role/NetLossPerCommonShare Net Loss Per Common Share Notes 20 false false R21.htm 0000021 - Disclosure - Statements of Cash Flows and Restricted Cash Sheet http://www.esperion.com/role/StatementsofCashFlowsandRestrictedCash Statements of Cash Flows and Restricted Cash Notes 21 false false R22.htm 0000022 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.esperion.com/role/SummaryofSignificantAccountingPolicies 22 false false R23.htm 0000023 - Disclosure - Inventories, net (Tables) Sheet http://www.esperion.com/role/InventoriesnetTables Inventories, net (Tables) Tables http://www.esperion.com/role/Inventoriesnet 23 false false R24.htm 0000024 - Disclosure - Investments (Tables) Sheet http://www.esperion.com/role/InvestmentsTables Investments (Tables) Tables http://www.esperion.com/role/Investments 24 false false R25.htm 0000025 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.esperion.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.esperion.com/role/FairValueMeasurements 25 false false R26.htm 0000026 - Disclosure - Liability Related to the Revenue Interest Purchase Agreement (Tables) Sheet http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementTables Liability Related to the Revenue Interest Purchase Agreement (Tables) Tables http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreement 26 false false R27.htm 0000027 - Disclosure - Other Accrued Liabilities (Tables) Sheet http://www.esperion.com/role/OtherAccruedLiabilitiesTables Other Accrued Liabilities (Tables) Tables http://www.esperion.com/role/OtherAccruedLiabilities 27 false false R28.htm 0000028 - Disclosure - Stock Compensation (Tables) Sheet http://www.esperion.com/role/StockCompensationTables Stock Compensation (Tables) Tables http://www.esperion.com/role/StockCompensation 28 false false R29.htm 0000029 - Disclosure - Net Loss Per Common Share (Tables) Sheet http://www.esperion.com/role/NetLossPerCommonShareTables Net Loss Per Common Share (Tables) Tables http://www.esperion.com/role/NetLossPerCommonShare 29 false false R30.htm 0000030 - Disclosure - Statements of Cash Flows and Restricted Cash (Tables) Sheet http://www.esperion.com/role/StatementsofCashFlowsandRestrictedCashTables Statements of Cash Flows and Restricted Cash (Tables) Tables http://www.esperion.com/role/StatementsofCashFlowsandRestrictedCash 30 false false R31.htm 0000031 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesPolicies 31 false false R32.htm 0000032 - Disclosure - Collaborations with Third Parties (Details) Sheet http://www.esperion.com/role/CollaborationswithThirdPartiesDetails Collaborations with Third Parties (Details) Details http://www.esperion.com/role/CollaborationswithThirdParties 32 false false R33.htm 0000033 - Disclosure - Inventories, net (Details) Sheet http://www.esperion.com/role/InventoriesnetDetails Inventories, net (Details) Details http://www.esperion.com/role/InventoriesnetTables 33 false false R34.htm 0000034 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.esperion.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.esperion.com/role/CommitmentsandContingencies 34 false false R35.htm 0000035 - Disclosure - Investments - Summary of Cash Equivalents, Restricted Cash, and Short-Term Investments (Details) Sheet http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandShortTermInvestmentsDetails Investments - Summary of Cash Equivalents, Restricted Cash, and Short-Term Investments (Details) Details 35 false false R36.htm 0000036 - Disclosure - Investments - Narrative (Details) Sheet http://www.esperion.com/role/InvestmentsNarrativeDetails Investments - Narrative (Details) Details 36 false false R37.htm 0000037 - Disclosure - Fair Value Measurements (Details) Sheet http://www.esperion.com/role/FairValueMeasurementsDetails Fair Value Measurements (Details) Details http://www.esperion.com/role/FairValueMeasurementsTables 37 false false R38.htm 0000038 - Disclosure - Liability Related to the Revenue Interest Purchase Agreement - Narrative (Details) Sheet http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails Liability Related to the Revenue Interest Purchase Agreement - Narrative (Details) Details http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementTables 38 false false R39.htm 0000039 - Disclosure - Liability Related to the Revenue Interest Purchase Agreement - Summary of Revenue Interest Liability (Details) Sheet http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails Liability Related to the Revenue Interest Purchase Agreement - Summary of Revenue Interest Liability (Details) Details 39 false false R40.htm 0000040 - Disclosure - Convertible Notes (Details) Notes http://www.esperion.com/role/ConvertibleNotesDetails Convertible Notes (Details) Details http://www.esperion.com/role/ConvertibleNotes 40 false false R41.htm 0000041 - Disclosure - Other Accrued Liabilities (Details) Sheet http://www.esperion.com/role/OtherAccruedLiabilitiesDetails Other Accrued Liabilities (Details) Details http://www.esperion.com/role/OtherAccruedLiabilitiesTables 41 false false R42.htm 0000042 - Disclosure - Stock Compensation - Stock Options Additional Information (Details) Sheet http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails Stock Compensation - Stock Options Additional Information (Details) Details 42 false false R43.htm 0000043 - Disclosure - Stock Compensation - Schedule of Stock Options (Details) Sheet http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails Stock Compensation - Schedule of Stock Options (Details) Details 43 false false R44.htm 0000044 - Disclosure - Stock Compensation - PBSOs (Details) Sheet http://www.esperion.com/role/StockCompensationPBSOsDetails Stock Compensation - PBSOs (Details) Details 44 false false R45.htm 0000045 - Disclosure - Stock Compensation - RSUs (Details) Sheet http://www.esperion.com/role/StockCompensationRSUsDetails Stock Compensation - RSUs (Details) Details 45 false false R46.htm 0000046 - Disclosure - Stock Compensation - PBRSUs (Details) Sheet http://www.esperion.com/role/StockCompensationPBRSUsDetails Stock Compensation - PBRSUs (Details) Details 46 false false R47.htm 0000047 - Disclosure - Income Taxes (Details) Sheet http://www.esperion.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.esperion.com/role/IncomeTaxes 47 false false R48.htm 0000048 - Disclosure - Stockholders' Deficit (Details) Sheet http://www.esperion.com/role/StockholdersDeficitDetails Stockholders' Deficit (Details) Details http://www.esperion.com/role/StockholdersDeficit 48 false false R49.htm 0000049 - Disclosure - Net Loss Per Common Share (Details) Sheet http://www.esperion.com/role/NetLossPerCommonShareDetails Net Loss Per Common Share (Details) Details http://www.esperion.com/role/NetLossPerCommonShareTables 49 false false R50.htm 0000050 - Disclosure - Statements of Cash Flows and Restricted Cash (Details) Sheet http://www.esperion.com/role/StatementsofCashFlowsandRestrictedCashDetails Statements of Cash Flows and Restricted Cash (Details) Details http://www.esperion.com/role/StatementsofCashFlowsandRestrictedCashTables 50 false false R9999.htm Uncategorized Items - espr-20220930.htm Sheet http://xbrl.sec.gov/role/uncategorizedFacts Uncategorized Items - espr-20220930.htm Cover 51 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 3 fact(s) appearing in ix:hidden were eligible for transformation: espr:ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount, espr:DebtInstrumentExchangeAgreementConvertibleThresholdTradingDays, espr:PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment - espr-20220930.htm 4 espr-20220930.htm espr-20220930.xsd espr-20220930_cal.xml espr-20220930_def.xml espr-20220930_lab.xml espr-20220930_pre.xml espr-ex311x09302022.htm espr-ex312x09302022.htm espr-ex321x09302022.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 68 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "espr-20220930.htm": { "axisCustom": 1, "axisStandard": 24, "contextCount": 277, "dts": { "calculationLink": { "local": [ "espr-20220930_cal.xml" ] }, "definitionLink": { "local": [ "espr-20220930_def.xml" ] }, "inline": { "local": [ "espr-20220930.htm" ] }, "labelLink": { "local": [ "espr-20220930_lab.xml" ] }, "presentationLink": { "local": [ "espr-20220930_pre.xml" ] }, "schema": { "local": [ "espr-20220930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 472, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 1, "http://www.esperion.com/20220930": 3, "http://xbrl.sec.gov/dei/2022": 5, "total": 9 }, "keyCustom": 69, "keyStandard": 230, "memberCustom": 21, "memberStandard": 37, "nsprefix": "espr", "nsuri": "http://www.esperion.com/20220930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Page", "role": "http://www.esperion.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - Inventories, net", "role": "http://www.esperion.com/role/Inventoriesnet", "shortName": "Inventories, net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Commitments and Contingencies", "role": "http://www.esperion.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Investments", "role": "http://www.esperion.com/role/Investments", "shortName": "Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Fair Value Measurements", "role": "http://www.esperion.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "espr:LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Liability Related to the Revenue Interest Purchase Agreement", "role": "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreement", "shortName": "Liability Related to the Revenue Interest Purchase Agreement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "espr:LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Convertible Notes", "role": "http://www.esperion.com/role/ConvertibleNotes", "shortName": "Convertible Notes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Other Accrued Liabilities", "role": "http://www.esperion.com/role/OtherAccruedLiabilities", "shortName": "Other Accrued Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - Stock Compensation", "role": "http://www.esperion.com/role/StockCompensation", "shortName": "Stock Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - Income Taxes", "role": "http://www.esperion.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - Stockholders' Deficit", "role": "http://www.esperion.com/role/StockholdersDeficit", "shortName": "Stockholders' Deficit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i3ba422a44ee54c6fb80ecd91423f5405_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000002 - Statement - Condensed Balance Sheets", "role": "http://www.esperion.com/role/CondensedBalanceSheets", "shortName": "Condensed Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i3ba422a44ee54c6fb80ecd91423f5405_I20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - Net Loss Per Common Share", "role": "http://www.esperion.com/role/NetLossPerCommonShare", "shortName": "Net Loss Per Common Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - Statements of Cash Flows and Restricted Cash", "role": "http://www.esperion.com/role/StatementsofCashFlowsandRestrictedCash", "shortName": "Statements of Cash Flows and Restricted Cash", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - Inventories, net (Tables)", "role": "http://www.esperion.com/role/InventoriesnetTables", "shortName": "Inventories, net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - Investments (Tables)", "role": "http://www.esperion.com/role/InvestmentsTables", "shortName": "Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.esperion.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "espr:ScheduleOfRevenueInterestLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000026 - Disclosure - Liability Related to the Revenue Interest Purchase Agreement (Tables)", "role": "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementTables", "shortName": "Liability Related to the Revenue Interest Purchase Agreement (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "espr:ScheduleOfRevenueInterestLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - Other Accrued Liabilities (Tables)", "role": "http://www.esperion.com/role/OtherAccruedLiabilitiesTables", "shortName": "Other Accrued Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - Stock Compensation (Tables)", "role": "http://www.esperion.com/role/StockCompensationTables", "shortName": "Stock Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000029 - Disclosure - Net Loss Per Common Share (Tables)", "role": "http://www.esperion.com/role/NetLossPerCommonShareTables", "shortName": "Net Loss Per Common Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i3ba422a44ee54c6fb80ecd91423f5405_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - Condensed Balance Sheets (Parenthetical)", "role": "http://www.esperion.com/role/CondensedBalanceSheetsParenthetical", "shortName": "Condensed Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i3ba422a44ee54c6fb80ecd91423f5405_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000030 - Disclosure - Statements of Cash Flows and Restricted Cash (Tables)", "role": "http://www.esperion.com/role/StatementsofCashFlowsandRestrictedCashTables", "shortName": "Statements of Cash Flows and Restricted Cash (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i3ba422a44ee54c6fb80ecd91423f5405_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RestrictedCash", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000031 - Disclosure - Summary of Significant Accounting Policies (Details)", "role": "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails", "shortName": "Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:RevenueRecognitionPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": "INF", "lang": "en-US", "name": "espr:NumberOfSourcesOfRevenue", "reportCount": 1, "unique": true, "unitRef": "revenue_source", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i466edf1a06b740a28058e423840fb69c_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000032 - Disclosure - Collaborations with Third Parties (Details)", "role": "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails", "shortName": "Collaborations with Third Parties (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i9b9307c0c3cf4d8bb1eab3ddc049e082_D20220701-20220930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i3ba422a44ee54c6fb80ecd91423f5405_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000033 - Disclosure - Inventories, net (Details)", "role": "http://www.esperion.com/role/InventoriesnetDetails", "shortName": "Inventories, net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i3ba422a44ee54c6fb80ecd91423f5405_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i5b1327737f2e49a8a62c8ac0ecc68848_D20210824-20210824", "decimals": "-4", "first": true, "lang": "en-US", "name": "us-gaap:LitigationSettlementAmountAwardedToOtherParty", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000034 - Disclosure - Commitments and Contingencies (Details)", "role": "http://www.esperion.com/role/CommitmentsandContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i5b1327737f2e49a8a62c8ac0ecc68848_D20210824-20210824", "decimals": "-4", "first": true, "lang": "en-US", "name": "us-gaap:LitigationSettlementAmountAwardedToOtherParty", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i3ba422a44ee54c6fb80ecd91423f5405_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000035 - Disclosure - Investments - Summary of Cash Equivalents, Restricted Cash, and Short-Term Investments (Details)", "role": "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandShortTermInvestmentsDetails", "shortName": "Investments - Summary of Cash Equivalents, Restricted Cash, and Short-Term Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i3ba422a44ee54c6fb80ecd91423f5405_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i466edf1a06b740a28058e423840fb69c_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OtherNonoperatingIncomeExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000036 - Disclosure - Investments - Narrative (Details)", "role": "http://www.esperion.com/role/InvestmentsNarrativeDetails", "shortName": "Investments - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "id3fd97ff9acb407e94cb155a5dc69f43_D20220701-20220930", "decimals": "INF", "lang": "en-US", "name": "us-gaap:OtherNonoperatingIncomeExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i3ba422a44ee54c6fb80ecd91423f5405_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000037 - Disclosure - Fair Value Measurements (Details)", "role": "http://www.esperion.com/role/FairValueMeasurementsDetails", "shortName": "Fair Value Measurements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "espr:FairValueMeasurementAssetTransfersBetweenLevels", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i466edf1a06b740a28058e423840fb69c_D20220701-20220930", "decimals": "0", "lang": "en-US", "name": "espr:FairValueMeasurementAssetTransfersBetweenLevels", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i3ba422a44ee54c6fb80ecd91423f5405_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RestrictedCash", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000038 - Disclosure - Liability Related to the Revenue Interest Purchase Agreement - Narrative (Details)", "role": "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails", "shortName": "Liability Related to the Revenue Interest Purchase Agreement - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "ibfe5011eba8c4b04a339798829b6fc84_D20220101-20220930", "decimals": "-5", "lang": "en-US", "name": "espr:UnamortizedTransactionCostsOnRevenueInterestAgreement", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "espr:PaymentsFromRevenueInterestPurchaseAgreement", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000039 - Disclosure - Liability Related to the Revenue Interest Purchase Agreement - Summary of Revenue Interest Liability (Details)", "role": "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails", "shortName": "Liability Related to the Revenue Interest Purchase Agreement - Summary of Revenue Interest Liability (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "espr:ScheduleOfRevenueInterestLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "ibfe5011eba8c4b04a339798829b6fc84_D20220101-20220930", "decimals": "-3", "lang": "en-US", "name": "espr:RevenueInterestLiabilityIncreaseForInterestExpenseRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i466edf1a06b740a28058e423840fb69c_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - Condensed Statements of Operations and Comprehensive Loss", "role": "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss", "shortName": "Condensed Statements of Operations and Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i466edf1a06b740a28058e423840fb69c_D20220701-20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OtherCostAndExpenseOperating", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "if5dbae1b3d5f4b719463c488c8d92f62_D20201116-20201116", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsForDerivativeInstrumentFinancingActivities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000040 - Disclosure - Convertible Notes (Details)", "role": "http://www.esperion.com/role/ConvertibleNotesDetails", "shortName": "Convertible Notes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "if5dbae1b3d5f4b719463c488c8d92f62_D20201116-20201116", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsForDerivativeInstrumentFinancingActivities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i3ba422a44ee54c6fb80ecd91423f5405_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000041 - Disclosure - Other Accrued Liabilities (Details)", "role": "http://www.esperion.com/role/OtherAccruedLiabilitiesDetails", "shortName": "Other Accrued Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i3ba422a44ee54c6fb80ecd91423f5405_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "if9d01991365a4e6eb115722c008c3261_I20220531", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000042 - Disclosure - Stock Compensation - Stock Options Additional Information (Details)", "role": "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails", "shortName": "Stock Compensation - Stock Options Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "if9d01991365a4e6eb115722c008c3261_I20220531", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i4afe271824aa484ca9ba26eb1858cab3_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000043 - Disclosure - Stock Compensation - Schedule of Stock Options (Details)", "role": "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails", "shortName": "Stock Compensation - Schedule of Stock Options (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i4afe271824aa484ca9ba26eb1858cab3_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000044 - Disclosure - Stock Compensation - PBSOs (Details)", "role": "http://www.esperion.com/role/StockCompensationPBSOsDetails", "shortName": "Stock Compensation - PBSOs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i37b44387d98845b18a9aee93ce2ba538_D20220101-20220930", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "idee54dbe7d4f4041a2898d9f21fb40a0_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000045 - Disclosure - Stock Compensation - RSUs (Details)", "role": "http://www.esperion.com/role/StockCompensationRSUsDetails", "shortName": "Stock Compensation - RSUs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "idee54dbe7d4f4041a2898d9f21fb40a0_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i3039b9c1dcba4dca9c743312901eb841_I20211231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000046 - Disclosure - Stock Compensation - PBRSUs (Details)", "role": "http://www.esperion.com/role/StockCompensationPBRSUsDetails", "shortName": "Stock Compensation - PBRSUs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i3039b9c1dcba4dca9c743312901eb841_I20211231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxExpenseBenefit", "ix:continuation", "span", "div", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i466edf1a06b740a28058e423840fb69c_D20220701-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000047 - Disclosure - Income Taxes (Details)", "role": "http://www.esperion.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxExpenseBenefit", "ix:continuation", "span", "div", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i466edf1a06b740a28058e423840fb69c_D20220701-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsOfStockIssuanceCosts", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000048 - Disclosure - Stockholders' Deficit (Details)", "role": "http://www.esperion.com/role/StockholdersDeficitDetails", "shortName": "Stockholders' Deficit (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i509f46e30c4e44efa1e8e811372974c3_I20211202", "decimals": "0", "lang": "en-US", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000049 - Disclosure - Net Loss Per Common Share (Details)", "role": "http://www.esperion.com/role/NetLossPerCommonShareDetails", "shortName": "Net Loss Per Common Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i45f7480383704b758cc4169db9fde6a3_I20201231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - Condensed Statements of Stockholders' Deficit", "role": "http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit", "shortName": "Condensed Statements of Stockholders' Deficit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i9c7db388977d4e108a2dc7be7b26339b_D20210101-20210331", "decimals": "0", "lang": "en-US", "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i3ba422a44ee54c6fb80ecd91423f5405_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000050 - Disclosure - Statements of Cash Flows and Restricted Cash (Details)", "role": "http://www.esperion.com/role/StatementsofCashFlowsandRestrictedCashDetails", "shortName": "Statements of Cash Flows and Restricted Cash (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "id36c2d798799431eb6fcfa6f013c4cca_I20210930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - Condensed Statements of Cash Flows", "role": "http://www.esperion.com/role/CondensedStatementsofCashFlows", "shortName": "Condensed Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000007 - Disclosure - The Company and Basis of Presentation", "role": "http://www.esperion.com/role/TheCompanyandBasisofPresentation", "shortName": "The Company and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000008 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.esperion.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000009 - Disclosure - Collaborations with Third Parties", "role": "http://www.esperion.com/role/CollaborationswithThirdParties", "shortName": "Collaborations with Third Parties", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "espr-20220930.htm", "contextRef": "i8128b82d845f42bf93c9beab64970a32_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9999": { "firstAnchor": null, "groupType": "", "isDefault": "false", "longName": "Uncategorized Items - espr-20220930.htm", "role": "http://xbrl.sec.gov/role/uncategorizedFacts", "shortName": "Uncategorized Items - espr-20220930.htm", "subGroupType": "", "uniqueAnchor": null } }, "segmentCount": 63, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esperion.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esperion.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esperion.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esperion.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esperion.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esperion.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r580" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esperion.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r581" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esperion.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esperion.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esperion.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esperion.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esperion.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esperion.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r578" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esperion.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esperion.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esperion.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r578" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esperion.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esperion.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r578" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esperion.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esperion.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r590" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esperion.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r578" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esperion.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r578" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esperion.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r578" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esperion.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r578" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esperion.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esperion.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r577" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esperion.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r579" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esperion.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.esperion.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "espr_AccruedClinicalDevelopmentCostsCurrent": { "auth_ref": [], "calculation": { "http://www.esperion.com/role/CondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle, if longer).", "label": "Accrued Clinical Development Costs, Current", "terseLabel": "Accrued clinical development costs" } } }, "localname": "AccruedClinicalDevelopmentCostsCurrent", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.esperion.com/role/CondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.esperion.com/role/OtherAccruedLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Includes obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities and Employee-related Liabilities, Current", "terseLabel": "Other accrued liabilities", "totalLabel": "Total other accrued liabilities" } } }, "localname": "AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/CondensedBalanceSheets", "http://www.esperion.com/role/OtherAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "espr_AccruedVariableConsiderationCurrent": { "auth_ref": [], "calculation": { "http://www.esperion.com/role/OtherAccruedLiabilitiesDetails": { "order": 2.0, "parentTag": "espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Liabilities for co-pay assistance, expected product returns, rebates, and distributor fees", "label": "Accrued Variable Consideration, Current", "terseLabel": "Accrued variable consideration" } } }, "localname": "AccruedVariableConsiderationCurrent", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/OtherAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of potential future revenue which may be received under the terms of the agreement conditional upon achievement of specified total development and sales milestones.", "label": "Aggregate Amount of Potential Future Revenue, Total Development and Sales Milestones", "terseLabel": "Potential additional future payments" } } }, "localname": "AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails" ], "xbrltype": "monetaryItemType" }, "espr_AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the subsequent installment which is subject to the achievement of the Sales Threshold as defined in the Revenue Interest Purchase Agreement.", "label": "Amount of Subsequent Installment, Subject to Achievement of Sales Threshold", "terseLabel": "Amount of subsequent installment, subject to achievement of sales threshold" } } }, "localname": "AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "espr_AmountOfSubsequentInstallmentSubjectToRegulatoryApproval": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the subsequent installment which is subject to regulatory approval.", "label": "Amount of Subsequent Installment, Subject to Regulatory Approval", "terseLabel": "Amount of subsequent installment, subject to regulatory approval" } } }, "localname": "AmountOfSubsequentInstallmentSubjectToRegulatoryApproval", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "espr_AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of the subsequent installment, subject to the terms and conditions of the Revenue Interest Purchase Agreement.", "label": "Amount of Subsequent Installment, Subject to Revenue Interest Purchase Agreement Terms and Conditions", "terseLabel": "Total amount of subsequent installment, subject to RIPA terms and conditions" } } }, "localname": "AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "espr_AtTheMarketProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "At The Market Program", "label": "At The Market Program [Member]", "terseLabel": "At The Market Program" } } }, "localname": "AtTheMarketProgramMember", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/StockholdersDeficitDetails" ], "xbrltype": "domainItemType" }, "espr_BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Blocked Account Deposit Amount If Specified Net Revenue Does Not Meet Threshold", "label": "Blocked Account Deposit Amount If Specified Net Revenue Does Not Meet Threshold", "terseLabel": "Company deposit value in blocked account" } } }, "localname": "BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "espr_CappedCallMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Capped Call", "label": "Capped Call [Member]", "terseLabel": "Capped Call" } } }, "localname": "CappedCallMember", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "domainItemType" }, "espr_CashPaymentToBeReceivedUponCertainCommercialMilestones": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash Payment To Be Received Upon Certain Commercial Milestones", "label": "Cash Payment To Be Received Upon Certain Commercial Milestones", "terseLabel": "Cash payment to be received upon certain commercial milestones" } } }, "localname": "CashPaymentToBeReceivedUponCertainCommercialMilestones", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails" ], "xbrltype": "monetaryItemType" }, "espr_CashPaymentToBeReceivedUponFirstCommercialSales": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash payment to the Company upon first commercial sales in the DSE Territory.", "label": "Cash Payment to be Received upon First Commercial Sales", "terseLabel": "Cash payment to the Company upon first commercial sales in the DSE Territory" } } }, "localname": "CashPaymentToBeReceivedUponFirstCommercialSales", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails" ], "xbrltype": "monetaryItemType" }, "espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Premium Percentage", "label": "Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Premium Percentage", "terseLabel": "Class of warrant or right, premium percentage" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "percentItemType" }, "espr_CollaborationRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to collaboration revenue.", "label": "Collaboration Revenue [Member]", "terseLabel": "Collaboration revenue" } } }, "localname": "CollaborationRevenueMember", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails", "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "domainItemType" }, "espr_CollaborativeArrangementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "n/a", "label": "Collaborations with Third Parties", "terseLabel": "Collaborations with Third Parties" } } }, "localname": "CollaborativeArrangementAbstract", "nsuri": "http://www.esperion.com/20220930", "xbrltype": "stringItemType" }, "espr_CollaborativeArrangementLicenseToIntellectualPropertyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, License To Intellectual Property", "label": "Collaborative Arrangement, License To Intellectual Property [Member]", "terseLabel": "Collaborative Arrangement, License To Intellectual Property" } } }, "localname": "CollaborativeArrangementLicenseToIntellectualPropertyMember", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails" ], "xbrltype": "domainItemType" }, "espr_CollaborativeArrangementOngoingRegulatoryAndDevelopmentActivitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Ongoing Regulatory And Development Activities", "label": "Collaborative Arrangement, Ongoing Regulatory And Development Activities [Member]", "terseLabel": "Collaborative Arrangement, Ongoing Regulatory And Development Activities" } } }, "localname": "CollaborativeArrangementOngoingRegulatoryAndDevelopmentActivitiesMember", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails", "http://www.esperion.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "domainItemType" }, "espr_CommonStockIssuanceCostsIncurred": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Common Stock Issuance Costs Incurred", "label": "Common Stock Issuance Costs Incurred", "terseLabel": "Common stock issuance costs not yet paid" } } }, "localname": "CommonStockIssuanceCostsIncurred", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "espr_ConcentrationRiskNumberOfMajorCustomers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of the Company's major customers.", "label": "Concentration Risk, Number of Major Customers", "terseLabel": "Number of major customers" } } }, "localname": "ConcentrationRiskNumberOfMajorCustomers", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "integerItemType" }, "espr_ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The consecutive number of months sales must be at or above the milestone amount.", "label": "Consecutive Number of Months Sales Must Be At or Above Milestone Amount", "terseLabel": "Consecutive number of months sales must be at or above milestone amount" } } }, "localname": "ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" ], "xbrltype": "durationItemType" }, "espr_ConvertibleSeniorNotesDue2025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Senior Notes Due 2025", "label": "Convertible Senior Notes Due 2025 [Member]", "terseLabel": "Convertible Senior Notes Due 2025" } } }, "localname": "ConvertibleSeniorNotesDue2025Member", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "domainItemType" }, "espr_DaiichiSankyoCoLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Daiichi Sankyo Co. Ltd", "label": "Daiichi Sankyo Co. Ltd [Member]", "terseLabel": "Daiichi Sankyo Co. Ltd" } } }, "localname": "DaiichiSankyoCoLtdMember", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails", "http://www.esperion.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "domainItemType" }, "espr_DaiichiSankyoEuropeGmbhMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Member stands for the Daiichi Sankyo Europe GmbH (\"DSE\").", "label": "Daiichi Sankyo Europe Gmbh [Member]", "terseLabel": "Daiichi Sankyo Europe GmbH (\"DSE\")" } } }, "localname": "DaiichiSankyoEuropeGmbhMember", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails" ], "xbrltype": "domainItemType" }, "espr_DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Convertible, Threshold Percentage Of Last Reported Sale Price", "label": "Debt Instrument, Convertible, Threshold Percentage Of Last Reported Sale Price", "terseLabel": "Debt instrument, convertible, threshold percentage of last reported sale price" } } }, "localname": "DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "percentItemType" }, "espr_DebtInstrumentCovenantRequiredAmountOutstanding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Required Amount Outstanding", "label": "Debt Instrument, Covenant, Required Amount Outstanding", "terseLabel": "Debt instrument, required amount outstanding" } } }, "localname": "DebtInstrumentCovenantRequiredAmountOutstanding", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "espr_DebtInstrumentExchangeAgreementConversionWeightedAveragePricePerShareFloor": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Exchange Agreement, Conversion, Weighted Average Price Per Share Floor", "label": "Debt Instrument, Exchange Agreement, Conversion, Weighted Average Price Per Share Floor", "terseLabel": "Exchange Agreement, weighted average price per share floor (in dollars per share)" } } }, "localname": "DebtInstrumentExchangeAgreementConversionWeightedAveragePricePerShareFloor", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "perShareItemType" }, "espr_DebtInstrumentExchangeAgreementConvertibleThresholdTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Exchange Agreement, Convertible, Threshold Trading Days", "label": "Debt Instrument, Exchange Agreement, Convertible, Threshold Trading Days", "terseLabel": "Exchange Agreement, threshold trading days" } } }, "localname": "DebtInstrumentExchangeAgreementConvertibleThresholdTradingDays", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "durationItemType" }, "espr_DeferredUpFrontPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred Up-Front Payment", "label": "Deferred Up-Front Payment", "terseLabel": "Deferred up-front payment" } } }, "localname": "DeferredUpFrontPayment", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails" ], "xbrltype": "monetaryItemType" }, "espr_EigerIiiSaLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to revenue interest purchase agreement (\"RIPA\") with Oberland.", "label": "Eiger Iii Sa Llc [Member]", "terseLabel": "Oberland" } } }, "localname": "EigerIiiSaLlcMember", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" ], "xbrltype": "domainItemType" }, "espr_EmployeeStockPurchasePlanDurationOfOfferingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The duration of offering periods in which employees may purchase stock, , in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Employee Stock Purchase Plan, Duration of Offering Period", "terseLabel": "Duration of offering periods" } } }, "localname": "EmployeeStockPurchasePlanDurationOfOfferingPeriod", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Maximum amount the employee may contribute to an employee stock purchase plan.", "label": "Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Amount", "terseLabel": "Amount of maximum annual contributions per employee" } } }, "localname": "EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum percentage of employee gross pay the employee may contribute to an employee stock purchase plan.", "label": "Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Percent", "terseLabel": "Maximum annual contributions per employee, as a percentage of base salary" } } }, "localname": "EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "espr_EmployeeStockPurchasePlanPercentageDiscountOnShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The discount at which shares may be purchased under the employee stock purchase plan, calculated as a stated percentage of the lesser of the closing price of the Company's common stock on the NASDAQ Global Select Market (i) on the first trading day of the offering period or (ii) the last day of any offering period.", "label": "Employee Stock Purchase Plan, Percentage Discount on Shares", "terseLabel": "Purchase discount" } } }, "localname": "EmployeeStockPurchasePlanPercentageDiscountOnShares", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "espr_ExclusiveDevelopmentalActivitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to exclusive developmental activities.", "label": "Exclusive Developmental Activities [Member]", "terseLabel": "Exclusive Developmental Activities" } } }, "localname": "ExclusiveDevelopmentalActivitiesMember", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails" ], "xbrltype": "domainItemType" }, "espr_FairValueMeasurementAssetTransfersBetweenLevels": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the transfer of assets between the levels of fair value hierarchy that have taken place during the period.", "label": "Fair Value Measurement Asset Transfers between Levels", "terseLabel": "Transfer of assets between levels" } } }, "localname": "FairValueMeasurementAssetTransfersBetweenLevels", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "espr_FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of potential future payment which becomes due with the achievement of the primary MACE in the CLEAR Outcomes study and the CV risk reduction rate on the U.S. label, depending on the range of relative risk reduction in the CLEAR Outcomes study.", "label": "Future Payment Milestone, Achievement of Drug Trial Outcomes Studies", "terseLabel": "Milestone payment, achievement of the primary MACE in the CLEAR Outcomes study and CV risk reduction rate on the U.S. label" } } }, "localname": "FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails" ], "xbrltype": "monetaryItemType" }, "espr_FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of a potential future payment which becomes due with the first National Health Insurance price listing for NEXLETOL in the Otsuka Territory.", "label": "Future Payment Milestone, First National Health Insurance Price Listing, Otsuka Territory", "terseLabel": "Milestone payment, first NHI Price Listing for NEXLETOL in the Otsuka Territory" } } }, "localname": "FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails" ], "xbrltype": "monetaryItemType" }, "espr_FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of a potential future payment which becomes due with the submission of a Japanese New Drug Application (JNDA). in the Otsuka Territory.", "label": "Future Payment Milestone, First Submission of Japanese New Drug Application, Otsuka Territory", "terseLabel": "Milestone payment, first JNDA submissions" } } }, "localname": "FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails" ], "xbrltype": "monetaryItemType" }, "espr_FuturePaymentMilestoneSalesMilestones": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of potential future payments related to total net sales achievements for Otsuka in Japan.", "label": "Future Payment Milestone, Sales Milestones", "terseLabel": "Milestone payments related to total net sales achievements" } } }, "localname": "FuturePaymentMilestoneSalesMilestones", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails" ], "xbrltype": "monetaryItemType" }, "espr_FutureUpFrontPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Future Up-Front Payment", "label": "Future Up-Front Payment", "terseLabel": "Consideration cash payment" } } }, "localname": "FutureUpFrontPayment", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails" ], "xbrltype": "monetaryItemType" }, "espr_GrossProceedsFromRevenueInterestPurchaseAgreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a revenue interest purchase agreement.", "label": "Gross Proceeds from Revenue Interest Purchase Agreement", "terseLabel": "Gross proceeds from revenue interest liability" } } }, "localname": "GrossProceedsFromRevenueInterestPurchaseAgreement", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "espr_HypotheticalRepaymentObligationBasedOnSalesGenerated": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Hypothetical Repayment Obligation Based On Sales Generated", "label": "Hypothetical Repayment Obligation Based On Sales Generated", "terseLabel": "Hypothetical repayment obligation" } } }, "localname": "HypotheticalRepaymentObligationBasedOnSalesGenerated", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "espr_HypotheticalSalesGeneratedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Hypothetical Sales Generated Amount", "label": "Hypothetical Sales Generated Amount", "terseLabel": "Hypothetical sales generated amount" } } }, "localname": "HypotheticalSalesGeneratedAmount", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "espr_LiabilityFromSaleOfFutureRevenuesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Liability from Sale of Future Revenues [Line Items]", "terseLabel": "Liability Related to the Revenue Interest Purchase Agreement" } } }, "localname": "LiabilityFromSaleOfFutureRevenuesLineItems", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails", "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails" ], "xbrltype": "stringItemType" }, "espr_LiabilityFromSaleOfFutureRevenuesRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Liability From Sale Of Future Revenues", "label": "Liability From Sale Of Future Revenues [Roll Forward]", "terseLabel": "Liability From Sale Of Future Revenues [Roll Forward]" } } }, "localname": "LiabilityFromSaleOfFutureRevenuesRollForward", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails" ], "xbrltype": "stringItemType" }, "espr_LiabilityFromSaleOfFutureRevenuesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about liabilities from the sale of future royalty revenues.", "label": "Liability from Sale of Future Revenues [Table]", "terseLabel": "Liability from Sale of Future Revenues [Table]" } } }, "localname": "LiabilityFromSaleOfFutureRevenuesTable", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails", "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails" ], "xbrltype": "stringItemType" }, "espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition.", "label": "Liability Related to the Revenue Interest Purchase Agreement", "terseLabel": "Liability Related to the Revenue Interest Purchase Agreement" } } }, "localname": "LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract", "nsuri": "http://www.esperion.com/20220930", "xbrltype": "stringItemType" }, "espr_LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of liabilities related to the Revenue Interest Purchase Agreement entered into by the Company with Eiger III SA LLC (\"Oberland\").", "label": "Liability Related to The Revenue Interest Purchase Agreement [Text Block]", "terseLabel": "Liability Related to the Revenue Interest Purchase Agreement" } } }, "localname": "LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreement" ], "xbrltype": "textBlockItemType" }, "espr_MilestoneAmountForWorldwideSalesToReceiveThirdPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Milestone amount for worldwide sales to receive the Third Payment.", "label": "Milestone Amount for Worldwide Sales to Receive Third Payment", "terseLabel": "Milestone amount for worldwide sales to receive the third payment" } } }, "localname": "MilestoneAmountForWorldwideSalesToReceiveThirdPayment", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The minimum amount of annual net sales to qualify for reduced revenue interest rate by December 31, 2021.", "label": "Minimum Amount of Annual Net Sales To Qualify for Reduced Revenue Interest Rate", "terseLabel": "Minimum amount of annual net sales to qualify for reduced revenue interest rate by December 31, 2021" } } }, "localname": "MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum Amount of Annual Net Sales To Qualify for Reduced Revenue Interest Rate, Contingent Threshold", "label": "Minimum Amount of Annual Net Sales To Qualify for Reduced Revenue Interest Rate, Contingent Threshold", "terseLabel": "Minimum amount of annual net sales to qualify for reduced revenue interest rate by December 31, 2024, contingent on 100% invested capital received" } } }, "localname": "MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "espr_NetSalesThresholdAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net Sales Threshold", "label": "Net Sales Threshold [Axis]", "terseLabel": "Net Sales Threshold [Axis]" } } }, "localname": "NetSalesThresholdAxis", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" ], "xbrltype": "stringItemType" }, "espr_NetSalesThresholdDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net Sales Threshold", "label": "Net Sales Threshold [Domain]", "terseLabel": "Net Sales Threshold [Domain]" } } }, "localname": "NetSalesThresholdDomain", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" ], "xbrltype": "domainItemType" }, "espr_NetSalesThresholdOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net Sales Threshold One", "label": "Net Sales Threshold One [Member]", "terseLabel": "Net Sales Less Than $250 Million" } } }, "localname": "NetSalesThresholdOneMember", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" ], "xbrltype": "domainItemType" }, "espr_NetSalesThresholdThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net Sales Threshold Three", "label": "Net Sales Threshold Three [Member]", "terseLabel": "Net Sales Greater Than $350 Million" } } }, "localname": "NetSalesThresholdThreeMember", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" ], "xbrltype": "domainItemType" }, "espr_NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net Sales Threshold To Include Worldwide Sales In Covered Territory", "label": "Net Sales Threshold To Include Worldwide Sales In Covered Territory", "terseLabel": "Maximum amount of US net sales to qualify for the Covered Territory expansion to include worldwide sales by December 31, 2021" } } }, "localname": "NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "espr_NetSalesThresholdTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net Sales Threshold Two", "label": "Net Sales Threshold Two [Member]", "terseLabel": "Net Sales Greater Than $250 Million But Less Than $350 Million" } } }, "localname": "NetSalesThresholdTwoMember", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" ], "xbrltype": "domainItemType" }, "espr_NonCashInterestExpenseRelatedToRevenueInterestLiability": { "auth_ref": [], "calculation": { "http://www.esperion.com/role/CondensedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of non-cash expense included in interest expense associated with the revenue interest liability.", "label": "Non Cash Interest Expense Related to Revenue Interest Liability", "terseLabel": "Non-cash interest expense related to the revenue interest liability" } } }, "localname": "NonCashInterestExpenseRelatedToRevenueInterestLiability", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "espr_NonCashRightOfUseAsset": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the difference between the lease asset and the lease liability.", "label": "Non Cash Right Of Use Asset", "terseLabel": "Non cash right of use asset" } } }, "localname": "NonCashRightOfUseAsset", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "espr_NumberOfBusinessDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Business Days", "label": "Number Of Business Days", "terseLabel": "Number of business days" } } }, "localname": "NumberOfBusinessDays", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "integerItemType" }, "espr_NumberOfConsecutiveTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Consecutive Trading Days", "label": "Number Of Consecutive Trading Days", "terseLabel": "Number of consecutive trading days" } } }, "localname": "NumberOfConsecutiveTradingDays", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "integerItemType" }, "espr_NumberOfSourcesOfRevenue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Sources Of Revenue", "label": "Number Of Sources Of Revenue", "terseLabel": "Number of revenue sources" } } }, "localname": "NumberOfSourcesOfRevenue", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "integerItemType" }, "espr_OtsukaPharmaceuticalCoLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Otsuka Pharmaceutical Co, Ltd.", "label": "Otsuka Pharmaceutical Co Ltd [Member]", "terseLabel": "Otsuka Pharmaceutical Co, Ltd." } } }, "localname": "OtsukaPharmaceuticalCoLtdMember", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails" ], "xbrltype": "domainItemType" }, "espr_PaymentsFromRevenueInterestPurchaseAgreement": { "auth_ref": [], "calculation": { "http://www.esperion.com/role/CondensedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow from a revenue interest purchase agreement.", "label": "Payments From Revenue Interest Purchase Agreement", "negatedLabel": "Payments on revenue interest liability", "negatedTerseLabel": "Revenue Interests payments" } } }, "localname": "PaymentsFromRevenueInterestPurchaseAgreement", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofCashFlows", "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "espr_PercentageOfCumulativePurchaserPaymentsGuarantee": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage Of Cumulative Purchaser Payments, Guarantee", "label": "Percentage Of Cumulative Purchaser Payments, Guarantee", "terseLabel": "Percentage of cumulative purchaser payments" } } }, "localname": "PercentageOfCumulativePurchaserPaymentsGuarantee", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" ], "xbrltype": "percentItemType" }, "espr_PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of increase in the Royalty Rate upon drawdown of the Third Payment.", "label": "Percentage of Increase in Royalty Rate Upon Drawdown of Third Payment", "terseLabel": "Percentage of increase in royalty rate upon drawdown of third payment" } } }, "localname": "PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" ], "xbrltype": "percentItemType" }, "espr_PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of invested capital received by December 31, 2024, to qualify for second reduced revenue interest rate.", "label": "Percentage of Invested Capital Received By December 31, 2024, To Qualify For Second Reduced Revenue Interest Rate", "terseLabel": "Percentage of invested capital received by December 31, 2024, to qualify for second reduced revenue interest rate" } } }, "localname": "PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" ], "xbrltype": "percentItemType" }, "espr_PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage Of Revenue Interest Payments Received By December 31, 2024, To Qualify For Third Payment Applicable Percentage", "label": "Percentage Of Revenue Interest Payments Received By December 31, 2024, To Qualify For Third Payment Applicable Percentage", "terseLabel": "Percentage of revenue interest payments to qualify for third payment applicable percentage" } } }, "localname": "PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" ], "xbrltype": "percentItemType" }, "espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of revenue interests payment on which agreement terminates.", "label": "Percentage Of Revenue Interests Payment on Which Agreement Terminates", "terseLabel": "Percentage of revenue interests payment on which agreement terminates" } } }, "localname": "PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" ], "xbrltype": "percentItemType" }, "espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of revenue interests payment on which agreement terminates, after the third anniversary of the closing date, if put option is exercised.", "label": "Percentage Of Revenue Interests Payment on Which Agreement Terminates After the Third Anniversary Of Closing Date If Put Option Is Exercised", "terseLabel": "Percentage of revenue interests payment on which agreement terminates, after the third anniversary of the closing date, if put option is exercised" } } }, "localname": "PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" ], "xbrltype": "percentItemType" }, "espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesIfPriorToAnniversaryOfClosingDateIfPutOptionIsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of revenue interests payment on which agreement terminates, if prior to the anniversary of the closing date, if put option is exercised.", "label": "Percentage Of Revenue Interests Payment on Which Agreement Terminates If Prior to the Anniversary Of Closing Date If Put Option Is Exercised", "terseLabel": "Percentage of revenue interests payment on which agreement terminates, if prior to the anniversary of the closing date, if put option is exercised" } } }, "localname": "PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesIfPriorToAnniversaryOfClosingDateIfPutOptionIsExercised", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" ], "xbrltype": "percentItemType" }, "espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of revenue interests payment on which agreement terminates, prior to the third anniversary of the closing date, if put option is exercised.", "label": "Percentage Of Revenue Interests Payment on Which Agreement Terminates Prior to the Third Anniversary Of Closing Date If Put Option Is Exercised", "terseLabel": "Percentage of revenue interests payment on which agreement terminates, prior to the third anniversary of the closing date, if put option is exercised" } } }, "localname": "PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" ], "xbrltype": "percentItemType" }, "espr_PercentageOfRoyaltiesToBeReceivedOnNetSales": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of royalties to be received on net sales.", "label": "Percentage of Royalties to be Received on Net Sales", "terseLabel": "Percentage of royalties to be received on the net sales" } } }, "localname": "PercentageOfRoyaltiesToBeReceivedOnNetSales", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails" ], "xbrltype": "percentItemType" }, "espr_PrepaidClinicalDevelopmentCostsCurrent": { "auth_ref": [], "calculation": { "http://www.esperion.com/role/CondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of consideration paid in advance for clinical development that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Clinical Development Costs, Current", "terseLabel": "Prepaid clinical development costs" } } }, "localname": "PrepaidClinicalDevelopmentCostsCurrent", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "espr_ProceedsFromRevenueInterestPurchaseAgreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from Revenue Interest Purchase Agreement", "label": "Proceeds from Revenue Interest Purchase Agreement", "terseLabel": "Proceeds from Revenue Interest Purchase Agreement" } } }, "localname": "ProceedsFromRevenueInterestPurchaseAgreement", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "espr_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts": { "auth_ref": [], "calculation": { "http://www.esperion.com/role/CondensedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a revenue interest purchase agreement, net of issuance costs.", "label": "Proceeds from Revenue Interest Purchase Agreement, Net of Issuance Costs", "terseLabel": "Proceeds from revenue interest liability, net of issuance costs" } } }, "localname": "ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "espr_RIPAAmendmentToTheSecurityAgreementAndWaiverMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RIPA Amendment To The Security Agreement And Waiver", "label": "RIPA Amendment To The Security Agreement And Waiver [Member]", "terseLabel": "RIPA Amendment To The Security Agreement And Waiver" } } }, "localname": "RIPAAmendmentToTheSecurityAgreementAndWaiverMember", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" ], "xbrltype": "domainItemType" }, "espr_RevenueInterestLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the current and non-current portion of the Revenue Interest Liability.", "label": "Revenue Interest Liability", "periodEndLabel": "Revenue interest liability, ending balance", "periodStartLabel": "Revenue interest liability, beginning balance", "terseLabel": "Revenue interest liability" } } }, "localname": "RevenueInterestLiability", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails", "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "espr_RevenueInterestLiabilityCurrent": { "auth_ref": [], "calculation": { "http://www.esperion.com/role/CondensedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Liability related to Revenue Interest Purchase Agreement (\"RIPA\"), classified as current.", "label": "Revenue Interest Liability, Current", "verboseLabel": "Revenue interest liability" } } }, "localname": "RevenueInterestLiabilityCurrent", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "espr_RevenueInterestLiabilityIncreaseForInterestExpenseRecognized": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of increase in the revenue interest liability attributable to interest expense recognized during the period.", "label": "Revenue Interest Liability, Increase for Interest Expense Recognized", "terseLabel": "Interest expense recognized" } } }, "localname": "RevenueInterestLiabilityIncreaseForInterestExpenseRecognized", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "espr_RevenueInterestLiabilityNoncurrent": { "auth_ref": [], "calculation": { "http://www.esperion.com/role/CondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Liability related to Revenue Interest Purchase Agreement (\"RIPA\"), classified as noncurrent.", "label": "Revenue Interest Liability, NonCurrent", "terseLabel": "Revenue interest liability" } } }, "localname": "RevenueInterestLiabilityNoncurrent", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "espr_RevenueInterestPurchaseAgreementAmendmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue Interest Purchase Agreement Amendment", "label": "Revenue Interest Purchase Agreement Amendment [Member]", "terseLabel": "RIPA Amendment" } } }, "localname": "RevenueInterestPurchaseAgreementAmendmentMember", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" ], "xbrltype": "domainItemType" }, "espr_RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of effective annual imputed interest rate under the revenue interest purchase agreement.", "label": "Revenue Interest Purchase Agreement, Effective Annual Imputed Interest Rate", "terseLabel": "Effective annual imputed interest rate (as a percent)" } } }, "localname": "RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" ], "xbrltype": "percentItemType" }, "espr_RevenueInterestPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to revenue interest purchase agreement (\"RIPA\").", "label": "Revenue Interest Purchase Agreement [Member]", "terseLabel": "Revenue Interest Purchase Agreement (RIPA)" } } }, "localname": "RevenueInterestPurchaseAgreementMember", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails", "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails" ], "xbrltype": "domainItemType" }, "espr_RevenueInterestRateInitialRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The initial revenue interest rate, as a percentage of the Company's net sales in the Covered Territory.", "label": "Revenue Interest Rate, Initial Rate", "terseLabel": "Initial revenue interest rate" } } }, "localname": "RevenueInterestRateInitialRate", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" ], "xbrltype": "percentItemType" }, "espr_RevenueInterestRateTierThree": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The Revenue Interest Rate which will take effect if annual net sales equals or exceeds the Sales Threshold and if the Purchasers receive 100% of their invested capital by December 31, 2024.", "label": "Revenue Interest Rate, Tier Three", "terseLabel": "Revenue interest rate if annual net sales equal or exceed the Sales Threshold and if the Purchasers receive 100% of their invested capital by December 31, 2024" } } }, "localname": "RevenueInterestRateTierThree", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" ], "xbrltype": "percentItemType" }, "espr_RevenueInterestRateTierTwo": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The Revenue Interest Rate which will take effect if annual net sales equal or exceed $350.0 million by December 31, 2021.", "label": "Revenue Interest Rate, Tier Two", "terseLabel": "Revenue interest rate which will take effect if annual net sales equals or exceeds the sales threshold by December 31, 2021" } } }, "localname": "RevenueInterestRateTierTwo", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" ], "xbrltype": "percentItemType" }, "espr_RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue Interest, Repayment Obligation Amount Expected In Next Twelve Months", "label": "Revenue Interest, Repayment Obligation Amount Expected In Next Twelve Months", "terseLabel": "Repayment amount expected to pay in next twelve months" } } }, "localname": "RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "espr_RoyaltyRevenueAndProductSalesBulkTabletsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Revenue And Product Sales Bulk Tablets", "label": "Royalty Revenue And Product Sales Bulk Tablets [Member]", "terseLabel": "Royalty revenue and product sales bulk tablets" } } }, "localname": "RoyaltyRevenueAndProductSalesBulkTabletsMember", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails" ], "xbrltype": "domainItemType" }, "espr_SaleOfStockAuthorizedAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sale Of Stock, Authorized Amount", "label": "Sale Of Stock, Authorized Amount", "terseLabel": "Aggregate offering price shares" } } }, "localname": "SaleOfStockAuthorizedAmount", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/StockholdersDeficitDetails" ], "xbrltype": "monetaryItemType" }, "espr_ScheduleOfRevenueInterestLiabilityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to the revenue interest liability.", "label": "Schedule of Revenue Interest Liability [Table Text Block]", "terseLabel": "Summary of Revenue Interest Liability Activity During the Period" } } }, "localname": "ScheduleOfRevenueInterestLiabilityTableTextBlock", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementTables" ], "xbrltype": "textBlockItemType" }, "espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement by Share Based Payment Award Aggregate Intrinsic Value [Abstract]", "terseLabel": "Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/StockCompensationPBSOsDetails", "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails" ], "xbrltype": "stringItemType" }, "espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]", "terseLabel": "Weighted-Average Remaining Contractual Term (Years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/StockCompensationPBSOsDetails", "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails" ], "xbrltype": "stringItemType" }, "espr_ShareBasedPaymentArrangementOptionPerformanceBasedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Payment Arrangement, Option, Performance Based", "label": "Share Based Payment Arrangement, Option, Performance Based [Member]", "terseLabel": "PBSOs", "verboseLabel": "Common shares under PBSOs" } } }, "localname": "ShareBasedPaymentArrangementOptionPerformanceBasedMember", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/NetLossPerCommonShareDetails", "http://www.esperion.com/role/StockCompensationPBSOsDetails", "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "espr_SignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Significant Accounting Policies [Line Items]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesLineItems", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "espr_SignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about significant accounting policies.", "label": "Significant Accounting Policies [Table]", "terseLabel": "Significant Accounting Policies [Table]" } } }, "localname": "SignificantAccountingPoliciesTable", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "espr_SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum Amount of Net Revenue To Qualify For Deposit In Blocked Account", "label": "Specified Net Revenue Threshold Triggering Deposit In Blocked Account", "terseLabel": "Specified net revenue" } } }, "localname": "SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "espr_StockOptionAndIncentivePlan2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Option And Incentive Plan 2022", "label": "Stock Option And Incentive Plan 2022 [Member]", "terseLabel": "Stock Option And Incentive Plan 2022" } } }, "localname": "StockOptionAndIncentivePlan2022Member", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "espr_UnamortizedTransactionCostsOnRevenueInterestAgreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction costs on revenue interest agreement.", "label": "Unamortized Transaction Costs on Revenue Interest Agreement", "terseLabel": "Capitalized issuance costs" } } }, "localname": "UnamortizedTransactionCostsOnRevenueInterestAgreement", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "espr_UnvestedRestrictedStockAndRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to unvested restricted stock and restricted stock units.", "label": "Unvested Restricted Stock And Restricted Stock Units [Member]", "terseLabel": "Unvested RSUs" } } }, "localname": "UnvestedRestrictedStockAndRestrictedStockUnitsMember", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "domainItemType" }, "espr_UpFrontPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of up-front payment received (paid) .", "label": "Up-Front Payment", "terseLabel": "Upfront cash payment received (paid)" } } }, "localname": "UpFrontPayment", "nsuri": "http://www.esperion.com/20220930", "presentation": [ "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails" ], "xbrltype": "monetaryItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r49", "r51", "r106", "r107", "r256", "r294" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails", "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails", "http://www.esperion.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember": { "auth_ref": [ "r2", "r113", "r120", "r200", "r378", "r379", "r380", "r389", "r390", "r420", "r425", "r426", "r471" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjusted Balance [Member]", "terseLabel": "Cumulative Effect, Period of Adoption, Adjusted Balance" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r2", "r113", "r120", "r126", "r200", "r378", "r379", "r380", "r389", "r390", "r420", "r423", "r425", "r426", "r471" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit", "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r2", "r113", "r120", "r126", "r200", "r378", "r379", "r380", "r389", "r390", "r420", "r423", "r425", "r426", "r471" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit", "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r2", "r113", "r120", "r126", "r200", "r378", "r379", "r380", "r389", "r390", "r420", "r423", "r425", "r426", "r471" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit", "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r230", "r232", "r233", "r234", "r255", "r293", "r333", "r334", "r483", "r484", "r485", "r486", "r487", "r488", "r507", "r550", "r552", "r575", "r576" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails", "http://www.esperion.com/role/InvestmentsNarrativeDetails", "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r230", "r232", "r233", "r234", "r255", "r293", "r333", "r334", "r483", "r484", "r485", "r486", "r487", "r488", "r507", "r550", "r552", "r575", "r576" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r175", "r232", "r233", "r321", "r323", "r510", "r549", "r551" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails", "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss", "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r175", "r232", "r233", "r321", "r323", "r510", "r549", "r551" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails", "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss", "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r222", "r230", "r232", "r233", "r234", "r255", "r293", "r324", "r333", "r334", "r366", "r367", "r368", "r483", "r484", "r485", "r486", "r487", "r488", "r507", "r550", "r552", "r575", "r576" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails", "http://www.esperion.com/role/InvestmentsNarrativeDetails", "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r222", "r230", "r232", "r233", "r234", "r255", "r293", "r324", "r333", "r334", "r366", "r367", "r368", "r483", "r484", "r485", "r486", "r487", "r488", "r507", "r550", "r552", "r575", "r576" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails", "http://www.esperion.com/role/InvestmentsNarrativeDetails", "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r50", "r51", "r106", "r107", "r256", "r294" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails", "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails", "http://www.esperion.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdateExtensibleList": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r114", "r115", "r116", "r117", "r181", "r182", "r197", "r198", "r199", "r200", "r201", "r202", "r378", "r379", "r380", "r389", "r390", "r398", "r399", "r400", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r455", "r456", "r463", "r464", "r465", "r468", "r469", "r470", "r471", "r472", "r473", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564" ], "lang": { "en-us": { "role": { "documentation": "Indicates amendment to accounting standards.", "label": "Accounting Standards Update [Extensible Enumeration]", "terseLabel": "Accounting Standards Update [Extensible Enumeration]" } } }, "localname": "AccountingStandardsUpdateExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r37", "r476" ], "calculation": { "http://www.esperion.com/role/CondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r178", "r179" ], "calculation": { "http://www.esperion.com/role/CondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r88" ], "calculation": { "http://www.esperion.com/role/CondensedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedLabel": "Amortization of premiums and discounts on investments" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofCashFlows", "http://www.esperion.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedInvestmentIncomeReceivable": { "auth_ref": [ "r21", "r513", "r542" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest, dividends, rents, ancillary and other revenues earned but not yet received by the entity on its investments.", "label": "Accrued Investment Income Receivable", "terseLabel": "Accrued interest receivable" } } }, "localname": "AccruedInvestmentIncomeReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://www.esperion.com/role/OtherAccruedLiabilitiesDetails": { "order": 3.0, "parentTag": "espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/OtherAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r24", "r53", "r54", "r55", "r539", "r560", "r564" ], "calculation": { "http://www.esperion.com/role/CondensedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r52", "r55", "r62", "r63", "r64", "r110", "r111", "r112", "r410", "r473", "r555", "r556" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r22", "r476" ], "calculation": { "http://www.esperion.com/role/CondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "negatedTerseLabel": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedBalanceSheets", "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r110", "r111", "r112", "r378", "r379", "r380", "r425" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit", "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r336", "r381", "r382" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r251", "r307", "r313" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "terseLabel": "Fair value of warrants" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockholdersDeficitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r370" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r69", "r87", "r275", "r460" ], "calculation": { "http://www.esperion.com/role/CondensedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of debt issuance costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r136" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Total potential dilutive shares (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r136" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Net (Loss) Income Per Common Share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r136" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails", "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails", "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails", "http://www.esperion.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r14", "r102", "r164", "r167", "r173", "r196", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r407", "r411", "r439", "r474", "r476", "r514", "r536" ], "calculation": { "http://www.esperion.com/role/CondensedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r9", "r36", "r102", "r196", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r407", "r411", "r439", "r474", "r476" ], "calculation": { "http://www.esperion.com/role/CondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r429" ], "calculation": { "http://www.esperion.com/role/FairValueMeasurementsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets at fair value" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r188" ], "calculation": { "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandShortTermInvestmentsDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandShortTermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r189" ], "calculation": { "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandShortTermInvestmentsDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedTerseLabel": "Gross Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandShortTermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r185", "r208" ], "calculation": { "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandShortTermInvestmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandShortTermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r183", "r186", "r208", "r520" ], "calculation": { "http://www.esperion.com/role/FairValueMeasurementsDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 }, "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandShortTermInvestmentsDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale", "verboseLabel": "Short-term investments:" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/FairValueMeasurementsDetails", "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandShortTermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r340", "r341", "r342", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r353", "r354", "r355", "r356", "r357", "r358", "r360", "r361", "r363", "r364", "r365", "r366", "r367", "r368", "r369" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/NetLossPerCommonShareDetails", "http://www.esperion.com/role/StockCompensationPBRSUsDetails", "http://www.esperion.com/role/StockCompensationPBSOsDetails", "http://www.esperion.com/role/StockCompensationRSUsDetails", "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails", "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandShortTermInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r413", "r414" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails", "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r6", "r109", "r158" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]", "terseLabel": "The Company and Basis of Presentation" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/TheCompanyandBasisofPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r7", "r12", "r89" ], "calculation": { "http://www.esperion.com/role/CondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.esperion.com/role/StatementsofCashFlowsandRestrictedCashDetails": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedBalanceSheets", "http://www.esperion.com/role/StatementsofCashFlowsandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.", "label": "Cash and Cash Equivalents Disclosure [Text Block]", "terseLabel": "Statements of Cash Flows and Restricted Cash" } } }, "localname": "CashAndCashEquivalentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StatementsofCashFlowsandRestrictedCash" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.esperion.com/role/FairValueMeasurementsDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash and cash equivalents:" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r90" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r90", "r512" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Restricted Cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r84", "r89", "r93" ], "calculation": { "http://www.esperion.com/role/StatementsofCashFlowsandRestrictedCashDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period", "totalLabel": "Total cash and cash equivalents and restricted cash shown on the condensed statements of cash flows" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofCashFlows", "http://www.esperion.com/role/StatementsofCashFlowsandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]", "terseLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r84", "r448" ], "calculation": { "http://www.esperion.com/role/CondensedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net decrease in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsMember": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Equivalents [Member]", "terseLabel": "Cash Equivalents and Restricted Cash" } } }, "localname": "CashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CertificatesOfDepositMember": { "auth_ref": [ "r530" ], "lang": { "en-us": { "role": { "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.", "label": "Certificates of Deposit [Member]", "terseLabel": "Certificates of deposit" } } }, "localname": "CertificatesOfDepositMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/FairValueMeasurementsDetails", "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r18", "r19", "r20", "r99", "r102", "r129", "r130", "r131", "r133", "r135", "r144", "r145", "r146", "r196", "r239", "r243", "r244", "r245", "r248", "r249", "r291", "r292", "r296", "r300", "r307", "r439", "r582" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r316", "r338" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]", "terseLabel": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]", "terseLabel": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r308" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails", "http://www.esperion.com/role/StockholdersDeficitDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r308" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Warrants issued for shares of common stock (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockholdersDeficitDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Total shares of common stock from exercisable warrants outstanding" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockholdersDeficitDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r401", "r402", "r404" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Collaborations with Third Parties" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CollaborationswithThirdParties" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementMember": { "auth_ref": [ "r403" ], "lang": { "en-us": { "role": { "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.", "label": "Collaborative Arrangement [Member]", "terseLabel": "License and Collaboration Agreement" } } }, "localname": "CollaborativeArrangementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaborations with Third Parties" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r45", "r521", "r544" ], "calculation": { "http://www.esperion.com/role/CondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 5)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r224", "r225", "r226", "r235", "r574" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Common Class A [Member]", "terseLabel": "Common stock" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Shares reserved for future issuance (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r110", "r111", "r425" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common\u00a0Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedBalanceSheetsParenthetical", "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r20", "r476" ], "calculation": { "http://www.esperion.com/role/CondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock, $0.001 par value; 240,000,000 shares authorized as of September\u00a030, 2022 and 120,000,000 shares authorized as of December\u00a031, 2021; 73,739,320 shares issued at September\u00a030, 2022 and 62,873,694 shares issued at December\u00a031, 2021" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r58", "r60", "r61", "r67", "r523", "r546" ], "calculation": { "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r153", "r154", "r177", "r437", "r438", "r573" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r153", "r154", "r177", "r437", "r438", "r566", "r573" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r153", "r154", "r177", "r437", "r438", "r566", "r573" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r149", "r533" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r153", "r154", "r177", "r437", "r438", "r573" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r318", "r319", "r322" ], "calculation": { "http://www.esperion.com/role/CondensedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred revenue from collaborations" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r318", "r319", "r322" ], "calculation": { "http://www.esperion.com/role/CondensedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Deferred revenue from collaborations" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r250", "r252", "r253", "r255", "r265", "r266", "r267", "r271", "r272", "r273", "r274", "r275", "r285", "r286", "r287", "r288" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]", "terseLabel": "Convertible Debt" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleDebtSecuritiesMember": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.", "label": "Convertible Debt Securities [Member]", "terseLabel": "Shares issuable upon conversion of convertible notes" } } }, "localname": "ConvertibleDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleLongTermNotesPayable": { "auth_ref": [ "r44" ], "calculation": { "http://www.esperion.com/role/CondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible Notes Payable, Noncurrent", "terseLabel": "Convertible notes, net of issuance costs" } } }, "localname": "ConvertibleLongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r152", "r177" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r91", "r92" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Converted Instrument, Amount", "terseLabel": "Exchange Agreement, amount of principal amount converted into common stock" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r91", "r92" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Debt Conversion, Converted Instrument, Shares Issued", "terseLabel": "Common stock being exchanged (in shares)" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r98", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r269", "r276", "r277", "r279", "r290" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Convertible Notes" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/ConvertibleNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r15", "r16", "r17", "r101", "r108", "r252", "r253", "r254", "r255", "r256", "r257", "r259", "r265", "r266", "r267", "r268", "r270", "r271", "r272", "r273", "r274", "r275", "r285", "r286", "r287", "r288", "r461", "r515", "r516", "r534" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r17", "r281", "r516", "r534" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-Term Debt, Gross", "terseLabel": "Principal amount of convertible notes" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": { "auth_ref": [ "r280" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.", "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component", "terseLabel": "Debt instrument, convertible, carrying amount of equity component" } } }, "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r254", "r283" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Debt instrument, convertible, conversion price (in dollars per share)" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "auth_ref": [ "r43", "r254", "r308", "r309", "r311" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.", "label": "Debt Instrument, Convertible, Conversion Ratio", "terseLabel": "Debt instrument, convertible, conversion ratio" } } }, "localname": "DebtInstrumentConvertibleConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "pureItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.", "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days", "terseLabel": "Average trading-day period" } } }, "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.", "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger", "terseLabel": "Debt instrument, convertible, threshold percentage of stock price trigger" } } }, "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.", "label": "Debt Instrument, Convertible, Threshold Trading Days", "terseLabel": "Debt instrument, convertible, threshold trading days" } } }, "localname": "DebtInstrumentConvertibleThresholdTradingDays", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r252", "r285", "r286", "r459", "r461", "r462" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Debt instrument, face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r267", "r285", "r286", "r436" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Debt fair value" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r42", "r253" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt instrument, stated interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r44", "r101", "r108", "r252", "r253", "r254", "r255", "r256", "r257", "r259", "r265", "r266", "r267", "r268", "r270", "r271", "r272", "r273", "r274", "r275", "r285", "r286", "r287", "r288", "r461" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "Information about timing of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period [Axis]", "terseLabel": "Debt Instrument, Redemption, Period [Axis]" } } }, "localname": "DebtInstrumentRedemptionPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "Period as defined under terms of the debt agreement for debt redemption features.", "label": "Debt Instrument, Redemption, Period [Domain]", "terseLabel": "Debt Instrument, Redemption, Period [Domain]" } } }, "localname": "DebtInstrumentRedemptionPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodOneMember": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period One [Member]", "terseLabel": "Period One" } } }, "localname": "DebtInstrumentRedemptionPeriodOneMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period Two [Member]", "terseLabel": "Period Two" } } }, "localname": "DebtInstrumentRedemptionPeriodTwoMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.", "label": "Debt Instrument, Redemption Price, Percentage", "terseLabel": "Debt instrument, redemption price, percentage" } } }, "localname": "DebtInstrumentRedemptionPricePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r44", "r101", "r108", "r252", "r253", "r254", "r255", "r256", "r257", "r259", "r265", "r266", "r267", "r268", "r270", "r271", "r272", "r273", "r274", "r275", "r278", "r285", "r286", "r287", "r288", "r308", "r310", "r311", "r312", "r458", "r459", "r461", "r462", "r532" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Debt instrument, term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": { "auth_ref": [ "r187", "r208", "r211", "r212" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss", "terseLabel": "Allowance for credit loss" } } }, "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r192" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale [Table]", "terseLabel": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/InvestmentsNarrativeDetails", "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandShortTermInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredFinanceCostsGross": { "auth_ref": [ "r460" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Gross", "terseLabel": "Debt issuance costs" } } }, "localname": "DeferredFinanceCostsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r265", "r460" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "terseLabel": "Unamortized debt discount and issuance costs" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r87", "r219" ], "calculation": { "http://www.esperion.com/role/CondensedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r339", "r340", "r372", "r373", "r375", "r383" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Stock Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r68", "r118", "r119", "r120", "r121", "r122", "r127", "r129", "r133", "r134", "r135", "r139", "r140", "r426", "r427", "r524", "r547" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per common share - basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r68", "r118", "r119", "r120", "r121", "r122", "r129", "r133", "r134", "r135", "r139", "r140", "r426", "r427", "r524", "r547" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per common share - diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r136", "r137", "r138", "r141" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "verboseLabel": "Net Loss Per Common Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/NetLossPerCommonShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://www.esperion.com/role/OtherAccruedLiabilitiesDetails": { "order": 1.0, "parentTag": "espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/OtherAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": { "auth_ref": [ "r371" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost capitalized for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Amount Capitalized", "verboseLabel": "Stock-based compensation capitalized into inventory" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted-average period over which remaining unrecognized compensation cost will be recognized" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r374" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized stock-based compensation expense, RSUs" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r374" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized stock-based compensation expense, options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Shares issuable related to the ESPP", "verboseLabel": "ESPP" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/NetLossPerCommonShareDetails", "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "terseLabel": "Stock options", "verboseLabel": "Common shares under option" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/NetLossPerCommonShareDetails", "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r62", "r63", "r64", "r110", "r111", "r112", "r115", "r123", "r125", "r143", "r200", "r307", "r313", "r378", "r379", "r380", "r389", "r390", "r425", "r449", "r450", "r451", "r452", "r453", "r454", "r473", "r555", "r556", "r557" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair value measurements" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r429", "r430", "r434" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r267", "r285", "r286", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r430", "r480", "r481", "r482" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r429", "r430", "r431", "r432", "r435" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r267", "r325", "r326", "r331", "r332", "r430", "r480" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level\u00a01" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r267", "r285", "r286", "r325", "r326", "r331", "r332", "r430", "r481" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level\u00a02" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r267", "r285", "r286", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r430", "r482" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level\u00a03" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Fair Value, Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r267", "r285", "r286", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r480", "r481", "r482" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r433", "r435" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring fair value measurement" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r190", "r191", "r193", "r194", "r195", "r203", "r204", "r205", "r206", "r207", "r209", "r210", "r213", "r214", "r278", "r305", "r415", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r582", "r583", "r584", "r585", "r586", "r587", "r588" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/FairValueMeasurementsDetails", "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandShortTermInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GainLossRelatedToLitigationSettlement": { "auth_ref": [ "r227" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.", "label": "Gain (Loss) Related to Litigation Settlement", "negatedTerseLabel": "Loss related to litigation settlement" } } }, "localname": "GainLossRelatedToLitigationSettlement", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnRestructuringOfDebt": { "auth_ref": [ "r289" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete.", "label": "Gains (Losses) on Restructuring of Debt", "terseLabel": "Loss on modification of debt" } } }, "localname": "GainsLossesOnRestructuringOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r221", "r223" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/InvestmentsNarrativeDetails", "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/InvestmentsNarrativeDetails", "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r103", "r386", "r387", "r388", "r391", "r393", "r395", "r396", "r397" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r104", "r124", "r125", "r163", "r385", "r392", "r394", "r548" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r86" ], "calculation": { "http://www.esperion.com/role/CondensedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r86" ], "calculation": { "http://www.esperion.com/role/CondensedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r86", "r508" ], "calculation": { "http://www.esperion.com/role/CondensedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r86" ], "calculation": { "http://www.esperion.com/role/CondensedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "verboseLabel": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": { "auth_ref": [ "r86" ], "calculation": { "http://www.esperion.com/role/CondensedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.", "label": "Increase (Decrease) in Other Accrued Liabilities", "terseLabel": "Other accrued liabilities" } } }, "localname": "IncreaseDecreaseInOtherAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r86" ], "calculation": { "http://www.esperion.com/role/CondensedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaids and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_IntangibleAssetsNetIncludingGoodwill": { "auth_ref": [], "calculation": { "http://www.esperion.com/role/CondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.", "label": "Intangible Assets, Net (Including Goodwill)", "terseLabel": "Intangible assets" } } }, "localname": "IntangibleAssetsNetIncludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r65", "r162", "r457", "r460", "r525" ], "calculation": { "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss", "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r73", "r273", "r284", "r287", "r288" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "terseLabel": "Debt interest expense" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://www.esperion.com/role/OtherAccruedLiabilitiesDetails": { "order": 4.0, "parentTag": "espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest Payable, Current", "terseLabel": "Accrued interest on convertible notes" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/OtherAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]", "terseLabel": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r218" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventories, net" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/Inventoriesnet" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r28", "r217" ], "calculation": { "http://www.esperion.com/role/InventoriesnetDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/InventoriesnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r8", "r34", "r476" ], "calculation": { "http://www.esperion.com/role/CondensedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.esperion.com/role/InventoriesnetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories, net", "totalLabel": "Total Inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedBalanceSheets", "http://www.esperion.com/role/InventoriesnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r11", "r32", "r95", "r142", "r215", "r216", "r218", "r509" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r30", "r217" ], "calculation": { "http://www.esperion.com/role/InventoriesnetDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/InventoriesnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r29", "r217" ], "calculation": { "http://www.esperion.com/role/InventoriesnetDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/InventoriesnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r72", "r161" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest income on investments" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]", "terseLabel": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r192", "r511", "r528", "r571", "r589" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/Investments" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r38", "r102", "r168", "r196", "r239", "r240", "r241", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r408", "r411", "r412", "r439", "r474", "r475" ], "calculation": { "http://www.esperion.com/role/CondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r27", "r102", "r196", "r439", "r476", "r517", "r541" ], "calculation": { "http://www.esperion.com/role/CondensedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r10", "r41", "r102", "r196", "r239", "r240", "r241", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r408", "r411", "r412", "r439", "r474", "r475", "r476" ], "calculation": { "http://www.esperion.com/role/CondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount awarded to other party in judgment or settlement of litigation.", "label": "Litigation Settlement, Amount Awarded to Other Party", "terseLabel": "Payment to plaintiff" } } }, "localname": "LitigationSettlementAmountAwardedToOtherParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationStatusAxis": { "auth_ref": [ "r227" ], "lang": { "en-us": { "role": { "documentation": "Information by status of pending, threatened, or settled litigation.", "label": "Litigation Status [Axis]", "terseLabel": "Litigation Status [Axis]" } } }, "localname": "LitigationStatusAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationStatusDomain": { "auth_ref": [ "r227" ], "lang": { "en-us": { "role": { "documentation": "Status of pending, threatened, or settled litigation.", "label": "Litigation Status [Domain]", "terseLabel": "Litigation Status [Domain]" } } }, "localname": "LitigationStatusDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r17", "r266", "r282", "r285", "r286", "r516", "r537" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-Term Debt", "verboseLabel": "Long-term debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer.", "label": "Long-Term Debt [Member]", "terseLabel": "Long-term Debt" } } }, "localname": "LongTermDebtMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r44" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r44", "r238" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r227", "r229", "r230", "r231", "r232", "r236", "r237" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "auth_ref": [ "r227", "r228" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of loss contingency liability.", "label": "Loss Contingency Accrual", "terseLabel": "Litigation settlement" } } }, "localname": "LossContingencyAccrualAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyReceivable": { "auth_ref": [ "r237" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of receivable related to a loss contingency accrual. For example, an insurance recovery receivable.", "label": "Loss Contingency, Receivable", "terseLabel": "Insurance settlement recovery" } } }, "localname": "LossContingencyReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r527" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Securities, Policy [Policy Text Block]", "terseLabel": "Investments" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/FairValueMeasurementsDetails", "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r84" ], "calculation": { "http://www.esperion.com/role/CondensedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r84" ], "calculation": { "http://www.esperion.com/role/CondensedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r84", "r85", "r88" ], "calculation": { "http://www.esperion.com/role/CondensedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r5", "r56", "r59", "r64", "r66", "r88", "r102", "r114", "r118", "r119", "r120", "r121", "r124", "r125", "r132", "r164", "r166", "r169", "r172", "r174", "r196", "r239", "r240", "r241", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r427", "r439", "r522", "r545" ], "calculation": { "http://www.esperion.com/role/CondensedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofCashFlows", "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss", "http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "verboseLabel": "Recently Implemented Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r164", "r166", "r169", "r172", "r174" ], "calculation": { "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r467" ], "calculation": { "http://www.esperion.com/role/CondensedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r467" ], "calculation": { "http://www.esperion.com/role/CondensedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r466" ], "calculation": { "http://www.esperion.com/role/CondensedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right of use operating lease assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://www.esperion.com/role/OtherAccruedLiabilitiesDetails": { "order": 5.0, "parentTag": "espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "verboseLabel": "Accrued other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/OtherAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r405", "r406", "r409" ], "calculation": { "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Unrealized gain (loss) on investments" } } }, "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive loss:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r57", "r60", "r405", "r406", "r409" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other comprehensive loss" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCostAndExpenseOperating": { "auth_ref": [ "r70" ], "calculation": { "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.", "label": "Other Cost and Expense, Operating", "terseLabel": "Cost of goods sold" } } }, "localname": "OtherCostAndExpenseOperating", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r40" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other liabilities.", "label": "Other Liabilities Disclosure [Text Block]", "terseLabel": "Other Accrued Liabilities" } } }, "localname": "OtherLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/OtherAccruedLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r74" ], "calculation": { "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss", "http://www.esperion.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).", "label": "Other Nonoperating Income (Expense) [Member]", "terseLabel": "Other Nonoperating Income (Expense)" } } }, "localname": "OtherNonoperatingIncomeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/InvestmentsNarrativeDetails", "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]", "terseLabel": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForDerivativeInstrumentFinancingActivities": { "auth_ref": [ "r81", "r83" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments.", "label": "Payments for Derivative Instrument, Financing Activities", "terseLabel": "Purchase of capped call options associated with convertible notes" } } }, "localname": "PaymentsForDerivativeInstrumentFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r80" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "terseLabel": "Prepayment of forward stock repurchase transaction" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r82" ], "calculation": { "http://www.esperion.com/role/CondensedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "negatedTerseLabel": "Payment of issuance costs", "terseLabel": "Payment of issuance costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofCashFlows", "http://www.esperion.com/role/StockholdersDeficitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r77" ], "calculation": { "http://www.esperion.com/role/CondensedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "negatedLabel": "Purchases of investments" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PendingLitigationMember": { "auth_ref": [ "r227" ], "lang": { "en-us": { "role": { "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.", "label": "Pending Litigation [Member]", "terseLabel": "Pending Litigation" } } }, "localname": "PendingLitigationMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "PBRSUs", "verboseLabel": "Unvested PBRSUs" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/NetLossPerCommonShareDetails", "http://www.esperion.com/role/StockCompensationPBRSUsDetails", "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r340", "r341", "r342", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r353", "r354", "r355", "r356", "r357", "r358", "r360", "r361", "r363", "r364", "r365", "r366", "r367", "r368", "r369" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r340", "r341", "r342", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r353", "r354", "r355", "r356", "r357", "r358", "r360", "r361", "r363", "r364", "r365", "r366", "r367", "r368", "r369" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r19", "r291" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r19", "r291" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r19", "r476" ], "calculation": { "http://www.esperion.com/role/CondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.001 par value; 5,000,000 shares authorized and no shares issued or outstanding as of September\u00a030, 2022 and December 31, 2021" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r36" ], "calculation": { "http://www.esperion.com/role/CondensedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Other prepaid and current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": { "auth_ref": [ "r79" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.", "label": "Proceeds from Debt, Net of Issuance Costs", "terseLabel": "Proceeds from debt, net of issuance costs" } } }, "localname": "ProceedsFromDebtNetOfIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r78" ], "calculation": { "http://www.esperion.com/role/CondensedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": { "auth_ref": [ "r75", "r76", "r184" ], "calculation": { "http://www.esperion.com/role/CondensedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale", "terseLabel": "Proceeds from sales/maturities of investments" } } }, "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r78", "r377" ], "calculation": { "http://www.esperion.com/role/CondensedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of common stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product sales, net" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss", "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r220", "r476", "r529", "r543" ], "calculation": { "http://www.esperion.com/role/CondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "Item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "auth_ref": [ "r384" ], "calculation": { "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r12", "r93", "r512", "r538" ], "calculation": { "http://www.esperion.com/role/StatementsofCashFlowsandRestrictedCashDetails": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails", "http://www.esperion.com/role/StatementsofCashFlowsandRestrictedCashDetails", "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r13", "r93", "r572" ], "calculation": { "http://www.esperion.com/role/CondensedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "RSUs" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockCompensationRSUsDetails", "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r23", "r313", "r476", "r540", "r559", "r564" ], "calculation": { "http://www.esperion.com/role/CondensedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "negatedTerseLabel": "Accumulated Deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedBalanceSheets", "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r110", "r111", "r112", "r115", "r123", "r125", "r200", "r378", "r379", "r380", "r389", "r390", "r425", "r555", "r557" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r159", "r160", "r165", "r170", "r171", "r175", "r176", "r177", "r320", "r321", "r510" ], "calculation": { "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Total Revenues", "verboseLabel": "Collaboration revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails", "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss", "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r96", "r97" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Proceeds from stock offering, net" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockholdersDeficitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockholdersDeficitDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Issued stock (in shares)" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockholdersDeficitDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Other Accrued Liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/OtherAccruedLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r136" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r136" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Shares Excluded From Calculation of Diluted Net (Loss) Income Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/NetLossPerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-Sale [Line Items]", "terseLabel": "Investments" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/InvestmentsNarrativeDetails", "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandShortTermInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash and cash equivalents.", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of Cash and Cash Equivalents" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StatementsofCashFlowsandRestrictedCashTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r403" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r429", "r430" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of the Company's Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r11", "r31", "r32", "r33" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/InventoriesnetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": { "auth_ref": [ "r352" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units.", "label": "Schedule of Nonvested Performance-Based Units Activity [Table Text Block]", "terseLabel": "Summary of Activity Relating to the Company's PBRSU's" } } }, "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "auth_ref": [ "r93", "r512", "r538" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.", "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Restrictions on Cash and Cash Equivalents" } } }, "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StatementsofCashFlowsandRestrictedCashTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r335", "r337", "r340", "r341", "r342", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r353", "r354", "r355", "r356", "r357", "r358", "r360", "r361", "r363", "r364", "r365", "r366", "r367", "r368", "r369" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockCompensationPBRSUsDetails", "http://www.esperion.com/role/StockCompensationPBSOsDetails", "http://www.esperion.com/role/StockCompensationRSUsDetails", "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r343", "r359", "r362" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "verboseLabel": "Summary of Activity Relating to the Company's Options and Performance-Based Options to Purchase Common Stock" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Summary of Activity Relating to the Company's RSUs" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r71" ], "calculation": { "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r86" ], "calculation": { "http://www.esperion.com/role/CondensedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r358" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockCompensationPBRSUsDetails", "http://www.esperion.com/role/StockCompensationRSUsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r358" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockCompensationPBRSUsDetails", "http://www.esperion.com/role/StockCompensationRSUsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockCompensationPBRSUsDetails", "http://www.esperion.com/role/StockCompensationRSUsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockCompensationPBRSUsDetails", "http://www.esperion.com/role/StockCompensationRSUsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r353", "r354" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Outstanding and unvested at the ending of period (in shares)", "periodStartLabel": "Outstanding at the beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockCompensationPBRSUsDetails", "http://www.esperion.com/role/StockCompensationRSUsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Number of RSUs", "verboseLabel": "Number of PBRSUs" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockCompensationPBRSUsDetails", "http://www.esperion.com/role/StockCompensationRSUsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r353", "r354" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Outstanding and unvested at the at the end of the period (in dollars per share)", "periodStartLabel": "Outstanding and at the beginning of period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockCompensationPBRSUsDetails", "http://www.esperion.com/role/StockCompensationRSUsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted-Average Fair Value Per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockCompensationPBRSUsDetails", "http://www.esperion.com/role/StockCompensationRSUsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r357" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockCompensationRSUsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r357" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockCompensationRSUsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Stock compensation" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockCompensationPBRSUsDetails", "http://www.esperion.com/role/StockCompensationPBSOsDetails", "http://www.esperion.com/role/StockCompensationRSUsDetails", "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r342" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "terseLabel": "Number of commons stock shares available for issuance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "verboseLabel": "Exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockCompensationPBSOsDetails", "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockCompensationPBSOsDetails", "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r347" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "negatedLabel": "Forfeited or expired (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockCompensationPBSOsDetails", "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r347" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited or expired (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockCompensationPBSOsDetails", "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockCompensationPBSOsDetails", "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r376" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockCompensationPBSOsDetails", "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r344", "r345" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at the end of the period (in shares)", "periodStartLabel": "Outstanding at the beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockCompensationPBSOsDetails", "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockCompensationPBSOsDetails", "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r344", "r345" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding at the end of the period (in dollars per share)", "periodStartLabel": "Outstanding at the beginning of period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockCompensationPBSOsDetails", "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted-Average Exercise Price Per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockCompensationPBSOsDetails", "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r363" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockCompensationPBSOsDetails", "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Vested and expected to vest (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockCompensationPBSOsDetails", "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Vested and expected to vest (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockCompensationPBSOsDetails", "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period", "terseLabel": "Shares issued (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r340", "r341", "r342", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r353", "r354", "r355", "r356", "r357", "r358", "r360", "r361", "r363", "r364", "r365", "r366", "r367", "r368", "r369" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/NetLossPerCommonShareDetails", "http://www.esperion.com/role/StockCompensationPBRSUsDetails", "http://www.esperion.com/role/StockCompensationPBSOsDetails", "http://www.esperion.com/role/StockCompensationRSUsDetails", "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r349" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockCompensationPBSOsDetails", "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockCompensationPBSOsDetails", "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r376" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockCompensationPBSOsDetails", "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockCompensationPBSOsDetails", "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockCompensationPBSOsDetails", "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Vested and expected to vest" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockCompensationPBSOsDetails", "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r35", "r518", "r519", "r535" ], "calculation": { "http://www.esperion.com/role/CondensedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-Term Investments", "terseLabel": "Short-term investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermInvestmentsMember": { "auth_ref": [ "r567", "r568", "r569", "r570" ], "lang": { "en-us": { "role": { "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.", "label": "Short-Term Investments [Member]", "terseLabel": "Short-term Investments" } } }, "localname": "ShortTermInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r94", "r109" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r18", "r19", "r20", "r99", "r102", "r129", "r130", "r131", "r133", "r135", "r144", "r145", "r146", "r196", "r239", "r243", "r244", "r245", "r248", "r249", "r291", "r292", "r296", "r300", "r307", "r439", "r582" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r48", "r62", "r63", "r64", "r110", "r111", "r112", "r115", "r123", "r125", "r143", "r200", "r307", "r313", "r378", "r379", "r380", "r389", "r390", "r425", "r449", "r450", "r451", "r452", "r453", "r454", "r473", "r555", "r556", "r557" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss", "http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r110", "r111", "r112", "r143", "r510" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss", "http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r19", "r20", "r307", "r313" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Vesting of ESPP Shares (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r19", "r20", "r307", "r313" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock, net of issuance costs (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r307", "r313" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "terseLabel": "Vesting of restricted stock units (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r19", "r20", "r307", "r313", "r349" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised (in shares)", "verboseLabel": "Exercise of stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit", "http://www.esperion.com/role/StockCompensationPBSOsDetails", "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued": { "auth_ref": [ "r20", "r307", "r313" ], "lang": { "en-us": { "role": { "documentation": "Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.", "label": "Stock Issued During Period, Shares, Treasury Stock Reissued", "terseLabel": "Shares delivered to the company (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesTreasuryStockReissued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r19", "r20", "r307", "r313" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Vesting of ESPP Shares" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r19", "r20", "r307", "r313" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock from ATM program, net of issuance costs" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r48", "r307", "r313" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r20", "r25", "r26", "r102", "r180", "r196", "r439", "r476" ], "calculation": { "http://www.esperion.com/role/CondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders\u2019 deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedBalanceSheets", "http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r100", "r292", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r306", "r313", "r317", "r416" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "Stockholders' Deficit" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockholdersDeficit" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]", "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockholdersDeficitDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockholdersDeficitDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]", "terseLabel": "Subsidiary, Sale of Stock [Line Items]" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/StockholdersDeficitDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TradeAccountsReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business.", "label": "Trade Accounts Receivable [Member]", "terseLabel": "Trade Receivables" } } }, "localname": "TradeAccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r190", "r191", "r193", "r194", "r195", "r278", "r305", "r415", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r582", "r583", "r584", "r585", "r586", "r587", "r588" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/FairValueMeasurementsDetails", "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r47", "r314" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r47", "r314" ], "lang": { "en-us": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "terseLabel": "Treasury stock (in shares)" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r20", "r307", "r313" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "terseLabel": "Underlying common stock (in shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/ConvertibleNotesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r47", "r314", "r315" ], "calculation": { "http://www.esperion.com/role/CondensedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedTerseLabel": "Treasury stock, at cost; 1,994,198 shares at September\u00a030, 2022 and December 31, 2021" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r403" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails", "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails", "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails", "http://www.esperion.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_USTreasuryAndGovernmentMember": { "auth_ref": [ "r325", "r526", "r565" ], "lang": { "en-us": { "role": { "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).", "label": "US Treasury and Government [Member]", "terseLabel": "U.S. treasury notes" } } }, "localname": "USTreasuryAndGovernmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r105", "r325", "r332", "r526" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]", "terseLabel": "U.S. treasury notes" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsRestrictedCashandShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of unrealized gains and losses on investments.", "label": "Unrealized Gain (Loss) on Investments [Table Text Block]", "terseLabel": "Schedule of Company's Cash Equivalents, Restricted Cash, and Short-Term Investments" } } }, "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r147", "r148", "r150", "r151", "r155", "r156", "r157" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrants" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r128", "r135" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted-average shares outstanding - diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r127", "r135" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average shares outstanding - basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "sharesItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r109": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r141": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r158": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563" }, "r192": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(i)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r218": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r226": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r235": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=6402221&loc=d3e15743-112638" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r317": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907" }, "r383": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r397": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20,24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r404": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "https://asc.fasb.org/topic&trid=5833765" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r511": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "https://asc.fasb.org/subtopic&trid=2176304" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62652-112803" }, "r528": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/subtopic&trid=2209399" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r571": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "https://asc.fasb.org/subtopic&trid=2324412" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r577": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r578": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r579": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r580": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r581": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r582": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r583": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r584": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r585": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r586": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r587": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r588": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r589": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r590": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r6": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3505-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" } }, "version": "2.1" } ZIP 69 0001628280-22-027479-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-22-027479-xbrl.zip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end

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�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